Biomarker pairs for predicting preterm birth
11987846 ยท 2024-05-21
Assignee
Inventors
- John Jay Boniface (Salt Lake City, UT)
- Andrew Gassman (Salt Lake City, UT)
- Jeff Flick (Salt Lake City, UT)
- Chad Bradford (Salt Lake City, UT)
- Ashoka Polpitiya (Salt Lake City, UT)
- Tracey Cristine Fleischer (Sandy, UT)
- Durlin Edward Hickok (Seattle, WA)
- Paul Kearney (Seattle, WA)
- Gregory Charles Critchfield (Holladay, UT)
Cpc classification
C12Q1/6883
CHEMISTRY; METALLURGY
International classification
Abstract
The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.
Claims
1. A method for providing prophylactic treatment of preterm birth in a pregnant human patient, the method comprising: (i) measuring in a biological sample obtained from said patient a panel of isolated biomarkers comprising IBP4 and SHBG, wherein measuring comprises subjecting the biological sample to a proteomics work-flow comprised of mass spectrometry (MS); (ii) calculating a risk score using a reversal value for IBP4/SHBG; and (iii) administering to said patient, where said risk score is above a reference risk score, a treatment regimen comprising a progesterone treatment, cervical cerclage, serial cervical length measurements, or an antenatal corticosteroid.
2. The method of claim 1, wherein said treatment regimen further comprises an enhanced monitoring and clinical management regimen compared to a pregnant human patient not at risk for preterm birth comprising one or more of (a) more frequent prenatal care visits, (b) enhanced education regarding signs and symptoms of early preterm labor, or (c) alteration of treatment for diabetes and/or high blood pressure.
3. The method of claim 1, wherein said progesterone treatment comprises administration of progestogen, 17-? hydroxyprogesterone caproate, or vaginal progesterone.
4. The method of claim 3, wherein said 17-? hydroxyprogesterone caproate is administered as an injection.
5. The method of claim 3, wherein said vaginal progesterone is administered in gel form.
6. The method of claim 1, further comprising an initial step of detecting a measurable feature for one or more risk indicia.
7. The method of claim 6, wherein said risk indicia is selected from the group consisting of Body Mass Index (BMI), gravidity and fetal gender.
8. The method of claim 6, wherein said risk indicia is Body Mass Index (BMI).
9. The method of claim 8, wherein said BMI is greater than 22 and less or equal to 37 kg/m.sup.2.
10. The method of claim 1, wherein said biological sample is selected from the group consisting of whole blood, plasma, serum, amniotic fluid, vaginal secretions, saliva, and urine.
11. The method of claim 10, wherein said biological sample is whole blood, plasma or serum.
12. The method of claim 1, wherein said biological sample is obtained between 19 and 21 weeks of gestational age.
13. The method of claim 1, wherein said proteomic work-flow comprises quantification of a stable isotope labeled (SIS) surrogate peptide of said biomarkers.
14. The method of claim 1, wherein said MS is selected from the group consisting of a) matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS); b) matrix-assisted laser desorption/ionization time-of-flight post-source-decay (MALDI-TOF post-source-decay (PSD)); c) matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF); d) surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS); e) electrospray ionization mass spectrometry (ESI-MS); f) electrospray ionization-mass spectrometry/mass spectrometry (ESI-MS/MS); g) electrospray ionization mass spectrometry/mass spectrometry, wherein is an integer greater than zero (ESI-MS/(MS)n (n is an integer greater than zero)); h) electrospray ionization 3D (ESI 3D) or linear 2D ion trap mass spectrometry (ESI linear (2D)) ion trap MS; i) electrospray ionization triple quadrupole mass spectrometry (ESI triple quadrupole MS); j) electrospray ionization quadrupole orthogonal time-of-flight (ESI Q-TOF); k) electrospray ionization Fourier transform mass spectrometry systems (ESI Fourier transform MS systems); l) desorption/ionization on silicon (DIOS); m) secondary ion mass spectrometry (SIMS); n) atmospheric pressure chemical ionization mass spectrometry (APCI-MS); o) atmospheric pressure chemical ionization-mass spectrometry/mass spectrometry (APCI-MS/MS); p) atmospheric pressure chemical ionization-mass spectrometry.sup.n (APCI-(MS)n); q) ion mobility spectrometry (IMS); r) inductively coupled plasma mass spectrometry (ICP-MS); s) atmospheric pressure photoionization mass spectrometry (APPI-MS); t) atmospheric pressure photoionization-mass spectrometry/mass spectrometry (APPI-MS/MS); and u) atmospheric pressure photoionization-mass spectrometry.sup.n (APPI-(MS)n).
15. The method of claim 1, wherein said MS comprises co-immunoprecipitation-mass spectrometry (co-IP MS).
16. The method of claim 1, wherein said MS comprises liquid chromatography-mass spectrometry (LC-MS).
17. The method of claim 1, wherein said MS comprises multiple reaction monitoring (MRM) or selected reaction monitoring (SRM).
18. The method of claim 1, wherein said treatment regimen further comprises administration of cervical pessaries.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)
(57)
(58)
(59)
(60)
(61)
(62)
(63)
(64)
(65)
(66)
(67)
(68)
(69)
(70)
(71)
(72)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(80)
(81)
(82)
(83)
(84)
(85)
(86)
(87)
(88)
(89)
(90)
(91)
(92)
(93)
(94)
(95)
(96)
(97)
(98)
(99)
(100)
(101)
(102)
(103)
(104)
(105)
(106)
(107)
(108)
(109)
(110)
(111)
(112)
DETAILED DESCRIPTION
(113) The present disclosure is based, generally, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of preterm birth relative to controls. The present disclosure is further specifically based, in part, on the unexpected discovery that reversal values of pairs of biomarkers disclosed herein can be utilized in methods of determining the probability for preterm birth in a pregnant female with high sensitivity and specificity. The proteins and peptides disclosed herein as components of ratios and/or reversal pairs serve as biomarkers for classifying test samples, predicting probability of preterm birth, predicting probability of term birth, predicting gestational age at birth (GAB), predicting time to birth (TTB) and/or monitoring of progress of preventative therapy in a pregnant female at risk for PTB, either individually, in ratios, reversal pairs or in panels of biomarkers/reversal pairs. A reversal value is the ratio of the relative peak area of an up regulated biomarker over the relative peak area of a down regulated biomarker and serves to both normalize variability and amplify diagnostic signal. The invention lies, in part, in the selection of particular biomarkers that, when paired together, can predict the probability of pre-term birth based on reversal values. Accordingly, it is human ingenuity in selecting the specific biomarkers that are informative upon being paired in novel reversals that underlies the present invention.
(114) The term reversal value refers to the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal. Out of all the possible reversals within a narrow window, a subset can selected based on individual univariate performance. As disclosed herein, the ratio of the relative peak area of an up regulated biomarker over the relative peak area of a down regulated biomarker, referred herein as a reversal value, can be used to identify robust and accurate classifiers and predict probability of preterm birth, predicting probability of term birth, predicting gestational age at birth (GAB), predicting time to birth and/or monitoring of progress of preventative therapy in a pregnant female. The present invention is thus based, in part, on the identification of biomarker pairs where the relative expression of a biomarker pair is reversed that exhibit a change in reversal value between PTB and non-PTB. Use of a ratio of biomarkers in the methods disclosed herein corrects for variability that is the result of human manipulation after the removal of the biological sample from the pregnant female. Such variability can be introduced, for example, during sample collection, processing, depletion, digestion or any other step of the methods used to measure the biomarkers present in a sample and is independent of how the biomarkers behave in nature. Accordingly, the invention generally encompasses the use of a reversal pair in a method of diagnosis or prognosis to reduce variability and/or amplify, normalize or clarify diagnostic signal.
(115) While the term reversal value refers to the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal, it is also contemplated that a pair of biomarkers of the invention could be measured by any other means, for example, by substraction, addition or multiplication of relative peak areas. The methods disclosed herein encompass the measurement of biomarker pairs by such other means.
(116) This method is advantageous because it provides the simplest possible classifier that is independent of data normalization, helps to avoid overfitting, and results in a very simple experimental test that is easy to implement in the clinic. The use of marker pairs based on changes in reversal values that are independent of data normalization enabled the development of the clinically relevant biomarkers disclosed herein. Because quantification of any single protein is subject to uncertainties caused by measurement variability, normal fluctuations, and individual related variation in baseline expression, identification of pairs of markers that may be under coordinated, systematic regulation enables robust methods for individualized diagnosis and prognosis.
(117) The disclosure provides biomarker reversal pairs and associated panels of reversal pairs, methods and kits for determining the probability for preterm birth in a pregnant female. One major advantage of the present disclosure is that risk of developing preterm birth can be assessed early during pregnancy so that appropriate monitoring and clinical management to prevent preterm delivery can be initiated in a timely fashion. The present invention is of particular benefit to females lacking any risk factors for preterm birth and who would not otherwise be identified and treated.
(118) By way of example, the present disclosure includes methods for generating a result useful in determining probability for preterm birth in a pregnant female by obtaining a dataset associated with a sample, where the dataset at least includes quantitative data about the relative expression of biomarker pairs that have been identified as exhibiting changes in reversal value predictive of preterm birth, and inputting the dataset into an analytic process that uses the dataset to generate a result useful in determining probability for preterm birth in a pregnant female. As described further below, quantitative data can include amino acids, peptides, polypeptides, proteins, nucleotides, nucleic acids, nucleosides, sugars, fatty acids, steroids, metabolites, carbohydrates, lipids, hormones, antibodies, regions of interest that serve as surrogates for biological macromolecules and combinations thereof.
(119) In addition to the specific biomarkers identified in this disclosure, for example, by accession number in a public database, sequence, or reference, the invention also contemplates use of biomarker variants that are at least 90% or at least 95% or at least 97% identical to the exemplified sequences and that are now known or later discovered and that have utility for the methods of the invention. These variants may represent polymorphisms, splice variants, mutations, and the like. In this regard, the instant specification discloses multiple art-known proteins in the context of the invention and provides exemplary accession numbers associated with one or more public databases as well as exemplary references to published journal articles relating to these art-known proteins. However, those skilled in the art appreciate that additional accession numbers and journal articles can easily be identified that can provide additional characteristics of the disclosed biomarkers and that the exemplified references are in no way limiting with regard to the disclosed biomarkers. As described herein, various techniques and reagents find use in the methods of the present invention. Suitable samples in the context of the present invention include, for example, blood, plasma, serum, amniotic fluid, vaginal secretions, saliva, and urine. In some embodiments, the biological sample is selected from the group consisting of whole blood, plasma, and serum. In a particular embodiment, the biological sample is serum. As described herein, biomarkers can be detected through a variety of assays and techniques known in the art. As further described herein, such assays include, without limitation, mass spectrometry (MS)-based assays, antibody-based assays as well as assays that combine aspects of the two.
(120) Protein biomarkers that are components of reversal pairs described herein include, for example, Insulin-Like Growth Factor Binding Protein 4 (IBP4), Sex Hormone Binding Globulin (SHBG), Vitronectin (VTNC), Group-Specific Component (Vitamin D Binding Protein) (VTDB), cathepsin D (lysosomal aspartyl protease) (CATD), pregnancy specific beta-1-glycoprotein 2 (PSG2), Inter-Alpha-Trypsin Inhibitor Heavy Chain Family, Member 4 (ITIH4), cell adhesion molecule L1-like (CHL1), Complement Component 1, Q Subcomponent, B Chain (C1QB), Fibulin 3 (FBLN3), Hemopexin (HEMO or HPX), Insulin-Like Growth Factor Binding Protein 6 (IBP6), prostaglandin D2 synthase 21 kDa (PTGDS)
(121) In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group comprising those pairs listed in any of the accompanying figures and tables, including
(122) In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, HPX/PTGDS to determine the probability for preterm birth in said pregnant female.
(123) The invention provides isolated biomarkers selected from the group set forth in Table 26. The biomarkers of the invention can predict risk for pre-term birth in a pregnant female. In some embodiments, the isolated biomarkers are selected from the group consisting of IBP4, SHBG, VTNC, VTDB, CATD, PSG2, ITIH4, CHL1, C1QB, FBLN3, HPX, and PTGDS. In some embodiments, the isolated biomarkers are selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.
(124) The invention provides surrogate peptides of the isolated biomarkers selected from the group set forth in Table 26. In some embodiments, the surrogate peptides of the isolated biomarkers are selected from the group of surrogate peptides set forth in Table 26. The biomarkers of the invention and their surrogate peptides can be used in methods to predict risk for pre-term birth in a pregnant female. In some embodiments, the surrogate peptides correspond to isolated biomarkers selected from the group consisting of IBP4, SHBG, VTNC, VTDB, CATD, PSG2, ITIH4, CHL1, C1QB, FBLN3, HPX, and PTGDS. In some embodiments, the surrogate peptides correspond to isolated biomarkers selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.
(125) The invention provides stable isotope labeled standard peptides (SIS peptides) corresponding to the surrogate peptides selected from the group set forth in Table 26. The biomarkers of the invention, their surrogate peptides and the SIS peptides can be used in methods to predict risk for pre-term birth in a pregnant female. In some embodiments, the SIS peptides correspond to surrogate peptides of the isolated biomarkers selected from the group consisting of IBP4, SHBG, VTNC, VTDB, CATD, PSG2, ITIH4, CHL1, C1QB, FBLN3, HPX, and PTGDS. In some embodiments, the SIS peptides correspond to surrogate peptides of the isolated biomarkers selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.
(126) In some embodiments, the invention provides a pair of isolated biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth compared to term controls. In a further embodiment, the invention provides a pair of isolated biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a higher ratio in pregnant females at risk for pre-term birth compared to term controls.
(127) In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, and CATD/SHBG to determine the probability for preterm birth in said pregnant female. In additional embodiments the sample is obtained between 19 and 21 weeks of GABD. In further embodiments the sample is obtained between 19 and 22 weeks of GABD.
(128) In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for IBP4/SHBG to determine the probability for preterm birth in said pregnant female. In additional embodiments the sample is obtained between 19 and 21 weeks of GABD. In further embodiments the sample is obtained between 19 and 22 weeks of GABD.
(129) In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, HPX/PTGDS to determine the probability for preterm birth in said pregnant female, wherein the existence of a change in reversal value between the pregnant female and a term control determines the probability for preterm birth in the pregnant female. In additional embodiments the sample is obtained between 19 and 21 weeks of GABD. In further embodiments the sample is obtained between 19 and 22 weeks of GABD.
(130) Included within the embodiments of the invention, are iterative methods of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, HPX/PTGDS and any other pair of biomarkers selected from the proteins described and/or exemplified herein to determine the probability for preterm birth in said pregnant female, wherein the existence of a change in reversal value between the pregnant female and a term control determines the probability for preterm birth in the pregnant female. Iterative performance of the methods described herein includes subsequent measurements obtained from a single sample as well as obtaining subsequent samples for measurement. For example, if it is determined that the probability for preterm birth in a pregnant female, which can be expressed as a risk score, is above a specified value, the method can be repeated using a distinct reversal pair from the same sample or the same or a distinct reversal pair from a subsequent sample to further stratify the risk for sPTB.
(131) In addition to the specific biomarkers, the disclosure further includes biomarker variants that are about 90%, about 95%, or about 97% identical to the exemplified sequences. Variants, as used herein, include polymorphisms, splice variants, mutations, and the like. Although described with reference to protein biomarkers, changes in reversal value can be identified in protein or gene expression levels for pairs of biomarkers.
(132) Additional markers can be selected from one or more risk indicia, including but not limited to, maternal characteristics, medical history, past pregnancy history, and obstetrical history. Such additional markers can include, for example, previous low birth weight or preterm delivery, multiple 2nd trimester spontaneous abortions, prior first trimester induced abortion, familial and intergenerational factors, history of infertility, nulliparity, placental abnormalities, cervical and uterine anomalies, short cervical length measurements, gestational bleeding, intrauterine growth restriction, in utero diethylstilbestrol exposure, multiple gestations, infant sex, short stature, low prepregnancy weight, low or high body mass index, diabetes, hypertension, urogenital infections (i.e. urinary tract infection), asthma, anxiety and depression, asthma, hypertension, hypothyroidism. Demographic risk indicia for preterm birth can include, for example, maternal age, race/ethnicity, single marital status, low socioeconomic status, maternal age, employment-related physical activity, occupational exposures and environment exposures and stress. Further risk indicia can include, inadequate prenatal care, cigarette smoking, use of marijuana and other illicit drugs, cocaine use, alcohol consumption, caffeine intake, maternal weight gain, dietary intake, sexual activity during late pregnancy and leisure-time physical activities. (Preterm Birth: Causes, Consequences, and Prevention, Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman R E, Butler A S, editors. Washington (DC): National Academies Press (US); 2007). Additional risk indicia useful for as markers can be identified using learning algorithms known in the art, such as linear discriminant analysis, support vector machine classification, recursive feature elimination, prediction analysis of microarray, logistic regression, CART, FlexTree, LART, random forest, MART, and/or survival analysis regression, which are known to those of skill in the art and are further described herein.
(133) It must be noted that, as used in this specification and the appended claims, the singular forms a, an and the include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a biomarker includes a mixture of two or more biomarkers, and the like.
(134) The term about, particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.
(135) As used in this application, including the appended claims, the singular forms a, an, and the include plural references, unless the content clearly dictates otherwise, and are used interchangeably with at least one and one or more.
(136) As used herein, the terms comprises, comprising, includes, including, contains, containing, and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, product-by-process, or composition of matter that comprises, includes, or contains an element or list of elements does not include only those elements but can include other elements not expressly listed or inherent to such process, method, product-by-process, or composition of matter.
(137) As used herein, the term panel refers to a composition, such as an array or a collection, comprising one or more biomarkers. The term can also refer to a profile or index of expression patterns of one or more biomarkers described herein. The number of biomarkers useful for a biomarker panel is based on the sensitivity and specificity value for the particular combination of biomarker values.
(138) As used herein, and unless otherwise specified, the terms isolated and purified generally describes a composition of matter that has been removed from its native environment (e.g., the natural environment if it is naturally occurring), and thus is altered by the hand of man from its natural state so as to possess markedly different characteristics with regard to at least one of structure, function and properties. An isolated protein or nucleic acid is distinct from the way it exists in nature and includes synthetic peptides and proteins.
(139) The term biomarker refers to a biological molecule, or a fragment of a biological molecule, the change and/or the detection of which can be correlated with a particular physical condition or state. The terms marker and biomarker are used interchangeably throughout the disclosure. For example, the biomarkers of the present invention are correlated with an increased likelihood of preterm birth. Such biomarkers include any suitable analyte, but are not limited to, biological molecules comprising nucleotides, nucleic acids, nucleosides, amino acids, sugars, fatty acids, steroids, metabolites, peptides, polypeptides, proteins, carbohydrates, lipids, hormones, antibodies, regions of interest that serve as surrogates for biological macromolecules and combinations thereof (e.g., glycoproteins, ribonucleoproteins, lipoproteins). The term also encompasses portions or fragments of a biological molecule, for example, peptide fragment of a protein or polypeptide that comprises at least 5 consecutive amino acid residues, at least 6 consecutive amino acid residues, at least 7 consecutive amino acid residues, at least 8 consecutive amino acid residues, at least 9 consecutive amino acid residues, at least 10 consecutive amino acid residues, at least 11 consecutive amino acid residues, at least 12 consecutive amino acid residues, at least 13 consecutive amino acid residues, at least 14 consecutive amino acid residues, at least 15 consecutive amino acid residues, at least 5 consecutive amino acid residues, at least 16 consecutive amino acid residues, at least 17 consecutive amino acid residues, at least 18 consecutive amino acid residues, at least 19 consecutive amino acid residues, at least 20 consecutive amino acid residues, at least 21 consecutive amino acid residues, at least 22 consecutive amino acid residues, at least 23 consecutive amino acid residues, at least 24 consecutive amino acid residues, at least 25 consecutive amino acid residues, or more consecutive amino acid residues.
(140) As used herein, the term surrogate peptide refers to a peptide that is selected to serve as a surrogate for quantification of a biomarker of interest in an MRM assay configuration. Quantification of surrogate peptides is best achieved using stable isotope labeled standard surrogate peptides (SIS surrogate peptides or SIS peptides) in conjunction with the MRM detection technique. A surrogate peptide can be synthetic. An SIS surrogate peptide can be synthesized with heavy labeled for example, with an Arginine or Lysine, or any other amino acid at the C-terminus of the peptide to serve as an internal standard in the MRM assay. An SIS surrogate peptide is not a naturally occurring peptide and has markedly different structure and properties compared to its naturally occurring counterpart.
(141) In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a ratio for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, HPX/PTGDS to determine the probability for preterm birth in said pregnant female, wherein the existence of a change in the ratio between the pregnant female and a term control determines the probability for preterm birth in the pregnant female. In some embodiments, the ratio may include an up-regulated protein in the numerator, a down-regulated protein in the denominator or both. For example, as exemplified herein, IBP4/SHBG is a ratio of an up-regulated protein in the numerator and a down-regulated protein in the denominator, which is defined herein as a reversal. In the instances where the ratio includes an up-regulated protein in the numerator, or a down-regulated protein in the denominator, the un-regulated protein would serve to normalize (e.g. decrease pre-analytical or analytical variability). In the particular case of a ratio that is a reversal both amplification and normalization are possible. It is understood, that the methods of the invention are not limited to the subset of reversals, but also encompass ratios of biomarkers.
(142) As used herein, the term reversal refers to the ratio of the measured value of an upregulated analyte over that of a down-regulated analyte. In some embodiments, the analyte value is itself a ratio of the peak area of the endogenous analyte over that of the peak area of the corresponding stable isotopic standard analyte, referred to herein as: response ratio or relative ratio.
(143) As used herein, the term reversal pair refers to biomarkers in pairs that exhibit a change in value between the classes being compared. The detection of reversals in protein concentrations or gene expression levels eliminates the need for data normalization or the establishment of population-wide thresholds. In some embodiments, the reversal pair is a pair of isolated biomarkers IBP4/SHBG, wherein the reversal pair exhibits a change in reversal value between pregnant females at risk for pre-term birth compared to term controls. In a further embodiment, the reversal pair IBP4/SHBG exhibits a higher ratio in pregnant females at risk for pre-term birth compared to term controls. Encompassed within the definition of any reversal pair is the corresponding reversal pair wherein individual biomarkers are switched between the numerator and denominator. One skilled in the art will appreciate that such a corresponding reversal pair is equally informative with regard to its predictive power.
(144) The term reversal value refers to the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal. Out of all the possible reversals within a narrow window, a subset can selected based on individual univariate performance. As disclosed herein, the ratio of the relative peak area of an up regulated biomarker over the relative peak area of a down regulated biomarker, referred herein as a reversal value, can be used to identify robust and accurate classifiers and predict probability of preterm birth, predicting probability of term birth, predicting gestational age at birth (GAB), predicting time to birth and/or monitoring of progress of preventative therapy in a pregnant female.
(145) This reversal method is advantageous because it provides the simplest possible classifier that is independent of data normalization, helps to avoid overfitting, and results in a very simple experimental test that is easy to implement in the clinic. The use of biomarker pairs based on reversals that are independent of data normalization as described herein has tremendous power as a method for the identification of clinically relevant PTB biomarkers. Because quantification of any single protein is subject to uncertainties caused by measurement variability, normal fluctuations, and individual related variation in baseline expression, identification of pairs of markers that can be under coordinated, systematic regulation should prove to be more robust for individualized diagnosis and prognosis.
(146) The invention provides a composition comprising a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the compositions comprises stable isotope labeled standard peptides (SIS peptides) for surrogate peptides derived from each of said biomarkers.
(147) In particular embodiments, the invention provides a pair of isolated biomarkers consisting of IBP4 and SHBG, wherein the pair exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.
(148) IBP4 is a member of a family of insulin-like growth factor binding proteins (IBP) that negatively regulate the insulin-like growth factors IGF1 and IGF2. (Forbes et al. Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. Am J Physiol, Cell Physiol. 2008; 294(6):C1313-22). IBP4 is expressed by syncytiotrophoblasts (Crosley et al., IGFBP-4 and -5 are expressed in first-trimester villi and differentially regulate the migration of HTR-8/SVneo cells. Reprod Biol Endocrinol. 2014; 12(1):123) and is the dominant IBP expressed by extravillous trophoblasts (Qiu et al. Significance of IGFBP-4 in the development of fetal growth restriction. J Clin Endocrinol Metab. 2012; 97(8):E1429-39). Compared to term pregnancies, maternal IBP4 levels in early pregnancy are higher in pregnancies complicated by fetal growth restriction and preeclampsia. (Qiu et al., supra, 2012)
(149) SHBG regulates the availability of biologically active unbound steroid hormones. Hammond G L. Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod. 2011; 85(3):431-41. Plasma SHBG levels increase 5-10 fold during pregnancy (Anderson D C. Sex-hormone-binding globulin. Clin Endocrinol (Oxf). 1974; 3(1):69-96) and evidence exists for extra-hepatic expression, including placental trophoblastic cells. (Larrea et al. Evidence that human placenta is a site of sex hormone-binding globulin gene expression. J Steroid Biochem Mol Biol. 1993; 46(4):497-505) Physiologically, SHBG levels negatively correlate with triglycerides, insulin levels and BMI. (Sim? et al. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015; 26(7):376-83) BMI's effect on SHBG levels may explain, in part, the improved predictive performance with BMI stratification.
(150) Intra-amniotic infection and inflammation have been associated with PTB, as has increased levels of proinflammatory cytokines including TNF-? and IL1-? (Mendelson C R. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol. 2009; 23(7):947-54; Gomez-Lopez et al. Immune cells in term and preterm labor. Cell Mol Immunol. 2014; 11(6):571-81). SHBG transcription in liver is suppressed by IL1-? and NF-kB mediated TNF-? signaling (Sim? et al. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015; 26(7):376-83), a pathway implicated in initiation of normal and abnormal labor (Lindstrom T M, Bennett P R. The role of nuclear factor kappa B in human labour. Reproduction. 2005; 130(5):569-81). Lower levels of SHBG in women destined for sPTB may be a result of infection and/or inflammation. Hence, SHBG may be critical for control of androgen and estrogen action in the placental-fetal unit in response to upstream inflammatory signals.
(151) In one embodiment, the invention provides a composition comprising a pair of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.
(152) In a further embodiment, the invention provides a panel of at least two pairs of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.
(153) In an additional embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.
(154) In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS to determine the probability for preterm birth in the pregnant female.
(155) In another embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a change in reversal value for a panel of at least two pairs of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS to determine the probability for preterm birth in the pregnant female. In some embodiments, the reversal value reveals the existence of a change in reversal value between the pregnant female and a term control and indicates the probability for preterm birth in the pregnant female. In some embodiments, the measuring step comprises measuring surrogate peptides of the biomarkers in the biological sample obtained from the pregnant female.
(156) In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of the biomarkers listed in any of Tables 1 through 77 and
(157) In an additional embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of the biomarker pairs specified in Tables 27 through 59, 61 through 72, 76 and 77 in a pregnant female to determine the probability for preterm birth in the pregnant female.
(158) In an further embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of the biomarkers listed in Table 26 in a pregnant female to determine the probability for preterm birth in the pregnant female.
(159) In another embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a change in reversal value for a panel of at least two pairs of biomarkers selected from the group consisting of the biomarker pairs specified in any of Tables 1 through 77 and
(160) In another embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a change in reversal value for a panel of at least two pairs of biomarkers selected from the group consisting of the biomarker pairs specified in Tables 27 through 59, 61 through 72, 76 and 77 in a pregnant female to determine the probability for preterm birth in the pregnant female. In some embodiments, the reversal value reveals the existence of a change in reversal value between the pregnant female and a term control and indicates the probability for preterm birth in the pregnant female. In some embodiments, the measuring step comprises measuring surrogate peptides of the biomarkers in the biological sample obtained from the pregnant female.
(161) In another embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a change in reversal value for a panel of at least two pairs of biomarkers selected from the group consisting of the biomarkers specified in Table 26 in a pregnant female to determine the probability for preterm birth in the pregnant female. In some embodiments, the reversal value reveals the existence of a change in reversal value between the pregnant female and a term control and indicates the probability for preterm birth in the pregnant female. In some embodiments, the measuring step comprises measuring surrogate peptides of the biomarkers in the biological sample obtained from the pregnant female.
(162) For methods directed to predicating time to birth, it is understood that birth means birth following spontaneous onset of labor, with or without rupture of membranes.
(163) Although described and exemplified with reference to methods of determining probability for preterm birth in a pregnant female, the present disclosure is similarly applicable to methods of predicting gestational age at birth (GAB), methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth (TTB) in a pregnant female. It will be apparent to one skilled in the art that each of the aforementioned methods has specific and substantial utilities and benefits with regard maternal-fetal health considerations.
(164) Furthermore, although described and exemplified with reference to methods of determining probability for preterm birth in a pregnant female, the present disclosure is similarly applicable to methods of predicting an abnormal glucola test, gestational diabetes, hypertension, preeclampsia, intrauterine growth restriction, stillbirth, fetal growth restriction, HELLP syndrome, oligohyramnios, chorioamnionitis, chorioamnionitis, placental previa, placental acreta, abruption, abruptio placenta, placental hemorrhage, preterm premature rupture of membranes, preterm labor, unfavorable cervix, postterm pregnancy, cholelithiasis, uterine over distention, stress. As described in more detail below, the classifier described herein is sensitive to a component of medically indicated PTB based on conditions such as, for example, preeclampsia or gestational diabetes.
(165) In some embodiments, the present disclosure provides biomarkers, biomarker pairs and/or reversals, exemplified here by using ITIH4/CSH, that are strong predictors of time to birth (TTB) (
(166) In additional embodiments, the methods of determining probability for preterm birth in a pregnant female further encompass detecting a measurable feature for one or more risk indicia associated with preterm birth. In additional embodiments the risk indicia are selected form the group consisting of previous low birth weight or preterm delivery, multiple 2nd trimester spontaneous abortions, prior first trimester induced abortion, familial and intergenerational factors, history of infertility, nulliparity, gravidity, primigravida, multigravida, placental abnormalities, cervical and uterine anomalies, gestational bleeding, intrauterine growth restriction, in utero diethylstilbestrol exposure, multiple gestations, infant sex, short stature, low prepregnancy weight, low or high body mass index, diabetes, hypertension, and urogenital infections.
(167) A measurable feature is any property, characteristic or aspect that can be determined and correlated with the probability for preterm birth in a subject. The term further encompasses any property, characteristic or aspect that can be determined and correlated in connection with a prediction of GAB, a prediction of term birth, or a prediction of time to birth in a pregnant female. For a biomarker, such a measurable feature can include, for example, the presence, absence, or concentration of the biomarker, or a fragment thereof, in the biological sample, an altered structure, such as, for example, the presence or amount of a post-translational modification, such as oxidation at one or more positions on the amino acid sequence of the biomarker or, for example, the presence of an altered conformation in comparison to the conformation of the biomarker in term control subjects, and/or the presence, amount, or altered structure of the biomarker as a part of a profile of more than one biomarker.
(168) In addition to biomarkers, measurable features can further include risk indicia including, for example, maternal characteristics, age, race, ethnicity, medical history, past pregnancy history, obstetrical history. For a risk indicium, a measurable feature can include, for example, previous low birth weight or preterm delivery, multiple 2nd trimester spontaneous abortions, prior first trimester induced abortion, familial and intergenerational factors, history of infertility, nulliparity, placental abnormalities, cervical and uterine anomalies, short cervical length measurements, gestational bleeding, intrauterine growth restriction, in utero diethylstilbestrol exposure, multiple gestations, infant sex, short stature, low prepregnancy weight/low body mass index, diabetes, hypertension, urogenital infections, hypothyroidism, asthma, low educational attainment, cigarette smoking, drug use and alcohol consumption.
(169) In some embodiments, the methods of the invention comprise calculation of body mass index (BMI).
(170) In some embodiments, the disclosed methods for determining the probability of preterm birth encompass detecting and/or quantifying one or more biomarkers using mass spectrometry, a capture agent or a combination thereof.
(171) In additional embodiments, the disclosed methods of determining probability for preterm birth in a pregnant female encompass an initial step of providing a biological sample from the pregnant female.
(172) In some embodiments, the disclosed methods of determining probability for preterm birth in a pregnant female encompass communicating the probability to a health care provider. The disclosed of predicting GAB, the methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth in a pregnant female similarly encompass communicating the probability to a health care provider. As stated above, although described and exemplified with reference to determining probability for preterm birth in a pregnant female, all embodiments described throughout this disclosure are similarly applicable to the methods of predicting GAB, the methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth in a pregnant female. Specifically, the biomarkers and panels recited throughout this application with express reference to methods for preterm birth can also be used in methods for predicting GAB, the methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth in a pregnant female. It will be apparent to one skilled in the art that each of the aforementioned methods has specific and substantial utilities and benefits with regard maternal-fetal health considerations.
(173) In additional embodiments, the communication informs a subsequent treatment decision for the pregnant female. In some embodiments, the method of determining probability for preterm birth in a pregnant female encompasses the additional feature of expressing the probability as a risk score.
(174) In the methods disclosed herein, determining the probability for preterm birth in a pregnant female encompasses an initial step that includes formation of a probability/risk index by measuring the ratio of isolated biomarkers selected from the group in a cohort of preterm pregnancies and term pregnancies with known gestational age at birth. For an individual pregnancy, determining the probability of for preterm birth in a pregnant female encompasses measuring the ratio of the isolated biomarker using the same measurement method as used in the initial step of creating the probability/risk index, and comparing the measured ratio to the risk index to derive the personalized risk for the individual pregnancy. In one embodiment, a preterm risk index is formed by measuring the ratio of IBP4/SHBG in a cohort of preterm and term pregnancies where the gestational age at birth is recorded. Then, in clinical practice the measured ratio of IBP4/SHBG in an individual pregnancy is compared in the index to derive the preterm risk using the same isolation and measurement technologies to derive IBP4/SHBG as in the index group.
(175) As used herein, the term risk score refers to a score that can be assigned based on comparing the amount of one or more biomarkers or reversal values in a biological sample obtained from a pregnant female to a standard or reference score that represents an average amount of the one or more biomarkers calculated from biological samples obtained from a random pool of pregnant females. In some embodiments, the risk score is expressed as the log of the reversal value, i.e. the ratio of the relative intensities of the individual biomarkers. One skilled in the art will appreciate that a risk score can be expressed based on a various data transformations as well as being expressed as the ratio itself. Furthermore, with particular regard to reversal pairs, one skilled in the art will appreciate the any ratio is equally informative if the biomarkers in the numerator and denominator are switched or that related data transformations (e.g. subtraction) are applied. Because the level of a biomarker may not be static throughout pregnancy, a standard or reference score has to have been obtained for the gestational time point that corresponds to that of the pregnant female at the time the sample was taken. The standard or reference score can be predetermined and built into a predictor model such that the comparison is indirect rather than actually performed every time the probability is determined for a subject. A risk score can be a standard (e.g., a number) or a threshold (e.g., a line on a graph). The value of the risk score correlates to the deviation, upwards or downwards, from the average amount of the one or more biomarkers calculated from biological samples obtained from a random pool of pregnant females. In certain embodiments, if a risk score is greater than a standard or reference risk score, the pregnant female can have an increased likelihood of preterm birth. In some embodiments, the magnitude of a pregnant female's risk score, or the amount by which it exceeds a reference risk score, can be indicative of or correlated to that pregnant female's level of risk.
(176) As exemplified herein, the PreTRM? Classifier is defined as the natural log of the SIS normalized intensities of the IBP4 peptide transition (QCHPALDGQR_394.5_475.2 (SEQ ID NO: 2)) and the SHBG peptide transition (IALGGLLFPASNLR_481.3_657.4 (SEQ ID NO: 18)). Score=ln(P.sup.1.sub.n/P.sup.2.sub.n), where P.sup.1.sub.n and P.sup.2.sub.n denote the SIS normalized peak area values for the IBP4 and SHBG transitions, respectively. SIS normalization is defined as the relative ratio of the endogenous peak area divided by the corresponding SIS peak area: e.g. P.sup.1.sub.n=P.sup.1.sub.e/P.sup.1.sub.SIS, where P.sup.1.sub.e=the peak area for the IBP4 endogenous transition and P.sup.1.sub.SIS=the peak area for IBP4 SIS transition. From the identified association between the distribution of PreTRM? scores and the corresponding prevalence adjusted positive predictive value a probability of sPTB can be assigned to an unknown subject based on the determination of their score. This relationship or association is shown in
(177) While the PreTRM? Classifier is defined as the natural log of the SIS normalized intensities of the IBP4 peptide transition (QCHPALDGQR_394.5_475.2 (SEQ ID NO: 2)) and the SHBG peptide transition (IALGGLLFPASNLR_481.3_657.4 (SEQ ID NO: 18)), the invention also comprises classifiers that include multiple reversals. Improved performance can be achieved by constructing predictors formed from more than one reversal. In additional embodiments, the invention methods therefore comprise multiple reversals that have a strong predictive performance for example, for separate GABD windows, preterm premature rupture of membranes (PPROM) versus preterm labor in the absence of PPROM (PTL), fetal gender, primigravida versus multigravida. This embodiment is exemplified in Example 10, and Table 61, for either reversals that produced strong predictive performance either early (e.g. weeks 17-19) or later (e.g. weeks 19-21) in the gestational age range. As exemplified, performance of predictors formed from combinations (SumLog) of multiple reversals were evaluated for the entire blood draw range and a predictor score was derived from summing the Log values of the individual reversal (SumLog). One skilled in the art can select other models (e.g. logistic regression) to construct a predictor formed from more than one reversal.
(178) The methods of the invention further include classifiers that contain an indicator variable that selects one or a subset of reversals based on known clinical factors, for example, blood draw period, fetal gender, gravidity as well as any other knowable patient features and/or risk factors described throughout this application. This embodiment is exemplified in Example 10, Tables 61 through 64, which exemplify reversal performance (weeks 17-21) independently for two different phenotypes of sPTB, PPROM and PTL. This embodiment is similarly exemplified in Example 10, Tables 76 and 77 and
(179) As exemplified herein, the predictive performance of the claimed methods can be improved with a BMI stratification of greater than 22 and equal or less than 37 kg/m.sup.2. Accordingly, in some embodiments, the methods of the invention can be practiced with samples obtained from pregnant females with a specified BMI. Briefly, BMI is an individual's weight in kilograms divided by the square of height in meters. BMI does not measure body fat directly, but research has shown that BMI is correlated with more direct measures of body fat obtained from skinfold thickness measurements, bioelectrical impedance, densitometry (underwater weighing), dual energy x-ray absorptiometry (DXA) and other methods. Furthermore, BMI appears to be as strongly correlated with various metabolic and disease outcome as are these more direct measures of body fatness. Generally, an individual with a BMI below 18.5 is considered underweight, an individual with a BMI of equal or greater than 18.5 to 24.9 normal weight, while an individual with a BMI of equal or greater than 25.0 to 29.9 is considered overweight and an individual with a BMI of equal or greater than 30.0 is considered obese. In some embodiments, the predictive performance of the claimed methods can be improved with a BMI stratification of equal or greater than 18, equal or greater than 19, equal or greater than 20, equal or greater than 21, equal or greater than 22, equal or greater than 23, equal or greater than 24, equal or greater than 25, equal or greater than 26, equal or greater than 27, equal or greater than 28, equal or greater than 29 or equal or greater than 30. In other embodiments, the predictive performance of the claimed methods can be improved with a BMI stratification of equal or less than 18, equal or less than 19, equal or less than 20, equal or less than 21, equal or less than 22, equal or less than 23, equal or less than 24, equal or less than 25, equal or less than 26, equal or less than 27, equal or less than 28, equal or less than 29 or equal or less than 30.
(180) In the context of the present invention, the term biological sample, encompasses any sample that is taken from pregnant female and contains one or more of the biomarkers disclosed herein. Suitable samples in the context of the present invention include, for example, blood, plasma, serum, amniotic fluid, vaginal secretions, saliva, and urine. In some embodiments, the biological sample is selected from the group consisting of whole blood, plasma, and serum. In a particular embodiment, the biological sample is serum. As will be appreciated by those skilled in the art, a biological sample can include any fraction or component of blood, without limitation, T cells, monocytes, neutrophils, erythrocytes, platelets and microvesicles such as exosomes and exosome-like vesicles. In a particular embodiment, the biological sample is serum.
(181) As used herein, the term preterm birth refers to delivery or birth at a gestational age less than 37 completed weeks. Other commonly used subcategories of preterm birth have been established and delineate moderately preterm (birth at 33 to 36 weeks of gestation), very preterm (birth at <33 weeks of gestation), and extremely preterm (birth at ?28 weeks of gestation). With regard to the methods disclosed herein, those skilled in the art understand that the cut-offs that delineate preterm birth and term birth as well as the cut-offs that delineate subcategories of preterm birth can be adjusted in practicing the methods disclosed herein, for example, to maximize a particular health benefit. In various embodiments of the invention, cut-off that delineate preterm birth include, for example, birth at ?37 weeks of gestation, ?36 weeks of gestation, ?35 weeks of gestation, ?34 weeks of gestation, ?33 weeks of gestation, ?32 weeks of gestation, ?30 weeks of gestation, ?29 weeks of gestation, ?28 weeks of gestation, ?27 weeks of gestation, ?26 weeks of gestation, ?25 weeks of gestation, ?24 weeks of gestation, ?23 weeks of gestation or ?22 weeks of gestation. In some embodiments, the cut-off delineating preterm birth is ?35 weeks of gestation. It is further understood that such adjustments are well within the skill set of individuals considered skilled in the art and encompassed within the scope of the inventions disclosed herein. Gestational age is a proxy for the extent of fetal development and the fetus's readiness for birth. Gestational age has typically been defined as the length of time from the date of the last normal menses to the date of birth. However, obstetric measures and ultrasound estimates also can aid in estimating gestational age. Preterm births have generally been classified into two separate subgroups. One, spontaneous preterm births are those occurring subsequent to spontaneous onset of preterm labor or preterm premature rupture of membranes regardless of subsequent labor augmentation or cesarean delivery. Two, medically indicated preterm births are those occurring following induction or cesarean section for one or more conditions that the woman's caregiver determines to threaten the health or life of the mother and/or fetus. In some embodiments, the methods disclosed herein are directed to determining the probability for spontaneous preterm birth or medically indicated preterm birth. In some embodiments, the methods disclosed herein are directed to determining the probability for spontaneous preterm birth. In additional embodiments, the methods disclosed herein are directed to medically indicated preterm birth. In additional embodiments, the methods disclosed herein are directed to predicting gestational age at birth.
(182) As used herein, the term estimated gestational age or estimated GA refers to the GA determined based on the date of the last normal menses and additional obstetric measures, ultrasound estimates or other clinical parameters including, without limitation, those described in the preceding paragraph. In contrast the term predicted gestational age at birth or predicted GAB refers to the GAB determined based on the methods of the invention as disclosed herein. As used herein, term birth refers to birth at a gestational age equal or more than 37 completed weeks.
(183) In some embodiments, the pregnant female is between 17 and 28 weeks of gestation at the time the biological sample is collected, also referred to as GABD (Gestational Age at Blood Draw). In other embodiments, the pregnant female is between 16 and 29 weeks, between 17 and 28 weeks, between 18 and 27 weeks, between 19 and 26 weeks, between 20 and 25 weeks, between 21 and 24 weeks, or between 22 and 23 weeks of gestation at the time the biological sample is collected. In further embodiments, the pregnant female is between about 17 and 22 weeks, between about 16 and 22 weeks between about 22 and 25 weeks, between about 13 and 25 weeks, between about 26 and 28, or between about 26 and 29 weeks of gestation at the time the biological sample is collected. Accordingly, the gestational age of a pregnant female at the time the biological sample is collected can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 weeks. In particular embodiments, the biological sample is collected between 19 and 21 weeks of gestational age. In particular embodiments, the biological sample is collected between 19 and 22 weeks of gestational age. In particular embodiments, the biological sample is collected between 19 and 21 weeks of gestational age. In particular embodiments, the biological sample is collected between 19 and 22 weeks of gestational age. In particular embodiments, the biological sample is collected at 18 weeks of gestational age. In further embodiments, the highest performing reversals for consecutive or overlapping time windows can be combined in a single classifier to predict the probability of sPTB over a wider window of gestational age at blood draw.
(184) The term amount or level as used herein refers to a quantity of a biomarker that is detectable or measurable in a biological sample and/or control. The quantity of a biomarker can be, for example, a quantity of polypeptide, the quantity of nucleic acid, or the quantity of a fragment or surrogate. The term can alternatively include combinations thereof. The term amount or level of a biomarker is a measurable feature of that biomarker.
(185) The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of the biomarker pairs specified in any of Tables 1 through 77 and
(186) The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of the biomarker pairs specified in Tables 27 through 59, 61 through 72, 76 and 77 in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent.
(187) The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent. In one embodiment the invention provides a method of detecting IBP4 and SHBG in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether IBP4 and SHBG are present in the biological sample by contacting the biological sample with a capture agent that specifically binds IBP4 and a capture agent that specifically binds SHBG; and c. detecting binding between IBP4 and the capture agent and between SHBG and the capture agent. In one embodiment, the method comprises measuring a reversal value for the pair of biomarkers. In a further embodiment, the existence of a change in reversal value between the pregnant female and a term control indicates the probability for preterm birth in the pregnant female. In one embodiment, the sample is obtained between 19 and 21 weeks of gestational age. In a further embodiment, the capture agent is selected from the group consisting of and antibody, antibody fragment, nucleic acid-based protein binding reagent, small molecule or variant thereof. In an additional embodiment, the method is performed by an assay selected from the group consisting of enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (MA).
(188) The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; and b. detecting whether the pair of isolated biomarkers is present in the biological sample comprising subjecting the sample to a proteomics work-flow comprised of mass spectrometry quantification.
(189) In one embodiment the invention provides a method of detecting IBP4 and SHBG in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; and b. detecting whether the pair of isolated biomarkers is present in the biological sample comprising subjecting the sample to a proteomics work-flow comprised of mass spectrometry quantification.
(190) A proteomics work-flow generally encompasses one or more of the following steps: Serum samples are thawed and depleted of the 14 highest abundance proteins by immune-affinity chromatography. Depleted serum is digested with a protease, for example, trypsin, to yield peptides. The digest is subsequently fortified with a mixture of SIS peptides and then desalted and subjected to LC-MS/MS with a triple quadrapole instrument operated in MRM mode. Response ratios are formed from the area ratios of endogenous peptide peaks and the corresponding SIS peptide counterpart peaks. Those skilled in the art appreciate that other types of MS such as, for example, MALDI-TOF, or ESI-TOF, can be used in the methods of the invention. In addition, one skilled in the art can modify a proteomics work-flow, for example, by selecting particular reagents (such as proteases) or omitting or changing the order of certain steps, for example, it may not be necessary to immunodeplete, the SIS peptide could be added earlier or later and stable isotope labeled proteins could be used as standards instead of peptides.
(191) Any existing, available or conventional separation, detection and quantification methods can be used herein to measure the presence or absence (e.g., readout being present vs. absent; or detectable amount vs. undetectable amount) and/or quantity (e.g., readout being an absolute or relative quantity, such as, for example, absolute or relative concentration) of biomarkers, peptides, polypeptides, proteins and/or fragments thereof and optionally of the one or more other biomarkers or fragments thereof in samples. In some embodiments, detection and/or quantification of one or more biomarkers comprises an assay that utilizes a capture agent. In further embodiments, the capture agent is an antibody, antibody fragment, nucleic acid-based protein binding reagent, small molecule or variant thereof. In additional embodiments, the assay is an enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (MA). In some embodiments, detection and/or quantification of one or more biomarkers further comprises mass spectrometry (MS). In yet further embodiments, the mass spectrometry is co-immunoprecitipation-mass spectrometry (co-IP MS), where coimmunoprecipitation, a technique suitable for the isolation of whole protein complexes is followed by mass spectrometric analysis.
(192) As used herein, the term mass spectrometer refers to a device able to volatilize/ionize analytes to form gas-phase ions and determine their absolute or relative molecular masses. Suitable methods of volatilization/ionization are matrix-assisted laser desorption ionization (MALDI), electrospray, laser/light, thermal, electrical, atomized/sprayed and the like, or combinations thereof. Suitable forms of mass spectrometry include, but are not limited to, ion trap instruments, quadrupole instruments, electrostatic and magnetic sector instruments, time of flight instruments, time of flight tandem mass spectrometer (TOF MS/MS), Fourier-transform mass spectrometers, Orbitraps and hybrid instruments composed of various combinations of these types of mass analyzers. These instruments can, in turn, be interfaced with a variety of other instruments that fractionate the samples (for example, liquid chromatography or solid-phase adsorption techniques based on chemical, or biological properties) and that ionize the samples for introduction into the mass spectrometer, including matrix-assisted laser desorption (MALDI), electrospray, or nanospray ionization (ESI) or combinations thereof.
(193) Generally, any mass spectrometric (MS) technique that can provide precise information on the mass of peptides, and preferably also on fragmentation and/or (partial) amino acid sequence of selected peptides (e.g., in tandem mass spectrometry, MS/MS; or in post source decay, TOF MS), can be used in the methods disclosed herein. Suitable peptide MS and MS/MS techniques and systems are well-known per se (see, e.g., Methods in Molecular Biology, vol. 146: Mass Spectrometry of Proteins and Peptides, by Chapman, ed., Humana Press 2000; Biemann 1990. Methods Enzymol 193: 455-79; or Methods in Enzymology, vol. 402: Biological Mass Spectrometry, by Burlingame, ed., Academic Press 2005) and can be used in practicing the methods disclosed herein. Accordingly, in some embodiments, the disclosed methods comprise performing quantitative MS to measure one or more biomarkers. Such quantitative methods can be performed in an automated (Villanueva, et al., Nature Protocols (2006) 1(2):880-891) or semi-automated format. In particular embodiments, MS can be operably linked to a liquid chromatography device (LC-MS/MS or LC-MS) or gas chromatography device (GC-MS or GC-MS/MS). Other methods useful in this context include isotope-coded affinity tag (ICAT), tandem mass tags (TMT), or stable isotope labeling by amino acids in cell culture (SILAC), followed by chromatography and MS/MS.
(194) As used herein, the terms multiple reaction monitoring (MRM) or selected reaction monitoring (SRM) refer to an MS-based quantification method that is particularly useful for quantifying analytes that are in low abundance. In an SRM experiment, a predefined precursor ion and one or more of its fragments are selected by the two mass filters of a triple quadrupole instrument and monitored over time for precise quantification. Multiple SRM precursor and fragment ion pairs can be measured within the same experiment on the chromatographic time scale by rapidly toggling between the different precursor/fragment pairs to perform an MRM experiment. A series of transitions (precursor/fragment ion pairs) in combination with the retention time of the targeted analyte (e.g., peptide or small molecule such as chemical entity, steroid, hormone) can constitute a definitive assay. A large number of analytes can be quantified during a single LC-MS experiment. The term scheduled, or dynamic in reference to MRM or SRM, refers to a variation of the assay wherein the transitions for a particular analyte are only acquired in a time window around the expected retention time, significantly increasing the number of analytes that can be detected and quantified in a single LC-MS experiment and contributing to the selectivity of the test, as retention time is a property dependent on the physical nature of the analyte. A single analyte can also be monitored with more than one transition. Finally, included in the assay can be standards that correspond to the analytes of interest (e.g., same amino acid sequence), but differ by the inclusion of stable isotopes. Stable isotopic standards (SIS) can be incorporated into the assay at precise levels and used to quantify the corresponding unknown analyte. An additional level of specificity is contributed by the co-elution of the unknown analyte and its corresponding SIS and properties of their transitions (e.g., the similarity in the ratio of the level of two transitions of the unknown and the ratio of the two transitions of its corresponding SIS).
(195) Mass spectrometry assays, instruments and systems suitable for biomarker peptide analysis can include, without limitation, matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS; MALDI-TOF post-source-decay (PSD); MALDI-TOF/TOF; surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF) MS; electrospray ionization mass spectrometry (ESI-MS); ESI-MS/MS; ESI-MS/(MS).sub.n (n is an integer greater than zero); ESI 3D or linear (2D) ion trap MS; ESI triple quadrupole MS; ESI quadrupole orthogonal TOF (Q-TOF); ESI Fourier transform MS systems; desorption/ionization on silicon (DIOS); secondary ion mass spectrometry (SIMS); atmospheric pressure chemical ionization mass spectrometry (APCI-MS); APCI-MS/MS; APCI-(MS).sub.n; ion mobility spectrometry (IMS); inductively coupled plasma mass spectrometry (ICP-MS) atmospheric pressure photoionization mass spectrometry (APPI-MS); APPI-MS/MS; and APPI-(MS).sub.n. Peptide ion fragmentation in tandem MS (MS/MS) arrangements can be achieved using manners established in the art, such as, e.g., collision induced dissociation (CID). As described herein, detection and quantification of biomarkers by mass spectrometry can involve multiple reaction monitoring (MRM), such as described among others by Kuhn et al. Proteomics 4: 1175-86 (2004). Scheduled multiple-reaction-monitoring (Scheduled MRM) mode acquisition during LC-MS/MS analysis enhances the sensitivity and accuracy of peptide quantitation. Anderson and Hunter, Molecular and Cellular Proteomics 5(4):573 (2006). As described herein, mass spectrometry-based assays can be advantageously combined with upstream peptide or protein separation or fractionation methods, such as for example with the chromatographic and other methods described herein below. As further described herein, shotgun quantitative proteomics can be combined with SRM/MRM-based assays for high-throughput identification and verification of prognostic biomarkers of preterm birth.
(196) A person skilled in the art will appreciate that a number of methods can be used to determine the amount of a biomarker, including mass spectrometry approaches, such as MS/MS, LC-MS/MS, multiple reaction monitoring (MRM) or SRM and product-ion monitoring (PIM) and also including antibody based methods such as immunoassays such as Western blots, enzyme-linked immunosorbant assay (ELISA), immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, and FACS. Accordingly, in some embodiments, determining the level of the at least one biomarker comprises using an immunoassay and/or mass spectrometric methods. In additional embodiments, the mass spectrometric methods are selected from MS, MS/MS, LC-MS/MS, SRM, PIM, and other such methods that are known in the art. In other embodiments, LC-MS/MS further comprises 1D LC-MS/MS, 2D LC-MS/MS or 3D LC-MS/MS. Immunoassay techniques and protocols are generally known to those skilled in the art (Price and Newman, Principles and Practice of Immunoassay, 2nd Edition, Grove's Dictionaries, 1997; and Gosling, Immunoassays: A Practical Approach, Oxford University Press, 2000.) A variety of immunoassay techniques, including competitive and non-competitive immunoassays, can be used (Self et al., Curr. Opin. Biotechnol., 7:60-65 (1996).
(197) In further embodiments, the immunoassay is selected from Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay (MA), dot blotting, and FACS. In certain embodiments, the immunoassay is an ELISA. In yet a further embodiment, the ELISA is direct ELISA (enzyme-linked immunosorbent assay), indirect ELISA, sandwich ELISA, competitive ELISA, multiplex ELISA, ELISPOT technologies, and other similar techniques known in the art. Principles of these immunoassay methods are known in the art, for example John R. Crowther, The ELISA Guidebook, 1st ed., Humana Press 2000, ISBN 0896037282. Typically ELISAs are performed with antibodies but they can be performed with any capture agents that bind specifically to one or more biomarkers of the invention and that can be detected. Multiplex ELISA allows simultaneous detection of two or more analytes within a single compartment (e.g., microplate well) usually at a plurality of array addresses (Nielsen and Geierstanger 2004. J Immunol Methods 290: 107-20 (2004) and Ling et al. 2007. Expert Rev Mol Diagn 7: 87-98 (2007)).
(198) In some embodiments, Radioimmunoassay (RIA) can be used to detect one or more biomarkers in the methods of the invention. RIA is a competition-based assay that is well known in the art and involves mixing known quantities of radioactively-labelled (e.g., .sup.125I or .sup.131I-labelled) target analyte with antibody specific for the analyte, then adding non-labeled analyte from a sample and measuring the amount of labeled analyte that is displaced (see, e.g., An Introduction to Radioimmunoassay and Related Techniques, by Chard T, ed., Elsevier Science 1995, ISBN 0444821198 for guidance).
(199) A detectable label can be used in the assays described herein for direct or indirect detection of the biomarkers in the methods of the invention. A wide variety of detectable labels can be used, with the choice of label depending on the sensitivity required, ease of conjugation with the antibody, stability requirements, and available instrumentation and disposal provisions. Those skilled in the art are familiar with selection of a suitable detectable label based on the assay detection of the biomarkers in the methods of the invention. Suitable detectable labels include, but are not limited to, fluorescent dyes (e.g., fluorescein, fluorescein isothiocyanate (FITC), Oregon Green?, rhodamine, Texas red, tetrarhodimine isothiocynate (TRITC), Cy3, Cy5, etc.), fluorescent markers (e.g., green fluorescent protein (GFP), phycoerythrin, etc.), enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, etc.), nanoparticles, biotin, digoxigenin, metals, and the like.
(200) For mass-spectrometry based analysis, differential tagging with isotopic reagents, e.g., isotope-coded affinity tags (ICAT) or the more recent variation that uses isobaric tagging reagents, iTRAQ (Applied Biosystems, Foster City, Calif.), or tandem mass tags, TMT, (Thermo Scientific, Rockford, IL), followed by multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS/MS) analysis can provide a further methodology in practicing the methods of the invention.
(201) A chemiluminescence assay using a chemiluminescent antibody can be used for sensitive, non-radioactive detection of protein levels. An antibody labeled with fluorochrome also can be suitable. Examples of fluorochromes include, without limitation, DAPI, fluorescein, Hoechst 33258, R-phycocyanin, B-phycoerythrin, R-phycoerythrin, rhodamine, Texas red, and lissamine. Indirect labels include various enzymes well known in the art, such as horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase, urease, and the like. Detection systems using suitable substrates for horseradish-peroxidase, alkaline phosphatase, and beta-galactosidase are well known in the art.
(202) A signal from the direct or indirect label can be analyzed, for example, using a spectrophotometer to detect color from a chromogenic substrate; a radiation counter to detect radiation such as a gamma counter for detection of .sup.125I; or a fluorometer to detect fluorescence in the presence of light of a certain wavelength. For detection of enzyme-linked antibodies, a quantitative analysis can be made using a spectrophotometer such as an EMAX Microplate Reader (Molecular Devices; Menlo Park, Calif.) in accordance with the manufacturer's instructions. If desired, assays used to practice the invention can be automated or performed robotically, and the signal from multiple samples can be detected simultaneously.
(203) In some embodiments, the methods described herein encompass quantification of the biomarkers using mass spectrometry (MS). In further embodiments, the mass spectrometry can be liquid chromatography-mass spectrometry (LC-MS), multiple reaction monitoring (MRM) or selected reaction monitoring (SRM). In additional embodiments, the MRM or SRM can further encompass scheduled MRM or scheduled SRM.
(204) As described above, chromatography can also be used in practicing the methods of the invention. Chromatography encompasses methods for separating chemical substances and generally involves a process in which a mixture of analytes is carried by a moving stream of liquid or gas (mobile phase) and separated into components as a result of differential distribution of the analytes as they flow around or over a stationary liquid or solid phase (stationary phase), between the mobile phase and said stationary phase. The stationary phase can be usually a finely divided solid, a sheet of filter material, or a thin film of a liquid on the surface of a solid, or the like. Chromatography is well understood by those skilled in the art as a technique applicable for the separation of chemical compounds of biological origin, such as, e.g., amino acids, proteins, fragments of proteins or peptides, etc.
(205) Chromatography can be columnar (i.e., wherein the stationary phase is deposited or packed in a column), preferably liquid chromatography, and yet more preferably high-performance liquid chromatography (HPLC), or ultra high performance/pressure liquid chromatography (UHPLC). Particulars of chromatography are well known in the art (Bidlingmeyer, Practical HPLC Methodology and Applications, John Wiley & Sons Inc., 1993). Exemplary types of chromatography include, without limitation, high-performance liquid chromatography (HPLC), UHPLC, normal phase HPLC (NP-HPLC), reversed phase HPLC (RP-HPLC), ion exchange chromatography (IEC), such as cation or anion exchange chromatography, hydrophilic interaction chromatography (HILIC), hydrophobic interaction chromatography (HIC), size exclusion chromatography (SEC) including gel filtration chromatography or gel permeation chromatography, chromatofocusing, affinity chromatography such as immuno-affinity, immobilized metal affinity chromatography, and the like. Chromatography, including single-, two- or more-dimensional chromatography, can be used as a peptide fractionation method in conjunction with a further peptide analysis method, such as for example, with a downstream mass spectrometry analysis as described elsewhere in this specification.
(206) Further peptide or polypeptide separation, identification or quantification methods can be used, optionally in conjunction with any of the above described analysis methods, for measuring biomarkers in the present disclosure. Such methods include, without limitation, chemical extraction partitioning, isoelectric focusing (IEF) including capillary isoelectric focusing (CIEF), capillary isotachophoresis (CITP), capillary electrochromatography (CEC), and the like, one-dimensional polyacrylamide gel electrophoresis (PAGE), two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), capillary gel electrophoresis (CGE), capillary zone electrophoresis (CZE), micellar electrokinetic chromatography (MEKC), free flow electrophoresis (FFE), etc.
(207) In the context of the invention, the term capture agent refers to a compound that can specifically bind to a target, in particular a biomarker. The term includes antibodies, antibody fragments, nucleic acid-based protein binding reagents (e.g. aptamers, Slow Off-rate Modified Aptamers (SOMAmer?)), protein-capture agents, natural ligands (i.e. a hormone for its receptor or vice versa), small molecules or variants thereof.
(208) Capture agents can be configured to specifically bind to a target, in particular a biomarker. Capture agents can include but are not limited to organic molecules, such as polypeptides, polynucleotides and other non polymeric molecules that are identifiable to a skilled person. In the embodiments disclosed herein, capture agents include any agent that can be used to detect, purify, isolate, or enrich a target, in particular a biomarker. Any art-known affinity capture technologies can be used to selectively isolate and enrich/concentrate biomarkers that are components of complex mixtures of biological media for use in the disclosed methods.
(209) Antibody capture agents that specifically bind to a biomarker can be prepared using any suitable methods known in the art. See, e.g., Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies: A Laboratory Manual (1988); Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986). Antibody capture agents can be any immunoglobulin or derivative thereof, whether natural or wholly or partially synthetically produced. All derivatives thereof which maintain specific binding ability are also included in the term. Antibody capture agents have a binding domain that is homologous or largely homologous to an immunoglobulin binding domain and can be derived from natural sources, or partly or wholly synthetically produced. Antibody capture agents can be monoclonal or polyclonal antibodies. In some embodiments, an antibody is a single chain antibody. Those of ordinary skill in the art will appreciate that antibodies can be provided in any of a variety of forms including, for example, humanized, partially humanized, chimeric, chimeric humanized, etc. Antibody capture agents can be antibody fragments including, but not limited to, Fab, Fab, F(ab)2, scFv, Fv, dsFv diabody, and Fd fragments. An antibody capture agent can be produced by any means. For example, an antibody capture agent can be enzymatically or chemically produced by fragmentation of an intact antibody and/or it can be recombinantly produced from a gene encoding the partial antibody sequence. An antibody capture agent can comprise a single chain antibody fragment. Alternatively or additionally, antibody capture agent can comprise multiple chains which are linked together, for example, by disulfide linkages; and, any functional fragments obtained from such molecules, wherein such fragments retain specific-binding properties of the parent antibody molecule. Because of their smaller size as functional components of the whole molecule, antibody fragments can offer advantages over intact antibodies for use in certain immunochemical techniques and experimental applications.
(210) Suitable capture agents useful for practicing the invention also include aptamers. Aptamers are oligonucleotide sequences that can bind to their targets specifically via unique three dimensional (3-D) structures. An aptamer can include any suitable number of nucleotides and different aptamers can have either the same or different numbers of nucleotides. Aptamers can be DNA or RNA or chemically modified nucleic acids and can be single stranded, double stranded, or contain double stranded regions, and can include higher ordered structures. An aptamer can also be a photoaptamer, where a photoreactive or chemically reactive functional group is included in the aptamer to allow it to be covalently linked to its corresponding target. Use of an aptamer capture agent can include the use of two or more aptamers that specifically bind the same biomarker. An aptamer can include a tag. An aptamer can be identified using any known method, including the SELEX (systematic evolution of ligands by exponential enrichment), process. Once identified, an aptamer can be prepared or synthesized in accordance with any known method, including chemical synthetic methods and enzymatic synthetic methods and used in a variety of applications for biomarker detection. Liu et al., Curr Med Chem. 18(27):4117-25 (2011). Capture agents useful in practicing the methods of the invention also include SOMAmers (Slow Off-Rate Modified Aptamers) known in the art to have improved off-rate characteristics. Brody et al., J Mol Biol. 422(5):595-606 (2012). SOMAmers can be generated using any known method, including the SELEX method.
(211) It is understood by those skilled in the art that biomarkers can be modified prior to analysis to improve their resolution or to determine their identity. For example, the biomarkers can be subject to proteolytic digestion before analysis. Any protease can be used. Proteases, such as trypsin, that are likely to cleave the biomarkers into a discrete number of fragments are particularly useful. The fragments that result from digestion function as a fingerprint for the biomarkers, thereby enabling their detection indirectly. This is particularly useful where there are biomarkers with similar molecular masses that might be confused for the biomarker in question. Also, proteolytic fragmentation is useful for high molecular weight biomarkers because smaller biomarkers are more easily resolved by mass spectrometry. In another example, biomarkers can be modified to improve detection resolution. For instance, neuraminidase can be used to remove terminal sialic acid residues from glycoproteins to improve binding to an anionic adsorbent and to improve detection resolution. In another example, the biomarkers can be modified by the attachment of a tag of particular molecular weight that specifically binds to molecular biomarkers, further distinguishing them. Optionally, after detecting such modified biomarkers, the identity of the biomarkers can be further determined by matching the physical and chemical characteristics of the modified biomarkers in a protein database (e.g., SwissProt).
(212) It is further appreciated in the art that biomarkers in a sample can be captured on a substrate for detection. Traditional substrates include antibody-coated 96-well plates or nitrocellulose membranes that are subsequently probed for the presence of the proteins. Alternatively, protein-binding molecules attached to microspheres, microparticles, microbeads, beads, or other particles can be used for capture and detection of biomarkers. The protein-binding molecules can be antibodies, peptides, peptoids, aptamers, small molecule ligands or other protein-binding capture agents attached to the surface of particles. Each protein-binding molecule can include unique detectable label that is coded such that it can be distinguished from other detectable labels attached to other protein-binding molecules to allow detection of biomarkers in multiplex assays. Examples include, but are not limited to, color-coded microspheres with known fluorescent light intensities (see e.g., microspheres with xMAP technology produced by Luminex (Austin, Tex.); microspheres containing quantum dot nanocrystals, for example, having different ratios and combinations of quantum dot colors (e.g., Qdot nanocrystals produced by Life Technologies (Carlsbad, Calif.); glass coated metal nanoparticles (see e.g., SERS nanotags produced by Nanoplex Technologies, Inc. (Mountain View, Calif.); barcode materials (see e.g., sub-micron sized striped metallic rods such as Nanobarcodes produced by Nanoplex Technologies, Inc.), encoded microparticles with colored bar codes (see e.g., CellCard produced by Vitra Bioscience, vitrabio.com), glass microparticles with digital holographic code images (see e.g., CyVera microbeads produced by Illumina (San Diego, Calif.); chemiluminescent dyes, combinations of dye compounds; and beads of detectably different sizes.
(213) In another aspect, biochips can be used for capture and detection of the biomarkers of the invention. Many protein biochips are known in the art. These include, for example, protein biochips produced by Packard BioScience Company (Meriden Conn.), Zyomyx (Hayward, Calif.) and Phylos (Lexington, Mass.). In general, protein biochips comprise a substrate having a surface. A capture reagent or adsorbent is attached to the surface of the substrate. Frequently, the surface comprises a plurality of addressable locations, each of which location has the capture agent bound there. The capture agent can be a biological molecule, such as a polypeptide or a nucleic acid, which captures other biomarkers in a specific manner. Alternatively, the capture agent can be a chromatographic material, such as an anion exchange material or a hydrophilic material. Examples of protein biochips are well known in the art.
(214) The present disclosure also provides methods for predicting the probability of pre-term birth comprising measuring a change in reversal value of a biomarker pair. For example, a biological sample can be contacted with a panel comprising one or more polynucleotide binding agents. The expression of one or more of the biomarkers detected can then be evaluated according to the methods disclosed below, e.g., with or without the use of nucleic acid amplification methods. Skilled practitioners appreciate that in the methods described herein, a measurement of gene expression can be automated. For example, a system that can carry out multiplexed measurement of gene expression can be used, e.g., providing digital readouts of the relative abundance of hundreds of mRNA species simultaneously.
(215) In some embodiments, nucleic acid amplification methods can be used to detect a polynucleotide biomarker. For example, the oligonucleotide primers and probes of the present invention can be used in amplification and detection methods that use nucleic acid substrates isolated by any of a variety of well-known and established methodologies (e.g., Sambrook et al., Molecular Cloning, A laboratory Manual, pp. 7.37-7.57 (2nd ed., 1989); Lin et al., in Diagnostic Molecular Microbiology, Principles and Applications, pp. 605-16 (Persing et al., eds. (1993); Ausubel et al., Current Protocols in Molecular Biology (2001 and subsequent updates)). Methods for amplifying nucleic acids include, but are not limited to, for example the polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR) (see e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; 4,965,188), ligase chain reaction (LCR) (see, e.g., Weiss, Science 254:1292-93 (1991)), strand displacement amplification (SDA) (see e.g., Walker et al., Proc. Natl. Acad. Sci. USA 89:392-396 (1992); U.S. Pat. Nos. 5,270,184 and 5,455,166), Thermophilic SDA (tSDA) (see e.g., European Pat. No. 0 684 315) and methods described in U.S. Pat. No. 5,130,238; Lizardi et al., BioTechnol. 6:1197-1202 (1988); Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173-77 (1989); Guatelli et al., Proc. Natl. Acad. Sci. USA 87:1874-78 (1990); U.S. Pat. Nos. 5,480,784; 5,399,491; US Publication No. 2006/46265.
(216) In some embodiments, measuring mRNA in a biological sample can be used as a surrogate for detection of the level of the corresponding protein biomarker in a biological sample. Thus, any of the biomarkers, biomarker pairs or biomarker reversal panels described herein can also be detected by detecting the appropriate RNA. Levels of mRNA can measured by reverse transcription quantitative polymerase chain reaction (RT-PCR followed with qPCR). RT-PCR is used to create a cDNA from the mRNA. The cDNA can be used in a qPCR assay to produce fluorescence as the DNA amplification process progresses. By comparison to a standard curve, qPCR can produce an absolute measurement such as number of copies of mRNA per cell. Northern blots, microarrays, Invader assays, and RT-PCR combined with capillary electrophoresis have all been used to measure expression levels of mRNA in a sample. See Gene Expression Profiling: Methods and Protocols, Richard A. Shimkets, editor, Humana Press, 2004.
(217) Some embodiments disclosed herein relate to diagnostic and prognostic methods of determining the probability for preterm birth in a pregnant female. The detection of the level of expression of one or more biomarkers and/or the determination of a ratio of biomarkers can be used to determine the probability for preterm birth in a pregnant female. Such detection methods can be used, for example, for early diagnosis of the condition, to determine whether a subject is predisposed to preterm birth, to monitor the progress of preterm birth or the progress of treatment protocols, to assess the severity of preterm birth, to forecast the outcome of preterm birth and/or prospects of recovery or birth at full term, or to aid in the determination of a suitable treatment for preterm birth.
(218) The quantitation of biomarkers in a biological sample can be determined, without limitation, by the methods described above as well as any other method known in the art. The quantitative data thus obtained is then subjected to an analytic classification process. In such a process, the raw data is manipulated according to an algorithm, where the algorithm has been pre-defined by a training set of data, for example as described in the examples provided herein. An algorithm can utilize the training set of data provided herein, or can utilize the guidelines provided herein to generate an algorithm with a different set of data.
(219) In some embodiments, analyzing a measurable feature to determine the probability for preterm birth in a pregnant female encompasses the use of a predictive model. In further embodiments, analyzing a measurable feature to determine the probability for preterm birth in a pregnant female encompasses comparing said measurable feature with a reference feature. As those skilled in the art can appreciate, such comparison can be a direct comparison to the reference feature or an indirect comparison where the reference feature has been incorporated into the predictive model. In further embodiments, analyzing a measurable feature to determine the probability for preterm birth in a pregnant female encompasses one or more of a linear discriminant analysis model, a support vector machine classification algorithm, a recursive feature elimination model, a prediction analysis of microarray model, a logistic regression model, a CART algorithm, a flex tree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, a machine learning algorithm, a penalized regression method, or a combination thereof. In particular embodiments, the analysis comprises logistic regression.
(220) An analytic classification process can use any one of a variety of statistical analytic methods to manipulate the quantitative data and provide for classification of the sample. Examples of useful methods include linear discriminant analysis, recursive feature elimination, a prediction analysis of microarray, a logistic regression, a CART algorithm, a FlexTree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, machine learning algorithms; etc.
(221) For creation of a random forest for prediction of GAB one skilled in the art can consider a set of k subjects (pregnant women) for whom the gestational age at birth (GAB) is known, and for whom N analytes (transitions) have been measured in a blood specimen taken several weeks prior to birth. A regression tree begins with a root node that contains all the subjects. The average GAB for all subjects can be calculated in the root node. The variance of the GAB within the root node will be high, because there is a mixture of women with different GAB's. The root node is then divided (partitioned) into two branches, so that each branch contains women with a similar GAB. The average GAB for subjects in each branch is again calculated. The variance of the GAB within each branch will be lower than in the root node, because the subset of women within each branch has relatively more similar GAB's than those in the root node. The two branches are created by selecting an analyte and a threshold value for the analyte that creates branches with similar GAB. The analyte and threshold value are chosen from among the set of all analytes and threshold values, usually with a random subset of the analytes at each node. The procedure continues recursively producing branches to create leaves (terminal nodes) in which the subjects have very similar GAB's. The predicted GAB in each terminal node is the average GAB for subjects in that terminal node. This procedure creates a single regression tree. A random forest can consist of several hundred or several thousand such trees.
(222) Classification can be made according to predictive modeling methods that set a threshold for determining the probability that a sample belongs to a given class. The probability preferably is at least 50%, or at least 60%, or at least 70%, or at least 80% or higher. Classifications also can be made by determining whether a comparison between an obtained dataset and a reference dataset yields a statistically significant difference. If so, then the sample from which the dataset was obtained is classified as not belonging to the reference dataset class. Conversely, if such a comparison is not statistically significantly different from the reference dataset, then the sample from which the dataset was obtained is classified as belonging to the reference dataset class.
(223) The predictive ability of a model can be evaluated according to its ability to provide a quality metric, e.g. AUROC (area under the ROC curve) or accuracy, of a particular value, or range of values. Area under the curve measures are useful for comparing the accuracy of a classifier across the complete data range. Classifiers with a greater AUC have a greater capacity to classify unknowns correctly between two groups of interest. In some embodiments, a desired quality threshold is a predictive model that will classify a sample with an accuracy of at least about 0.5, at least about 0.55, at least about 0.6, at least about 0.7, at least about 0.75, at least about 0.8, at least about 0.85, at least about 0.9, at least about 0.95, or higher. As an alternative measure, a desired quality threshold can refer to a predictive model that will classify a sample with an AUC of at least about 0.7, at least about 0.75, at least about 0.8, at least about 0.85, at least about 0.9, or higher.
(224) As is known in the art, the relative sensitivity and specificity of a predictive model can be adjusted to favor either the selectivity metric or the sensitivity metric, where the two metrics have an inverse relationship. The limits in a model as described above can be adjusted to provide a selected sensitivity or specificity level, depending on the particular requirements of the test being performed. One or both of sensitivity and specificity can be at least about 0.7, at least about 0.75, at least about 0.8, at least about 0.85, at least about 0.9, or higher.
(225) The raw data can be initially analyzed by measuring the values for each biomarker, usually in triplicate or in multiple triplicates. The data can be manipulated, for example, raw data can be transformed using standard curves, and the average of triplicate measurements used to calculate the average and standard deviation for each patient. These values can be transformed before being used in the models, e.g. log-transformed, Box-Cox transformed (Box and Cox, Royal Stat. Soc., Series B, 26:211-246(1964). The data are then input into a predictive model, which will classify the sample according to the state. The resulting information can be communicated to a patient or health care provider.
(226) To generate a predictive model for preterm birth, a robust data set, comprising known control samples and samples corresponding to the preterm birth classification of interest is used in a training set. A sample size can be selected using generally accepted criteria. As discussed above, different statistical methods can be used to obtain a highly accurate predictive model. Examples of such analysis are provided in Example 2.
(227) In one embodiment, hierarchical clustering is performed in the derivation of a predictive model, where the Pearson correlation is employed as the clustering metric. One approach is to consider a preterm birth dataset as a learning sample in a problem of supervised learning. CART is a standard in applications to medicine (Singer, Recursive Partitioning in the Health Sciences, Springer (1999)) and can be modified by transforming any qualitative features to quantitative features; sorting them by attained significance levels, evaluated by sample reuse methods for Hotelling's T.sup.2 statistic; and suitable application of the lasso method. Problems in prediction are turned into problems in regression without losing sight of prediction, indeed by making suitable use of the Gini criterion for classification in evaluating the quality of regressions.
(228) This approach led to what is termed FlexTree (Huang, Proc. Nat. Acad. Sci. U.S.A 101:10529-10534(2004)). FlexTree performs very well in simulations and when applied to multiple forms of data and is useful for practicing the claimed methods. Software automating FlexTree has been developed. Alternatively, LARTree or LART can be used (Turnbull (2005) Classification Trees with Subset Analysis Selection by the Lasso, Stanford University). The name reflects binary trees, as in CART and FlexTree; the lasso, as has been noted; and the implementation of the lasso through what is termed LARS by Efron et al. (2004) Annals of Statistics 32:407-451 (2004). See, also, Huang et al., Proc. Natl. Acad. Sci. USA. 101(29):10529-34 (2004). Other methods of analysis that can be used include logic regression. One method of logic regression Ruczinski, Journal of Computational and Graphical Statistics 12:475-512 (2003). Logic regression resembles CART in that its classifier can be displayed as a binary tree. It is different in that each node has Boolean statements about features that are more general than the simple and statements produced by CART.
(229) Another approach is that of nearest shrunken centroids (Tibshirani, Proc. Natl. Acad. Sci. U.S.A 99:6567-72(2002)). The technology is k-means-like, but has the advantage that by shrinking cluster centers, one automatically selects features, as is the case in the lasso, to focus attention on small numbers of those that are informative. The approach is available as PAM software and is widely used. Two further sets of algorithms that can be used are random forests (Breiman, Machine Learning 45:5-32 (2001)) and MART (Hastie, The Elements of Statistical Learning, Springer (2001)). These two methods are known in the art as committee methods, that involve predictors that vote on outcome.
(230) To provide significance ordering, the false discovery rate (FDR) can be determined. First, a set of null distributions of dissimilarity values is generated. In one embodiment, the values of observed profiles are permuted to create a sequence of distributions of correlation coefficients obtained out of chance, thereby creating an appropriate set of null distributions of correlation coefficients (Tusher et al., Proc. Natl. Acad. Sci. U.S.A 98, 5116-21 (2001)). The set of null distribution is obtained by: permuting the values of each profile for all available profiles; calculating the pair-wise correlation coefficients for all profile; calculating the probability density function of the correlation coefficients for this permutation; and repeating the procedure for N times, where N is a large number, usually 300. Using the N distributions, one calculates an appropriate measure (mean, median, etc.) of the count of correlation coefficient values that their values exceed the value (of similarity) that is obtained from the distribution of experimentally observed similarity values at given significance level.
(231) The FDR is the ratio of the number of the expected falsely significant correlations (estimated from the correlations greater than this selected Pearson correlation in the set of randomized data) to the number of correlations greater than this selected Pearson correlation in the empirical data (significant correlations). This cut-off correlation value can be applied to the correlations between experimental profiles. Using the aforementioned distribution, a level of confidence is chosen for significance. This is used to determine the lowest value of the correlation coefficient that exceeds the result that would have obtained by chance. Using this method, one obtains thresholds for positive correlation, negative correlation or both. Using this threshold(s), the user can filter the observed values of the pair wise correlation coefficients and eliminate those that do not exceed the threshold(s). Furthermore, an estimate of the false positive rate can be obtained for a given threshold. For each of the individual random correlation distributions, one can find how many observations fall outside the threshold range. This procedure provides a sequence of counts. The mean and the standard deviation of the sequence provide the average number of potential false positives and its standard deviation.
(232) In an alternative analytical approach, variables chosen in the cross-sectional analysis are separately employed as predictors in a time-to-event analysis (survival analysis), where the event is the occurrence of preterm birth, and subjects with no event are considered censored at the time of giving birth. Given the specific pregnancy outcome (preterm birth event or no event), the random lengths of time each patient will be observed, and selection of proteomic and other features, a parametric approach to analyzing survival can be better than the widely applied semi-parametric Cox model. A Weibull parametric fit of survival permits the hazard rate to be monotonically increasing, decreasing, or constant, and also has a proportional hazards representation (as does the Cox model) and an accelerated failure-time representation. All the standard tools available in obtaining approximate maximum likelihood estimators of regression coefficients and corresponding functions are available with this model.
(233) In addition the Cox models can be used, especially since reductions of numbers of covariates to manageable size with the lasso will significantly simplify the analysis, allowing the possibility of a nonparametric or semi-parametric approach to prediction of time to preterm birth. These statistical tools are known in the art and applicable to all manner of proteomic data. A set of biomarker, clinical and genetic data that can be easily determined, and that is highly informative regarding the probability for preterm birth and predicted time to a preterm birth event in said pregnant female is provided. Also, algorithms provide information regarding the probability for preterm birth in the pregnant female.
(234) Accordingly, one skilled in the art understands that the probability for preterm birth according to the invention can be determined using either a quantitative or a categorical variable. For example, in practicing the methods of the invention the measurable feature of each of N biomarkers can be subjected to categorical data analysis to determine the probability for preterm birth as a binary categorical outcome. Alternatively, the methods of the invention may analyze the measurable feature of each of N biomarkers by initially calculating quantitative variables, in particular, predicted gestational age at birth. The predicted gestational age at birth can subsequently be used as a basis to predict risk of preterm birth. By initially using a quantitative variable and subsequently converting the quantitative variable into a categorical variable the methods of the invention take into account the continuum of measurements detected for the measurable features. For example, by predicting the gestational age at birth rather than making a binary prediction of preterm birth versus term birth, it is possible to tailor the treatment for the pregnant female. For example, an earlier predicted gestational age at birth will result in more intensive prenatal intervention, i.e. monitoring and treatment, than a predicted gestational age that approaches full term.
(235) Among women with a predicted GAB of j days plus or minus k days, p(PTB) can estimated as the proportion of women in the PAPR clinical trial (see Example 1) with a predicted GAB of j days plus or minus k days who actually deliver before 37 weeks gestational age. More generally, for women with a predicted GAB of j days plus or minus k days, the probability that the actual gestational age at birth will be less than a specified gestational age, p(actual GAB<specified GAB), was estimated as the proportion of women in the PAPR clinical trial with a predicted GAB of j days plus or minus k days who actually deliver before the specified gestational age.
(236) In the development of a predictive model, it can be desirable to select a subset of markers, i.e. at least 3, at least 4, at least 5, at least 6, up to the complete set of markers. Usually a subset of markers will be chosen that provides for the needs of the quantitative sample analysis, e.g. availability of reagents, convenience of quantitation, etc., while maintaining a highly accurate predictive model. The selection of a number of informative markers for building classification models requires the definition of a performance metric and a user-defined threshold for producing a model with useful predictive ability based on this metric. For example, the performance metric can be the AUC, the sensitivity and/or specificity of the prediction as well as the overall accuracy of the prediction model.
(237) As will be understood by those skilled in the art, an analytic classification process can use any one of a variety of statistical analytic methods to manipulate the quantitative data and provide for classification of the sample. Examples of useful methods include, without limitation, linear discriminant analysis, recursive feature elimination, a prediction analysis of microarray, a logistic regression, a CART algorithm, a FlexTree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, and machine learning algorithms. Various methods are used in a training model. The selection of a subset of markers can be for a forward selection or a backward selection of a marker subset. The number of markers can be selected that will optimize the performance of a model without the use of all the markers. One way to define the optimum number of terms is to choose the number of terms that produce a model with desired predictive ability (e.g. an AUC>0.75, or equivalent measures of sensitivity/specificity) that lies no more than one standard error from the maximum value obtained for this metric using any combination and number of terms used for the given algorithm.
(238) In yet another aspect, the invention provides kits for determining probability of preterm birth. The kit can include one or more agents for detection of biomarkers, a container for holding a biological sample isolated from a pregnant female; and printed instructions for reacting agents with the biological sample or a portion of the biological sample to detect the presence or amount of the isolated biomarkers in the biological sample. The agents can be packaged in separate containers. The kit can further comprise one or more control reference samples and reagents for performing an immunoassay.
(239) The kit can comprise one or more containers for compositions contained in the kit. Compositions can be in liquid form or can be lyophilized. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. The kit can also comprise a package insert containing written instructions for methods of determining probability of preterm birth.
(240) From the foregoing description, it will be apparent that variations and modifications can be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
(241) The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
(242) All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
(243) The following examples are provided by way of illustration, not limitation.
EXAMPLES
Example 1. Development of Sample Set for Discovery and Validation of Biomarkers for Preterm Birth
(244) A standard protocol was developed governing conduct of the Proteomic Assessment of Preterm Risk (PAPR) clinical study. Specimens were obtained from women at 11 Institutional Review Board (IRB) approved sites across the United States. After providing informed consent, serum and plasma samples were obtained, as well as pertinent information regarding the patient's demographic characteristics, past medical and pregnancy history, current pregnancy history and concurrent medications. Following delivery, data were collected relating to maternal and infant conditions and complications. Serum and plasma samples were processed according to a protocol that requires standardized refrigerated centrifugation, aliquoting of the samples into 2-D bar-coded cryovials and subsequent freezing at ?80? C.
(245) Following delivery, preterm birth cases were individually reviewed to determine their status as either a spontaneous preterm birth or a medically indicated preterm birth. Only spontaneous preterm birth cases were used for this analysis. For discovery of biomarkers of preterm birth, serum samples from 86 preterm cases and 172 controls were analyzed covering gestational ages at blood draw (GABD) of 17 weeks and 0 days (17.0) to 28 weeks and 6 days (28.6). A separate sample set was also analyzed for purposes of verification and was composed of serum from 50 preterm cases and 100 controls, across the same gestational age range. The two controls for each case were matched by GABD and selected from several randomly generated panels of controls that matched the distribution of births reported in the 2012 National Vital Statistics Report. A protocol was instituted to ensure that laboratory staff were blinded to gestation age at birth and case vs control status of subjects used for both sample sets. Informatics staff were also blinded to the verification sample set until analytical analysis of samples was complete.
(246) Serum samples were depleted of high abundance proteins using the Human 14 Multiple Affinity Removal System (MARS 14), which removes 14 of the most abundant proteins that are treated as uninformative with regard to the identification for disease-relevant changes in the serum proteome. To this end, equal volumes (50 ?l) of each clinical, pooled human serum sample (HGS) sample, or a human pooled pregnant women serum sample (pHGS) were diluted with 150 ?l Agilent column buffer A and filtered on a Captiva filter plate to remove precipitates. Filtered samples were depleted using a MARS-14 column (4.6?100 mm, Cat. #5188-6558, Agilent Technologies), according to manufacturer's protocol. Samples were chilled to 4? C. in the autosampler, the depletion column was run at room temperature, and collected fractions were kept at 4? C. until further analysis. The unbound fractions were collected for further analysis.
(247) Depleted serum samples were, reduced with dithiothreitol, alkylated using iodoacetamide, and then digested with 5.0 ?g Trypsin Gold-Mass Spec Grade (Promega) at 37? C. for 17 hours(?1 hour). Following trypsin digestion, a mixture of 187 Stable Isotope Standard (SIS) peptides were added to the samples and half of each sample was desalted on an Empore C18 96-well Solid Phase Extraction Plate (3M Bioanalytical Technologies). The plate was conditioned according to the manufacture's protocol. Peptides were washed with 300 ?l 1.5% trifluoroacetic acid, 2% acetonitrile, eluted with 250 ?l 1.5% trifluoroacetic acid, 95% acetonitrile, frozen at ?80? C. for 30 minutes, and then lyophilized to dryness. Lyophilized peptides were reconstituted with 2% acetontile/0.1% formic acid containing three non-human internal standard (IS) peptides. Peptides were separated with a 30 min acetonitrile gradient at 400 ?l/min on an Agilent Poroshell 120 EC-C18 column (2.1?100 mm, 2.7 ?m) at 40? C. and injected into an Agilent 6490 Triple Quadrapole mass spectrometer.
(248) Depleted and trypsin digested samples were analyzed using a scheduled Multiple Reaction Monitoring method (sMRM). The sMRM assay monitored 898 transitions that measured 259 biological peptides and 190 IS peptides (187 SIS+3 IS), representing 148 proteins. Chromatographic peaks were integrated using Mass Hunter Quantitative Analysis software (Agilent Technologies).
(249) Data Analysis
(250) Analysis of discovery and verification sample data was performed in two phases. In the first phase robust biomarkers were identified by selection using the discovery samples and confirmation using the independent verification sample set. In the second phase the discovery and verification data were combined and used to identify best analytes and panels of analytes for classifier development.
(251) Phase I: Blinded Analysis
(252) Initial classifier development focused on gestational ages 17.0 to 25.6. Using discovery samples a set of peptides corresponding to 62 proteins were selected based on preanalytic and analytic criteria. Analyte diagnostic performance was assessed in a series of narrow GABD windows that span three weeks with two weeks of overlap between adjacent windows. Based on consistency in diagnostic performance (up and down regulation in cases vs controls across GABD), a subset of 43 analytes was selected for further analysis.
(253) For each narrow GABD window a set of reversals was formed using all the combinations of up and down regulated analytes within the narrow window. A reversal value is the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal. Out of all the possible reversals within a narrow window, a subset was selected based on their individual univariate performance (AUC>=0.6).
(254) For each window reversal panels of varying sizes were formed (sizes of 2, 3, 4, 6, 8). For each panel size within a window, a Monte Carlo Cross Validation (MCCV) was performed by training and testing a logistic classifier iteratively 1,000 times on 70% and 30% of the samples, respectively. A panel size of 4, determined to be optimal by mean MCCV AUC, was subsequently used for identification of candidate reversals that perform well on panels. Candidate reversals were identified by frequency of occurrence on top performing logistic classifiers of panels of size 4 in MCCV analysis. For each window, three sets of reversal frequency tables were created using performance measures of either AUC, or partial AUC (pAUC) for sensitivity ranging from 0.7 to 1, or correlation of the classifier output score to time to birth value (TTB) (difference in days between GABD and gestational age at birth). From each of these reversal lists, the top 15 reversals were selected for further analysis.
(255) For each GABD narrow window, reversal panels of size 2, 3, 4 were formed from each of the three lists (AUC, pAUC, and TTB) and based on the performance of a MCCV analysis, the top 15 panels for each panel size in each window were selected. Along with the top 15 reversals from each of the three lists (AUC, pAUC, and TTB) for each window, these top 15 panels of size 2, 3, 4, were used to train logistic classifiers on the discovery samples and the classification scores were generated for verification samples in a blinded fashion.
(256) A third party statistician assessed the performance of all reversals and classifier panels and the AUC, pAUC for ROC curves and the TTB correlation of the classifier scores were reported.
(257) Phase II: Unblinded Analysis
(258) Following unblinding, discovery and verification data sets were combined and reanalyzed. Because the expression of diagnostic proteins may change across pregnancy we examined the levels of proteins as a function of GABD. A median smoothing window of +/?10 days was applied to generate the kinetic plots. Relative levels of proteins were expressed as the ratio of the endogenous peptide peak area over its corresponding SIS standard (relative ratio). Examples of proteins with levels that increase in pregnancy but are not different in PTB cases and controls are shown in
(259) Reversal selection and classifier development in the combined discovery and verification data set mirrored earlier studies. We focused on the 3rd overlapping GABD window (Days 133-153) to exemplify analysis. MCCV analysis was performed to identify candidate reversals. To assess performance of panels, reversal values were combined in a simple LogSum classifier. The LogSum classifier assigns a score to each sample based on the sum of the logs of each reversal's relative ratio value for that sample. The lack of coefficients in a classifier of this type helps to avoid problems of overfitting. Anyone skilled in the art can derive an equivalent logistic classifier using the same analytes with well-established techniques. Multivariate performance of a panel of three top reversals formed from four proteins is shown as a histogram of AUC values obtained by cross validation and in ROC curves in
(260) We determined proteins and/or reversals, exemplified here by using ITIH4/CSH, that are strong predictors of time to birth (TTB) (
Example 2. Validation of the IBP4/SHBG sPTB Predictor
(261) This example demonstrates validation of the IBP4/SHBG sPTB predictor identified in a large maternal serum proteomics effort in asymptomatic women early in pregnancy.
(262) Subjects
(263) The Proteomic Assessment of Preterm Risk (PAPR) study was conducted under a standardized protocol at eleven Institutional Review Board (IRB)-approved sites across the U.S. (Clinicaltrials.gov identifier: NCT01371019). Subjects were enrolled between 17 0/7 and 28 6/7 weeks GA. Dating was established using a predefined protocol of menstrual dating confirmed by early ultrasound biometry, or ultrasound alone, to provide the best clinically estimated gestational age. Body mass index (BMI) was derived from height and pre-pregnancy self-reported weight. Pregnancies with multiple gestations and with known or suspected major fetal anomalies were excluded. Pertinent information regarding subject demographic characteristics, past medical and pregnancy history, current pregnancy history and concurrent medications was collected and entered into an electronic case report form. Following delivery, data were collected for maternal and infant outcomes and complications. All deliveries were adjudicated as term (?37 0/7 weeks GA), spontaneous preterm (including preterm premature rupture of membranes) or medically indicated preterm births. As indicated, discrepancies were clarified with the Principal Investigator at the study site. Adjudication was completed and the data locked prior to validation studies.
(264) Sample Collection
(265) Maternal blood was collected and processed as follows: a 10 minute room temperature clotting period, followed by immediate refrigerated centrifugation or placement on an ice water bath at 4-8? C. until centrifugation. Blood was centrifuged within 2.5 hours of collection and 0.5 ml serum aliquots were stored at ?80? C. until analyzed.
(266) Predictor Development Principles
(267) Development of the IBP4/SHBG predictor included independent and sequential discovery, verification and validation steps consistent with Institute of Medicine (TOM) guidelines for best practices in omics research. IOM (Institute of Medicine). Evolution of Translation Omics: Lessons Learned and the Path Forward. (Micheel C M, Nass S J, Omenn GS, eds.). Washington, D.C.: The National Academies Press.; 2012:1-355. Analytical validation preceded clinical validation sample analysis and included assessment of inter- and intra-batch precision, carryover and limit of detection.
(268) The validation nested case/control analysis was performed on prespecified sPTB cases and control specimens independent of discovery and verification. sPTB cases included samples from nine sites in total, with two sites being unique to validation. Validation cases and controls underwent 100% on-site source document verification with each subject's medical record prior to mass spectrometry (MS) serum analysis. This process ensured that all subjects satisfied the inclusion and exclusion criteria, as well as confirmed medical/pregnancy complications and GA at birth assignments for all subjects at time of sample collection and delivery. Detailed analysis protocols, including the validation study design, analysis plan and a blinding protocol were pre-established. Personnel were blinded to subject case, control and GA at birth data assignments with the exception of the Director of Clinical Operations (DCO) and Clinical Data Manager. The data analysis plan included prespecified validation claims and a protocol for double independent external analyses. Predictor scores, calculated as described below, were determined for all subject samples by a blinded statistician. Case, control and GA data, linked to the predictor scores by the DCO, were subjected to independent external statistical analysis. Area under the receiver operating characteristic curve (AUROC) and significance testing results were then transferred back to the DCO. Transfer of data incorporated the use of the SUMPRODUCT function (Microsoft. Microsoft Excel. 2013) to ensure maintenance of data integrity. To provide an audit trail of data from each subject through to validation results, real-time digital time-stamping was applied to analytical data, plans and reports.
(269) Validation Study Design
(270) In the primary analysis, sPTB cases were defined as subjects with deliveries due to preterm premature rupture of the membranes (PPROM) or spontaneous onset of labor <37 0/7 weeks GA. Controls were subjects who delivered at ?37 0/7 weeks GA. Prior discovery and verification analyses investigated 44 candidate biomarkers using serum samples collected across broad gestational age (17 0/7 through 25 6/7 weeks GA) (Supplementary Material). Discovery and verification identified an optimal narrow GA at blood draw interval (19 0/7 through 21 6/7 weeks) and two proteins, IBP4 and SHBG, used in a ratio (IBP4/SHBG) as the best predictor by AUROC for sPTB (Supplementary Material). In discovery and verification, subjects without extreme BMI values had improved classification performance by IBP4/SHBG (Supplementary Results). Following discovery and verification analyses, we proceeded to analytical and clinical validation.
(271) Validation sPTB cases totaled 18 subjects collected between 19 0/7 through 21 6/7 weeks GA at blood draw (GABD), from a total available of 81 subjects across 17 0/7 through 28 6/7 weeks GA. Sets of controls, comprising two controls per sPTB case matched by GABD, were randomly selected using R Statistical program (R 3.0.2) (Team R C. R: a Language and Environment for Statistical Computing. Vienna, Austria; 2014. 2015; Matei A, Tin? Y. The R sampling package. European Conference on Quality in Survey Statistics. 2006) and compared to the term delivery distribution as outlined in the 2012 National Vital Statistics Report (Martin J A, Hamilton B E, Osterman M J, Curtin S C, Mathews T J. Births: Final Data for 2012. National Vital Statistics Reports. 2014; 63(09):1-86) using Chi-Square test. Randomly created control sets (in groups of 10) were examined for sets yielding a p-value approaching 1.0.
(272) The primary objective was to validate the performance of the IBP4/SHBG ratio as a predictor for sPTB using AUROC (Team R C. R: a Language and Environment for Statistical Computing. Vienna, Austria; 2014. 2015; Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005; 21(20):7881). To control the overall multiple testing error rate (?=0.05), the fixed sequence approach (Dmitrienko A, Tamhane A C, Bretz F, eds. Multiple Testing Problems in Pharmaceutical Statistics. Boca Raton, Florida: CRC Press; 2009:1-320; Dmitrienko A, D'Agostino R B, Huque M F. Key multiplicity issues in clinical drug development. Stat Med. 2012; 32(7):1079-111. doi:10.1002/sim.5642.) was applied to GABD increments within the optimal interval (19 0/7 through 21 6/7 weeks GA) identified in discovery and verification with and without the application of a BMI stratification (see Supplementary Material). Significance was assessed by the Wilcoxon-Mann-Whitney statistic that tests equivalence to AUROC=0.5 (random chance). (Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. Journal of mathematical psychology. 1975; 12(4):387-415. doi:10.1016/0022-2496(75)90001-2; Mason S J, Graham N E. Areas beneath the relative operating characteristics (ROC) and relative operating levels (ROL) curves: Statistical significance and interpretation. QJR Meteorol Soc. 2002; 128(584):2145-2166. doi:10.1256/003590002320603584.) For determinations of classification performance at GA boundaries other than <37 0/7 vs. ?37 0/7 weeks GA (e.g. <36 0/7 vs. ?36 0/7, <35 0/7 vs. ?35 0/7), cases and controls were redefined as all subjects below and equal to/above the specific boundary, respectively.
(273) Laboratory Methods
(274) A systems biology approach was employed to generate a highly multiplexed multiple reaction monitoring (MRM) MS assay (Supplementary Methods and Results). The validation assay quantified proteotypic peptides specific to predictor proteins IBP4 and SHBG and other controls. Samples were processed in batches of 32, which were comprised of clinical subjects (24), pooled serum standards from healthy non-pregnant donors (HGS)(3), pooled serum standards from healthy pregnant donors (pHGS)(3) and phosphate buffered saline that served as process controls (2). For all analyses, serum samples were first depleted of high abundance and non-diagnostic proteins using MARS-14 immuno-depletion columns (Agilent Technologies), reduced with dithiothreitol, alkylated with iodoacetamide, and digested with trypsin. Heavy-labeled stable isotope standard (SIS) peptides were then added to samples, which were subsequently desalted and analyzed by reversed-phase liquid chromatography (LC)/MRM-MS. SIS peptides were used for normalization by generating response ratios (RR), where the peak area of a peptide fragment ion (i.e. transition) measured in serum was divided by that of the corresponding SIS transition spiked into the same serum sample.
(275) The IBP4/SHBG Predictor
(276) The predictor score was defined as the natural log of the ratio of the IBP4 and SHBG peptide transition response ratios:
(277)
(278) where RR are the measured response ratios of the respective peptides.
(279) Results
(280)
(281) Validation Analysis
(282) In discovery and verification analyses the ratio of IBP4/SHBG and the interval between 19 0/7 through 21 6/7 weeks GA was identified as the best performing sPTB predictor by AUROC and GA interval, respectively (Supplementary Results, below). For validation, a predefined fixed sequence approach validated the IBP4/SHBG predictor with and without BMI stratification, with optimal performance identified for the GA interval of 19 1/7 through 20 6/7 weeks. Without taking BMI into consideration, validated performance was AUROC=0.67 (p=0.02) (Supplementary Results). However, as expected, performance was improved with a BMI stratification of >22 and ?37 kg/m.sup.2 which corresponded to an AUROC of 0.75 (p=0.016, 95% CI 0.56-0.91) (
(283) The prevalence adjusted positive predictive value (PPV), a measure of clinical risk, is shown as a function of predictor score in
(284) Post Validation Analyses
(285) Predictor performance was measured using a combination of subjects from the blinded verification (Supplementary data, below) and validation analyses within the optimal BMI and GA interval. The ROC curve for the combined sample set is shown and corresponds to an AUROC of 0.72 (p=0.013) (
(286) Using an 'omics approach we developed a maternal serum predictor comprised of the ratio of IBP4/SHBG levels at 19-20 weeks with a BMI interval of >22 and ?37 kg/m2 that identified 75% of women destined for sPTB. Prior history of sPTB (Goldenberg et al., Epidemiology and causes of preterm birth. Lancet. 2008; 371(9606):75-84. doi:10.1016/50140-6736(08)60074-4, Petrini et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005; 105(2):267-272) and cervical length measurements (Jams et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med. 1996; 334(9):567-72; Hassan et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011; 38(1):18-31) are considered the best measures of clinical risk to date; however, either individually or in combination they fail to predict the majority of sPTBs.
(287) An ideal sPTB prediction tool would be minimally invasive, performed early in gestation coinciding with timing of routine obstetrical visits, and would accurately identify those at highest risk. Current 'omics studies suggest that perturbations in the physiological state of pregnancy can be detected in maternal serum analytes measured in sPTB subjects. 'Omics discovery studies in PTB have included proteomic (Gravett et al. Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J Proteome Res. 2007; 6(1):89-96; Goldenberg et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health. 1998; 88(2):233-8; Gravett et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA. 2004; 292(4):462-469; Pereira et al. Insights into the multifactorial nature of preterm birth: proteomic profiling of the maternal serum glycoproteome and maternal serum peptidome among women in preterm labor. Am J Obstet Gynecol. 2010; 202(6):555.e1-10; 32. Pereira et al. Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. J Proteome Res. 2007; 6(4):1269-76; Dasari et al. Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res. 2007; 6(4):1258-1268; Esplin et al. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2010; 204(5):391.e1-8), transcriptomic (Weiner et al. Human effector/initiator gene sets that regulate myometrial contractility during term and preterm labor. Am J Obstet Gynecol. 2010; 202(5):474.e1-20; Chim et al. Systematic identification of spontaneous preterm birth-associated RNA transcripts in maternal plasma. PLoS ONE. 2012; 7(4):e34328. Enquobahrie et al. Early pregnancy peripheral blood gene expression and risk of preterm delivery: a nested case control study. BMC Pregnancy Childbirth. 2009; 9(1):56), genomic (Bezold et al. The genomics of preterm birth: from animal models to human studies. Genome Med. 2013; 5(4):34; Romero et al. Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol. 2010; 202(5):431.e1-34; Swaggart et al. Genomics of preterm birth. Cold Spring Harb Perspect Med. 2015; 5(2):a023127; Haataja et al. Mapping a new spontaneous preterm birth susceptibility gene, IGF1R, using linkage, haplotype sharing, and association analysis. PLoS Genet. 2011; 7(2):e1001293; McElroy et al. Maternal coding variants in complement receptor 1 and spontaneous idiopathic preterm birth. Hum Genet. 2013; 132(8):935-42), and metabolomic (Menon et al. Amniotic fluid metabolomic analysis in spontaneous preterm birth. Reprod Sci. 2014; 21(6):791-803) approaches. However, to date none of these approaches have produced validated testing methods to reliably predict the risk of sPTB in asymptomatic women.
(288) The current invention is the result of a large prospective and contemporaneous clinical study that allowed independent discovery, verification and validation analyses, while adhering to TOM guidelines regarding omics' test development. It involved construction of a large and standardized multiplexed proteomic assay to probe biological pathways of relevance in pregnancy. The study size and relatively broad blood collection window (17 0/7 through 28 6/7 weeks GA) also enabled the identification of a GA interval where there were marked alterations in protein concentrations between sPTB cases and term controls. Use of a low complexity predictor model (i.e. the ratio of two proteins) limited the pitfalls of overfitting.
(289) Application of the proteomic assay and model building led to the identification of a pair of critical proteins (IBP4 and SHBG) with consistently good predictive performance for sPTB. Despite the challenges of building a classifier for a condition attributed to multiple etiologies, the predictor demonstrated good performance at a cutoff of <37 0/7 vs. ?37 0/7 weeks GA with an AUROC of 0.75. Importantly, accuracy of the predictor improves for earlier sPTBs (e.g. <35 0/7 weeks GA), enabling the detection of those sPTBs with the greatest potential for morbidity. Subjects determined to be at high risk for sPTB using the IBP4/SHBG predictor delivered significantly earlier than subjects identified as low risk. Our findings suggest that IBP4 and SHBG may perform important functions related to the etiologies of sPTB and/or act as convergence points in relevant biological pathways.
(290) Universal transvaginal ultrasound (TVU) measurement of cervical length (CL) was not performed routinely at the majority of our study centers and was available for less than 1/3 of study subjects. It will be of interest to assess whether CL measurements improve upon the proteomic predictor in future studies or alternatively, if risk stratification by the IBP4/SHBG classifier identifies women that benefit most from serial CL measurements. Finally it will be intriguing to investigate the performance of the molecular predictor together with a BMI variable, or perhaps in combination with other medical/pregnancy history and sociodemographic characteristics.
(291) In conclusion, a predefined predictive test for sPTB based on serum measurements of IBP4 and SHBG in asymptomatic parous and nulliparous women was validated in a completely independent set of subjects. Further functional studies on these proteins, their gene regulation and related pathways may help to elucidate the molecular and physiological underpinnings of sPTB. Application of this predictor should enable early and sensitive detection of women at risk of sPTB. This may improve pregnancy outcomes through increased clinical surveillance as well as to accelerate the development of clinical interventions for PTB prevention.
(292) Supplementary Materials and Methods
(293) Discovery and Verification Subjects
(294) Discovery and verification subjects were derived from the PAPR study described above in this Example.
(295) Discovery and Verification Principles
(296) sPTB cases were defined as described above in this Example. Discovery and verification of the predictor was conducted according to guidelines for best practices in omics research. (IOM (Institute of Medicine). Evolution of Translation Omics: Lessons Learned and the Path Forward. (Micheel C M, Nass S J, Omenn G S, eds.). Washington, DC: The National Academies Press.; 2012:1-355). Nested case/control analyses used sample sets completely independent of each other. Cases and controls selected for discovery and verification underwent central review for within-subject data discrepancies; no source document verification (SDV) with the medical record was performed. All sPTB cases and controls for discovery and verification were individually adjudicated by the Chief Medical Officer and discrepancies were clarified with the PI at the clinical site. Detailed analysis protocols, including study designs, analysis plans and a verification blinding protocol were pre-established. Laboratory and data analysis personnel were blinded to verification subject's case, control and GA data assignments. Predictor scores, calculated as described below, were assigned to all subjects by an internal blinded statistician. Case, control and GA data, linked to the predictor scores by the DCO, were provided to an independent external statistician for analysis. AUROC results were then transferred back to the DCO. Transfer of data utilized a SUMPRODUCT (Microsoft. Microsoft Excel. 2013) function in Excel to ensure maintenance of data integrity. To provide an audit trail of data from subjects through to verification results, digital timestamping was applied to analytical data, plans and reports.
(297) Discovery and Verification Study Design
(298) Discovery and verification sPTB cases totaled 86 and 50 subjects, respectively, collected across 17 0/7 through 28 6/7 weeks GA at blood draw (GABD). Subjects used in discovery and verification were completely independent of each other and independent from those used in validation. Matched controls were identified for sPTB cases in discovery and verification as described above in this Example.
(299) Prevalence Analyses
(300) Following discovery, verification and validation analyses, additional term controls, not used in prior studies, were selected from the PAPR database and processed in the laboratory using the MRM-MS assay applied in validation and described above in this Example. Using the Sampling package in R Statistical software (version 3.0.3) (Team R C. R: a Language and Environment for Statistical Computing. Vienna, Austria; 2014. 2015; Matei A, Till? Y. The R sampling package. European Conference on Quality in Survey Statistics. 2006), sets of 187 subjects were randomly selected from the validated GA blood draw interval and compared via univariate statistical analyses (Chi-Square Test) against the gestational age at birth (GAB) data from the 2012 National Vital Statistics Report (NVSR). Martin et al.: Final Data for 2012. National Vital Statistics Reports. 2014; 63(09):1-86 Sets of controls most closely approximating the distribution of deliveries in the 2012 NVSR based on the best p value (approaching 1.0 with minimum acceptable value of 0.950) were then selected for comparison against the BMI distribution in the PAPR study as a whole. Using univariate statistical analyses (Chi-Square Test) against the BMI data from the PAPR study database, the sets of controls most closely approximating the distribution of BMI (approaching 1.0 with minimum acceptable value of 0.950) and the distribution of delivery timing in the NVSR were selected and compared to the GABD of the validated blood draw samples. The set that most closely approximated all three distributions was selected as the subject set for the Prevalence Study. Predictor score values for verification, validation and prevalence within the validation GABD interval and BMI restriction totaled 150 subjects. This composite dataset was used to obtain the best estimates of confidence intervals about the PPV curve in
(301) Laboratory Methods
(302) A systems biology approach was employed to generate a highly multiplexed multiple reaction monitoring (MRM) mass spectrometry (MS) assay by iterative application of: literature curation, targeted and un-targeted proteomic discovery and small scale MRM-MS analyses of subject samples. The mature MRM-MS assay, measuring 147 proteins, was applied in discovery and verification studies. For all analyses, serum samples were processed in the laboratory as described above in this Example. Aliquots of pooled serum controls (pHGS) were used to calculate the inter-batch analytical coefficient of variation (CV) for IBP4 and SHBG.
(303) General Predictor Development Strategy
(304) A strategy was developed to avoid over-fitting and to overcome the dilution of biomarker performance expected across broad gestational age ranges due to the dynamic nature of protein expression during pregnancy. Ratios of up-regulated over down-regulated analyte intensities were employed in predictor development. Such reversals are similar to the top-scoring pair and 2-gene classifier strategies. (Geman et al. Classifying gene expression profiles from pair wise mRNA comparisons. Stat Appl Genet Mol Biol. 2004; 3(1):Article19; Price et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci USA. 2007; 104(9):3414-9) This approach allowed amplification of the diagnostic signal and self-normalization as both proteins in a reversal underwent the same pre-analytical and analytical processing steps. As a strategy to normalize peptide intensity measures in complex proteomics workflows, reversals are also similar to a recently introduced approach termed endogenous protein normalization (EPN). (Li et al. An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples. Clin Proteomics. 2015; 12(1):3; Li et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013; 5(207):207ra142) The number of candidate analytes used for model building was reduced by analytic criteria. Analytic filters included: cut-offs for analytical precision, intensity, evidence of interference, sample processing order dependence and pre-analytical stability. The total number of analytes in any one predictor was limited to a single reversal, thus avoiding complex mathematical models. Predictor scores were defined as the natural log of a single reversal value, where the reversal itself was a response ratio (defined above in this Example). Lastly, predictive performance was investigated in narrow overlapping 3-week intervals of gestation.
(305) Receiver Operating Characteristic Curves
(306) AUROC values and associated p-values were calculated for reversals as described above in this Example. The distribution and mean value for predictor AUROC in the combined discovery and verification set was calculated using a bootstrap sampling performed iteratively by selecting random sets of samples with replacement. Efron B, Tibshirani R J. An Introduction to the Bootstrap. Boca Raton, Florida: Chapman and Hall/CRC Press; 1994. The total number of selected samples at each iteration corresponded to the total available in the starting pool.
(307) Supplementary Results
(308) Discovery, verification and validation subject characteristics are summarized in Table 3. The percentage of subjects with one or more prior sPTBs in discovery sPTB cases were higher than in verification or validation, and other characteristics were largely consistent across the studies.
(309) Discovery and Verification Analyses
(310) Forty-four proteins were either up- or down-regulated in overlapping 3-week GA intervals and passed analytic filters (
(311) The blinded IBP4/SHBG AUROC performance on verification samples was 0.77 and 0.79 for all subjects and BMI stratified subjects, respectively, in good agreement with performance obtained in discovery (Table 5). Following blinded verification, discovery and verification samples were combined for a bootstrap performance determination. A mean AUROC of 0.76 was obtained from 2,000 bootstrap iterations (
(312) BMI Validation Analyses
(313) The performance of the IBP4/SHBG predictor was evaluated at several cut-offs of BMI in the validation samples (Table 5). AUROC measured performance modestly improved by elimination of either very high (e.g. >37 kg/m2) or low BMI (e.g. ?22 kg/m2). Stratification by a combination of those two cut-offs gave an AUROC of 0.75 (Table 5).
Example 3. Correlation of Mass Spectrometry and Immunoassay Data
(314) This example demonstrates results of a Myriad RBM screen identifying IBP4 and other biomarkers individual biomarkers for sPTB in the early, middle, and late gestational age collection windows, (2) correlation of MS and immunoassay results for SHBG/IBP4, and (3) clinical data relating to SHBG as a biomarker for sPTB.
(315) RBM Data
(316) Briefly, RBM assayed 40 cases and 40 controls from PAPR (20/20 from Early Window), 10/10 from Middle Window, 10/10 from Late Window). RBM used the Human Discovery MAP 250+ v2.0 (Myriad RBM, Austin, TX). The objective of these analyses is to develop multivariate models to predict PTB using multiple analytes. We used four modeling methods: random forest (rf), boosting, lasso, and logistic (logit). We perform a first round of variable selection in which each method independently selects the 15 best variables for that method. From the 15, the best analytes were selected independently by each of the four modeling methods using backward stepwise selection and estimation of area under the ROC curve (AUC) using out-of-bag bootstrap samples. Table 6 shows the top hits from several multivariable models. Table 7 shows Early Window (GABD 17-22 wks) Analyte Ranking by Different Multivariate Models. Table 8 shows Middle Window (GABD 23-25 wks) Analyte Ranking by Different Multivariate Models. Table 9 shows Late Window (GABD 26-28 weeks) Analyte Ranking by Different Multivariate Model.
(317) Identifying Commercial ELISA Kits that Correlate With Mass Spec Data
(318) Briefly, ELISA versus MS comparisons involved multiple studies using PAPR samples and ranging in size from 30-40 subjects. Each ELISA was performed according to the manufacture's protocol. The predicted concentration of each analyte by ELISA was then compared to MS derived relative ratios from identical samples. A Person's r correlation value was then generated for comparison. ELISA versus MS comparisons involved multiple studies using PAPR samples and ranging in size from 30-40 subjects. Each ELISA was performed according to the manufacture's protocol. The predicted concentration of each analyte by ELISA was then compared to MS derived relative ratios from identical samples. A Person's r correlation value was then generated for comparison. Table 10 provides epitope and clonality information for kits tested for analytes IBP4_HUMAN and SHBG_HUMAN. Table 11 shows that not all ELISA kits correlate with MS, even for proteins where correlation exists. See for example: IBP4, CHL1, ANGT, PAPP1.
(319) One hundred and twenty previously frozen serum samples with known outcomes from the PAPR study were selected for comparison between ELISA and MS assays. These samples have a Gestational Age at Blood Draw (GABD) between 119 and 180 days. Samples were not excluded due to maternal BMI. ELISA's were performed on commercially available kits for IBP4 (AL-126, ANSCH Labs Webster, Texas), and SHBG (DSHBGOB, R&D Systems Minneapolis, Minnesota). Assays were run according to the manufactures' protocols. Internal standards were used for plate-to-plate normalization. The score was calculated from the ELISA concentration values according to LN([IBP4]/[SHBG]), and by MS according to LN(IBP4.sup.RR/SHBG.sup.RR), where RR refers to the relative ratio of endogenous peptide to SIS peptide peak areas. Scores derived from the two approaches were compared in case versus control separation (p values derived from unpaired t-tests assuming equal standard deviations) (
(320) Fifty seven previously frozen serum samples (19 sPTB cases, 38 term controls) with known outcomes from the PAPR study were selected for comparison between ELISA and MS assays. These samples have a Gestational Age at Blood Draw (GABD) between 133 and 148 days. ELISA's were performed on commercially available kits for IBP4 (AL-126, ANSCH Labs Webster, Texas), and SHBG (DSHBGOB, R&D Systems Minneapolis, Minnesota). Assays were run according to the manufactures' protocols. Samples run on different plates were normalized using internal standards. The score was calculated from the ELISA concentration values according to LN([IBP4]/[SHBG]), and by MS according to LN(IBP4.sup.RR/SHBG.sup.RR), where RR refers to the relative ratio of endogenous peptide to SIS peptide peak areas. Performance of the immunoassay by area under the receiver operating characteristic curve (AUC) was then determined and compared to the MS derived AUC on the same sample sets (
(321) Sixty previously frozen serum samples with known outcomes from the PAPR study were analyzed by ELISA and MS assays. These samples have a predicted Gestational Age at Blood Draw (GABD) between 133 and 146 days. Correlation analyses were performed for samples at all BMI (
(322) Comparison of SHBG Measurements by Mass Spectrometry and Clinical Analyzers
(323) Thirty five samples from individual subjects and serum pools of pregnant and non-pregnant women were simultaneously analyzed at Sera Prognostics and two independent reference laboratories, ARUP Laboratories and Intermountain Laboratory Services. Aliquots were transported refrigerated to each laboratory and shipping was coordinated so testing would begin on the same date for all three laboratories. ARUP utilizes a Roche cobas e602 analyzer and Intermountain uses the Abbott Architect CMIA, both semi-automated immunoassay instruments. Sera Prognostics employs a unique proteomic analysis method involving immuno-depletion of samples, enzymatic digestion and analyzed on an Agilent 6490 Mass Spectrometer. Results from both ARUP and IHC were reported in nmol/L while Sera uses the Relative Ratio (RR) of heavy and light peptide surrogates. Data from ARUP and Intermountain were compared to each other to determine accuracy (
Example 4. SNPs, Insertions and Deletions and Structural Variants within the PreTRM IBP4 and SHBG Peptides
(324) This example shows the known SNPs, insertions and deletions (indels) and structural variants within the PreTRM IBP4 and SHBG peptides.
(325) Table 13 and Table 14 detail the known SNPs, insertions and deletions (indels) and structural variants within the PreTRM IBP4 and SHBG peptides. The information is derived from the Single Nucleotide Polymorphism database (dbSNP) Build 146. A single missense variation (G>C) in SHBG, A179P (dbSNP id: rs115336700) has the highest overall allelic frequency of 0.0048. While this allelic frequency is low, several subpopulations studied in the 1000 genomes project had significantly higher frequencies. These populations (allele frequencies) are; Americans of African Ancestry in SW USA (0.0492); African Carribbeans in Barbados (0.0313); Yourba in Ibadan, Nigeria (0.0278); Luhya in Webuye, Kenya (0.0101); Esan in Nigeria (0.0101); Colombians from Medellin, Colombia (0.0053); Gambian in Western Divisions in The Gambia (0.0044). All other studied subpopulations had no variation in this nucleotide position. The table header includes the cluster id(dbSNP rs number), Heterozygosityaverage heterozygosity, Validationvalidation method (or blank with no validation), MAFMinor Allele Frequency, Functionfunctional characteristic of the polymorphism, dbSNP alleleidentity of allelic nucleotide, Protein residueresidue resulting from allele, Codon posposition in codon, NP_001031.2 Amino acid posamino acid position in reference sequence NP_001031.2, and NM_001040.2 mRNA posnucleotide position in a reference sequence NM_001040.2.
Example 5. IBP4/SHBG Reversal Amplifies Diagnostic Signal for sPTB and Reduces Analytical Variability
(326) This example demonstrates the amplification of diagnostic signal and reduction of variability obtained employing the IBP4/SHBG reversal strategy.
(327) Shown are the levels of IBP4 and SHBG determined by MS across the indicated gestation age range for sPTB cases and term controls separately (
(328) Forming the ratio of the levels of two proteins may reduce the variability because each protein experiences the same analytical and preanalytical processing steps. To examine the impact on variability the CVs were determined for the individual proteins (RR of IBP4 and SHBG) and for IBP4 RR/SHBG RR ratio in pooled control serum samples from pregnant donors (pHGS). Pooled control samples, free of biological variability, were analyzed in multiple batches and across several days. Reversal variability is less than the variability associated with the individual proteins. (
(329) To investigate whether formation of reversals in general amplifies diagnostic signal we examined ROC performance (AUC) performance of high performing reversals (AUC >0.6) formed by the ratio of many proteins. Shown in the top panel of
(330) To investigate whether formation of reversals more generally reduces variability we examined the analytical variability for 72 different reversal values (i.e. ratio of relative peak areas versus the analytical variability of the individual proteins that comprise the reversals in pooled control serum samples from pregnant donors (pHGS). Pooled control samples, free of biological variability, were analyzed in multiple batches and across several days. Reversal variability is less than the variability associated with the individual proteins (
(331) Generalizability of the Reversal Strategy to Reduce Analytic Variability.
(332)
Example 6. Medically Indicated PTB Analysis
(333) This example confirms that the classifier is sensitive to a component of medically indicated PTB based on conditions such as preeclampsia or gestational diabetes.
(334) PreTRM? was developed and validated as a predictor for spontaneous PTB. About 75% of all PTB in the U.S. are spontaneous, the remaining are medically indicated due to some maternal or fetal complication (e.g. preeclampsia, intrauterine growth restriction, infection). 41 medically indicated PTB samples from the PAPR biobank were analyzed in the lab and PreTRM scores were calculated. The PreTRM? scores were compared for those subjects annotated as medically indicated for preeclampsia versus other indications were compared. Subjects medically indicated for preterm delivery because of preeclampsia had significantly higher scores than others (
(335)
Example 7. Other Transitions and Peptides
(336) Table 16 shows comparative IBP4 peptide and transition MS data. Four different heavy labeled peptides (R*+10 daltons) exemplify various transitions and their relative intensities that could be monitored to quantify IBP4. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify IBP4.
(337) Table 17 shows comparative IBP4 peptide and transition MS data. IBP4 tryptic peptides derived from recombinant protein was analyzed by MRM-MS to identify candidate surrogate peptide and their transitions. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify IBP4. IBP4 was identified in RBM (above), then the synthetic peptide was ordered to build the assay.
(338) Table 18 shows Comparative SHBG peptide and transition MS data. SHBG tryptic peptides derived from recombinant protein or pooled pregnant serum was analyzed by MRM-MS to identify candidate surrogate peptide and their transitions. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify SHBG. Also shown are isoform specific peptides identified in serum.
(339) Table 19 shows proteins with altered serum levels across 17-25 weeks GA in PTB samples. * Additional proteins limited to weeks 19-21 GA in PTB. LC-MS (MRM) assay of 148 proteins from multiple pathways and analyzed serum samples from gestational age (GA) weeks 17-25 from 312 women (104 sPTB cases, 208 term controls). MRM peak area data was analyzed by hierarchical clustering, t-tests, and relationship to GA. Following analytic filtering, 25 proteins exhibited significant differences (p<0.05) in sPTB vs term subjects (Table 1). Levels of 14 proteins were higher and 3 were lower in sPTB samples across the entire GA range. Other proteins were found to be dynamically regulated in sub-intervals of the GA period. For example, in GA weeks 19-21, an additional 7 proteins were elevated and 1 was lower in sPTB.
(340) Table 20 lists 44 proteins meeting analytical filters that were up- or down-regulated in sPTB vs. term controls.
Example 8. Mechanistic Insights from Serum Proteomic Biomarkers Predictive of Spontaneous Preterm Birth
(341) This example demonstrates that, as specific protein expression changes dynamically throughout pregnancy, biomarker performance varies considerably across GA. Differentially expressed proteins have functions in steroid metabolism, placental development, immune tolerance, angiogenesis and maintenance of pregnancy.
(342) Briefly, the objective of the study described in this example was to gain insight into the physiological basis for biomarker association with spontaneous preterm birth (sPTB) prediction.
(343) Study Design
(344) Pathways such as inflammation, infection and bleeding have been implicated in the etiology of preterm birth. However, less is known about which proteins are measurable in blood and when in gestation they are disrupted. To answer these questions we created an LC-MS (MRM) assay of 148 proteins from multiple pathways and analyzed serum samples from gestational age (GA) weeks 17-25 from 312 women (104 sPTB cases, 208 term controls).
(345) Briefly, serum samples were depleted of high abundance proteins, digested with trypsin and fortified with heavy-labeled stable isotope standard (SIS) peptides for nearly all of the proteins. SIS peptides were used for normalization by generating response ratios, where the peak area of a peptide fragment ion (i.e. transition) measured in serum was divided by that of the corresponding SIS transition. Response ratios of MRM peak area data were analyzed by hierarchical clustering, t-tests and relationship to GA.
(346) As shown in
(347)
(348)
(349)
(350)
(351)
(352)
(353)
(354)
(355)
(356)
(357)
(358)
(359)
(360)
Example 9. SDT4/SV4 Kinetic Analysis
(361) This example provides kinetic analysis for all analytes initially exemplified in Example 1, supra, with data from 17 weeks 0 days, through 28 weeks, 6 days.
(362) For
(363) The kinetic analyses exemplified herein serve several purposes. These analyses demonstrate whether analyte levels are changing during pregnancy and in which direction, whether they change differently for cases and controls, and illustrate diagnostic differences as a function of gestational age. In some cases, the diagnostic signal is located in a narrow gestational age range, and increases or decreases across time. The shape of kinetic plots also provides visual guidance for selection of proteins that pair well in reversals.
(364) Analytes that were discovered to show significant case versus control separation in an early window, e.g. sample collection between 18 and 20 weeks of gestational age, include, for example, AFAM, B2M, CATD, CAH1, C1QB, C1S, F13A, GELS, FETUA, HEMO, LBP, PEDF, PEPD, PLMN, PRG2, SHBG, TENX, THRB, and VCAM1. Analytes that were discovered to show significant case versus control separation in a later window, e.g. sample collection between 26 and 28 weeks of gestational age, include, for example, ITIH4, HEP2, IBP3, IGF2, KNG1, PSG11, PZP, VASN, and VTDB. Separation of cases versus controls improved using cutoff of less than 35 0/7 versus greater or equal to 35 0/7 weeks versus less than 37 0/7 versus greater or equal to 37 0/7 weeks, as seen for analytes including, for example, AFAM, APOH, CAH1, CATD, CD14, CLUS, CRIS3, F13B, IBP6, ITIH4, LYAM1, PGRP2, PRDX, PSG2, PTGDS, SHBG and SPRL1. It was discovered that many inflammatory and immuno-modulatory molecules show improved separation using the lower gestational at birth cutoff. One skilled in the art will appreciate that any of the analytes showing significant separation between cases and controls shown in the accompanying Figures for a given time window are candidates for use in a reversal pair of the present inventions, as a single biomarker or as part of a biomarker panel of analytes.
(365) Lastly, kinetic plots for analytes that lack a case versus control difference, but demonstrate changes in analyte intensity across pregnancy, are useful in a pregnancy clock according to the methods of the invention. These analytes, also referred to herein as clock proteins, can be used to date a pregnancy in the absence of or in conjunction with other dating methods (e.g. date of last menstrual period, ultrasound dating). Table 60 provides a list of clock proteins useful in a pregnancy clock of the invention.
Example 10. Discovery 2 Analysis of sPTB Cases
(366) This example describes analysis of all previously analyzed sPTB cases as described in the preceding examples, their matched controls (2 per every case) and 2 new controls. This analysis described in this example expanded the commercial blood draw window beyond weeks 19 and 20, generated additional data with regards to prediction of sPTB <35 weeks based on larger number of samples from all previous examples, led to discovery of new analytes and reversals, defined molecular clock proteins, clarified risk thresholds and formed accurate validation claims for future clinical studies.
(367) Sample Processing Methods
(368) A standard protocol was developed governing conduct of the Proteomic Assessment of Preterm Risk (PAPR) clinical study. This protocol also specified that the samples and clinical information could be used to study other pregnancy complications. Specimens were obtained from women at 11 Internal Review Board (IRB) approved sites across the United States. After providing informed consent, serum and plasma samples were obtained, as well as pertinent information regarding the patient's demographic characteristics, past medical and pregnancy history, current pregnancy history and concurrent medications. Following delivery, data were collected relating to maternal and infant conditions and complications. Serum and plasma samples were processed according to a protocol that requires standardized refrigerated centrifugation, aliquoting of the samples into 0.5 ml 2-D bar-coded cryovials and subsequent freezing at ?80? C.
(369) Following delivery, preterm birth cases were individually reviewed to determine their status as either a spontaneous preterm birth or a medically indicated preterm birth. Only spontaneous preterm birth cases were used for this analysis. For discovery of biomarkers of preterm birth, LC-MS data was generated for 413 samples (82 sPTB cases, 331 term controls) spanning gestational ages 17 0/7-21 6/7 weeks, with each preterm sample matched to 4 term controls by gestational age at blood draw. Every gestational age day within 17 0/7-21 6/7 weeks included at least one sPTB case (and matched term controls), except for one day. 4 term controls were selected with blood draws from that day. One term control in the study that failed laboratory analysis was not reanalyzed.
(370) The serum samples were subsequently depleted of high abundance proteins using the Human 14 Multiple Affinity Removal System (MARS-14), which removes 14 of the most abundant proteins. Equal volumes of each clinical sample or replicates of two quality control serum pools were diluted with column buffer and filtered to remove precipitates. Filtered samples were depleted using a MARS-14 column (4.6?100 mm, Agilent Technologies). Samples were chilled to 4? C. in the autosampler, the depletion column was run at room temperature, and collected fractions were kept at 4? C. until further analysis. The unbound fractions were collected for further analysis.
(371) Depleted serum samples were reduced with dithiothreitol, alkylated using iodoacetamide, and then digested with trypsin. Following trypsin digestion, samples were fortified with a pool of stable isotope standards at concentrations that approximated the concentration of the surrogate peptide analyte. SIS fortified samples were mixed and split into two equal volumes. Each split was placed in ?80? C. storage until ready to continue the work process. One frozen split from each sample was retrieved from ?80? C. storage, allowed to thaw, and then desalted on a C18 solid phase extraction plate (Empore, 3M). Eluted peptides were lyophilized to dryness. The lyophilized samples were resolubilized in a reconstitution solution containing internal standards that monitor quality of the LC-MS step only (IS Recon).
(372) Fully processed samples were analyzed using a dynamic Multiple Reaction Monitoring method (dMRM). The peptides were separated on a 2.1?100 mm Poroshell EC-C18, 2.7? particle size column at a flow rate of 0.4 mL/min using an Agilent 1290 UPLC and eluted using an acetonitrile gradient into an Agilent 6490 triple quadrupole mass spectrometer with an electrospray source, operating in positive ion mode. The dMRM assay measured 442 transitions that correspond to 119 peptides and 77 proteins serving both diagnostic and quality roles. Chromatographic peaks were integrated using MassHunter Quantitative Analysis software (Agilent Technologies). Ratios of the chromatographic peak area of the surrogate peptide analyte to the corresponding SIS chromatographic peak area were reported.
(373) A summary of the proteins, peptides and transitions for serum analytes, SIS transitions and IS Recon standards measured in the dMRM method is shown in Table 21. MARS-14 Depletion proteins identify analytes targeted by the MARS-14 immunodepletion column and are measured for quality control purposes. Quant transitions are used for relative response ratios and qual transitions serve quality control purposes. The asterisk (*) denotes name changes. CSH denotes that the peptide corresponds to both CSH1 and CSH2. HLAG now referred to as HLACI since the peptide is conserved in several class I HLA isotypes. LYAM3 now referred to as LYAM1 because, while the peptide sequence is present in each, it is only derived by trypsin cleavage from LYAM1. SOM2 now referred to as SOM2.CSH as the peptides are specific to both SOM2 and CSH.
(374) Significant Protein and Reversal Selection
(375) For each analyte, in each of the two week and three week overlapping window, with and without the BMI restriction, and with two SPTB definitions (37/37 and 35/35), the fold change value that denotes if the mean of the SPTB case samples was higher or lower than the mean of the TERM control samples, was calculated. Tables 22 and 23 show protein/transition AUROC for two week gestational age windows overlapping by one week (e.g. 119-132 refers to days 119-132 of pregnancy which equals gestational weeks 17 and 18). Performance in each two week window is reported for two different case vs control cut-offs (<37 0/7 vs >=37 0/7, <35 0/7 vs >=35 0/7) and with (rBMI) and without (aBMI) a BMI stratification. Tables 24 and 25 show protein/transition AUROC for three week gestational windows overlapping by two weeks (show in days, e.g. 119-139 refers to days 119-139 of pregnancy which equals gestational weeks 17, 18 and 19). Performance in each three week window is reported for two different case vs control cut-offs (<37 0/7 vs >=37 0/7, <35 0/7 vs >=35 0/7) and with (rBMI) and without (aBMI) a BMI stratification.
(376)
(377) Based on the fold change value, which denotes if the mean of the SPTB case samples was higher or lower than the mean of the TERM control samples, each analyte was marked as up or down regulated for each of the combinations (i.e. overlapping 2 or 3 week window, BMI restriction, and SPTB definition) and if an analyte had majority of the combinations marked as up regulated it was called an overall up regulated analyte and vice versa. This is shown in Table 26.
(378) Based on these up and down regulation assignments (55 up regulated and 30 down regulated), reversals were created by dividing each of the up regulated analyte relative ratio value by that of a down regulated analyte and taking the natural logarithm of the result. This results in 1650 reversals (55?30=1650). For each reversal, an area under the ROC curve (AUCROC) denoting SPTB and TERM separation and a p-value denoting if the AUCROC value is significantly different from AUCROC=0.5 (i.e. no significant SPTB and TERM separation) was calculated. Performance of each reversal was tabulated for different conditions (e.g. gestational windows, with and without BMI restriction, and the two sPTB cut-offs), for those reversals with an AUCROC>0.6 and a p-value<0.05. Tables 27 to 42 show reversal classification performance for gestational weeks 17 and 18. Tables 47 to 58 show reversal classification performance for gestational weeks 17, 18 and 19. Tables 43 to 46 show reversal classification performance for gestational weeks 17 through 21. Additional reversals of potential significance are shown in Table 59.
(379) Also demonstrated, was improved performance of predictors formed from more than one reversal (weeks 17-21). Briefly, reversals that gave strong predictive performance either early (e.g. weeks 17-19) or later (e.g. weeks 19-21) in this gestational age range were combined and performance was evaluated of predictors formed from combinations (SumLog) of multiple reversals for the entire blood draw range. This is shown in Table 61. Predictor score was derived from summing the Log values of the individual reversal (SumLog) but one skilled in the art could select other models (e.g. logistic regression). It is also contemplated to apply this multiple reversal approach to combinations of reversals specific to preterm premature rupture of membranes (PPROM) versus preterm labor in the absence of PPROM (PTL), fetal gender and gravidity. It is further contemplated that the predictor could contain an indicator variable that selects a subset of reversals to be used given knowledge of the blood draw period, fetal gender or gravidity.
(380)
(381)
(382) Clinical Observations: sPTB, PPROM and PTL
(383) Reversal performance (GABD weeks 17-21) was evaluated independently for two different phenotypes of sPTB, PPROM and PTL. PPROM more often occurs early and is associated with infection or inflammation. PTL can occur later and is generally considered a less severe phenotype. There were more significant reversals and with higher performance for PPROM and those reversals are populated with proteins known to be involved in inflammation and infection. Selection of reversals to build independent testing methods of PPROM and PTL, or to maximize performance overall with the combination of more than one reversal in a single predictor is contemplated. In the analysis shown in Tables 61 to 64, an AUC>0.65 and p<0.05 for either PPROM or PTL was required.
(384) Table 61 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >37 0/7 weeks, without BMI stratification, separately for PPROM and PTL. Table 62 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22 <=37), separately for PPROM and PTL. Table 63 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately for PPROM and PTL. Table 64 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37), separately for PPROM and PTL.
(385) The best performing analytes for PTL and best performing analytes for PPROM for GABD weeks 19-20 were also determined and several reversals were constructed from the strongest performers. IBP4 is present as a good performer in both PTL and PPROM enabling its utility in general for sPTB. Table 76 lists transition AUROC for gestational weeks 19 1/7 through 20 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, for PTL. Table 77 lists transition AUROC for gestational weeks 19 1/7 through 20 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, for PPROM.
(386) Clinical Observations: Primigravida and Multigravida
(387) Reversal performance (weeks 17-21) was further evaluated independently for two different phenotypes of sPTB, primigravida and multigravida. In Tables 65-68, the top performing reversals (weeks 17-21) are shown for primigravida (first time mothers) and multigravida subjects separately. First time mothers are most in need of a test to predict probability of PTB because they have no pregnancy history for physicians to determine/estimate risk. These results enable a test independent for these two groups, or to combine high performing reversals in a single classifier to predict risk for both. In the analysis shown in Tables 65-68, an AUC >0.65 and p<0.05 for either primigravida or multigravida was required.
(388) Table 65 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, separately for primigravida and multigravida. Table 66 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22<=37), separately for primigravida and multigravida. Table 67 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately for primigravida and multigravida. Table 68 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37), separately for primigravida and multigravida.
(389) Clinical Observations: Fetal Gender
(390) Reversal performance (weeks 17-21) was further evaluated independently for subjects pregnant with a male vs a female fetus. Some reversals were discovered to have fetal gender specific predictive performance.
(391) Table 69 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, separately by fetal gender. Table 70 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22 <=37), separately by fetal gender. Table 71 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately by fetal gender. Table 72 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37), separately by fetal gender.
Example 11. Correlation of Mass Spectrometry and Immunoassay Data
(392) This example demonstrates implementation of an immunoassays using an MSD platform (e.g. MSD data correlating with commercial ELISA data and MS data for IBP4 and SHBG).
(393) Materials
(394) The following antibodies were used: sex hormone binding globulin (Biospacific Catalog #s 6002-100051 and 6001-100050; R&D Systems Catalog #s MAB2656 and AF2656), IGFBP-4 (Ansh Catalog #s AB-308-A1039 and AB-308-A1042). SHBG proteins from Origene (Catalog #TP328307), Biospacific (Catalog 065200), NIBSC (code: 95/560), and R&D Systems (only available as part of the ELISA SHBG kit) were tested as calibrator. Recombinant Human IGFBP-4 (Ansh, Catalog #AG-308-A1050) was used as a calibrator.
(395) Creating Individual U-PLEX-Coupled Antibody Solutions
(396) Each biotinylated antibody was diluted to 10 ?g/mL in Diluent 100 for a final volume of >200 ?L. Biotinylated antibody was then added to 300 ?L of assigned U-PLEX Linker. (A different linker was used for each biotinylated antibody). Samples were vortexed and incubated at room temperature for 30 minutes. Stop Solution (200 ?l) was added to each tube. Tubes were vortexed and incubated at room temperature for 30 minutes.
(397) Preparation of Multiplex Coating Solution
(398) Each U-PLEX-coupled antibody (600 ?L) solution was combined into a single tube and vortexed to mix. When combining fewer than 10 antibodies, the solution volume was brought to up to 6 mL with stop solution to result in a final 1? concentration. Note that in these experiments, there was only a single antibody per well.
(399) Coating the U-PLEX Plate.
(400) Multiplex Coating Solution (50 ?L) was added to each well. Plates were sealed with adhesive plate seal and incubated at room temperature for 1 hour or at 2-8? C. for overnight, with shaking at around 700 rpm. After washing 3 times with at least 1504, of 1? MSD wash buffer, plates were ready to use.
(401) Sample Analysis
(402) Aliquots, 50 ?l, of sample or calibrator were added to each well. The plate was sealed and incubated at room temperature for 1 hour with shaking at around 700 rpm. The plate was then washed 3 times with at least 150 ?L of 1?MSD wash buffer*. Detection antibody solution, 50 ?L, was added to each well. After sealing, the plate was incubated at room temperature for 1 hour with shaking at around 700 rpm. The plate was washed 3 times with at least 150 ?L of 1?MSD wash buffer. After addition of 150 ?L of 2? Read Buffer to each well, the plate was read immediately on an MSD instrument.
(403) SHBG Antibody and Calibrator Screening
(404) All antibodies were tested in both capture-detector orientations, all pair wise combinations. Capture antibodies were prepared at 10 ?g/mL, coupled to U-PLEX linkers, and coated onto the U-PLEX plate. The SHBG R&D Systems calibrator was diluted in Diluent 43 to create a 7-point standard curve with assay diluent blank. Samples were diluted as follows in Diluent 43 and tested in the assays: Sera SHBG high and low samples: 100- and 500-fold dilutions, and the Sera Pregnant pool: 100-, 200-, 400-, 800-fold dilutions. Detection antibodies were tested at 1 ?g/mL in Diluent 3. Standard curves and binding to native analyte in serum were evaluated. Top analyte pairs were then tested with the NIB SC and Biospacific calibrators, with dilutions made as above.
(405) IGFBP-4 Antibody and Calibrator Screening.
(406) The two antibodies were tested in both capture-detector orientations. Capture antibodies were prepared at 10 ?g/mL, coupled to U-PLEX linkers, and coated onto the U-PLEX plate. IGFBP-4 calibrator was diluted in Diluent 12 and to create a 7-point standard curve with assay diluent blank. Samples were diluted as follows in Diluent 12 and tested in the assays: Sera IGFBP-4 high and low samples: 5-fold, Sera Pregnant pool: 2-fold dilutions from 2- to 64-fold, and 2 individual human serum samples (MSD samples): 2-, 4-, 8- and 16-fold. Detection antibodies were tested at 1 ?g/mL in Diluent 12. Standard curves and binding to native analyte in serum were evaluated.
(407) SHBG and IGFBP-4 Testing Using 60 Sera Samples.
(408) Antibody pair 12 was selected to measure SHBG in 60 plasma samples in duplicate from Sera. For IGFBP-4, pair 2 was selected. Plasma samples were diluted 1:1000 and 1:20 for SHBG and IGFBP-4, respectively. Results from the MSD ELISA were compared to commercial ELISA kits and to MS-MRM data.
(409) Results:
(410) SHBG Antibody Screen
(411) Only antibody pair 1 (R&D mono capture, poly detection), gave a strong signal with the Origene calibrator, suggesting that this calibrator may represent a subpopulation of the endogenous SHBG analyte. Thus, additional calibrators were tested in subsequent studies to identify a calibrator that works with all pairs. Nevertheless, all antibody pairs recognized native analyte in the Sera High, Low, and Pregnant pool samples. R&D poly AF2656 and Biospacific mono 6001-100050 gave similar performance. Pairs 2, 3, and 12 showed roughly linear titration with sample dilution (Table 73). The top four antibody pairs were then tested for performance with three additional calibrators. Good calibrator curves were achieved for the 4 top pairs across the 3 calibrators (Table 74). Differences in signal may be in part due to differences in assigned concentration.
(412) The bottom panel shows that the NIBSC or Biospacific signals relative to the R&D calibrator varied depending on antibody pair. Pairs 3 and 10 (same antibodies with the capture-detection orientation flipped) had a similar profile. Pair 2 gave lower signals for NIBSC and Biospacific (compare with Pair 3, same capture). Pair 12 gave higher signals for Biospacific and more than 3-fold higher signals for the NIBSC standard.
(413) IGFBP-4 Antibody Screen
(414) The antibody pair 2 standard curve gave 4-6 fold higher specific calibrator signals and background compared to Pair 1 (Table 75). Serum sample signals fell in the linear range for most dilutions tested; the pregnant pool approached background at the 32 and 64-fold dilutions. Pair 2 gave ?12 fold higher signals for samples resulting in a 2-4 fold difference in quantification. Signal CVs were generally <5% for both pairs.
(415) Measurement of SHBG and IGFBP-4 in 60 Serum Samples
(416) For SHBG, with the 1000-fold dilution, samples fell between calibrator standards 1-3. The median measured concentration was 58.4 ?g/mL. CVs of duplicate measurements were low with a median CV 2.4%. The median measured concentration for IGFBP-4 was 234 ng/ml and the median CV between duplicate samples was 2.2%. As shown in
(417) From the foregoing description, it will be apparent that variations and modifications can be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
(418) The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
(419) All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
(420) TABLE-US-00001 TABLE 1 Maternal Characteristics and Pregnancy Outcomes Stratified by Timing of Delivery (sPTB and Term) PAPR Validation Cases Controls Case Control PAPR vs. Validation N (%) N (%) N (%) N (%) p-value p-value (N = 217) (N = 4,292) p-value (N = 81) (N = 162) p-value (Cases) (Controls) Maternal Characteristics Maternal Age at Enrollment, y 0.245 0.239 0.741 0.226 18-22 yrs 58 (26.7) 990 (23.1) 22 (27.2) 47 (29.0) 23-27 yrs 56 (25.8) 1,222 (28.5) 17 (21.0) 41 (25.3) 28-32 yrs 54 (24.9) 1,154 (26.9) 25 (30.9) 34 (21.0) 33-37 yrs 31 (14.3) 692 (16.1) 9 (11.1) 30 (18.5) 38 or More 18 (8.3) 234 (5.5) 8 (9.9) 10 (6.2) Mean 28 28 28 28 Median 27 27 28 27 Interquartile Range 22-32 23-32 21-32 22-32 Body Mass Index, kg/m2 0.380 0.802 0.630 0.191 Less than 18.5 10 (4.7) 129 (3.1) 1 (1.3) 2 (1.3) 18.5-24.9 78 (36.8) 1,789 (42.3) 25 (31.3) 55 (34.6) 25.0-29.9 54 (25.5) 1,091 (25.8) 26 (32.5) 46 (28.9) 30.0-34.9 39 (18.4) 617 (15.6) 17 (21.3) 25 (15.7) 35.0-39.9 17 (8.0) 320 (7.6) 6 (7.5) 17 (10.7) Greater than 40.0 14 (6.6) 286 (6.7) 5 (6.3) 14 (8.8) Mean 27.8 27.5 28.4 29.1 Median 26.5 25.7 27.4 27.8 Interquartile Range 22.7-31.8 22.3-31.1 23.6-32.0 23.4-32.4 Education Level <0.0002 0.201 0.711 0.094 Graduate Degree 13 (6.0) 461 (10.9) 6 (7.7) 14 (8.7) College Diploma 34 (15.8) 701 (16.6) 10 (12.6) 22 (13.8) Some College 51 (23.7) 936 (22.2) 19 (24.0) 23 (14.4) High School 46 (21.4) 1,032 (24.5) 16 (20.2) 50 (31.3) Diploma/Equivalent Some High School 53 (24.6) 774 (18.4) 25 (31.6) 36 (22.5) 9 Grade or less 12 (5.8) 292 (6.9) 3 (3.8) 14 (8.7) Other 6 (2.8) 23 (0.6) 0 1 (0.6) Ethnicity 0.157 0.035 0.226 0.003 Hispanic or Latino 89 (41.0) 1,557 (36.3) 27 (33.3) 77 (47.5) Non-Hispanic or Latino 128 (59.0) 2,735 (63.7) 54 (66.7) 85 (52.5) Race 0.887 0.811 0.953 0.071 American Indian/Alaskan 1 (0.5) 29 (0.7) 0 2 (1.2) Native Asian 4 (1.8) 131 (3.1) 1 (1.2) 1 (0.6) Black or African-American 45 (20.7) 838 (19.5) 19 (23.5) 37 (22.8) Native Hawaiian or Other 0 12 (0.30) 0 2 (1.2) Pacific Islander White 156 (71.9) 3,101 (72.3) 58 (71.6) 114 (70.4) Other 11 (5.1) 193 (4.5) 3 (3.7) 6 (3.7) Obstetrical Characteristics Primigravida 64 (29.5) 1,212 (28.2) 0.689 27 (33.3) 39 (24.1) 0.126 0.522 0.247 Multigravida 153 (70.5) 3,080 (71.8) 54 (66.7) 123 (75.9) Number of prior full-term 0.007 0.326 0.816 0.881 deliveries 1 or More 113 (73.8) 2,538 (82.4) 40 (74.5) 102 (82.9) None 40 (26.2) 542 (17.6) 13 (24.5) 21 (17.1) Number of prior Spontaneous <0.0001 0.221 0.337 0.472 PTBs 1 or More 35 (22.9) 339 (11.0) 9 (16.7) 11 (8.9) None 118 (77.1) 2,741 (89.0) 45 (83.3) 112 (91.1) Lifestyle Characteristics Smoking 0.412 0.719 0.555 0.283 Yes 34 (15.7) 588 (13.7) 15 (18.5) 27 (16.7) No 183 (84.3) 3,704 (86.3) 66 (81.5) 135 (83.3) Illicit Drugs 0.283 0.628 0.992 0.052 Yes 16 (7.4) 242 (5.6) 6 (7.4) 15 (9.3) No 201 (92.6) 4,050 (94.4) 75 (92.6) 147 (90.7) Alcohol 0.096 0.628 0.622 0.141 Yes 20 (9.2) 273 (6.4) 6 (7.4) 15 (9.3) No 197 (90.8) 4,018 (93.6) 75 (92.6) 147 (90.7) Alcohol Use 0.108 0.592 0.880 0.317 Yes (amount unknown) 3 (1.4) 39 (0.9) 0 2 (1.2) Social (occasional) 16 (7.4) 230 (5.4) 6 (7.4) 13 (8.0) Heavy (daily) 1 (0.5) 4 (0.09) 0 0 No 197 (90.8) 4,018 (93.6) 75 (92.6) 147 (90.7) Medical Characteristics Bleeding During Pregnancy 0.006 0.360 0.785 0.892 after 12 Wks Yes 21 (9.7) 228 (5.3) 7 (8.6) 9 (5.6) No 196 (90.3) 4,064 (94.7) 74 (91.4) 153 (94.4) sPTB, spontaneous preterm birth; PTB, preterm birth; N, number of subjects. Comparisons of clinical data between cases and controls were performed using Chi-square test or Fisher exact test or Mann-Whitney test, as appropriate (SAS System 9.4) and R (3.1.0). Missing values are excluded in the frequency tables.
(421) TABLE-US-00002 TABLE 2 GA Boundary AUC Sensitivity Specificity OR (95% CI) <37 vs. ? 37 0.75 (p = 0.016) 0.75 0.74 5.04 (1.4-18) <36 vs. ? 36 0.79 (p = 0.027) 0.83 0.83 17.33 (2.2-138) <35 vs. ? 35 0.93 (p = 0.001) 1.00 0.83 34.47 (1.7-699)
(422) TABLE-US-00003 TABLE 3 Maternal Characteristics and Pregnancy Outcomes Stratified by Timing of Delivery (sPTD and Term) Entire Validation Cohort Validated Window PAPR Study (17 0/7- 28 weeks) (191/7-206/7) Cases Controls Cases Controls Cases Controls N (%) N (%) N (%) N (%) N (%) N (%) Variables (N = 217) (N = 4,292) P Value (N = 81) (N = 162) P Value (N = 18) (N = 36) P Value Maternal Characteristics Maternal Age at Enrollment, y 0.245 0.239 0.387 18-22 yrs 58 (26.7) 990 (23.1) 22 (27.2) 47 (29.0) 6 (33.3) 13 (36.1) 23-27 yrs 56 (25.8) 1,222 (28.5) 17 (21.0) 41 (25.3) 6 (33.3) 9 (25.0) 28-32 yrs 54 (24.9) 1,154 (26.9) 25 (30.9) 34 (21.0) 5 (27.8) 5 (13.9) 33-37 yrs 31 (14.3) 692 (16.1) 9 (11.1) 30 (18.5) 1 (5.6) 7 (19.4) 38 or More 18 (8.3) 234 (5.5) 8 (9.9) 10 (6.2) 0 2 (5.6) Mean 28 28 28 28 25 27 Median 27 27 28 27 25 25 Interquartile Range 22-32 23-32 21-32 22-32 21-30 22-33 Body Mass Index, kg/m2 0.380 0.802 0.959 Less than 18.5 10 (4.7) 129 (3.1) 1 (1.3) 2 (1.3) 0 0 18.5-24.9 78 (36.8) 1,789 (42.3) 25 (31.3) 55 (34.6) 8 (44.4) 16 (45.7) 25.0-29.9 54 (25.5) 1,091 (25.8) 26 (32.5) 46 (28.9) 4 (22.2) 9 (25.7) 30.0-34.9 39 (18.4) 617 (15.6) 17 (21.3) 25 (15.7) 3 (16.7) 4 (11.4) 35.0-39.9 17 (8.0) 320 (7.6) 6 (7.5) 17 (10.7) 2 (11.1) 5 (14.3) Greater than 40.0 14 (6.6) 286 (6.7) 5 (6.3) 14 (8.8) 1 (5.6) 1 (2.9) Mean 27.8 27.5 28.4 29.1 28.2 27.4 Median 26.5 25.7 27.4 27.8 26.5 27 Interquartile Range 22.7-31.8 22.3-31.1 23.6-32.0 23.4-32.4 23.8-33.7 22.3-30.6 Education Level <0.0002 0.201 0.263 Graduate Degree 13 (6.0) 461 (10.9) 6 (7.7) 14 (8.7) 0 2 (5.7) College Diploma 34 (15.8) 701 (16.6) 10 (12.6) 22 (13.8) 2 (11.1) 5 (14.3) Some College 51 (23.7) 936 (22.2) 19 (24.0) 23 (14.4) 1 (5.6) 5 (14.3) High School 46 (21.4) 1,032 (24.5) 16 (20.2) 50 (31.3) 5 (27.8) 14 (40.0) Diploma/Equivalent Some High School 53 (24.6) 774 (18.4) 25 (31.6) 36 (22.5) 9 (50.0) 6 (17.1) 9 Grade or less 12 (5.8) 292 (6.9) 3 (3.8) 14 (8.7) 1 (5.6) 3 (8.6) Other 6 (2.8) 23 (0.6) 0 1 (0.6) 0 0 Ethnicity 0.157 0.035 0.844 Hispanic or Latino 89 (41.0) 1,557 (36.3) 27 (33.3) 77 (47.5) 7 (38.9) 15 (41.7) Non-Hispanic or Latino 128 (59.0) 2,735 (63.7) 54 (66.7) 85 (52.5) 11 (61.1) 21 (58.3) Race 0.887 0.811 0.319 American Indian/Alaskan 1 (0.5) 29 (0.7) 0 2 (1.2) 0 1 (2.8) Native Asian 4 (1.8) 131 (3.1) 1 (1.2) 1 (0.6) 0 1 (2.8) Black or African-American 45 (20.7) 838 (19.5) 19 (23.5) 37 (22.8) 2 (11.1) 11 (30.6) Native Hawaiian or Other 0 12 (0.30) 0 2 (1.2) 0 1 (2.8) Pacific Islander White 156 (71.9) 3,101 (72.3) 58 (71.6) 114 (70.4) 16 (88.9) 22 (61.1) Other 11 (5.1) 193 (4.5) 3 (3.7) 6 (3.7) 0 0 Obstetrical Characteristics Primigravida 64 (29.5) 1,212 (28.2) 0.689 27 (33.3) 39 (24.1) 0.126 5 (27.8) 8 (22.2) 0.652 Multigravida 153 (70.5) 3,080 (71.8) 54 (66.7) 123 (75.9) 13 (72.2) 28 (77.8) Number of prior full-term deliveries 0.007 0.326 0.790 1 or More 113 (73.8) 2,538 (82.4) 40 (74.5) 102 (82.9) 10 (76.9) 22 (78.6) None 40 (26.2) 542 (17.6) 13 (24.5) 21 (17.1) 3 (23.1) 6 (21.4) Number of prior Spontaneous PTDs <0.0001 0.221 0.524 1 or More 35 (22.9) 339 (11.0) 9 (16.7) 11 (8.9) 1 (7.7) 6 (21.4) None 118 (77.1) 2,741 (89.0) 45 (83.3) 112 (91.1) 12 (92.3) 22 (78.6) Lifestyle Characteristics Smoking 0.412 0.719 1.000 Yes 34 (15.7) 588 (13.7) 15 (18.5) 27 (16.7) 3 (16.7) 6 (16.7) No 183 (84.3) 3,704 (86.3) 66 (81.5) 135 (83.3) 15 (83.3) 30 (83.3) Illicit Drugs 0.283 0.628 0.739 Yes 16 (7.4) 242 (5.6) 6 (7.4) 15 (9.3) 2 (11.1) 3 (8.3) No 201 (92.6) 4,050 (94.4) 75 (92.6) 147 (90.7) 16 (88.9) 33 (91.7) Alcohol 0.096 0.628 0.278 Yes 20 (9.2) 273 (6.4) 6 (7.4) 15 (9.3) 4 (22.2) 4 (11.1) No 197 (90.8) 4,018 (93.6) 75 (92.6) 147 (90.7) 14 (77.8) 32 (88.9) Alcohol Use 0.108 0.592 0.278 Yes (amount unknown) 3 (1.4) 39 (0.9) 0 2 (1.2) 0 0 Social (occasional) 16 (7.4) 230 (5.4) 6 (7.4) 13 (8.0) 4 (22.2) 4 (11.1) Heavy (daily) 1 (0.5) 4 (0.09) 0 0 0 0 No 197 (90.8) 4,018 (93.6) 75 (92.6) 147 (90.7) 14 (77.8) 32 (88.9) Medical Characteristics Bleeding During Pregnancy after 12 Wks 0.006 0.360 0.308 Yes 21 (9.7) 228 (5.3) 7 (8.6) 9 (5.6) 0 2 (5.6) No 196 (90.3) 4,064 (94.7) 74 (91.4) 153 (94.4) 18 (100.0) 34 (94.4) sPTD, spontaneous preterm delivery; PTD, preterm delivery; N, number of subjects. Comparisons of clinical data between cases and controls were performed using Chi-square test or Fisher exact test or Mann-Whitney test, as appropriate (SAS System 9.4) and R (3.1.0). Missing values are excluded in the frequency tables.
(423) TABLE-US-00004 TABLE 4 Discovery Verification Validation Sample # 86, 172 50, 100 81, 162 (17-28 wks)* Sample # 22, 44 9, 18 18, 36 (All BMI)* AUC 0.74 (p = 8e?4) 0.77 (p = 0.01) 0.67 (p = 0.02) (All BMI) Sample # 17, 33 6, 17 15, 29 (BMI < 35)* AUC 0.79 (p = 3e?4) 0.79 (p = 0.015) 0.70 (p = 0.02) (BMI < 35) p values test equivalence to AUC = 0.5 by one-sided Wilcoxon-Mann-Whitney statistic *Number of Cases , Number of Controls GA at blood draw weeks 19/0-21/6 Optimal GA at blood draw interval from fixed sequence validation (19/1-20/6)
(424) TABLE-US-00005 TABLE 5 BMI (kg/m.sup.2) AUROC All BMI 0.67 (p = 0.044) BMI Less or equal to 45 0.67 (p = 0.047) BMI Less or equal 40 0.68 (p = 0.048) BMI Less or equal 37 0.71 (p = 0.020) BMI Larger than 18 0.67 (p = 0.047) BMI Larger than 20 0.65 (p = 0.087) BMI Larger than 22 0.69 (p = 0.048) BMI larger than 22 and less or equal to 37 0.75 (p = 0.016) p-values determined by Wilcoxon-Mann-Whitney statistic GA at Blood Draw 19/1-20/6 weeks
(425) TABLE-US-00006 TABLE 6 RBM Screen Early Window (17-22 weeks) Middle Window (23-25 weeks) Late Window (26-28 weeks) ANALYTE AUC ANALYTE AUC ANALYTE AUC Fibrinogen 0.76 Vascular.Cell.Adhesion.Molecule.1..VCAM.1. 0.96 Apolipoprotein.C.III..Apo.C.III. 0.97 Antileukoproteinase..ALP. 0.75 Epidermal.Growth.Factor.Receptor..EGFR. 0.79 Apolipoprotein.B..Apo.B. 0.85 Kidney.Injury.Molecule.1..KIM.1. 0.73 Carcinoembryonic.antigen.related.cell.ad- 0.78 Apolipoprotein.E..Apo.E. 0.85 Tissue.Inhibitor.of.Metallo- 0.72 hesion.molecule.1..CEACAM1. Glutathione.S.Transferase.alpha.. 0.82 proteinases.1..TIMP.1. Carcinoembryonic.antigen.related.cell.ad- 0.76 GST.alpha. Beta.2.Microglobulin..B2M. 0.69 hesion.molecule.6..CEACAM6. Insulin.like.Growth.Factor.Binding. 0.81 Trefoil.Factor.3..TFF3. 0.69 Angiotensinogen 0.75 Protein.6..IGFBP6. Tyrosine.kinase.with.Ig.and.EGF.ho- 0.69 Interleukin.6.receptor.subunit.beta..IL.6R.beta. 0.75 Tyrosine.kinase.with.Ig.and.EGF. 0.78 mology.domains.2..TIE.2. CD5.Antigen.like..CD5L. 0.72 homology.domains.1..Tie.1. Angiotensinogen 0.67 Pulmonary.surfactant.associated.protein.D..SP.D. 0.7 Insulin.like.Growth.Factor.Binding. 0.78 P.Selectin 0.67 Cathepsin.B..pro...CTSB. 0.7 Protein.4..IGFBP4. Pepsinogen.I..PGI. 0.66 Growth.Hormone..GH. 0.69 Stem.Cell.Factor..SCF. 0.77 Prostate.Specific.Antigen..total..tPSA. 0.66 Beta.microseminoprotein..PSP94. 0.69 Phosphoserine.Aminotransferase..PSAT. 0.76 Pulmonary.and.Activation.Regulated. 0.66 Serotransferrin..Transferrin. 0.68 Trefoil.Factor.3..TFF3. 0.72 Chemokine..PARC. Neuronal.Cell.Adhesion.Molecule..Nr.CAM. 0.67 Chemokine.CC.4..HCC.4. 0.71 Serum.Amyloid.P.Component..SAP. 0.66 Urokinase.type.Plasminogen.Activator..uPA. 0.67 Macrophage.Colony.Stimulating.Factor. 0.7 Tumor Necrosis.Factor.Receptor.I.. 0.66 Vitronectin 0.65 1..M.CSF. TNF.RI. von.Willebrand.Factor..vWF. 0.65 Complement.Factor.H...Related.Protein. 0.7 Vascular.endothelial.growth.factor.re- 0.66 Testosterone..Total 0.65 1..CFHR1. ceptor.3..VEGFR.3. Lipocalin.1..LCN1. 0.65 Tyrosine.kinase.with.Ig.and.EGF. 0.69 Cathepsin.D 0.65 Squamous.Cell.Carcinoma.Antigen.1..SCCA.1. 0.64 homology.domains.2..TIE.2. Fetuin.A 0.65 Monocyte.Chemotactic.Protein.1..MCP.1. 0.64 Prostate.Specific.Antigen..total..tPSA. 0.68 Platelet.endothelial.cell.adhesion.mo- 0.65 Tenascin.C..TN.C. 0.63 Glucagon.like.Peptide.1..total..GLP.1. 0.68 lecule..PECAM.1. Complement.C3..C3. 0.63 total. Cadherin.1..E.Cad. 0.64 Tamm.Horsfall.Urinary.Glycoprotein..THP 0.63 FASLG.Receptor..FAS. 0.67 Cancer.Antigen.15.3..CA.15.3. 0.64 Neuropilin.1 0.63 Insulin.like.Growth.Factor.Binding. 0.67 Progesterone 0.64 Midkine 0.62 Protein.5..IGFBP5. Tenascin.C..TN.C. 0.64 Cortisol..Cortisol. 0.62 Urokinase.type.plasminogen.activator. 0.66 Aldose.Reductase 0.63 Immunoglobulin.M..IgM. 0.62 receptor..uPAR. Angiopoietin.1..ANG.1. 0.63 Receptor.for.advanced.glycosylation.end. 0.62 Haptoglobin 0.66 Apolipoprotein.A.II..Apo.A.II. 0.63 products..RAGE. Insulin.like.Growth.Factor.Binding. 0.66 Osteoprotegerin..OPG. 0.63 N.terminal.prohormone.of.brain.natriuretic. 0.62 Protein.2..IGFBP.2. Follicle.Stimulating.Hormone..FSH. 0.62 peptide..NT.proBNP. Kallikrein.5 0.66 Growth.Regulated.alpha.protein.. 0.62 Macrophage.inflammatory.protein.3.beta.. 0.62 Tenascin.C..TN.C. 0.65 GRO.alpha. MIP.3.beta. Cathepsin.D 0.65 Matrix.Metalloproteinase.7..MMP.7. 0.62 Kidney.Injury.Molecule.1..KIM.1. 0.61 Tumor Necrosis.Factor.Receptor.I.. 0.65 Phosphoserine.Aminotransferase..PSAT. 0.62 Matrix.Metalloproteinase.9..total..MMP.9..total. 0.61 TNF.RI. Serotransferrin..Transferrin. 0.62 Cellular.Fibronectin..cFib. 0.6 Interleukin.1.receptor.antagonist..IL.1ra. 0.64 Apolipoprotein.C.III..Apo.C.III. 0.61 Mesothelin..MSLN. 0.6 Proinsulin..Intact 0.64 Carbonic.anhydrase.9..CA.9. 0.61 Transthyretin..TTR. 0.6 Proinsulin..Total 0.64 Complement.C3..C3. 0.61 Collagen.IV 0.6 Matrix.Metalloproteinase.9..MMP.9. 0.64 Cystatin.C 0.61 Myeloid.Progenitor.Inhibitory.Factor.1. 0.64 Insulin.like.Growth.Factor.Binding.Pro- 0.61 MPIF.1. tein.4..IGFBP4. Angiopoietin.2..ANG.2. 0.64 Intercellular.Adhesion.Molecule.1.. 0.61 von.Willebrand.Factor..vWF. 0.63 ICAM.1. Cystatin.B 0.63 Macrophage.Colony.Stimulating.Fac- 0.61 Complement.C3..C3. 0.62 tor.1..M.CSF. Midkine 0.62 Midkine 0.61 Matrix.Metalloproteinase.9..total.. 0.62 Angiogenin 0.6 MMP.9..total. C.Reactive.Protein..CRP. 0.6 Monokine.Induced.by.Gamma.Inter. 0.62 CD.40.antigen..CD40. 0.6 feron..MIG. Cellular.Fibronectin..cFib. 0.6 Pulmonary.and.Activation.Regulated. 0.62 Interleukin.2.receptor.alpha..IL.2.re- 0.6 Chemokine..PARC. ceptor.alpha. Interleukin.2.receptor.alpha..IL.2. 0.62 Thrombospondin.4..TSP4. 0.6 receptor.alpha. Interleukin.6.receptor.subunit.beta.. 0.61 IL.6R.beta. CD5.Antigen.like..CD5L. 0.61 Hepsin 0.61 Fetuin.A 0.61 B.Lymphocyte.Chemoattractant..BLC. 0.61 Antileukoproteinase..ALP. 0.61 Alpha.2.Macroglobulin..A2Macro. 0.61 Tissue.Inhibitor.of.Metalloproteinases. 0.61 1..TIMP.1. Receptor.for.advanced.glycosylation. 0.6 end.products..RAGE. Pancreatic.secretory.trypsin.inhibitor.. 0.6 TATI. Adiponectin 0.6 Lumican 0.6 Apolipoprotein.C.I..Apo.C.I. 0.6 Apolipoprotein.H..Apo.H. 0.6 Hepatocyte.Growth.Factor..HGF. 0.6
(426) TABLE-US-00007 TABLE 7 Early Window (GABD 17-22 wks) Analyte Ranking by Different Multivariate Models rank rf boosting lasso logit 1 B.cell.activating.factor..BAFF. Macrophage.inflammatory.pro- Antileukoproteinase..ALP. Apolipoprotein.A.II..Apo.A. tein.3.beta..MIP.3.beta. II. 2 Macrophage.inflammatory.pro- B.cell.activating.factor..BAFF Angiotensinogen Apolipoprotein.a...Lp.a.. tein.3.beta..MIP.3.beta. 3 Fibrinogen Kidney.Injury.Molecule.1.. Kidney.Injury.Molecule.1..KIM.1 Apolipoprotein.A.IV..Apo.A. KIM.1. IV. 4 Kidney.Injury.Molecule.1.. Fibrinogen Progesterone Apolipoprotein.B..Apo.B. KIM.1. 5 Tissue.Inhibitor.of.Metallopro- Beta.2.Microglobulin..B2M. Monocyte.Chemotactic.Protein.1. Apolipoprotein.C.III..Apo.C. teinases.1..TIMP.1. MCP.1. III. 6 Tumor.necrosis.factor.ligand. Tissue.Inhibitor.of.Metallopro- Follicle.Stimulating.Hormone.. Apolipoprotein.H..Apo.H. superfamily.member.12..Tweak teinases.1..TIMP.1. FSH. 7 Pulmonary.and.Activation.Reg- N.terminal.prohormone.of. Serotransferrin..Transferrin. Angiotensin.Converting.En- ulated.Chemokine..PARC. brain.natriuretic.peptide..NT. zyme..ACE. proBNP. 8 Pancreatic.Polypeptide..PPP. Antileukoproteinase..ALP. Tyrosine.kinase.with.Ig.and.EGF. Apolipoprotein.C.I..Apo.C.I. homology.domains.2..TIE.2. 9 Angiotensinogen Prostate.Specific.Antigen..total.. Thyroglobulin..TG. B.Lymphocyte.Chemo- tPSA. attractant..BLC. 10 Prostate.Specific.Antigen..total.. Pancreatic.Polypeptide..PPP. Cancer.Antigen.15.3..CA.15.3. Adiponectin tPSA. 11 Antileukoproteinase..ALP. Collagen.IV Pulmonary.and.Activation. Angiotensinogen Regulated.Chemokine..PARC. 12 Tyrosine.kinase.with.Ig.and.EGF. Tyrosine.kinase.with.Ig.and.EGF. Trefoil.Factor.3..TFF3. AXL.Receptor.Tyrosine. homology.domains.2..TIE.2. homology.domains.2..TIE.2. Kinase..AXL. 13 Cathepsin.D Angiotensinogen Midkine Angiogenin 14 Beta.2.Microglobulin..B2M. Cathepsin.D Beta.2.Microglobulin..B2M. Aldose.Reductase
(427) TABLE-US-00008 TABLE 8 Middle Window (GABD 23-25 wks) Analyte Ranking by Different Multivariate Models rank rf boosting lasso logit 1 Vascular.Cell.Adhesion.Mole- Vascular.Cell.Adhesion.Mole- Vascular.Cell.Adhesion.Mole- Alpha.Fetoprotein..AFP. cule.1..VCAM.1. cule.1..VCAM.1. cule.1..VCAM.1. 2 Aldose.Reductase Aldose.Reductase Osteoprotegerin..OPG. Adiponectin 3 Osteoprotegerin..OPG. Osteoprotegerin..OPG. Apolipoprotein.E..Apo.E. Angiogenin 4 Insulin.like.Growth.Factor. Angiotensinogen Aldose.Reductase Alpha.1.Antitrypsin..AAT. Binding.Protein.3..IGFBP.3. 5 Carcinoembryonic.antigen.re- Apolipoprotein.E..Apo.E. Cancer.Antigen.72.4..CA.72.4 Angiotensin.Converting.En- lated.cell.adhesion.molecule.1. zyme..ACE. CEACAM1. 6 Angiotensinogen Interleukin.16..IL.16. Epidermal.Growth.Factor.Re- Alpha.1.Microglobulin.. ceptor..EGFR. A1Micro. 7 Interleukin.16..IL.16. Epidermal.Growth Factor. Progesterone Alpha.1.Antichymotrypsin.. Receptor..EGFR. AACT. 8 Insulin.like.Growth.Factor. Alpha.Fetoprotein..AFP. Human.Chorionic.Gonado- Alpha.2.Macroglobulin.. Binding.Protein.4..IGFBP4. tropin.beta..hCG. A2Macro. 9 Epidermal.Growth.Factor.Re- Alpha.2.Macroglobulin.. Tissue.Inhibitor.of.Metallopro- Aldose.Reductase ceptor..EGFR. A2Macro. teinases.1..TIMP.1. 10 Carcinoembryonic.antigen.re- Angiopoietin.2..ANG.2. Alpha.Fetoprotein..AFP. X6Ckine lated.cell.adhesion.molecule.6. CEACAM6. 11 Urokinase.type.Plasminogen. Apolipoprotein.a...Lp.a.. Carcinoembryonic.antigen.re- Angiopoietin.2..ANG.2. Activator..uPA. lated.cell.adhesion.molecule.1. CEACAM1. 12 Tissue.Inhibitor.of.Metallopro- Alpha.1.Microglobulin.. Insulin.like.Growth.Factor.Bi- MHC.class.I.chain.related.pro- teinases.1..TIMP.1. A1Micro. nding.Protein.5..IGFBP5. tein.A..MICA. 13 Progesterone Angiogenin Lectin.Like.Oxidized.LDL.Re- Neutrophil.Gelatinase. ceptor.1..LOX.1. Associated.Lipocalin..NGAL. 14 Interleukin.6.receptor.subunit. B.cell.activating.factor..BAFF FASLG.Receptor..FAS. P.Selectin beta..IL.6R.beta. 15 Thrombospondin.4..TSP4. Adiponectin Serotransferrin..Transferrin. Tissue.Inhibitor.of.Metallopro- teinases.2..TIMP.2.
(428) TABLE-US-00009 TABLE 9 Late Window (GABD 26-28 weeks) Analyte Ranking by Different Multivariate Models rank rf boosting 1 Apolipoprotein.C.III..Apo.C.III. Apolipoprotein.C.III..Apo.C.III. 2 Apolipoprotein.E..Apo.E. Apolipoprotein.E..Apo.E. 3 Insulin.like.Growth.Factor.Binding.Protein.4..IGFBP4. EN.RAGE 4 Insulin.like.Growth.Factor.Binding.Protein.6..IGFBP6. Alpha.Fetoprotein..AFP. 5 Apolipoprotein.B..Apo.B. Apolipoprotein.B..Apo.B. 6 Interleukin.18..IL.18. Angiotensinogen 7 Glutathione.S.Transferase.alpha..GST.alpha. Angiotensin.Converting.Enzyme..ACE. 8 Stem.Cell.Factor..SCF. Aldose.Reductase 9 Phosphoserine.Aminotransferase..PSAT. Apolipoprotein.a...Lp.a.. 10 Tyrosine.kinase.with.Ig.and.EGF.homology.domains.1..Tie.1. Angiopoietin.2..ANG.2. 11 EN.RAGE X6Ckine 12 Vascular.Endothelial.Growth.Factor.Receptor.1..VEGFR.1. Alpha.2.Macroglobulin..A2Macro. 13 Insulin.like.Growth.Factor.Binding.Protein.2..IGFBP.2. Angiogenin 14 Chemokine.CC.4..HCC.4. Alpha.1.Antichymotrypsin..AACT. 15 Tyrosine.kinase.with.Ig.and.EGF.homology.domains.2..TIE.2. Adiponectin rank lasso logit 1 Apolipoprotein.C.III..Apo.C.III. Alpha.1.Microglobulin..A1Micro. 2 Interleukin.18..IL.18. Aldose.Reductase 3 Apolipoprotein.B..Apo.B. Angiogenin 4 Glutathione.S.Transferase.alpha..GST.alpha. Alpha.Fetoprotein..AFP. 5 Tyrosine.kinase.with.Ig.and.EGF.homology.domains.1..Tie.1. Alpha.1.Antichymotrypsin..AACT. 6 Trefoil.Factor.3..TFF3. Alpha.1.Antitrypsin..AAT. 7 Apolipoprotein.E..Apo.E. X6Ckine 8 Insulin.like.Growth.Factor.Binding.Protein.4..IGFBP4. Alpha.2.Macroglobulin..A2Macro. 9 FASLG.Receptor..FAS. Adiponectin 10 Tyrosine.kinase.with.Ig.and.EGF.homology.domains.2..TIE.2. Chromogranin.A..CgA. 11 Creatine.Kinase.MB..CK.MB. Macrophage.Inflammatory.Protein.1.beta..MIP.1.beta. 12 Stem.Cell.Factor..SCF. Angiopoietin.2..ANG.2. 13 Chemokine.CC.4..HCC.4. Angiotensin.Converting.Enzyme..ACE. 14 Complement.Factor.H...Related.Protein.1..CFHR1. Angiotensinogen 15 Alpha.2.Macroglobulin..A2Macro. Apolipoprotein.a...Lp.a..
(429) TABLE-US-00010 TABLE 10 Table of epitope and clonality information for kits tested for analytes IBP4_HUMAN and SHBG_HUMAN when available. Person's r Correlation Value Catalog Capture Detection ELISA Analyte Vendor Number Antibody Antibody Epitopes vs MS IBP4_HUMAN ANSCH Webster, AL-126 Monoclonal Monoclonal C-terminal 0.8631 Labs Texas SHBG_HUMAN R&D Minneapolis, DSHBGOB Monoclonal Monoclonal Unmapped 0.9228 Systems Minnesota SHBG_HUMAN Raybiotech Norcross, ELH-SHBG Monoclonal Monoclonal Unmapped 0.8675 Georgia IBP4_HUMAN ABNOVA Taipei, KA1873 Monoclonal Polyclonal Unknown 0.2635 Taiwan IBP4_HUMAN ABCAM Cambridge, ab 100542 Monoclonal Polyclonal Asp22- 0.3439 Massachusetts Glu258 IBP4_HUMAN ANSCH Webster, AL-128 Monoclonal Monoclonal N-terminus 0.2954 Labs Texas and C-terminus
(430) TABLE-US-00011 TABLE 11 Analytes showing kits that either correlate with MS data or do not. Correlating Data Non-Correlating Data Person's r Person's r Analyte Correlation Value Analyte Correlation Value (ELISA Kit #) ELISA vs MS (ELISA Kit #) ELISA vs MS ANGT_HUMAN #1 0.6192 A2GL_HUMAN ?0.2933 B2MG_HUMAN 0.8414 ANGT_HUMAN #2 ?0.01351 BGH3_HUMAN 0.7159 APOH_HUMAN 0.2669 C06_HUMAN 0.8045 CHL1_HUMAN 0.0795 CD14_HUMAN 0.8004 CLUS_HUMAN 0.3132 CHL1_HUMAN 0.9271 CPN1_HUMAN 0.1775 FETUA_HUMAN 0.7259 CSH_HUMAN ?0.3172 IBP4_HUMAN#1 0.8631 FBLN1_HUMAN 0.1141 IGF2_HUMAN 0.6346 IBP4_HUMAN #2 0.3439 LBP_HUMAN 0.7389 IBP4_HUMAN #3 0.2365 PAPP1_HUMAN #1 0.9163 IBP4_HUMAN #4 0.2954 SHBG_HUMAN #1 0.9228 PAPP1_HUMAN #2 0.04381 SHBG_HUMAN #2 0.8675 PRG2_HUMAN #1 0.2699 PSG2_HUMAN #2 ?0.06944 PTGDS_HUMAN 0.1627 TENX_HUMAN ?0.1116 TIE1_HUMAN 0.0384 VTDB_HUMAN ?0.2459 VTNC_HUMAN 0.1243
(431) TABLE-US-00012 TABLE 12 IBP4 and SHBG ELISA Kits Demonstrating sPTB vs Control Separation (univariate) Control vs Case Person's Separation P- Analyte R Value Vendor Catalogue # IBP4_HUMAN 0.8631 0.0009 ANSCH Labs Webster, Texas AL-126 SHBG_HUMAN 0.8675 0.0374 R&D Systems Minneapolis, DSHBG0B Minnesota
(432) TABLE-US-00013 TABLE 13 dbSNP rs# Hetero- Protein Codon NP_001543.2 NM_001552.2 cluster id zygosity Validation MAF Function dbSNP allele residue position Amino acid pos mRNA pos rs757185079 0 missense C Pro [P] 2 214 953 contig reference A GIn [Q] 2 214 rs759609271 0 nonsense T 1 222 976 contig reference C Gln [Q] 1 222 rs765360682 0 missense A His [H] 2 223 980 contig reference G Arg [R] 2 223
(433) TABLE-US-00014 TABLE 14 NP_001031.2 dbSNP rs# Hetero- dbSNP Protein Codon Amino acid NM_001040.2 cluster id zygosity Validation MAF Function allelle residue pos pos mRNA pos rs751519873 0 missense T Val [V] 2 171 591 contig reference C Ala [A] 2 171 rs528701583 0 byCluster synonymous A Ala [A] 3 171 592 contig reference G Ala [A] 3 171 rs201120578 0 byClusterWith1000- 0.0002 missense T Phe [F] 1 172 593 GenomeData contig reference C Leu [L] 1 172 rs747379879 0 synonymous C Leu [L] 3 172 595 contig reference T Leu [L] 3 172 rs769030967 0 missense C Arg [R] 1 173 596 contig reference G Gly [G] 1 173 rs777068397 0 missense C Ala [A] 2 173 597 contig reference G Gly [G] 2 173 synonymous C Gly [G] 3 173 contig reference G Gly [G] 3 173 rs567677603 0 byCluster synonymous T Pro [P] 3 178 613 contig reference C Pro [P] 3 178 rs115336700 0.01 byClusterbyFreqWith- 0.0048 missense C Pro [P] 1 179 614 1000GenomeData contig reference G Ala [A] 1 179 rs765896254 0 missense G Ser [S] 2 181 621 contig reference A Asn [N] 2 181 rs143134553 0 byClusterWith1000- 0.0002 missense A Lys [K] 3 181 622 GenomeData contig reference C Asn [N] 3 181 rs139379650 0 missense T Trp [W] 1 183 626 contig reference C Arg [R] 1 183 rs759318203 0 missense A Gln [Q] 2 183 627 contig reference G Arg [R] 2 183 rs367555757 0 byCluster synonymous A Gly [G] 3 173 598
(434) TABLE-US-00015 TABLE 15 Discovery_BMI > 22 ? 37 Discovery_AllBMI Discovery_BMI < 35 GABD MW MW MW (days) AUC p-value Cases Control AUC p-value Cases Control AUC p-value Cases Control 133:143 0.822 0.0018 10 18 0.719 0.0064 16 32 0.788 0.0023 12 22 133:144 0.791 0.0031 11 20 0.702 0.0089 17 34 0.763 0.0037 13 24 133:145 0.786 0.0027 12 21 0.711 0.0053 18 36 0.766 0.0023 14 26 133:146 0.788 0.0023 12 22 0.726 0.0025 19 38 0.773 0.0016 14 28 133:147 0.804 0.001 13 22 0.730 0.0016 20 40 0.791 0.0006 15 29 133:148 0.804 0.001 13 22 0.730 0.0016 20 40 0.791 0.0006 15 29 133:149 0.804 0.001 13 22 0.730 0.0016 20 40 0.791 0.0006 15 29 133:150 0.804 0.001 13 22 0.730 0.0016 20 40 0.791 0.0006 15 29 133:151 0.773 0.0003 14 23 0.722 0.0018 21 42 0.778 0.0007 16 31 133:152 0.773 0.0023 14 23 0.722 0.0018 21 42 0.778 0.0007 16 31 133:153 0.787 0.0009 15 25 0.736 0.0008 22 44 0.790 0.0003 17 33 Verification_BMI > 22 ? 37 Verification_AllBMI Verification_BMI < 35 GABD MW MW MW (days) AUC p-value Cases Control AUC p-value Cases Control AUC p-value Cases Control 133:143 0.889 0.0364 2 9 0.750 0.0415 6 12 0.818 0.0278 4 11 133:144 0.889 0.0364 2 9 0.750 0.0415 6 12 0.818 0.0278 4 11 133:145 0.867 0.0245 3 10 0.765 0.023 7 14 0.815 0.0175 5 13 133:146 0.867 0.0245 3 10 0.765 0.023 7 14 0.815 0.0175 5 13 133:147 0.867 0.0245 3 10 0.765 0.023 7 14 0.815 0.0175 6 13 133:148 0.813 0.0291 4 12 0.727 0.0351 8 16 0.767 0.0274 6 15 133:149 0.839 0.0173 4 14 0.772 0.01 9 18 0.794 0.0149 6 17 133:150 0.839 0.0173 4 14 0.772 0.01 9 18 0.794 0.0149 6 17 133:151 0.839 0.0173 4 14 0.772 0.01 9 18 0.794 0.0149 6 17 133:152 0.839 0.0173 4 14 0.772 0.01 9 18 0.794 0.0149 6 17 133:153 0.839 0.0173 4 14 0.772 0.01 9 18 0.794 0.0149 6 17 Validation_BMI > 22 ? 37 Validation_AllBMI Validation_BMI < 35 GABD MW MW MW (days) AUC p-value Cases Control AUC p-value Cases Control AUC p-value Cases Control 133-143 0.867 0.0051 7 15 0.698 0.0572 12 24 0.766 0.0248 9 19 133-144 0.768 0.0185 10 19 0.670 0.058 16 32 0.695 0.0501 13 26 133-145 0.788 0.0073 11 21 0.685 0.0342 17 34 0.707 0.0305 14 28 133-146 0.750 0.0157 12 23 0.670 0.0438 18 36 0.697 0.0342 15 29 133-147 0.750 0.0157 12 23 0.670 0.0438 18 36 0.697 0.0342 15 29 133-148 0.750 0.0157 12 23 0.670 0.0438 18 36 0.697 0.0342 15 29 133-149 0.684 0.0157 14 26 0.623 0.127 20 40 0.649 0.091 17 32 133-150 0.684 0.0587 14 26 0.623 0.127 20 40 0.649 0.091 17 32 133-151 0.609 0.0587 16 27 0.555 0.4782 22 43 0.598 0.2489 19 33 133-152 0.628 0.1582 17 28 0.573 0.3327 23 46 0.609 0.1897 20 34 133-153 0.646 0.0988 18 29 0.574 0.3152 24 48 0.609 0.1897 20 34 GABD (days) refers to the interval of gestation age at blood draw in days MW p-value tests equivalence to AUC = 0.5 by a one-sided Wilcoxon Mann Whitney statistic
(435) TABLE-US-00016 TABLE16 SummaryofpeakareasfortransitionstofourIBP4_HUMANsyntheticheavypeptides SEQ Peptide ID Protein Precursor Precursor Product Product Fragment Retention Sequence NO: Name Mz Charge Mz Charge Ion Time Area LPGGLEPK 1 IBP4_HUMAN 409.75 2 211.14 1 b2 4.62 252768 LPGGLEPK 1 IBP4_HUMAN 409.75 2 325.19 1 b4 4.66 76266 LPGGLEPK 1 IBP4_HUMAN 409.75 2 705.40 1 y7 4.66 844128 LPGGLEPK 1 IBP4_HUMAN 409.75 2 608.35 1 y6 4.66 866360 LPGGLEPK 1 IBP4_HUMAN 409.75 2 551.33 1 y5 4.62 96412 LPGGLEPK 1 IBP4_HUMAN 409.75 2 252.18 1 y2 4.66 939572 LPGGLEPK 1 IBP4_HUMAN 409.75 2 353.20 2 y7 4.66 3489414 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 289.10 1 b2 1.85 9703 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 426.16 1 b3 1.85 14713 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 822.36 1 b7 1.85 2136 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 903.47 1 y8 1.85 17798 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 766.41 1 y7 1.85 73221 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 669.36 1 y6 1.85 5019 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 598.32 1 y5 1.85 4078 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 485.23 1 y4 1.85 4383 QCHPALDGQR 2 IBP4_HUMAN 596.28 2 370.21 1 y3 1.85 25859 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 289.10 1 b2 1.85 57043 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 426.16 1 b3 1.85 109467 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 523.21 1 b4 1.85 12019 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 594.25 1 b5 1.85 30122 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 213.58 2 b3 1.85 7249 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 262.11 2 b4 1.85 11989 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 297.63 2 b5 1.85 71677 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 354.17 2 b6 1.85 10532 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 411.68 2 b7 1.85 8062 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 766.41 1 y7 1.85 118740 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 669.36 1 y6 1.85 79410 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 598.32 1 y5 1.85 235615 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 485.23 1 y4 1.85 637333 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 370.21 1 y3 1.85 440794 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 313.19 1 y2 1.85 26708 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 532.25 2 y9 1.85 52271 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 452.24 2 y8 1.85 24399 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 383.71 2 y7 1.85 238180 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 335.18 2 y6 1.85 64484 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 299.66 2 y5 1.85 18478 QCHPALDGQR 2 IBP4_HUMAN 397.86 3 243.12 2 y4 1.85 50903 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 239.11 1 b2 8.25 35797 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 368.16 1 b3 8.25 15185 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 483.18 1 b4 8.25 14411 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 596.27 1 b5 8.25 19740 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 759.33 1 b6 8.25 35904 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 872.41 1 b7 8.25 38201 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 985.50 1 b8 8.25 38297 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 1195.64 1 b10 8.2 11054 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 1107.59 1 y9 8.25 22635 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 994.50 1 y8 8.25 33493 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 881.42 1 y7 8.25 98887 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 784.36 1 y6 8.25 2565 THEDLYIIPIPNCDR 3 IBP4_HUMAN 933.46 2 671.28 1 y5 8.25 31935 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 239.11 1 b2 8.25 13586 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 368.16 1 b3 8.25 6976 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 483.18 1 b4 8.25 12635 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 596.27 1 b5 8.25 36886 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 759.33 1 b6 8.25 138833 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 872.41 1 b7 8.25 190646 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 985.50 1 b8 8.25 54139 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 493.25 2 b8 8.25 13320 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 541.78 2 b9 8.25 6168 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 994.50 1 y8 8.25 5893 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 881.42 1 y7 8.25 297346 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 784.36 1 y6 8.25 14422 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 671.28 1 y5 8.25 212081 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 574.23 1 y4 8.25 10550 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 460.18 1 y3 8.25 4183 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 441.21 2 y7 8.25 59487 THEDLYIIPIPNCDR 3 IBP4_HUMAN 622.64 3 336.14 2 y5 8.25 48606 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 245.08 1 b2 2.94 1864 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 472.22 1 b4 2.94 7355 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 569.27 1 b5 2.94 1648 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 668.34 1 b6 2.94 30775 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 765.39 1 b7 2.94 1033 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 893.45 1 b8 2.94 6138 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 950.47 1 b9 2.94 4242 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 285.14 2 b5 2.94 680 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 334.67 2 b6 2.94 1704 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 383.20 2 b7 2.9 3561 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 447.23 2 b8 2.94 3333 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 475.74 2 b9 2.94 6911 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 1083.49 1 y9 2.94 11083 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 1026.47 1 y8 2.94 4195 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 939.43 1 y7 2.94 8994 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 779.40 1 y6 2.94 13897 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 651.34 1 y5 2.94 23600 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 564.31 1 y4 2.94 7164 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 435.27 1 y3 2.94 8441 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 322.19 1 y2 2.94 10343 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 866.43 2 y15 2.94 2751 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 830.91 2 y14 2.94 994 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 752.86 2 y13 2.94 2065 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 654.80 2 y11 2.94 26747 EDARPVPQGSCQSELHR 4 IBP4_HUMAN 659.31 3 542.25 2 y9 2.94 7872 Comparative IBP4 peptide and transition MS data. Four different heavy labelled peptides (R*+10 daltons) exemplify various transitions and their relative intensities that could be monitored to quantify IBP4. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify IBP4.
(436) TABLE-US-00017 TABLE17 PeakAreaSummaryforTransitionstoIBP4_HUMANSurveyedUsingRecombinantProtein SEQ Peptide ID Precursor Precursor Product Product Fragment Retention Sequence NO: ProteinName Mz Charge Mz Charge lon Time Area CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 317.14 1 b2 6.4 20339 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 414.19 1 b3 6.35 21220 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 610.31 1 b5 6.46 13132 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 667.33 1 b6 6.46 14894 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 207.60 2 b3 6.4 5605 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 256.13 2 b4 6.4 13853 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 414.19 2 b7 6.4 21460 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 862.41 1 y7 6.4 16655 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 805.39 1 y6 6.4 7047 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 645.36 1 y5 6.4 19298 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 516.31 1 y4 6.4 14093 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 387.27 1 y3 6.35 11771 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 274.19 1 y2 6.46 8168 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 578.29 2 y10 6.35 7367 CRPPVGCEELVR 5 sp|P22692|IBP4_HUMAN 491.24 3 403.20 2 y6 6.46 5605 VNGAPR 6 sp|P22692|IBP4_HUMAN 307.17 2 214.12 1 b2 1.28 227017 VNGAPR 6 sp|P22692|IBP4_HUMAN 307.17 2 220.12 2 b5 1.2 17711 VNGAPR 6 sp|P22692|IBP4_HUMAN 307.17 2 272.17 1 y2 1.16 9908 VNGAPR 6 sp|P22692|IBP4_HUMAN 307.17 2 257.64 2 y5 1.2 8484 VNGAPR 6 sp|P22692|IBP4_HUMAN 307.17 2 200.62 2 y4 1.2 3592 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 245.08 1 b2 5.45 1059 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 472.22 1 b4 5.35 1968 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 668.34 1 b6 5.45 7567 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 950.47 1 b9 5.35 908 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 519.25 2 b10 5.45 1513 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 1016.46 1 y8 5.45 757 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 929.43 1 y7 5.4 2876 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 641.34 1 y5 5.35 4389 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 312.18 1 y2 5.35 3481 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 649.80 2 y11 5.35 5449 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 537.24 2 y9 5.5 1513 EDARPVPQGSCQSELHR 4 sp|P22692|IBP4_HUMAN 655.98 3 321.17 2 y5 5.4 605 LAASQSR 7 sp|P22692|IBP4_HUMAN 366.70 2 343.20 1 b4 1.31 4692 LAASQSR 7 sp|P22692|IBP4_HUMAN 366.70 2 279.65 2 b6 1.31 45027 LAASQSR 7 sp|P22692|IBP4_HUMAN 366.70 2 262.15 1 y2 1.31 3481 LAASQSR 7 sp|P22692|IBP4_HUMAN 366.70 2 310.16 2 y6 1.26 8097 LAASQSR 7 sp|P22692|IBP4_HUMAN 366.70 2 274.64 2 y5 1.31 22173 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 483.18 1 b4 8.96 619 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 596.27 1 b5 8.96 1115 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 759.33 1 b6 9.08 1610 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 872.41 1 b7 8.96 3468 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 985.50 1 b8 9.04 3096 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 1097.58 1 y9 8.96 867 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 984.49 1 y8 9.04 1734 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 871.41 1 y7 9 4211 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 661.27 1 y5 8.96 2477 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 928.45 2 744.88 2 y12 9.04 743 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 239.11 1 b2 8.96 4211 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 368.16 1 b3 9 1486 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 483.18 1 b4 8.96 5511 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 596.27 1 b5 9.04 11580 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 759.33 1 b6 8.96 30343 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 872.41 1 b7 8.96 53318 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 985.50 1 b8 8.96 9660 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 380.17 2 b6 9 2353 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 436.71 2 b7 8.96 8174 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 493.25 2 b8 8.96 4830 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 541.78 2 b9 9.41 2477 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 984.49 1 y8 9 2229 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 871.41 1 y7 9 55981 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 774.36 1 y6 8.96 5202 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 661.27 1 y5 8.96 52141 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 564.22 1 y4 8.92 4582 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 492.75 2 y8 8.96 5264 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 436.21 2 y7 8.96 11147 THEDLYIIPIPNCDR 3 sp|P22692|IBP4_HUMAN 619.31 3 331.14 2 y5 8.96 10280 NGNFHPK 8 sp|P22692|IBP4_HUMAN 407.20 2 286.11 1 b3 1.41 26865 NGNFHPK 8 sp|P22692|IBP4_HUMAN 407.20 2 285.62 2 b5 1.41 21038 NGNFHPK 8 sp|P22692|IBP4_HUMAN 407.20 2 334.15 2 b6 1.36 1665 NGNFHPK 8 sp|P22692|IBP4_HUMAN 407.20 2 244.17 1 y2 1.31 1665 NGNFHPK 8 sp|P22692|IBP4_HUMAN 407.20 2 321.67 2 y5 1.36 2422 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 426.16 1 b3 4.96 2882 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 297.63 2 b5 4.96 2401 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 756.40 1 y7 4.96 4483 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 659.35 1 y6 4.91 2722 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 588.31 1 y5 4.96 4963 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 475.23 1 y4 4.96 23535 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 360.20 1 y3 4.96 13448 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 527.25 2 y9 5.02 640 QCHPALDGQR 2 sp|P22692|IBP4_HUMAN 394.52 3 378.70 2 y7 4.91 7204 CWCVDR 9 sp|P22692|IBP4_HUMAN 448.18 2 347.12 1 b2 6.46 2497 CWCVDR 9 sp|P22692|IBP4_HUMAN 448.18 2 735.32 1 y5 6.41 2573 CWCVDR 9 sp|P22692|IBP4_HUMAN 448.18 2 549.24 1 y4 6.46 14908 CWCVDR 9 sp|P22692|IBP4_HUMAN 448.18 2 389.21 1 y3 6.46 6584 CWCVDR 9 sp|P22692|IBP4_HUMAN 448.18 2 290.15 1 y2 6.46 4086 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 211.14 1 b2 6.81 24216 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 325.19 1 b4 6.81 16119 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 567.31 1 b6 6.76 8778 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 697.39 1 y7 6.76 71815 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 600.34 1 y6 6.76 141209 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 543.31 1 y5 6.76 17481 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 244.17 1 y2 6.81 149987 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 349.20 2 y7 6.76 370277 LPGGLEPK 1 sp|P22692|IBP4_HUMAN 405.74 2 243.65 2 y4 6.76 7265 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 300.16 1 b3 7.47 5764 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 575.21 1 b5 7.42 1121 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 712.27 1 b6 7.47 961 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 840.33 1 b7 7.53 6084 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 953.41 1 b8 7.42 3682 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 420.67 2 b7 7.47 3682 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 477.21 2 b8 7.42 3282 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 570.24 2 b10 7.42 961 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 973.49 1 y8 7.47 5764 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 836.43 1 y7 7.47 29618 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 708.37 1 y6 7.47 22734 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 595.28 1 y5 7.47 39705 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 524.25 1 y4 7.47 23535 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 409.22 1 y3 7.47 35862 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 322.19 1 y2 7.47 3682 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 681.32 2 y11 7.42 103024 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 624.77 2 y10 7.47 58757 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 567.26 2 y9 7.42 31860 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 487.25 2 y8 7.47 18411 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 354.69 2 y6 7.47 2401 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 298.15 2 y5 7.53 6084 GELDCHQLADSFR 10 sp|P22692|IBP4_HUMAN 516.57 3 262.63 2 y4 7.47 1601
(437) TABLE-US-00018 TABLE18 PeakareasummaryforthedifferenttransitionsforSHBGHUMAN Pooled Pregnant SEQ Pre- Pre- Prod- Prod- Frag- Reten- rSHBG Serum ID cursor cursor uct uct ment tion Peak Peak PeptideSequence NO: ProteinName Mz Charge Mz Charge Ion Time Area Area TSSSFEVR 11 sp|P04278|SHBG_HUMAN 456.72 2 811.39 1 y7 6.18 26852 96178 TSSSFEVR 11 sp|P04278|SHBG_HUMAN 456.72 2 724.36 1 y6 6.18 104140 406657 TSSSFEVR 11 sp|P04278|SHBG_HUMAN 456.72 2 637.33 1 y5 6.18 39819 152232 TSSSFEVR 11 sp|P04278|SHBG_HUMAN 456.72 2 550.30 1 y4 6.18 33489 134866 TSSSFEVR 11 sp|P04278|SHBG_HUMAN 456.72 2 403.23 1 y3 6.18 27156 91485 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 288.13 1 b2 9.44 28789 430926 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 403.16 1 b3 9.44 48399 551674 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 629.26 1 b5 9.44 5719 37766 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 686.28 1 b6 9.44 4288 48075 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 785.35 1 b7 9.44 19603 255484 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 898.43 1 b8 9.44 9799 106444 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 1045.50 1 b9 9.44 2959 34703 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 1153.59 1 y10 9.49 2043 48983 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 1054.52 1 y9 9.44 23075 403061 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 941.44 1 y8 9.44 17663 302129 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 794.37 1 y7 9.39 10616 212103 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 631.30 1 y6 9.44 13070 199732 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 574.28 1 y5 9.44 2040 35430 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 459.26 1 y4 9.49 5716 86862 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 358.21 1 y3 9.44 1836 39288 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 244.17 1 y2 9.49 11027 123399 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 776.37 2 y14 9.44 12561 174726 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 718.86 2 y13 9.44 38597 604225 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 919.93 2 287.65 2 y5 9.49 4901 88390 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 288.13 1 b2 9.44 8782 30219 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 403.16 1 b3 9.44 7759 81236 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 686.28 1 b6 9.44 8984 65110 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 785.35 1 b7 9.44 30014 161864 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 898.43 1 b8 9.44 12149 65219 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 1045.50 1 b9 9.44 20004 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 343.64 2 b6 9.44 22039 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 449.72 2 b8 9.44 13058 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 523.25 2 b9 9.49 10924 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 633.30 2 b11 9.39 27875 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 741.33 2 b13 9.44 23467 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 1054.52 1 y9 9.49 22048 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 941.44 1 y8 9.39 27157 111649 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 794.37 1 y7 9.44 43700 251500 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 631.30 1 y6 9.44 56356 290887 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 574.28 1 y5 9.39 7863 50921 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 459.26 1 y4 9.49 12457 66024 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 358.21 1 y3 9.39 8376 26955 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 244.17 1 y2 9.39 17667 74103 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 776.37 2 y14 9.49 22867 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 718.86 2 y13 9.44 11628 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 471.22 2 y8 9.44 21129 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 397.69 2 y7 9.39 9192 46444 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 316.16 2 y6 9.49 37345 TWDPEGVIFYGDTNPK 12 sp|P04278|SHBG_HUMAN 613.62 3 287.65 2 y5 9.44 17354 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 231.06 1 b2 10.57 2450 218844 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 417.14 1 b3 10.62 4085 660895 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 564.21 1 b4 10.67 2652 190972 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 695.25 1 b5 10.62 56841 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 922.50 1 y7 10.62 206072 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 736.42 1 y6 10.62 12655 1487537 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 589.35 1 y5 10.62 16227 1563060 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 458.31 1 y4 10.67 4489 681922 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 345.22 1 y3 10.57 7755 826140 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 288.20 1 y2 10.62 100631 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 519.27 2 y8 10.62 25104 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 576.78 2 461.75 2 y7 10.62 83186 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 384.86 3 417.14 1 b3 10.62 11229 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 384.86 3 564.21 1 b4 10.57 7349 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 384.86 3 589.35 1 y5 10.57 2450 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 384.86 3 458.31 1 y4 10.62 16538 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 384.86 3 345.22 1 y3 10.62 30524 DDWFMLGLR 13 sp|P04278|SHBG_HUMAN 384.86 3 288.20 1 y2 10.51 3880 DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 329.16 1 b3 7.84 5943 24455 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 555.25 1 b5 7.72 8188 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 796.39 1 b7 7.84 3326 13408 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 909.48 1 b8 7.84 5227 15675 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 1046.54 1 b9 7.72 12351 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 1160.58 1 b10 7.84 5462 11163 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 523.77 2 b9 7.72 8555 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 580.79 2 b10 7.84 4630 24587 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 649.32 2 b11 7.78 8555 24107 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 742.36 2 b12 7.9 4753 20193 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 777.88 2 b13 7.9 8312 19238 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 841.91 2 b14 7.72 8551 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 898.45 2 b15 7.84 6656 29217 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 1062.54 2 b19 7.84 3328 6649 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 1155.63 1 y11 7.9 11995 32069 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 969.55 1 y10 7.84 16386 47509 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 898.51 1 y9 7.84 9025 26601 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 770.45 1 y8 7.78 6410 16278 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 657.37 1 y7 7.84 4990 21850 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 556.32 1 y6 7.9 3089 8193 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 457.25 1 y5 7.9 3324 9848 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 329.19 1 y3 7.9 7600 11648 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 1062.56 2 y19 7.78 3802 9572 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 646.85 2 y12 7.9 3328 7497 AGPR DGRPEIQLHNHWAQLTVG 14 sp|P04278|SHBG_HUMAN 818.09 3 329.19 2 y7 7.84 10685 5422 AGPR WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 324.15 1 b2 5.82 95843 143834 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 452.20 1 b3 5.88 24228 30155 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 551.27 1 b4 5.82 10215 16269 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 680.32 1 b5 5.88 31354 35986 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 779.38 1 b6 5.82 8316 12828 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 739.41 1 y6 5.82 29929 37874 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 602.35 1 y5 5.82 57721 77194 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 246.18 1 y2 5.82 91450 141340 WHQVEVK 15 sp|P04278|SHBG_HUMAN 463.25 2 370.21 2 y6 5.82 88601 90134 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 324.15 1 b2 5.82 89310 94424 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 452.20 1 b3 5.88 82658 107490 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 551.27 1 b4 5.82 57008 47029 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 340.66 2 b5 5.82 47270 48456 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 602.35 1 y5 5.82 20904 24944 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 474.29 1 y4 5.82 43114 35632 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 246.18 1 y2 5.82 284438 306895 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 370.21 2 y6 5.82 431957 434922 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 301.68 2 y5 5.82 32539 42866 WHQVEVK 15 sp|P04278|SHBG_HUMAN 309.17 3 237.65 2 y4 5.82 24000 22570 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 261.09 1 b2 9.56 9976 176237 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 318.11 1 b3 9.5 4160 68533 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 433.14 1 b4 9.56 11047 235634 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 520.17 1 b5 9.44 89909 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 619.24 1 b6 9.56 21139 230412 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 732.32 1 b7 9.56 13304 236332 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 845.41 1 b8 9.56 12592 166750 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 974.45 1 b9 9.56 5708 94539 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 1073.52 1 b10 9.44 58323 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 1188.55 1 b11 9.44 32055 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 260.59 2 b5 9.44 29113 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 1158.60 1 y10 9.5 20897 448830 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 1045.52 1 y9 9.56 32183 563430 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 916.47 1 y8 9.56 29571 345839 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 817.41 1 y7 9.62 26010 438470 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 702.38 1 y6 9.56 13669 211762 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 645.36 1 y5 9.5 4037 32785 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 516.31 1 y4 9.56 5585 68764 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 387.27 1 y3 9.56 5459 81359 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 945.46 2 288.20 1 y2 9.5 9506 114023 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 261.09 1 b2 9.56 6062 51794 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 433.14 1 b4 9.5 9495 42761 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 619.24 1 b6 9.38 12348 65809 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 732.32 1 b7 9.5 21619 85170 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 974.45 1 b9 9.5 22572 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 366.67 2 b7 9.56 4985 27676 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 423.21 2 b8 9.44 36344 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 487.73 2 b9 9.5 20069 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 1045.52 1 y9 9.56 9148 74821 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 916.47 1 y8 9.56 21496 135854 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 817.41 1 y7 9.5 57831 380769 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 702.38 1 y6 9.56 46795 236942 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 645.36 1 y5 9.56 8320 42640 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 516.31 1 y4 9.62 21264 102732 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 387.27 1 y3 9.5 9267 84073 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 288.20 1 y2 9.32 12234 53912 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 685.88 2 y12 9.44 17945 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 458.74 2 y8 9.44 19110 MEGDSVLLEVDGEEVLR 16 sp|P04278|SHBG_HUMAN 630.64 3 323.18 2 y5 9.56 24717 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 228.13 1 b2 5.86 11214 57191 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 788.45 1 y8 5.86 2990 19062 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 689.38 1 y7 5.86 61053 282713 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 602.35 1 y6 5.86 22679 104538 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 545.33 1 y5 5.86 27536 123604 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 448.28 1 y4 5.86 5233 26420 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 335.19 1 y3 5.86 29403 111637 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 234.14 1 y2 5.86 21802 79995 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 345.20 2 y7 5.86 14455 58815 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 301.68 2 y6 5.86 2990 18189 QVSGPLTSK 17 sp|P04278|SHBG_HUMAN 458.76 2 273.17 2 y5 5.86 16948 89586 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 298.21 1 b3 10.65 6981 63802 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 355.23 1 b4 10.72 4236 56059 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 412.26 1 b5 10.65 25923 402833 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 525.34 1 b6 10.65 41881 404680 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 638.42 1 b7 10.59 14960 144040 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 785.49 1 b8 10.65 10219 105535 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 1144.65 1 y11 10.65 22931 282840 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 1087.63 1 y10 10.65 10465 140548 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 1030.60 1 y9 10.72 6483 125959 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 917.52 1 y8 10.65 49362 594214 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 804.44 1 y7 10.65 76280 973633 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 657.37 1 y6 10.65 93730 1204642 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 560.32 1 y5 10.59 3242 53952 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 489.28 1 y4 10.65 49330 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 402.25 1 y3 10.65 23177 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 288.20 1 y2 10.65 18686 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 629.37 2 y12 10.65 5481 73517 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 572.83 2 y11 10.72 11466 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 402.72 2 y7 10.65 20181 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 329.19 2 y6 10.65 21538 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 721.43 2 245.14 2 y4 10.65 6485 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 298.21 1 b3 10.65 15331 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 412.26 1 b5 10.65 13956 193878 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 525.34 1 b6 10.65 24679 323212 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 638.42 1 b7 10.65 11589 110026 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 785.49 1 b8 10.59 2494 16200 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 319.72 2 b7 10.65 14451 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 393.25 2 b8 10.59 3745 12199 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 917.52 1 y8 10.65 21931 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 804.44 1 y7 10.65 7478 96064 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 657.37 1 y6 10.65 79020 937227 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 560.32 1 y5 10.65 19940 364330 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 489.28 1 y4 10.65 14459 185782 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 402.25 1 y3 10.59 4236 37877 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 288.20 1 y2 10.59 15698 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 402.72 2 y7 10.59 9968 81983 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 329.19 2 y6 10.65 67299 722053 IALGGLLFPASNLR 18 sp|P04278|SHBG_HUMAN 481.29 3 245.14 2 y4 10.72 16079 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 211.14 1 b2 9.72 142292 756192 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 324.23 1 b3 9.72 160489 866724 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 423.30 1 b4 9.66 194131 842302 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 212.15 2 b4 9.66 3491 131435 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 296.20 2 b6 9.66 4983 68644 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 1113.61 1 y10 9.72 24667 97571 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 1000.52 1 y9 9.66 27161 108785 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 901.46 1 y8 9.72 469991 1998965 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 804.40 1 y7 9.66 9969 74638 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 733.37 1 y6 9.66 9723 52218 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 620.28 1 y5 9.66 9966 75133 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 505.26 1 y4 9.72 28658 150379 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 605.83 2 y11 9.66 39377 199487 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 500.77 2 y9 9.66 11339 51218 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 451.23 2 y8 9.66 47221 214689 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 662.38 2 310.64 2 y5 9.66 48970 270761 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 211.14 1 b2 9.72 3988 4863 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 324.23 1 b3 9.72 3235 20432 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 423.30 1 b4 9.66 12709 38129 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 591.39 1 b6 9.72 20185 50468 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 704.47 1 b7 9.72 4615 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 260.68 2 b5 9.66 2987 5981 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 733.37 1 y6 9.66 3988 9096 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 620.28 1 y5 9.66 23677 67284 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 505.26 1 y4 9.66 19692 45854 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 448.23 1 y3 9.66 2243 8470 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 367.19 2 y6 9.72 5484 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 310.64 2 y5 9.59 4736 6356 LPLVPALDGCLR 19 sp|P04278|SHBG_HUMAN 441.92 3 253.13 2 y4 9.72 3491 8842 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 203.07 1 b2 7.1 36632 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 389.15 1 b3 7.1 2990 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 648.34 1 y5 7.1 10216 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 561.30 1 y4 7.1 59060 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 375.22 1 y3 7.1 75758 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 262.14 1 y2 7.1 71394 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 324.67 2 y5 7.1 11711 DSWLDK 20 sp|P04278|SHBG_HUMAN 382.18 2 281.16 2 y4 7.1 7726 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 200.10 1 b2 6.84 126856 265599 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 329.15 1 b3 6.84 225724 470069 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 442.23 1 b4 6.8 64901 134361 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 529.26 1 b5 6.84 20563 41566 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 600.30 1 b6 6.88 15019 27276 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 687.33 1 b7 6.84 7335 19406 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 758.37 1 b8 6.84 8226 19758 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 1131.60 1 y11 6.84 80998 171464 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 1002.56 1 y10 6.84 83503 195346 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 889.47 1 y9 6.84 365275 865394 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 802.44 1 y8 6.84 170577 346969 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 731.40 1 y7 6.84 184606 420174 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 644.37 1 y6 6.84 99233 217518 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 573.34 1 y5 6.84 204455 471407 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 476.28 1 y4 6.8 9298 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 375.24 1 y3 6.8 9116 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 288.20 1 y2 6.84 7689 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 566.30 2 y11 6.8 7063 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 665.85 2 501.78 2 y10 6.84 8043 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 200.10 1 b2 6.84 4738 70979 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 329.15 1 b3 6.8 8223 26541 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 442.23 1 b4 6.84 9478 15644 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 529.26 1 b5 6.8 6614 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 600.30 1 b6 6.8 5900 23599 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 687.33 1 b7 6.75 2859 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 344.17 2 b7 6.84 2682 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 731.40 1 y7 6.84 7869 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 644.37 1 y6 6.88 12335 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 573.34 1 y5 6.84 138213 82159 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 476.28 1 y4 6.8 33434 19037 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 375.24 1 y3 6.88 18686 11795 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 288.20 1 y2 6.8 139993 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 445.24 2 y9 6.84 1789 8675 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 401.72 2 y8 6.75 75276 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 322.69 2 y6 6.84 4828 QAEISASAPTSLR 21 sp|P04278|SHBG_HUMAN 444.24 3 287.17 2 y5 6.8 99236 33965 SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 248.07 1 b2 9.75 42019 101416 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 363.10 1 b3 9.7 85912 184040 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 462.17 1 b4 9.7 38534 77277 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 591.21 1 b5 9.7 40944 79511 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 678.24 1 b6 9.7 23602 59566 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 792.28 1 b7 9.75 48097 86937 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 946.36 1 b9 9.75 58289 107231 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 1059.44 1 b10 9.7 53017 96052 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 445.17 2 b8 9.75 12607 47034 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 473.68 2 b9 9.7 50063 86740 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 530.22 2 b10 9.7 36838 58848 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 603.76 2 b11 9.7 11442 36577 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 660.30 2 b12 9.75 15913 24059 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 757.35 2 b14 9.7 25030 42298 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 1132.57 1 y10 9.7 110857 213116 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 1035.52 1 y9 9.7 34689 70918 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 978.50 1 y8 9.66 13408 29510 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 877.45 1 y7 9.75 21816 44261 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 749.39 1 y6 9.7 44877 76365 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 678.36 1 y5 9.7 30398 67608 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 549.31 1 y4 9.75 29679 77350 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 288.20 1 y2 9.7 24322 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 878.97 2 y16 9.75 10731 14845 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 671.86 2 y12 9.75 8226 15831 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 615.32 2 y11 9.7 754906 1053051 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 566.79 2 y10 9.7 83146 139155 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 375.20 2 y6 9.7 10192 19233 NLR SCDVESNPGIFLPPGTQAEF 22 sp|P04278|SHBG_HUMAN 850.08 3 275.16 2 y4 9.79 19761 NLR DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 229.12 1 b2 10.33 5965 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 326.17 1 b3 10.46 11667 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 454.23 1 b4 10.4 8742 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 551.28 1 b5 10.4 6984 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 688.34 1 b6 10.33 16485 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 759.38 1 b7 10.33 19657 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 888.42 1 b8 10.4 38546 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 1171.55 1 b10 10.4 8234 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 276.14 2 b5 10.52 7732 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 586.28 2 b10 10.46 6088 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 695.33 2 b12 10.46 5961 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 738.85 2 b13 10.4 8373 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 852.90 2 b15 10.4 6596 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 909.45 2 b16 10.27 7093 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 937.96 2 b17 10.4 12049 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 994.50 2 b18 10.4 6720 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 963.55 1 y9 10.46 8243 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 892.51 1 y8 10.4 28277 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 745.45 1 y7 10.4 17877 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 658.41 1 y6 10.33 6455 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 545.33 1 y5 10.33 15214 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 430.30 1 y4 10.4 51478 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 317.22 1 y3 10.4 24348 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 260.20 1 y2 10.4 11287 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 1010.04 2 y18 10.33 67074 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 953.50 2 y17 10.4 226206 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 904.97 2 y16 10.33 7357 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 840.94 2 y15 10.4 137962 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 792.41 2 y14 10.4 11410 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 688.37 2 y12 10.33 12934 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 575.32 2 y10 10.33 3557 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 373.23 2 y7 10.33 16856 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 1067.55 2 215.65 2 y4 10.27 6851 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 229.12 1 b2 10.33 54641 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 888.42 1 b8 10.33 15214 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 1149.63 1 y10 10.33 11157 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 963.55 1 y9 10.33 3928 87243 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 892.51 1 y8 10.38 8027 165351 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 745.45 1 y7 10.33 6318 159006 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 658.41 1 y6 10.33 67207 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 545.33 1 y5 10.33 2393 59596 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 430.30 1 y4 10.38 3584 86992 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 317.22 1 y3 10.33 2390 60223 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 260.20 1 y2 10.33 19028 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 953.50 2 y17 10.38 6828 77604 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 840.94 2 y15 10.38 9905 125911 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 792.41 2 y14 10.33 17238 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 688.37 2 y12 10.4 8880 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 623.85 2 y11 10.38 4778 57062 DIPQPHAEPWAFSLDLGLK 23 sp|P04278|SHBG_HUMAN 712.04 3 446.76 2 y8 10.33 28150 VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 312.23 1 b3 12.14 14018 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 399.26 1 b4 12.09 13357 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 486.29 1 b5 12.09 10441 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 543.31 1 b6 12.14 15143 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 630.35 1 b7 12.17 3930 14951 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 687.37 1 b8 12.13 3925 26904 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 784.42 1 b9 12.09 7900 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 841.44 1 b10 12.13 3930 10719 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 954.53 1 b11 12.13 2903 25772 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 1069.55 1 b12 12.13 4955 16747 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 1182.64 1 b13 12.04 4099 31707 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 535.28 2 b12 12.04 5641 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 936.55 2 b20 12.04 13640 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 1190.79 1 y11 12.13 17593 91335 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 1093.73 1 y10 12.09 8089 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 980.65 1 y9 12.09 21070 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 881.58 1 y8 12.08 18961 80043 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 768.50 1 y7 12.13 18444 102065 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 711.48 1 y6 12.08 3074 21355 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 598.39 1 y5 12.08 47057 292259 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 501.34 1 y4 12.09 3760 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 388.26 1 y3 12.08 2732 21073 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 260.20 1 y2 12.04 3074 11477 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 1087.64 2 y22 12.08 3077 21073 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 1031.10 2 y21 12.09 15240 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 987.59 2 y20 12.09 8371 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 944.07 2 y19 12.13 3415 11761 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 915.56 2 y18 12.14 8558 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 872.04 2 y17 12.13 4609 19566 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 843.53 2 y16 12.04 15899 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 766.49 2 y14 12.14 4141 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 652.44 2 y12 12.14 8088 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 1186.71 2 441.29 2 y8 12.09 6774 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 312.23 1 b3 12.13 42888 65949 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 399.26 1 b4 12.13 21029 43367 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 486.29 1 b5 12.07 7286 7151 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 543.31 1 b6 12.18 9370 12223 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 630.35 1 b7 12.13 18326 24266 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 687.37 1 b8 12.13 19156 21728 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 784.42 1 b9 12.13 11660 23424 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 841.44 1 b10 12.13 16347 20317 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 954.53 1 b11 12.13 15821 19379 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 1069.55 1 b12 12.07 46738 71574 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 1182.64 1 b13 12.13 47885 64624 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 421.22 2 b10 12.13 5101 13732 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 477.77 2 b11 12.18 5206 6681 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 535.28 2 b12 12.13 11661 18625 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 591.82 2 b13 12.07 30187 42141 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 640.35 2 b14 12.13 52254 63769 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 696.89 2 b15 12.13 16655 17121 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 746.42 2 b16 12.13 8535 10155 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 936.55 2 b20 12.07 5000 8561 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 1190.79 1 y11 12.13 51215 73554 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 1093.73 1 y10 12.07 23529 31977 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 980.65 1 y9 12.07 51626 77042 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 881.58 1 y8 12.13 153018 225474 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 768.50 1 y7 12.07 369345 512663 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 711.48 1 y6 12.13 64333 87008 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 598.39 1 y5 12.13 329370 537778 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 501.34 1 y4 12.13 10510 16372 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 388.26 1 y3 12.13 30707 60384 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 260.20 1 y2 12.07 18529 33308 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 872.04 2 y17 12.13 4166 6771 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 766.49 2 y14 12.07 12077 14396 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 652.44 2 y12 12.07 7494 10257 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 595.90 2 y11 12.07 33522 42701 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 547.37 2 y10 12.13 3954 4984 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 441.29 2 y8 12.13 7701 15425 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 356.24 2 y6 12.07 6871 8751 LQLK VVLSSGSGPGLDLPLVLGLP 24 sp|P04278|SHBG_HUMAN 791.48 3 299.70 2 y5 12.07 7701 9689 LQLK VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 312.23 1 b3 5.25 14004 16657 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 584.34 1 b6 5.22 9128 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 718.41 1 y7 5.25 101369 154048 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 619.34 1 y6 5.25 860577 1157529 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 506.26 1 y5 5.21 168229 273074 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 419.22 1 y4 5.25 40477 58906 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 291.17 1 y3 5.25 56277 98421 VVLSQGSK 25 sp|P04278|SHBG_HUMAN 409.24 2 234.14 1 y2 5.3 18448 21652 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 229.12 1 b2 7.22 175928 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 328.19 1 b3 7.22 30537 50598 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 443.21 1 b4 7.22 24914 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 571.27 1 b5 7.18 8188 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 642.31 1 b6 7.06 27320 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 869.44 1 b8 7.06 22459 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 435.22 2 b8 7.06 24039 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 930.46 1 y8 7.22 66345 99621 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 815.44 1 y7 7.22 128600 224769 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 716.37 1 y6 7.22 176273 329489 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 601.34 1 y5 7.22 112569 239451 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 473.28 1 y4 7.18 84667 185259 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 402.25 1 y3 7.18 69746 100254 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 289.16 1 y2 7.22 55177 96879 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 408.22 2 y7 7.18 21442 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 358.69 2 y6 7.18 4997 LDVDQALNR 26 sp|P04278|SHBG_HUMAN 522.28 2 201.63 2 y3 7.22 10549 ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 256.17 1 b3 12.18 79381 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 369.25 1 b4 12.12 20134 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 466.30 1 b5 12.23 11181 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 676.44 1 b7 12.12 14124 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 733.46 1 b8 12.07 12965 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 846.54 1 b9 12.18 19293 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 917.58 1 b10 12.18 14550 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 282.18 2 b6 12.07 7805 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 1069.59 1 y9 12.12 6538 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 842.46 1 y7 12.07 8531 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 656.38 1 y6 12.23 14766 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 585.35 1 y5 12.18 9813 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 457.25 1 y4 12.18 45762 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 1063.14 2 y20 12.12 8012 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 1027.62 2 y19 12.07 17082 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 971.08 2 y18 12.12 214978 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 922.55 2 y17 12.12 7694 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 1155.20 2 478.28 2 y8 12.12 7702 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 256.17 1 b3 12.07 842606 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 369.25 1 b4 12.12 82661 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 466.30 1 b5 12.07 17819 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 563.36 1 b6 12.02 10122 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 733.46 1 b8 12.12 9487 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 282.18 2 b6 12.07 48813 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 367.23 2 b8 12.07 11705 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 1182.67 1 y10 12.07 25519 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 1069.59 1 y9 12.12 53562 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 955.55 1 y8 12.12 29098 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 842.46 1 y7 12.07 164685 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 656.38 1 y6 12.12 180607 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 585.35 1 y5 12.07 93202 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 457.25 1 y4 12.12 285196 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 360.20 1 y3 12.12 8859 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 232.14 1 y2 12.12 13702 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 1027.62 2 y19 12.07 7692 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 971.08 2 y18 12.07 616149 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 922.55 2 y17 12.12 82239 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 874.02 2 y16 12.12 25832 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 817.48 2 y15 12.07 64945 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 788.97 2 y14 12.12 12867 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 732.43 2 y13 12.07 48079 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 696.91 2 y12 12.07 72642 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 648.38 2 y11 12.12 238495 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 591.84 2 y10 12.12 11281 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 535.30 2 y9 12.12 19196 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 478.28 2 y8 12.07 92887 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 421.74 2 y7 12.12 29947 QGR ALALPPLGLAPLLNLWAKP 27 sp|P04278|SHBG_HUMAN 770.47 3 293.18 2 y5 12.02 12438 QGR SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 467.22 1 b4 7.56 7050 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 653.30 1 b5 7.46 43014 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 446.21 2 b7 7.61 9066 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 682.30 2 b11 7.41 6441 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 774.34 2 b13 7.46 6544 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 942.39 1 y10 7.46 4031 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 701.28 1 y7 7.41 8864 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 530.22 1 y5 7.41 6044 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 429.17 1 y4 7.46 13502 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 314.15 1 y3 7.41 19243 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 243.11 1 y2 7.51 46537 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 664.27 2 y13 7.41 9468 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 428.18 2 y9 7.51 13303 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 351.15 2 y7 7.46 6446 ASH SHEIWTHSCPQSPGNGTD 28 sp|P04278|SHBG_HUMAN 768.99 3 215.09 2 y4 7.51 11478 ASH DifferentIsoforms LPAEISASAPTSLR 29 sp|P04278- 706.89 2 211.14 1 b2 10.93 86522 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 282.18 1 b3 10.88 73637 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 411.22 1 b4 10.98 8856 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 682.38 1 b7 10.93 19344 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 840.45 1 b9 10.88 21252 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 937.50 1 b10 10.88 28413 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 341.69 2 b7 10.88 17422 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 385.21 2 b8 10.93 9772 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 573.34 1 y5 10.88 6857 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 476.28 1 y4 10.93 197840 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 288.20 1 y2 10.93 6351 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 445.24 2 y9 10.88 23775 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 706.89 2 287.17 2 y5 10.83 12993 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 211.14 1 b2 10.93 148281 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 282.18 1 b3 10.93 23973 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 411.22 1 b4 10.93 17728 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 524.31 1 b5 10.93 3629 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 682.38 1 b7 10.93 8865 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 840.45 1 b9 10.93 1614 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 937.50 1 b10 10.93 1914 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 341.69 2 b7 10.88 8765 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 385.21 2 b8 10.88 4734 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 469.25 2 b10 10.88 4633 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 563.29 2 b12 10.88 3025 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 644.37 1 y6 10.93 5434 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 476.28 1 y4 10.88 333632 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 288.20 1 y2 10.88 5642 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 650.35 2 y13 10.88 12993 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 566.30 2 y11 10.93 1813 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 445.24 2 y9 10.88 36867 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 366.21 2 y7 10.93 4734 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 322.69 2 y6 10.93 3424 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 287.17 2 y5 10.88 19746 5|SHBG_HUMAN LPAEISASAPTSLR 29 sp|P04278- 471.60 3 238.64 2 y4 10.83 9876 5|SHBG_HUMAN TLPPLFA 30 sp|P04278- 379.73 2 312.19 1 b3 5.99 99852 2|SHBG_HUMAN TLPPLFA 30 sp|P04278- 379.73 2 350.21 1 y3 5.99 830722 2|SHBG_HUMAN TLPPLFA 30 sp|P04278- 379.73 2 237.12 1 y2 5.99 1013802 2|SHBG_HUMAN TLPPLFA 30 sp|P04278- 379.73 2 272.66 2 y5 5.99 2760482 2|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 389.13 1 b4 10.84 355452 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 476.16 1 b5 10.84 71118 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 577.21 1 b6 10.84 15469 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 289.11 2 b6 10.84 29667 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 332.62 2 b7 10.84 471567 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 406.16 2 b8 10.84 26243 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 486.17 2 b9 10.84 28271 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 542.72 2 b10 10.84 11031 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 599.74 2 b11 10.84 15214 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 628.25 2 b12 10.84 27636 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 813.35 2 b15 10.84 12932 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 858.46 1 y7 10.84 12672 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 745.37 1 y6 10.84 32451 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 488.26 1 y4 10.84 16233 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 360.20 1 y3 10.84 54774 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 819.40 2 y14 10.84 40433 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 651.82 2 y11 10.9 31186 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 515.26 2 y9 10.78 15092 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 458.24 2 y8 10.78 16351 R 4|SHBG_HUMAN GEDSSTSFCLNGLWAQGQ 31 sp|P04278- 704.98 3 373.19 2 y6 10.84 39431 R 4|SHBG_HUMAN
(438) TABLE-US-00019 TABLE 19 Proteins with altered serum levels across 17-25 weeks GA in PTB samples Protein Change Functional Category THRB up coagulation/acute phase response VTNC up cell adhesion/acute phase response HEMO up heme transport/acute phase response FETUA up inflammation/acute phase response LBP up innate immunity/acute phase response IBP4 up growth factor regulation CD14 up innate immunity HABP2 up cell adhesion/migration INHBC up growth factor regulation CFAB up complement/acute phase response ICAM1 up cell adhesion/migration IC1 up complement/acute phase response APOH up coagulation/autoimmunity B2MG up MHC/immunity C1S up* Complement APOE up* cholesterol metabolism APOC3 up* triglyceride metabolism PEDF up* angiogenesis CATD up* ECM remodelling/cell migration INHBE up* growth factor regulation IBP6 up* growth factor regulation PRG2 down growth factor regulation SHBG down inflammation/steroid metabolism GELS down actin binding/acute phase response PSG4 down* growth factor regulation *Additional proteins limited to weeks 19-21 GA in PTB.
(439) TABLE-US-00020 TABLE 20 44 Proteins Meeting Analytical Filters That Were Up- or Down-Regulated in sPTD vs. Term Controls Short Uniprot ID Name Protein Name A2GL_HUMAN LRG1 Leucine-rich alpha-2-glycoprotein AFAM_HUMAN AFM Afamin ANGT_HUMAN AGT Angiotensinogen APOC3_HUMAN APOC3 Apolipoprotein C-III APOH_HUMAN APOH Beta-2-glycoprotein 1 B2MG_HUMAN B2M Beta-2-microglobulin BGH3_HUMAN TGFBI Transforming growth factor-beta-induced protein ig-h3 CATD_HUMAN CTSD Cathepsin D CBPN_HUMAN CPN1 Carboxypeptidase N catalytic chain CD14_HUMAN CD14 Monocyte differentiation antigen CD14 CFAB_HUMAN CFB Complement factor B CHL1_HUMAN CHL1 Neural cell adhesion molecule L1-like protein CO5_HUMAN C5 Complement C5 CO6_HUMAN C6 Complement component C6 CO8A_HUMAN C8A Complement component C8 alpha chain CRIS3_HUMAN CRISP3 Cysteine-rich secretory protein 3 ENPP2_HUMAN ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 F13B_HUMAN F13B Coagulation factor XIII B chain FBLN3_HUMAN EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 FETUA_HUMAN AHSG Alpha-2-HS-glycoprotein HABP2_HUMAN HABP2 Hyaluronan-binding protein 2 HEMO_HUMAN HPX Hemopexin HLAG_HUMAN HLA-G* HLA class I histocompatibility antigen, alpha chain G IBP2_HUMAN IGFBP2 Insulin-like growth factor-binding protein 2 IBP3_HUMAN IGFBP3 Insulin-like growth factor-binding protein 3 IBP4_HUMAN IGFBP4 Insulin-like growth factor-binding protein 4 INHBC_HUMAN INHBC Inhibin beta C chain ITIH3_HUMAN ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3 ITIH4_HUMAN ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 N-term ITIH4_HUMAN ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 C-Term KNG1_HUMAN KNG1 Kininogen-1 LBP_HUMAN LBP Lipopolysaccharide-binding protein LYAM3_HUMAN SELP P-selectin PAPP1_HUMAN PAPPA Pappalysin-1 PEDF_HUMAN SERPINF1 Pigment epithelium-derived factor PGRP2_HUMAN PGLYRP2 N-acetylmuramoyl-L-alanine amidase PRG2_HUMAN PRG2 Bone marrow proteoglycan PSG11_HUMAN PSG11 Pregnancy-specific beta-1-glycoprotein 11 PSG2_HUMAN PSG2 Pregnancy-specific beta-1-glycoprotein 2 PSG9_HUMAN PSG9 Pregnancy-specific beta-1-glycoprotein 9 SHBG_HUMAN SHBG Sex hormone-binding globulin TENX_HUMAN TNXB Tenascin-X TIE1_HUMAN TIE1 Tyrosine-protein kinase receptor Tie-1 VTNC_HUMAN VTN Vitronectin *peptide surrogate for HLA-G was not unique to this protein.
(440) TABLE-US-00021 TABLE21 SEQ Trans- MARS14 SEQ ID ition Depleted ID Protein Transition NO: Type Protein SISTransition NO: A1AG1_HUMAN NWGLSVYADKPETTK_570.3_301.1 32 quant Depleted IS_NWGLSVYADKPETTK_573.0_301.1 32 A1AG1_HUMAN NWGLSVYADKPETTK_570.3_818.4 32 qual Depleted IS_NWGLSVYADKPETTK_573.0_826.4 32 A1AT_HUMAN LSITGTYDLK_555.8_696.4 33 qual Depleted IS_LSITGTYDLK_559.8_704.4 33 A1AT_HUMAN LSITGTYDLK_555.8_797.4 33 quant Depleted IS_LSITGTYDLK_559.8_805.4 33 A2GL_HUMAN DLLLPQPDLR_590.3_229.1 34 qual IS_DLLLPQPDLR_595.3_229.1 34 A2GL_HUMAN DLLLPQPDLR_590.3_725.4 34 quant IS_DLLLPQPDLR_595.3_735.4 34 A2GL_HUMAN LQVLGK_329.2_204.1 35 qual A2GL_HUMAN LQVLGK_329.2_416.3 35 quant A2MG_HUMAN LHTEAQIQEEGTVVELTGR_704.0_674.4 36 qual Depleted IS_LHTEAQIQEEGTVVELTGR_707.4_680.3 36 A2MG_HUMAN LHTEAQIQEEGTVVELTGR_704.0_680.3 36 quant Depleted IS_LHTEAQIQEEGTVVELTGR_707.4_684.4 36 AFAM_HUMAN DADPDTFFAK_563.8_302.1 37 qual IS_DADPDTFFAK_567.8_302.1 37 AFAM_HUMAN DADPDTFFAK_563.8_825.4 37 quant IS_DADPDTFFAK_567.8_833.4 37 AFAM_HUMAN HFQNLGK_422.2_285.1 38 quant IS_HFQNLGK_426.2_285.1 38 AFAM_HUMAN HFQNLGK_422.2_527.2 38 qual IS_HFQNLGK_426.2_527.2 38 ALBU_HUMAN LVTDLTK_395.2_213.2 39 qual Depleted IS_LVTDLTK_399.2_213.2 39 ALBU_HUMAN LVTDLTK_395.2_577.3 39 quant Depleted IS_LVTDLTK_399.2_585.3 39 ALS_HUMAN IRPHTFTGLSGLR_485.6_432.3 40 quant IS_IRPHTFTGLSGLR_488.9_442.3 40 ALS_HUMAN IRPHTFTGLSGLR_485.6_545.3 40 qual IS_IRPHTFTGLSGLR_488.9_555.3 40 ALS_HUMAN LEYLLLSR_503.8_447.3 41 qual ALS_HUMAN LEYLLLSR_503.8_745.4 41 quant ANGT_HUMAN DPTFIPAPIQAK_433.2_461.2 42 qual IS_DPTFIPAPIQAK_435.9_461.2 42 ANGT_HUMAN DPTFIPAPIQAK_433.2_556.3 42 quant IS_DPTFIPAPIQAK_435.9_564.4 42 ANGT_HUMAN SLDFTELDVAAEK_719.4_316.2 43 quant ANGT_HUMAN SLDFTELDVAAEK_719.4_874.5 43 qual APOA1_HUMAN AKPALEDLR_506.8_288.2 44 qual Depleted IS_AKPALEDLR_511.8_298.2 44 APOA1_HUMAN AKPALEDLR_506.8_813.5 44 quant Depleted IS_AKPALEDLR_511.8_823.5 44 APOA2_HUMAN SPELQAEAK_486.8_659.4 45 qual Depleted IS_SPELQAEAK_490.8_667.4 45 APOA2_HUMAN SPELQAEAK_486.8_788.4 45 quant Depleted IS_SPELQAEAK_490.8_796.4 45 APOC3_HUMAN DYWSTVK_449.7_347.2 46 qual APOC3_HUMAN DYWSTVK_449.7_620.3 46 quant APOC3_HUMAN GWVTDGFSSLK_598.8_854.4 47 quant IS_GWVTDGFSSLK_602.8_862.4 47 APOC3_HUMAN GWVTDGFSSLK_598.8_953.5 47 qual IS_GWVTDGFSSLK_602.8_961.5 47 APOH_HUMAN ATVVYQGER_511.8_652.3 48 quant IS_ATVVYQGER_516.8_662.3 48 APOH_HUMAN ATVVYQGER_511.8_751.4 48 qual IS_ATVVYQGER_516.8_761.4 48 APOH_HUMAN EHSSLAFWK_552.8_267.1 49 qual APOH_HUMAN EHSSLAFWK_552.8_838.4 49 quant B2MG_HUMAN VEHSDLSFSK_383.5_234.1 50 qual IS_VEHSDLSFSK_386.2_242.2 50 B2MG_HUMAN VEHSDLSFSK_383.5_468.2 50 quant IS_VEHSDLSFSK_386.2_476.3 50 B2MG_HUMAN VNHVTLSQPK_374.9_244.2 51 qual IS_VNHVTLSQPK_377.6_252.2 51 B2MG_HUMAN VNHVTLSQPK_374.9_459.3 51 quant IS_VNHVTLSQPK_377.6_467.3 51 BGH3_HUMAN LTLLAPLNSVFK_658.4_804.5 52 quant IS_LTLLAPLNSVFK_662.4_812.5 52 BGH3_HUMAN LTLLAPLNSVFK_658.4_875.5 52 qual IS_LTLLAPLNSVFK_662.4_883.5 52 BGH3_HUMAN VLTDELK_409.2_605.3 53 quant BGH3_HUMAN VLTDELK_409.2_718.4 53 qual C163A_HUMAN INPASLDK_429.2_462.3 54 qual IS_INPASLDK_433.2_470.3 54 C163A_HUMAN INPASLDK_429.2_630.4 54 quant IS_INPASLDK_433.2_638.4 54 C1QB_HUMAN VPGLYYFTYHASSR_554.3_420.2 55 quant IS_VPGLYYFTYHASSR_557.6_430.2 55 C1QB_HUMAN VPGLYYFTYHASSR_554.3_720.3 55 qual IS_VPGLYYFTYHASSR_557.6_730.4 55 CAH1_HUMAN GGPFSDSYR_493.2_627.3 56 quant IS_GGPFSDSYR_498.2_637.3 56 CAH1_HUMAN GGPFSDSYR_493.2_774.3 56 qual IS_GGPFSDSYR_498.2_784.3 56 CATD_HUMAN VGFAEAAR_410.7_517.3 57 qual IS_VGFAEAAR_415.7_527.3 57 CATD_HUMAN VGFAEAAR_410.7_721.4 57 quant IS_VGFAEAAR_415.7_731.4 57 CATD_HUMAN VSTLPAITLK_521.8_642.4 58 quant IS_VSTLPAITLK_525.8_650.4 58 CATD_HUMAN VSTLPAITLK_521.8_856.6 58 qual IS_VSTLPAITLK_525.8_864.6 58 CBPN_HUMAN EALIQFLEQVHQGIK_585.0_526.3 59 qual IS_EALIQFLEQVHQGIK_587.7_530.3 59 CBPN_HUMAN EALIQFLEQVHQGIK_585.0_720.4 59 quant IS_EALIQFLEQVHQGIK_587.7_724.4 59 CBPN_HUMAN NNANGVDLNR_543.8_229.1 60 quant IS_NNANGVDLNR_548.8_229.1 60 CBPN_HUMAN NNANGVDLNR_543.8_858.4 60 qual IS_NNANGVDLNR_548.8_868.5 60 CD14_HUMAN LTVGAAQVPAQLLVGALR_8890_416.3 61 quant IS_LTVGAAQVPAQLLVGALR_894.0_426.3 61 CD14_HUMAN LTVGAAQVPAQLLVGALR_889.0_628.4 61 qual IS_LTVGAAQVPAQLLVGALR_894.0_638.4 61 CD14_HUMAN SWLAELQQWLKPGLK_599.7_274.1 62 quant IS_SWLAELQQWLKPGLK_602.3_274.1 62 CD14_HUMAN SWLAELQQWLKPGLK_599.7_670.4 62 qual IS_SWLAELQQWLKPGLK_602.3_674.4 62 CFAB_HUMAN VSEADSSNADWVTK_754.9_347.2 63 quant CFAB_HUMAN VSEADSSNADWVTK_754.9_533.3 63 qual CFAB_HUMAN YGLVTYATYPK_638.3_334.2 64 qual IS_YGLVTYATYPK_642.3_334.2 64 CFAB_HUMAN YGLVTYATYPK_638.3_843.4 64 quant IS_YGLVTYATYPK_642.3_851.4 64 CHL1_HUMAN TAVTANLDIR_537.3_288.2 65 qual CHL1_HUMAN TAVTANLDIR_537.3_802.4 65 quant CHL1_HUMAN VIAVNEVGR_478.8_574.3 66 qual IS_VIAVNEVGR_483.8_584.3 66 CHL1_HUMAN VIAVNEVGR_478.8_744.4 66 quant IS_VIAVNEVGR_483.8_754.4 66 CLUS_HUMAN ASSIIDELFQDR_697.4_678.4 67 qual IS_ASSIIDELFQDR_702.4_688.4 67 CLUS_HUMAN ASSIIDELFQDR_697.4_922.4 67 quant IS_ASSIIDELFQDR_702.4_932.4 67 CLUS_HUMAN LFDSDPITVTVPVEVSR_937.5_1086.6 68 quant IS_LFDSDPITVTVPVEVSR_942.5_1096.6 68 CLUS_HUMAN LFDSDPITVTVPVEVSR_937.5_985.6 68 qual IS_LFDSDPITVTVPVEVSR_942.5_995.6 68 CO3_HUMAN IHWESASLLR_606.3_251.2 69 quant Depleted IS_IHWESASLLR_611.3_251.2 69 CO3_HUMAN IHWESASLLR_606.3_437.2 69 qual Depleted IS_IHWESASLLR_611.3_437.2 69 CO5_HUMAN TLLPVSKPEIR_418.3_288.2 70 qual IS_TLLPVSKPEIR_421.6_298.2 70 CO5_HUMAN TLLPVSKPEIR_418.3_514.3 70 quant IS_TLLPVSKPEIR_421.6_524.3 70 CO5_HUMAN VFQFLEK_455.8_276.2 71 qual IS_VFQFLEK_459.8_284.2 71 CO5_HUMAN VFQFLEK_455.8_811.4 71 quant IS_VFQFLEK_459.8_819.4 71 CO6_HUMAN ALNHLPLEYNSALYSR_621.0_538.3 72 quant IS_ALNHLPLEYNSALYSR_624.3_548.3 72 CO6_HUMAN ALNHLPLEYNSALYSR_621.0_696.4 72 qual IS_ALNHLPLEYNSALYSR_624.3_706.4 72 CO6_HUMAN SEYGAALAWEK_612.8_788.4 73 qual CO6_HUMAN SEYGAALAWEK_612.8_845.5 73 quant CO8A_HUMAN SLLQPNK_400.2_358.2 74 qual IS_SLLQPNK_404.2_366.2 74 CO8A_HUMAN SLLQPNK_400.2_599.4 74 quant IS_SLLQPNK_404.2_607.4 74 CO8A_HUMAN YHFEALADTGISSEFYDNANDLL 75 quant SK_940.8_761.4 CO8A_HUMAN YHFEALADTGISSEFYDNANDLL 75 qual SK_940.8_874.5 CO8B_HUMAN QALEEFQK_496.8_551.3 76 qual IS_QALEEFQK_500.8_559.3 76 CO8B_HUMAN QALEEFQK_496.8_680.3 76 quant IS_QALEEFQK_500.8_688.3 76 CO8B_HUMAN SGFSFGFK_438.7_585.3 77 quant CO8B_HUMAN SGFSFGFK_438.7_732.4 77 qual CRIS3_HUMAN AVSPPAR_349.2_258.1 78 qual IS_AVSPPAR_354.2_258.1 78 CRIS3_HUMAN AVSPPAR_349.2_343.2 78 quant IS_AVSPPAR_354.2_353.2 78 CRIS3_HUMAN YEDLYSNCK_596.3_784.4 79 qual IS_YEDLYSNCK_600.3_792.4 79 CRIS3_HUMAN YEDLYSNCK_596.3_899.4 79 quant IS_YEDLYSNCK_600.3_907.4 79 CSH_HUMAN* AHQLAIDTYQEFEETYIPK_766.0_ 80 qual IS_AHQLAIDTYQEFEETYIPK_768.7_ 80 521.3 521.3 CSH_HUMAN* AHQLAIDTYQEFEETYIPK_766.0_ 80 quant IS_AHQLAIDTYQEFEETYIPK_768.7_ 80 634.4 634.4 CSH_HUMAN* ISLLLIESWLEPVR_834.5_371.2 81 qual IS_ISLLLIESWLEPVR_839.5_381.2 81 CSH_HUMAN* ISLLLIESWLEPVR_834.5_500.3 81 quant IS_ISLLLIESWLEPVR_839.5_510.3 81 ENPP2_HUMAN TEFLSNYLTNVDDITLVPGTLGR_ 82 quant IS_TEFLSNYLTNVDDITLVPGTLGR_ 82 846.8_600.3 850.1_610.4 ENPP2_HUMAN TEFLSNYLTNVDDITLVPGTLGR 82 qual IS_TEFLSNYLTNVDDITLVPGTLGR_ 82 846.8_699.4 850.1_709.4 ENPP2_HUMAN TYLHTYESEI_628.3_1124.5 83 quant IS_TYLHTYESEI_631.8_1124.5 83 ENPP2_HUMAN TYLHTYESEI_628.3_908.4 83 qual IS_TYLHTYESEI_631.8_908.4 83 F13B_HUMAN GDTYPAELYITGSILR_885.0_1332.8 84 quant IS_GDTYPAELYITGSILR_890.0_1342.8 84 F13B_HUMAN GDTYPAELYITGSILR_885.0_274.1 84 qual IS_GDTYPAELYITGSILR_890.0_274.1 84 F13B_HUMAN IAQYYYTFK_598.8_395.2 85 qual F13B_HUMAN IAQYYYTFK_598.8_884.4 85 quant FBLN1_HUMAN TGYYFDGISR_589.8_694.4 86 qual IS_TGYYFDGISR_594.8_704.4 86 FBLN1_HUMAN TGYYFDGISR_589.8_857.4 86 quant IS_TGYYFDGISR_594.8_867.4 86 FBLN3_HUMAN IPSNPSHR_303.2_496.3 87 quant IS_IPSNPSHR_306.5_506.3 87 FBLN3_HUMAN IPSNPSHR_303.2_610.3 87 qual IS_IPSNPSHR_306.5_620.3 87 FETUA_HUMAN FSVVYAK_407.2_381.2 88 qual IS_FSVVYAK_411.2_389.2 88 FETUA_HUMAN FSVVYAK_407.2_579.4 88 quant IS_FSVVYAK_411.2_587.4 88 FETUA_HUMAN HTLNQIDEVK_598.8_951.5 89 qual IS_HTLNQIDEVK_602.8_951.5 89 FETUA_HUMAN HTLNQIDEVK_598.8_958.5 89 quant IS_HTLNQIDEVK_602.8_966.5 89 FIBA_HUMAN ESSSHHPGIAEFPSR_546.6_353.7 90 qual Depleted IS_ESSSHHPGIAEFPSR_549.9_358.7 90 FIBA_HUMAN ESSSHHPGIAEFPSR_546.6_502.2 90 quant Depleted IS_ESSSHHPGIAEFPSR_549.9_502.2 90 FIBB_HUMAN QGFGNVATNTDGK_654.8_319.2 91 qual Depleted IS_QGFGNVATNTDGK_658.8_327.2 91 FIBB_HUMAN QGFGNVATNTDGK_654.8_706.3 91 quant Depleted IS_QGFGNVATNTDGK_658.8_714.4 91 HABP2_HUMAN FLNWIK_410.7_560.3 92 quant IS_FLNWIK_414.7_568.3 92 HABP2_HUMAN FLNWIK_410.7_673.4 92 qual IS_FLNWIK_414.7_681.4 92 HEMO_HUMAN NFPSPVDAAFR_610.8_775.4 93 qual IS_NFPSPVDAAFR_615.8_785.4 93 HEMO_HUMAN NFPSPVDAAFR_610.8_959.5 93 quant IS_NFPSPVDAAFR_615.8_969.5 93 HEMO_HUMAN SGAQATWTELPWPHEK_613.3_510.3 94 qual HEMO_HUMAN SGAQATWTELPWPHEK_613.3_793.4 94 quant HLAG_HUMAN* WAAVVVPSGEEQR_714.4_428.2 95 qual IS_WAAVVVPSGEEQR_719.4_428.2 95 HLAG_HUMAN* WAAVVVPSGEEQR_714.4_802.4 95 quant IS_WAAVVVPSGEEQR_719.4_812.4 95 HPT_HUMAN TEGDGVYTLNNEK_720.3_403.2 96 qual Depleted IS_TEGDGVYTLNNEK_724.3_403.2 96 HPT_HUMAN TEGDGVYTLNNEK_720.3_881.4 96 quant Depleted IS_TEGDGVYTLNNEK_724.3_889.5 96 IBP1_HUMAN VVESLAK_373.2_547.3 97 quant IS_VVESLAK_377.2_555.3 97 IBP1_HUMAN VVESLAK_373.2_646.4 97 qual IS_VVESLAK_377.2_654.4 97 IBP2_HUMAN LIQGAPTIR_484.8_227.2 98 qual IS_LIQGAPTIR_489.8_227.2 98 IBP2_HUMAN LIQGAPTIR_484.8_742.4 98 quant IS_LIQGAPTIR_489.8_752.4 98 IBP3_HUMAN FLNVLSPR_473.3_472.3 99 qual IS_FLNVLSPR_478.3_482.3 99 IBP3_HUMAN FLNVLSPR_473.3_685.4 99 quant IS_FLNVLSPR_478.3_695.4 99 IBP3_HUMAN YGQPLPGYTTK_612.8_666.3 100 qual IS_YGQPLPGYTTK_616.8_674.4 100 IBP3_HUMAN YGQPLPGYTTK_612.8_876.5 100 quant IS_YGQPLPGYTTK_616.8_884.5 100 IBP4_HUMAN QCHPALDGQR_394.5_360.2 2 qual IS_QCHPALDGQR_397.9_370.2 2 IBP4_HUMAN QCHPALDGQR_394.5_475.2 2 quant IS_QCHPALDGQR_397.9_485.2 2 IBP6_HUMAN GAQTLYVPNCDHR_510.9_312.2 101 qual IS_GAQTLYVPNCDHR_514.2_322.2 101 IBP6_HUMAN GAQTLYVPNCDHR_510.9_637.8 101 quant IS_GAQTLYVPNCDHR_514.2_642.8 101 IBP6_HUMAN HLDSVLQQLQTEVYR_610.3_667.3 102 qual IS_HLDSVLQQLQTEVYR_613.7_677.3 102 IBP6_HUMAN HLDSVLQQLQTEVYR_610.3_795.4 102 quant IS_HLDSVLQQLQTEVYR_613.7_805.4 102 IGF2_HUMAN GIVEECCFR_585.3_771.3 103 qual IS_GIVEECCFR_590.3_781.3 103 IGF2_HUMAN GIVEECCFR_585.3_900.3 103 quant IS_GIVEECCFR_590.3_910.3 103 IGF2_HUMAN SCDLALLETYCATPAK_906.9_1040.5 104 qual IGF2_HUMAN SCDLALLETYCATPAK_906.9_1153.6 104 quant IGHG3_HUMAN ALPAPIEK_419.8_327.7 105 quant Depleted IS_ALPAPIEK_423.8_331.7 105 IGHG3_HUMAN ALPAPIEK_419.8_654.4 105 qual Depleted IS_ALPAPIEK_423.8_662.4 105 IGHM_HUMAN GFPSVLR_388.2_286.2 106 quant Depleted IS_GFPSVLR_393.2_291.2 106 IGHM_HUMAN GFPSVLR_388.2_571.4 106 qual Depleted IS_GFPSVLR_393.2_581.4 106 INHBC_HUMAN LDFHFSSDR_375.2_448.2 107 qual IS_LDFHFSSDR_378.5_453.2 107 INHBC_HUMAN LDFHFSSDR_375.2_611.3 107 quant IS_LDFHFSSDR_378.5_621.3 107 IS_Recon IS_ASSILAT_662.4_313.1 108 qual IS_Recon IS_ASSILAT_662.4_359.2 108 quant IS_Recon IS_ELWFSDDPDVTK_726.3_559.3 109 quant IS_Recon IS_ELWFSDDPDVTK_726.3_876.4 109 qual IS_Recon IS_NVDQSLLELHK_432.6_397.3 110 quant IS_Recon IS_NVDQSLLELHK_432.6_639.4 110 qual ITIH3_HUMAN ALDLSLK_380.2_185.1 111 qual IS_ALDLSLK_384.2_185.1 111 ITIH3_HUMAN ALDLSLK_380.2_575.3 111 quant IS_ALDLSLK_384.2_583.4 111 ITIH4_HUMAN ILDDLSPR_464.8_587.3 112 qual IS_ILDDLSPR_469.8_597.3 112 ITIH4_HUMAN ILDDLSPR_464.8_702.3 112 quant IS_ILDDLSPR_469.8_712.4 112 ITIH4_HUMAN NPLVWVHASPEHVVVTR_647.4_325.2 113 quant IS_NPLVWVHASPEHVVVTR_650.7_325.2 113 ITIH4_HUMAN NPLVWVHASPEHVVVTR_647.4_936.5 113 qual IS_NPLVWVHASPEHVVVTR_650.7_946.5 113 ITIH4_HUMAN QLGLPGPPDVPDHAAYHPF_676.7_263.1 114 quant IS_QLGLPGPPDVPDHAAYHPF_680.0_273.2 114 ITIH4_HUMAN QLGLPGPPDVPDHAAYHPF_676.7_299.2 114 qual IS_QLGLPGPPDVPDHAAYHPF_680.0_299.2 114 ITIH4_HUMAN VRPQQLVK_484.3_609.4 115 quant ITIH4_HUMAN VRPQQLVK_484.3_722.4 115 qual KNG1_HUMAN DIPTNSPELEETLTHTITK_713.7_756.4 116 quant IS_DIPTNSPELEETLTHTITK_716.4_760.4 116 KNG1_HUMAN DIPTNSPELEETLTHTITK_713.7_799.9 116 qual IS_DIPTNSPELEETLTHTITK_716.4_803.9 116 KNG1_HUMAN QVVAGLNFR_502.3_606.3 117 qual IS_QVVAGLNFR_507.3_616.3 117 KNG1_HUMAN QVVAGLNFR_502.3_677.4 117 quant IS_QVVAGLNFR_507.3_687.4 117 LBP_HUMAN ITGFLKPGK_320.9_301.2 118 quant IS_ITGFLKPGK_323.5_309.2 118 LBP_HUMAN ITGFLKPGK_320.9_429.3 118 qual IS_ITGFLKPGK_323.5_437.3 118 LBP_HUMAN ITLPDFTGDLR_624.3_288.2 119 qual IS_ITLPDFTGDLR_629.3_298.2 119 LBP_HUMAN ITLPDFTGDLR_624.3_920.5 119 quant IS_ITLPDFTGDLR_629.3_930.5 119 LYAM3_HUMAN* SYYWIGIR_529.3_644.4 120 qual IS_SYYWIGIR_534.3_654.4 120 LYAM3_HUMAN* SYYWIGIR_529.3_807.5 120 quant IS_SYYWIGIR_534.3_817.5 120 NCAM1_HUMAN GLGEISAASEFK_604.8_357.2 121 qual IS_GLGEISAASEFK_608.8_357.2 121 NCAM1_HUMAN GLGEISAASEFK_604.8_739.4 121 quant IS_GLGEISAASEFK_608.8_747.4 121 PAPP1_HUMAN DIPHWLNPTR_416.9_373.2 122 quant IS_DIPHWLNPTR_420.2_383.2 122 PAPP1_HUMAN DIPHWLNPTR_416.9_600.4 122 qual IS_DIPHWLNPTR_420.2_610.4 122 PAPP1_HUMAN LDGSTHLNIFFAK_488.3_739.4 123 quant PAPP1_HUMAN LDGSTHLNIFFAK_488.3_852.5 123 qual PEDF_HUMAN LQSLFDSPDFSK_692.3_329.2 124 qual IS_LQSLFDSPDFSK_696.4_329.2 124 PEDF_HUMAN LQSLFDSPDFSK_692.3_942.4 124 quant IS_LQSLFDSPDFSK_696.4_950.4 124 PEDF_HUMAN TVQAVLTVPK_528.3_428.3 125 qual IS_TVQAVLTVPK_532.3_432.3 125 PEDF_HUMAN TVQAVLTVPK_528.3_855.5 125 quant IS_TVQAVLTVPK_532.3_863.5 125 PGRP2_HUMAN AGLLRPDYALLGHR_518.0_369.2 126 quant IS_AGLLRPDYALLGHR_521.3_379.2 126 PGRP2_HUMAN AGLLRPDYALLGHR_518.0_595.4 126 qual IS_AGLLRPDYALLGHR_521.3_605.4 126 PGRP2_HUMAN DGSPDVTTADIGANTPDATK_973.5_ 127 quant 531.3 PGRP2_HUMAN DGSPDVTTADIGANTPDATK_973.5_ 127 qual 844.4 PRDX2_HUMAN GLFIIDGK_431.8_319.2 128 qual IS_GLFIIDGK_435.8_327.2 128 PRDX2_HUMAN GLFIIDGK_431.8_545.3 128 quant IS_GLFIIDGK_435.8_553.3 128 PRG2_HUMAN WNFAYWAAHQPWSR_607.3_545.3 129 quant IS_WNFAYWAAHQPWSR_610.6_555.3 129 PRG2_HUMAN WNFAYWAAHQPWSR_607.3_673.3 129 qual IS_WNFAYWAAHQPWSR_610.6_683.3 129 PSG1_HUMAN DLYHYITSYVVDGEIIIYGPAYSGR_ 130 qual 955.5_650.3 PSG1_HUMAN DLYHYITSYVVDGEIIIYGPAYSGR_ 130 quant 955.5_707.3 PSG1_HUMAN FQLPGQK_409.2_276.1 131 quant IS_FQLPGQK_413.2_276.1 131 PSG1_HUMAN FQLPGQK_409.2_429.2 131 qual IS_FQLPGQK_413.2_437.3 131 PSG11_HUMAN LFIPQITPK_528.8_261.2 132 qual IS_LFIPQITPK_532.8_261.2 132 PSG11_HUMAN LFIPQITPK_528.8_683.4 132 quant IS_LFIPQITPK_532.8_691.4 132 PSG2_HUMAN IHPSYTNYR_384.2_338.2 133 qual IS_IHPSYTNYR_387.5_348.2 133 PSG2_HUMAN IHPSYTNYR_384.2_452.2 133 quant IS_IHPSYTNYR_387.5_462.2 133 PSG3_HUMAN VSAPSGTGHLPGLNPL_758.9_229.2 134 quant IS_VSAPSGTGHLPGLNPL_762.4_236.2 134 PSG3_HUMAN VSAPSGTGHLPGLNPL_758.9_610.4 134 qual IS_VSAPSGTGHLPGLNPL_762.4_617.4 134 PSG9_HUMAN DVLLLVHNLPQNLPGYFWYK_810.4_ 135 qual IS_DVLLLVHNLPQNLPGYFWYK_813.1_ 135 328.2 328.2 PSG9_HUMAN DVLLLVHNLPQNLPGYFWYK_810.4_ 135 quant IS_DVLLLVHNLPQNLPGYFWYK_813.1_ 135 960.5 968.5 PSG9_HUMAN LFIPQITR_494.3_614.4 136 quant IS_LFIPQITR_499.3_624.4 136 PSG9_HUMAN LFIPQITR_494.3_727.4 136 qual IS_LFIPQITR_499.3_737.5 136 PTGDS_HUMAN GPGEDFR_389.2_322.2 137 qual IS_GPGEDFR_394.2_332.2 137 PTGDS_HUMAN GPGEDFR_389.2_623.3 137 quant IS_GPGEDFR_394.2_633.3 137 SHBG_HUMAN ALALPPLGLAPLLNLWAKPQGR_770.5_ 27 quant 256.2 SHBG_HUMAN ALALPPLGLAPLLNLWAKPQGR_770.5_ 27 qual 457.3 SHBG_HUMAN IALGGLLFPASNLR_481.3_412.3 18 qual IS_IALGGLLFPASNLR_484.6_412.3 18 SHBG_HUMAN IALGGLLFPASNLR_481.3_6574 18 quant IS_IALGGLLFPASNLR_484.6_667.4 18 SOM2_HUMAN* NYGLLYCFR_603.3_278.1 138 quant IS_NYGLLYCFR_608.3_278.1 138 SOM2_HUMAN* NYGLLYCFR_603.3_758.4 138 qual IS_NYGLLYCFR_608.3_768.4 138 SOM2_HUMAN* SVEGSCGF_421.7_223.1 139 qual IS_SVEGSCGF_424.7_223.1 139 SOM2_HUMAN* SVEGSCGF_421.7_383.1 139 quant IS_SVEGSCGF_424.7_383.1 139 SPRL1_HUMAN VLTHSELAPLR_412.6_512.3 140 quant IS_VLTHSELAPLR_415.9_517.3 140 SPRL1_HUMAN VLTHSELAPLR_412.6_568.8 140 qual IS_VLTHSELAPLR_415.9_573.8 140 TENX_HUMAN LNWEAPPGAFDSFLLR_917.0_414.2 141 qual IS_LNWEAPPGAFDSFLLR_922.0_414.2 141 TENX_HUMAN LNWEAPPGAFDSFLLR_917.0_614.3 141 quant IS_LNWEAPPGAFDSFLLR_922.0_614.3 141 TENX_HUMAN LSQLSVTDVTTSSLR_803.9_1165.6 142 quant IS_LSQLSVTDVTTSSLR_808.9_1175.6 142 TENX_HUMAN LSQLSVTDVTTSSLR_803.9_979.5 142 qual IS_LSQLSVTDVTTSSLR_808.9_989.5 142 THBG_HUMAN AVLHIGEK_289.5_292.2 143 qual IS_AVLHIGEK_292.2_296.2 143 THBG_HUMAN AVLHIGEK_289.5_348.7 143 quant IS_AVLHIGEK_292.2_352.7 143 TIE1_HUMAN VSWSLPLVPGPLVGDGFLLR_708.1_ 144 qual IS_VSWSLPLVPGPLVGDGFLLR_711.4_ 144 543.8 548.8 TIE1_HUMAN VSWSLPLVPGPLVGDGFLLR_708.1_ 144 quant IS_VSWSLPLVPGPLVGDGFLLR_711.4_ 144 620.9 625.9 TRFE_HUMAN YLGEEYVK_500.8_277.2 145 qual Depleted IS_YLGEEYVK_504.8_277.2 145 TRFE_HUMAN YLGEEYVK_500.8_724.4 145 quant Depleted IS_YLGEEYVK_504.8_732.4 145 TTHY_HUMAN VEIDTK_352.7_476.3 146 quant Depleted IS_VEIDTK_356.7_484.3 146 TTHY_HUMAN VEIDTK_352.7_605.3 146 qual Depleted IS_VEIDTK_356.7_613.3 146 VTDB_HUMAN ELPEHTVK_476.8_347.2 147 qual IS_ELPEHTVK_480.8_355.2 147 VTDB_HUMAN ELPEHTVK_476.8_710.4 147 quant IS_ELPEHTVK_480.8_718.4 147 VTDB_HUMAN VLEPTLK_400.3_458.3 148 qual VTDB_HUMAN VLEPTLK_400.3_587.3 148 quant VTNC_HUMAN GQYCYELDEK_652.8_1119.5 149 quant IS_GQYCYELDEK_656.8_1127.5 149 VTNC_HUMAN GQYCYELDEK_652.8_276.2 149 qual IS_GQYCYELDEK_656.8_284.2 149 VTNC_HUMAN VDTVDPPYPR_579.8_629.3 150 quant IS_VDTVDPPYPR_584.8_639.3 150 VTNC_HUMAN VDTVDPPYPR_579.8_744.4 150 qual IS_VDTVDPPYPR_584.8_754.4 150 *Denotes name changes. CSH denotes that the peptide corresponds to both CSH1 and CSH2. HLAG now referred to as HLACI since the peptide is conserved in several class I HLA isotypes. LYAM3 now referred to as LYAM1 because, while the peptide sequence is present in each, it is only derived by trypsin cleavage from LYAM1. SOM2 now referred to as SOM2.CSH as the peptides are specific to both SOM2 and CSH.
(441) TABLE-US-00022 TABLE22 119_ 119_ 119_ 119_ 126_ 126_ 126_ 126_ 133_ 133_ SEQ 132_ 132_ 132_ 1322_ 139_ 139_ 139_ 139_ 146_ 146_ ID aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ Protein Transition NO: 37 37 35 35 37 37 35 35 37 37 A2GL A2GL_DLLLPQPDLR 34 0.508 0.511 0.534 0.513 0.568 0.608 0.519 0.522 0.562 0.602 AFAM AFAM_DADPDTFFAK 37 0.594 0.551 0.601 0.564 0.551 0.558 0.553 0.578 0.549 0.584 AFAM AFAM_HFQNLGK 38 0.583 0.533 0.589 0.540 0.540 0.534 0.534 0.556 0.554 0.591 ALS ALS_IRPHTFTGLSGLR 40 0.515 0.509 0.530 0.560 0.507 0.503 0.511 0.504 0.513 0.524 ANGT ANGT_DPTFIPAPIQAK 42 0.577 0.622 0.666 0.685 0.574 0.608 0.573 0.616 0.507 0.544 APOC3 APOC3_GWVTDGFSSLK 47 0.582 0.576 0.510 0.548 0.605 0.611 0.607 0.593 0.635 0.617 APOH APOH_ATVVYQGER 48 0.540 0.523 0.577 0.555 0.629 0.612 0.595 0.621 0.606 0.590 B2MG B2MG_VEHSDLSFSK 50 0.533 0.566 0.502 0.507 0.522 0.505 0.512 0.521 0.558 0.548 B2MG B2MG_VNHVTLSQPK 51 0.512 0.582 0.517 0.540 0.524 0.501 0.554 0.560 0.593 0.580 BGH3 BGH3_LTLLAPLNSVFK 52 0.562 0.575 0.557 0.610 0.509 0.512 0.531 0.538 0.522 0.557 C163A C163A_INPASLDK 54 0.520 0.561 0.604 0.617 0.546 0.583 0.594 0.605 0.511 0.515 C1QB C1QB_VPGLYYFTYHASSR 55 0.573 0.607 0.538 0.573 0.586 0.631 0.565 0.560 0.596 0.588 CAH1 CAH1_GGPFSDSYR 56 0.560 0.560 0.563 0.553 0.500 0.590 0.563 0.605 0.543 0.581 CATD CATD_VGFAEAAR 57 0.516 0.523 0.585 0.555 0.501 0.546 0.545 0.553 0.550 0.507 CATD CATD_VSTLPAITLK 58 0.525 0.512 0.606 0.613 0.515 0.550 0.540 0.536 0.542 0.530 CBPN CBPN_EALIQFLEQVHQGIK 59 0.508 0.563 0.567 0.585 0.508 0.509 0.549 0.582 0.517 0.507 CBPN CBPN_NNANGVDLNR 60 0.514 0.519 0.579 0.606 0.521 0.507 0.502 0.516 0.505 0.526 CD14 CD14_LTVGAAQVPAQLLVGALR 61 0.532 0.539 0.578 0.626 0.608 0.623 0.635 0.665 0.605 0.577 CD14 CD14_SWLAELQQWLKPGLK 62 0.550 0.547 0.540 0.549 0.589 0.594 0.599 0.608 0.594 0.567 CFAB CFAB_YGLVTYATYPK 64 0.635 0.605 0.514 0.522 0.574 0.556 0.530 0.572 0.564 0.592 CHL1 CHL1_VIAVNEVGR 66 0.670 0.680 0.669 0.661 0.550 0.592 0.549 0.554 0.514 0.522 CLUS CLUS_ASSIIDELFQDR 67 0.563 0.557 0.713 0.667 0.554 0.530 0.685 0.649 0.526 0.541 CLUS CLUS_LFDSDPITVTVPVEVSR 68 0.559 0.529 0.643 0.562 0.557 0.525 0.687 0.623 0.522 0.514 CO5 CO5_TLLPVSKPEIR 70 0.590 0.610 0.613 0.632 0.570 0.606 0.541 0.563 0.567 0.592 CO5 CO5_VFQFLEK 71 0.568 0.588 0.533 0.560 0.555 0.571 0.542 0.526 0.576 0.579 CO6 CO6_ALNHLPLEYNSALYSR 72 0.619 0.647 0.721 0.795 0.553 0.537 0.592 0.621 0.524 0.541 CO8A CO8A_SLLQPNK 74 0.512 0.536 0.515 0.537 0.574 0.566 0.561 0.547 0.610 0.638 CO8B CO8B_QALEEFQK 76 0.528 0.522 0.522 0.500 0.576 0.563 0.546 0.501 0.605 0.633 CRIS3 CRIS3_AVSPPAR 78 0.513 0.543 0.592 0.626 0.508 0.562 0.567 0.587 0.530 0.577 CRIS3 CRIS3_YEDLYSNCK 79 0.530 0.539 0.631 0.654 0.529 0.574 0.596 0.616 0.544 0.602 CSH CSH_AHQLAIDTYQEFEETYIPK 80 0.615 0.550 0.534 0.516 0.568 0.566 0.570 0.540 0.527 0.540 CSH CSH_ISLLLIESWLEPVR 81 0.597 0.528 0.515 0.506 0.530 0.521 0.550 0.520 0.543 0.558 ENPP2 ENPP2_TEFLSNYLTNVDDITLVPGTLGR 82 0.547 0.522 0.795 0.795 0.501 0.532 0.593 0.674 0.560 0.565 ENPP2 ENPP2_TYLHTYESEI 83 0.557 0.508 0.762 0.772 0.506 0.548 0.597 0.673 0.567 0.553 F13B F13B_GDTYPAELYITGSILR 84 0.563 0.557 0.528 0.533 0.569 0.576 0.588 0.623 0.503 0.516 FBLN1 FBLN1_TGYYFDGISR 86 0.609 0.585 0.506 0.560 0.594 0.581 0.562 0.519 0.536 0.550 FBLN3 FBLN3_IPSNPSHR 87 0.538 0.553 0.503 0.553 0.529 0.528 0.509 0.503 0.510 0.537 FETUA FETUA_FSVVYAK 88 0.527 0.519 0.521 0.531 0.502 0.539 0.544 0.586 0.525 0.513 FETUA FETUA_HTLNQIDEVK 89 0.532 0.506 0.559 0.599 0.503 0.528 0.587 0.618 0.523 0.514 HABP2 HABP2_FLNWIK 92 0.678 0.680 0.732 0.780 0.585 0.605 0.630 0.603 0.550 0.543 HEMO HEMO_NFPSPVDAAFR 93 0.524 0.502 0.575 0.555 0.557 0.529 0.522 0.519 0.552 0.502 HLACI HLACI_WAAVVVPSGEEQR 95 0.534 0.504 0.530 0.549 0.512 0.529 0.541 0.515 0.538 0.514 IBP1 IBP1_VVESLAK 97 0.578 0.556 0.559 0.516 0.546 0.528 0.557 0.542 0.516 0.518 IBP2 IBP2_LIQGAPTIR 98 0.539 0.525 0.521 0.518 0.505 0.507 0.517 0.563 0.501 0.500 IBP3 IBP3_FLNVLSPR 99 0.504 0.557 0.576 0.637 0.505 0.545 0.536 0.567 0.530 0.535 IBP3 IBP3_YGQPLPGYTTK 100 0.500 0.530 0.606 0.628 0.511 0.542 0.562 0.557 0.559 0.578 IBP4 IBP4_QCHPALDGQR 2 0.501 0.542 0.542 0.555 0.590 0.590 0.591 0.626 0.691 0.723 IBP6 IBP6_GAQTLYVPNCDHR 101 0.527 0.603 0.528 0.592 0.535 0.527 0.593 0.552 0.561 0.503 IBP6 IBP6_HLDSVLQQLQTEVYR 102 0.512 0.557 0.512 0.570 0.517 0.533 0.545 0.520 0.541 0.504 IGF2 IGF2_GIVEECCFR 103 0.523 0.545 0.704 0.743 0.542 0.558 0.627 0.667 0.567 0.573 INHBC INHBC_LDFHFSSDR 107 0.575 0.534 0.573 0.643 0.586 0.595 0.530 0.522 0.619 0.665 ITIH3 ITIH3_ALDLSLK 111 0.525 0.534 0.522 0.564 0.529 0.527 0.516 0.518 0.544 0.519 ITIH4 ITIH4_ILDDLSPR 112 0.513 0.553 0.541 0.599 0.537 0.563 0.504 0.552 0.551 0.546 ITIH4 ITIH4_NPLVWVHASPEHVVVTR 113 0.501 0.532 0.586 0.595 0.573 0.589 0.505 0.514 0.587 0.556 ITIH4 ITIH4_QLGLPGPPDVPDHAAYHPF 114 0.518 0.506 0.537 0.565 0.547 0.538 0.523 0.568 0.526 0.520 KNG1 KNG1_DIPTNSPELEETLTHTITK 116 0.529 0.530 0.560 0.652 0.557 0.542 0.559 0.617 0.564 0.522 KNG1 KNG1_QVVAGLNFR 117 0.511 0.501 0.587 0.667 0.542 0.539 0.593 0.646 0.584 0.557 LBP LBP_ITGFLKPGK 118 0.575 0.512 0.510 0.500 0.578 0.545 0.501 0.565 0.566 0.546 LBP LBP_ITLPDFTGDLR 119 0.598 0.546 0.508 0.533 0.590 0.569 0.515 0.535 0.591 0.585 LYAM1 LYAM1_SYYWIGIR 120 0.550 0.600 0.574 0.654 0.567 0.623 0.666 0.720 0.542 0.580 NCAM1 NCAM1_GLGEISAASEFK 121 0.592 0.570 0.595 0.615 0.541 0.545 0.502 0.579 0.515 0.530 PAPP1 PAPP1_DIPHWLNPTR 122 0.571 0.505 0.531 0.524 0.505 0.520 0.525 0.569 0.533 0.512 PEDF PEDF_LQSLFDSPDFSK 124 0.594 0.575 0.517 0.513 0.563 0.540 0.502 0.520 0.555 0.542 PEDF PEDF_TVQAVLTVPK 125 0.604 0.607 0.574 0.603 0.584 0.598 0.561 0.601 0.560 0.557 PGRP2 PGRP2_AGLLRPDYALLGHR 126 0.581 0.575 0.590 0.577 0.539 0.583 0.528 0.592 0.507 0.527 PRDX2 PRDX2_GLFIIDGK 128 0.544 0.533 0.615 0.588 0.510 0.604 0.535 0.570 0.582 0.613 PRG2 PRG2_WNFAYWAAHQPWSR 129 0.564 0.527 0.507 0.538 0.545 0.507 0.515 0.511 0.590 0.535 PSG11 PSG11_LFIPQITPK 132 0.503 0.520 0.532 0.575 0.521 0.578 0.520 0.576 0.502 0.541 PSG1 PSG1_FQLPGQK 131 0.600 0.571 0.646 0.582 0.546 0.564 0.501 0.511 0.501 0.507 PSG2 PSG2_IHPSYTNYR 133 0.520 0.597 0.681 0.742 0.509 0.562 0.638 0.704 0.536 0.568 PSG3 PSG3_VSAPSGTGHLPGLNPL 134 0.650 0.577 0.568 0.533 0.604 0.603 0.549 0.546 0.606 0.634 PSG9 PSG9_DVLLLVHNLPQNLPGYFWYK 135 0.602 0.596 0.569 0.526 0.562 0.578 0.623 0.599 0.526 0.558 PSG9 PSG9_LFIPQITR 136 0.575 0.565 0.638 0.555 0.543 0.552 0.654 0.670 0.521 0.547 PTGDS PTGDS_GPGEDFR 137 0.527 0.597 0.542 0.557 0.538 0.547 0.550 0.594 0.559 0.598 SHBG SHBG_IALGGLLFPASNLR 18 0.580 0.567 0.563 0.641 0.575 0.574 0.562 0.532 0.588 0.586 SOM2.CSH SOM2.CSH_NYGLLYCFR 138 0.604 0.535 0.547 0.509 0.531 0.515 0.525 0.517 0.554 0.590 SOM2.CSH SOM2.CSH_SVEGSCGF 139 0.589 0.528 0.570 0.537 0.529 0.547 0.507 0.502 0.544 0.511 SPRL1 SPRL1_VLTHSELAPLR 140 0.534 0.545 0.528 0.526 0.516 0.583 0.533 0.504 0.530 0.557 TENX TENX_LNWEAPPGAFDSFLLR 141 0.582 0.562 0.534 0.527 0.577 0.640 0.602 0.583 0.567 0.577 TENX TENX_LSQLSVTDVTTSSLR 142 0.519 0.523 0.534 0.562 0.568 0.634 0.578 0.560 0.560 0.571 THBG THBG_AVLHIGEK 143 0.558 0.571 0.503 0.564 0.506 0.521 0.509 0.507 0.550 0.554 TIE1 TIE1_VSWSLPLVPGPLVGDGFLLR 144 0.549 0.592 0.524 0.561 0.578 0.613 0.572 0.525 0.507 0.501 VTDB VTDB_ELPEHTVK 147 0.557 0.538 0.516 0.586 0.506 0.515 0.517 0.530 0.529 0.512 VTNC VTNC_GQYCYELDEK 149 0.663 0.674 0.641 0.694 0.612 0.638 0.618 0.641 0.582 0.606 VTNC VTNC_VDTVDPPYPR 150 0.622 0.633 0.547 0.555 0.603 0.621 0.585 0.586 0.624 0.634
(442) TABLE-US-00023 TABLE23 133_ 133_ 140_ 140_ 140_ 140_ 119_ 119_ 119_ 119_ SEQ 146_ 146_ 153_ 153_ 153_ 153_ 153_ 153_ 153_ 153_ ID aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ aBMI rBMI_ Protein Transition NO: 35 35 37 37 35 35 37 37 35 35 A2GL A2GL_DLLLPQPDLR 34 0.517 0.541 0.566 0.577 0.544 0.580 0.554 0.568 0.520 0.533 AFAM AFAM_DADPDTFFAK 37 0.573 0.676 0.589 0.615 0.658 0.691 0.557 0.557 0.590 0.620 AFAM AFAM_HFQNLGK 38 0.551 0.662 0.624 0.680 0.712 0.778 0.559 0.561 0.590 0.626 ALS ALS_IRPHTFTGLSGLR 40 0.531 0.501 0.542 0.505 0.509 0.510 0.504 0.513 0.521 0.519 ANGT ANGT_DPTFIPAPIQAK 42 0.567 0.547 0.557 0.601 0.555 0.586 0.549 0.589 0.558 0.593 APOC3 APOC3_GWVTDGFSSLK 47 0.672 0.596 0.674 0.635 0.591 0.501 0.622 0.599 0.587 0.539 APOH APOH_ATVVYQGER 48 0.674 0.733 0.531 0.547 0.588 0.626 0.580 0.563 0.573 0.591 B2MG B2MG_VEHSDLSFSK 50 0.519 0.591 0.599 0.596 0.553 0.503 0.543 0.520 0.536 0.508 B2MG B2MG_VNHVTLSQPK 51 0.568 0.505 0.659 0.642 0.615 0.557 0.570 0.539 0.571 0.553 BGH3 BGH3_LTLLAPLNSVFK 52 0.562 0.621 0.595 0.623 0.532 0.553 0.542 0.564 0.516 0.518 C163A C163A_INPASLDK 54 0.532 0.549 0.593 0.572 0.555 0.519 0.504 0.527 0.530 0.540 C1QB C1QB_VPGLYYFTYHASSR 55 0.593 0.672 0.603 0.574 0.509 0.555 0.575 0.583 0.539 0.547 CAH1 CAH1_GGPFSDSYR 56 0.626 0.623 0.514 0.584 0.585 0.524 0.507 0.500 0.557 0.549 CATD CATD_VGFAEAAR 57 0.660 0.637 0.693 0.686 0.819 0.817 0.576 0.547 0.626 0.634 CATD CATD_VSTLPAITLK 58 0.674 0.719 0.671 0.692 0.802 0.866 0.564 0.549 0.623 0.651 CBPN CBPN_EALIQFLEQVHQGIK 59 0.558 0.651 0.552 0.581 0.589 0.553 0.507 0.542 0.510 0.506 CBPN CBPN_NNANGVDLNR 60 0.512 0.551 0.589 0.604 0.619 0.604 0.516 0.541 0.550 0.546 CD14 CD14_LTVGAAQVPAQLLVGALR 61 0.648 0.617 0.586 0.568 0.612 0.579 0.577 0.558 0.615 0.600 CD14 CD14_SWLAELQQWLKPGLK 62 0.635 0.583 0.585 0.560 0.638 0.579 0.577 0.554 0.601 0.569 CFAB CFAB_YGLVTYATYPK 64 0.530 0.508 0.613 0.643 0.601 0.655 0.599 0.601 0.522 0.528 CHL1 CHL1_VIAVNEVGR 66 0.564 0.583 0.563 0.503 0.534 0.541 0.568 0.577 0.505 0.506 CLUS CLUS_ASSIIDELFQDR 67 0.618 0.568 0.512 0.563 0.500 0.521 0.534 0.546 0.628 0.592 CLUS CLUS_LFDSDPITVTVPVEVSR 68 0.669 0.615 0.512 0.517 0.562 0.611 0.521 0.511 0.610 0.543 CO5 CO5_TLLPVSKPEIR 70 0.528 0.540 0.580 0.560 0.531 0.566 0.577 0.589 0.548 0.525 CO5 CO5_VFQFLEK 71 0.547 0.522 0.599 0.568 0.556 0.515 0.577 0.575 0.540 0.511 CO6 CO6_ALNHLPLEYNSALYSR 72 0.508 0.517 0.516 0.508 0.591 0.637 0.554 0.566 0.549 0.560 CO8A COSA_SLLQPNK 74 0.602 0.585 0.604 0.588 0.584 0.582 0.574 0.557 0.563 0.553 CO8B CO8B_QALEEFQK 76 0.594 0.584 0.608 0.611 0.613 0.635 0.578 0.567 0.565 0.549 CRIS3 CRIS3_AVSPPAR 78 0.614 0.686 0.563 0.594 0.595 0.611 0.525 0.571 0.582 0.608 CRIS3 CRIS3_YEDLYSNCK 79 0.616 0.694 0.570 0.606 0.588 0.590 0.539 0.580 0.596 0.620 CSH CSH_AHQLAIDTYQEFEETYIPK 80 0.582 0.539 0.571 0.570 0.517 0.541 0.526 0.509 0.535 0.513 CSH CSH_ISLLLIESWLEPVR 81 0.569 0.525 0.542 0.542 0.525 0.533 0.515 0.505 0.531 0.511 ENPP2 ENPP2_TEFLSNYLTNVDDITLVPGTLGR 82 0.583 0.509 0.703 0.737 0.650 0.659 0.574 0.571 0.517 0.558 ENPP2 ENPP2_TYLHTYESEI 83 0.591 0.519 0.711 0.722 0.692 0.664 0.576 0.559 0.500 0.545 F13B F13B_GDTYPAELYITGSILR 84 0.590 0.614 0.526 0.515 0.578 0.571 0.529 0.528 0.584 0.590 FBLN1 FBLN1_TGYYFDGISR 86 0.632 0.575 0.519 0.588 0.562 0.537 0.537 0.521 0.542 0.550 FBLN3 FBLN3_IPSNPSHR 87 0.575 0.670 0.528 0.524 0.617 0.649 0.523 0.506 0.545 0.559 FETUA FETUA_FSVVYAK 88 0.568 0.692 0.658 0.652 0.659 0.660 0.552 0.534 0.530 0.517 FETUA FETUA_HTLNQIDEVK 89 0.611 0.699 0.656 0.655 0.715 0.761 0.544 0.529 0.524 0.531 HABP2 HABP2_FLNWIK 92 0.605 0.517 0.623 0.587 0.516 0.541 0.595 0.592 0.591 0.544 HEMO HEMO_NFPSPVDAAFR 93 0.509 0.587 0.634 0.658 0.502 0.514 0.567 0.536 0.501 0.538 HLACI HLACI_WAAVVVPSGEEQR 95 0.537 0.538 0.574 0.591 0.604 0.552 0.527 0.543 0.502 0.508 IBP1 IBP1_VVESLAK 97 0.619 0.625 0.525 0.518 0.650 0.702 0.537 0.510 0.597 0.563 IBP2 IBP2_LIQGAPTIR 98 0.548 0.576 0.527 0.526 0.685 0.734 0.522 0.507 0.554 0.552 IBP3 IBP3_FLNVLSPR 99 0.514 0.532 0.525 0.574 0.581 0.611 0.532 0.566 0.507 0.514 IBP3 IBP3_YGQPLPGYTTK 100 0.525 0.525 0.548 0.617 0.505 0.521 0.547 0.581 0.552 0.540 IBP4 IBP4_QCHPALDGQR 2 0.600 0.624 0.677 0.688 0.530 0.568 0.608 0.606 0.539 0.530 IBP6 IBP6_GAQTLYVPNCDHR 101 0.569 0.557 0.501 0.524 0.593 0.562 0.522 0.533 0.526 0.505 IBP6 IBP6_HLDSVLQQLQTEVYR 102 0.519 0.539 0.521 0.514 0.559 0.523 0.520 0.521 0.511 0.506 IGF2 IGF2_GIVEECCFR 103 0.527 0.513 0.580 0.623 0.529 0.590 0.569 0.592 0.578 0.579 INHBC INHBC_LDFHFSSDR 107 0.610 0.625 0.672 0.698 0.608 0.636 0.608 0.612 0.545 0.517 ITIH3 ITIH3_ALDLSLK 111 0.525 0.580 0.612 0.623 0.547 0.557 0.557 0.557 0.513 0.519 ITIH4 ITIH4_ILDDLSPR 112 0.500 0.546 0.538 0.510 0.521 0.626 0.531 0.537 0.501 0.508 ITIH4 ITIH4_NPLVWVHASPEHVVVTR 113 0.556 0.621 0.507 0.508 0.719 0.822 0.534 0.528 0.559 0.597 ITIH4 ITIH4_QLGLPGPPDVPDHAAYHPF 114 0.507 0.666 0.509 0.551 0.613 0.626 0.512 0.505 0.520 0.582 KNG1 KNG1_DIPTNSPELEETLTHTITK 116 0.522 0.599 0.609 0.593 0.512 0.588 0.558 0.535 0.523 0.525 KNG1 KNG1_QVVAGLNFR 117 0.581 0.528 0.664 0.653 0.634 0.548 0.562 0.554 0.602 0.602 LBP LBP_ITGFLKPGK 118 0.521 0.593 0.640 0.645 0.542 0.615 0.587 0.559 0.505 0.565 LBP LBP_ITLPDFTGDLR 119 0.524 0.581 0.672 0.681 0.505 0.550 0.609 0.588 0.524 0.521 LYAM1 LYAM1_SYYWIGIR 120 0.701 0.765 0.554 0.585 0.663 0.687 0.552 0.596 0.651 0.696 NCAM1 NCAM1_GLGEISAASEFK 121 0.587 0.501 0.515 0.505 0.535 0.553 0.536 0.531 0.501 0.557 PAPP1 PAPP1_DIPHWLNPTR 122 0.504 0.632 0.582 0.507 0.513 0.622 0.540 0.519 0.525 0.594 PEDF PEDF_LQSLFDSPDFSK 124 0.560 0.580 0.616 0.659 0.615 0.649 0.577 0.571 0.545 0.565 PEDF PEDF_TVQAVLTVPK 125 0.587 0.620 0.587 0.560 0.573 0.562 0.577 0.570 0.577 0.598 PGRP2 PGRP2_AGLLRPDYALLGHR 126 0.618 0.721 0.569 0.580 0.668 0.703 0.560 0.578 0.576 0.627 PRDX2 PRDX2_GLFIIDGK 128 0.620 0.598 0.551 0.537 0.609 0.542 0.525 0.530 0.547 0.536 PRG2 PRG2_WNFAYWAAHQPWSR 129 0.563 0.552 0.586 0.505 0.556 0.535 0.565 0.501 0.520 0.529 PSG11 PSG11_LFIPQITPK 132 0.570 0.523 0.562 0.544 0.517 0.604 0.511 0.516 0.500 0.501 PSG1 PSG1_FQLPGQK 131 0.606 0.524 0.558 0.577 0.510 0.548 0.524 0.509 0.508 0.535 PSG2 PSG2_IHPSYTNYR 133 0.592 0.721 0.551 0.544 0.515 0.537 0.522 0.563 0.597 0.660 PSG3 PSG3_VSAPSGTGHLPGLNPL 134 0.614 0.559 0.517 0.520 0.571 0.546 0.581 0.563 0.557 0.506 PSG9 PSG9_DVLLLVHNLPQNLPGYFWYK 135 0.535 0.516 0.525 0.604 0.605 0.669 0.546 0.567 0.547 0.500 PSG9 PSG9_LFIPQITR 136 0.527 0.541 0.506 0.585 0.573 0.617 0.528 0.541 0.571 0.554 PTGDS PTGDS_GPGEDFR 137 0.603 0.671 0.567 0.595 0.535 0.521 0.536 0.532 0.537 0.545 SHBG SHBG_IALGGLLFPASNLR 18 0.688 0.761 0.594 0.579 0.717 0.772 0.585 0.576 0.611 0.613 SOM2.CSH SOM2.CSH_NYGLLYCFR 138 0.538 0.529 0.608 0.612 0.509 0.501 0.501 0.527 0.513 0.520 SOM2.CSH SOM2.CSH_SVEGSCGF 139 0.538 0.579 0.531 0.539 0.612 0.684 0.525 0.539 0.542 0.565 SPRL1 SPRL1_VLTHSELAPLR 140 0.648 0.623 0.502 0.510 0.658 0.631 0.502 0.543 0.578 0.555 TENX TENX_LNWEAPPGAFDSFLLR 141 0.622 0.569 0.614 0.530 0.531 0.682 0.576 0.573 0.550 0.519 TENX TENX_LSQLSVTDVTTSSLR 142 0.606 0.546 0.571 0.519 0.644 0.825 0.550 0.542 0.508 0.588 THBG THBG_AVLHIGEK 143 0.534 0.539 0.556 0.571 0.532 0.530 0.518 0.507 0.520 0.500 TIE1 TIE1_VSWSLPLVPGPLVGDGFLLR 144 0.551 0.526 0.578 0.559 0.527 0.515 0.513 0.531 0.536 0.502 VTDB VTDB_ELPEHTVK 147 0.567 0.653 0.524 0.547 0.611 0.611 0.506 0.502 0.528 0.533 VTNC VTNC_GQYCYELDEK 149 0.560 0.555 0.680 0.698 0.625 0.651 0.623 0.635 0.598 0.617 VTNC VTNC_VDTVDPPYPR 150 0.595 0.566 0.673 0.670 0.568 0.533 0.625 0.629 0.574 0.553
(443) TABLE-US-00024 TABLE24 119_ 119_ 119_ 119_ 126_ 126_ 126_ 126_ SEQ 139_ 139_ 139_ 139_ 146_ 146_ 146_ 146_ ID aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ Protein Transition NO: 37 37 35 35 37 37 35 35 A2GL A2GL_DLLLPQPDLR 34 0.549 0.565 0.503 0.500 0.552 0.596 0.511 0.513 AFAM AFAM_DADPDTFFAK 37 0.543 0.531 0.554 0.579 0.575 0.594 0.586 0.633 AFAM AFAM_HFQNLGK 38 0.526 0.501 0.529 0.544 0.579 0.593 0.568 0.612 ALS ALS_IRPHTFTGLSGLR 40 0.516 0.526 0.532 0.533 0.536 0.530 0.518 0.511 ANGT ANGT_DPTFIPAPIQAK 42 0.541 0.564 0.565 0.590 0.561 0.616 0.534 0.578 APOC3 APOC3_GWVTDGFSSLK 47 0.596 0.579 0.582 0.557 0.624 0.627 0.626 0.605 APOH APOH_ATVVYQGER 48 0.604 0.573 0.567 0.577 0.597 0.591 0.610 0.654 B2MG B2MG_VEHSDLSFSK 50 0.510 0.528 0.521 0.519 0.529 0.520 0.506 0.556 B2MG B2MG_VNHVTLSQPK 51 0.523 0.531 0.545 0.538 0.556 0.539 0.563 0.535 BGH3 BGH3_LTLLAPLNSVFK 52 0.516 0.531 0.507 0.502 0.534 0.553 0.537 0.551 C163A C163A_INPASLDK 54 0.532 0.578 0.573 0.581 0.511 0.534 0.568 0.596 C1QB C1QB_VPGLYYFTYHASSR 55 0.564 0.582 0.544 0.544 0.606 0.640 0.556 0.572 CAH1 CAH1_GGPFSDSYR 56 0.500 0.550 0.547 0.569 0.502 0.546 0.571 0.578 CATD CATD_VGFAEAAR 57 0.519 0.534 0.531 0.531 0.525 0.512 0.580 0.572 CATD CATD_VSTLPAITLK 58 0.511 0.534 0.537 0.530 0.514 0.503 0.572 0.593 CBPN CBPN_EALIQFLEQVHQGIK 59 0.514 0.519 0.527 0.544 0.501 0.518 0.528 0.580 CBPN CBPN_NNANGVDLNR 60 0.525 0.504 0.510 0.506 0.506 0.530 0.530 0.504 CD14 CD14_LTVGAAQVPAQLLVGALR 61 0.573 0.558 0.616 0.623 0.604 0.611 0.647 0.662 CD14 CD14_SWLAELQQWLKPGLK 62 0.570 0.552 0.579 0.570 0.591 0.593 0.624 0.614 CFAB CFAB_YGLVTYATYPK 64 0.590 0.573 0.520 0.548 0.582 0.591 0.510 0.501 CHL1 CHL1_VIAVNEVGR 66 0.570 0.610 0.518 0.516 0.563 0.578 0.541 0.556 CLUS CLUS_ASSIIDELFQDR 67 0.545 0.533 0.695 0.666 0.547 0.548 0.644 0.590 CLUS CLUS_LFDSDPITVTVPVEVSR 68 0.539 0.507 0.697 0.635 0.547 0.531 0.657 0.584 CO5 CO5_TLLPVSKPEIR 70 0.580 0.603 0.560 0.584 0.565 0.596 0.541 0.512 CO5 CO5_VFQFLEK 71 0.564 0.576 0.537 0.527 0.566 0.577 0.547 0.509 CO6 CO6_ALNHLPLEYNSALYSR 72 0.572 0.582 0.604 0.643 0.547 0.555 0.573 0.599 CO8A CO8A_SLLQPNK 74 0.557 0.538 0.547 0.527 0.590 0.593 0.585 0.587 CO8B CO8B_QALEEFQK 76 0.563 0.544 0.535 0.512 0.587 0.590 0.578 0.563 CRIS3 CRIS3_AVSPPAR 78 0.509 0.559 0.579 0.608 0.526 0.568 0.596 0.640 CRIS3 CRIS3_YEDLYSNCK 79 0.528 0.564 0.603 0.632 0.544 0.585 0.613 0.657 CSH CSH_AHQLAIDTYQEFEETYIPK 80 0.574 0.571 0.555 0.535 0.519 0.505 0.574 0.559 CSH CSH_ISLLLIESWLEPVR 81 0.543 0.531 0.535 0.517 0.501 0.514 0.561 0.544 ENPP2 ENPP2_TEFLSNYLTNVDDITLVPGTLGR 82 0.511 0.522 0.611 0.700 0.550 0.543 0.535 0.606 ENPP2 ENPP2_TYLHTYESEI 83 0.509 0.535 0.607 0.689 0.553 0.528 0.529 0.609 F13B F13B_GDTYPAELYITGSILR 84 0.557 0.557 0.585 0.605 0.527 0.543 0.572 0.593 FBLN1 FBLN1_TGYYFDGISR 86 0.568 0.536 0.537 0.532 0.578 0.533 0.601 0.509 FBLN3 FBLN3_IPSNPSHR 87 0.522 0.503 0.503 0.505 0.527 0.524 0.550 0.571 FETUA FETUA_FSVVYAK 88 0.504 0.544 0.533 0.575 0.531 0.509 0.543 0.610 FETUA FETUA_HTLNQIDEVK 89 0.510 0.546 0.564 0.596 0.536 0.530 0.567 0.600 HABP2 HABP2_FLNWIK 92 0.576 0.593 0.630 0.598 0.606 0.610 0.650 0.615 HEMO HEMO_NFPSPVDAAFR 93 0.534 0.530 0.505 0.545 0.559 0.547 0.505 0.557 HLACI HLACI_WAAVVVPSGEEQR 95 0.503 0.513 0.556 0.542 0.503 0.521 0.525 0.525 IBP1 IBP1_VVESLAK 97 0.543 0.528 0.574 0.508 0.540 0.509 0.584 0.540 IBP2 IBP2_LIQGAPTIR 98 0.519 0.501 0.505 0.540 0.507 0.515 0.532 0.519 IBP3 IBP3_FLNVLSPR 99 0.537 0.565 0.556 0.588 0.506 0.531 0.504 0.518 IBP3 IBP3_YGQPLPGYTTK 100 0.544 0.563 0.583 0.582 0.508 0.542 0.538 0.518 IBP4 IBP4_QCHPALDGQR 2 0.572 0.552 0.573 0.589 0.626 0.636 0.563 0.568 IBP6 IBP6_GAQTLYVPNCDHR 101 0.532 0.540 0.584 0.531 0.528 0.531 0.544 0.515 IBP6 IBP6_HLDSVLQQLQTEVYR 102 0.519 0.543 0.546 0.504 0.516 0.522 0.508 0.501 IGF2 IGF2_GIVEECCFR 103 0.566 0.577 0.636 0.681 0.528 0.546 0.577 0.584 INHBC INHBC_LDFHFSSDR 107 0.575 0.564 0.511 0.551 0.613 0.637 0.566 0.546 ITIH3 ITIH3_ALDLSLK 111 0.531 0.526 0.501 0.504 0.534 0.529 0.522 0.544 ITIH4 ITIH4_ILDDLSPR 112 0.528 0.544 0.512 0.558 0.541 0.567 0.507 0.506 ITIH4 ITIH4_NPLVWVHASPEHVVVTR 113 0.546 0.536 0.523 0.529 0.572 0.587 0.523 0.545 ITIH4 ITIH4_QLGLPGPPDVPDHAAYHPF 114 0.514 0.520 0.532 0.547 0.547 0.555 0.506 0.587 KNG1 KNG1_DIPTNSPELEETLTHTITK 116 0.535 0.503 0.537 0.577 0.568 0.565 0.535 0.549 KNG1 KNG1_QVVAGLNFR 117 0.517 0.506 0.590 0.628 0.571 0.570 0.594 0.607 LBP LBP_ITGFLKPGK 118 0.562 0.511 0.523 0.526 0.582 0.562 0.507 0.591 LBP LBP_ITLPDFTGDLR 119 0.576 0.533 0.536 0.500 0.601 0.595 0.506 0.565 LYAM1 LYAM1_SYYWIGIR 120 0.558 0.603 0.646 0.691 0.548 0.594 0.672 0.739 NCAM1 NCAM1_GLGEISAASEFK 121 0.567 0.556 0.524 0.559 0.527 0.535 0.505 0.565 PAPP1 PAPP1_DIPHWLNPTR 122 0.518 0.524 0.539 0.582 0.548 0.510 0.515 0.555 PEDF PEDF_LQSLFDSPDFSK 124 0.558 0.530 0.514 0.526 0.577 0.570 0.527 0.540 PEDF PEDF_TVQAVLTVPK 125 0.571 0.569 0.575 0.606 0.586 0.597 0.574 0.609 PGRP2 PGRP2_AGLLRPDYALLGHR 126 0.554 0.574 0.525 0.574 0.524 0.553 0.548 0.610 PRDX2 PRDX2_GLFIIDGK 128 0.511 0.567 0.517 0.531 0.533 0.577 0.551 0.548 PRG2 PRG2_WNFAYWAAHQPWSR 129 0.555 0.505 0.502 0.519 0.577 0.518 0.563 0.511 PSG11 PSG11_LFIPQITPK 132 0.505 0.552 0.508 0.565 0.515 0.556 0.542 0.558 PSG1 PSG1_FQLPGQK 131 0.560 0.570 0.502 0.508 0.529 0.531 0.522 0.505 PSG2 PSG2_IHPSYTNYR 133 0.511 0.570 0.656 0.714 0.528 0.572 0.609 0.713 PSG3 PSG3_VSAPSGTGHLPGLNPL 134 0.615 0.611 0.547 0.538 0.615 0.603 0.603 0.561 PSG9 PSG9_DVLLLVHNLPQNLPGYFWYK 135 0.557 0.555 0.625 0.597 0.560 0.595 0.546 0.507 PSG9 PSG9_LFIPQITR 136 0.539 0.529 0.649 0.656 0.547 0.576 0.565 0.547 PTGDS PTGDS_GPGEDFR 137 0.520 0.502 0.542 0.572 0.540 0.551 0.561 0.594 SHBG SHBG_IALGGLLFPASNLR 18 0.576 0.578 0.541 0.509 0.584 0.570 0.613 0.613 SOM2.CSH SOM2.CSH_NYGLLYCFR 138 0.546 0.526 0.523 0.506 0.502 0.529 0.546 0.516 SOM2.CSH SOM2.CSH_SVEGSCGF 139 0.538 0.551 0.503 0.510 0.502 0.525 0.551 0.583 SPRL1 SPRL1_VLTHSELAPLR 140 0.508 0.559 0.536 0.515 0.523 0.571 0.585 0.548 TENX TENX_LNWEAPPGAFDSFLLR 141 0.556 0.590 0.590 0.568 0.588 0.606 0.598 0.536 TENX TENX_LSQLSVTDVTTSSLR 142 0.538 0.573 0.562 0.544 0.567 0.591 0.566 0.505 THBG THBG_AVLHIGEK 143 0.502 0.536 0.512 0.502 0.507 0.520 0.521 0.508 TIE1 TIE1_VSWSLPLVPGPLVGDGFLLR 144 0.559 0.596 0.563 0.514 0.537 0.550 0.553 0.506 VTDB VTDB_ELPEHTVK 147 0.505 0.528 0.513 0.504 0.501 0.501 0.561 0.580 VTNC VTNC_GQYCYELDEK 149 0.602 0.604 0.599 0.611 0.624 0.662 0.605 0.635 VTNC VTNC_VDTVDPPYPR 150 0.601 0.599 0.582 0.573 0.627 0.651 0.582 0.570
(444) TABLE-US-00025 TABLE25 133_ 133_ 133_ 133_ 119_ 119_ 119_ 119_ SEQ 153_ 153_ 153_ 153_ 153_ 153_ 153_ 153_ ID aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ aBMI_ rBMI_ Protein Transition NO: 37 37 35 35 37 37 35 35 A2GL A2GL_DLLLPQPDLR 34 0.581 0.597 0.538 0.549 0.554 0.568 0.520 0.533 AFAM AFAM_DADPDTFFAK 37 0.539 0.561 0.584 0.647 0.557 0.557 0.590 0.620 AFAM AFAM_HFQNLGK 38 0.549 0.584 0.595 0.679 0.559 0.561 0.590 0.626 ALS ALS_IRPHTFTGLSGLR 40 0.503 0.515 0.517 0.503 0.504 0.513 0.521 0.519 ANGT ANGT_DPTFIPAPIQAK 42 0.533 0.566 0.501 0.542 0.549 0.589 0.558 0.593 APOC3 APOC3_GWVTDGFSSLK 47 0.643 0.611 0.628 0.530 0.622 0.599 0.587 0.539 APOH APOH_ATVVYQGER 48 0.601 0.584 0.632 0.656 0.580 0.563 0.573 0.591 B2MG B2MG_VEHSDLSFSK 50 0.582 0.565 0.544 0.527 0.543 0.520 0.536 0.508 B2MG B2MG_VNHVTLSQPK 51 0.613 0.599 0.582 0.551 0.570 0.539 0.571 0.553 BGH3 BGH3_LTLLAPLNSVFK 52 0.533 0.562 0.549 0.586 0.542 0.564 0.516 0.518 C163A C163A_INPASLDK 54 0.524 0.505 0.509 0.515 0.504 0.527 0.530 0.540 C1QB C1QB_VPGLYYFTYHASSR 55 0.579 0.564 0.577 0.613 0.575 0.583 0.539 0.547 CAH1 CAH1_GGPFSDSYR 56 0.522 0.531 0.610 0.598 0.507 0.500 0.557 0.549 CATD CATD_VGFAEAAR 57 0.610 0.589 0.719 0.722 0.576 0.547 0.626 0.634 CATD CATD_VSTLPAITLK 58 0.593 0.594 0.729 0.772 0.564 0.549 0.623 0.651 CBPN CBPN_EALIQFLEQVHQGIK 59 0.504 0.530 0.516 0.552 0.507 0.542 0.510 0.506 CBPN CBPN_NNANGVDLNR 60 0.529 0.549 0.533 0.510 0.516 0.541 0.550 0.546 CD14 CD14_LTVGAAQVPAQLLVGALR 61 0.600 0.567 0.620 0.582 0.577 0.558 0.615 0.600 CD14 CD14_SWLAELQQWLKPGLK 62 0.591 0.556 0.617 0.569 0.577 0.554 0.601 0.569 CFAB CFAB_YGLVTYATYPK 64 0.579 0.596 0.529 0.523 0.599 0.601 0.522 0.528 CHL1 CHL1_VIAVNEVGR 66 0.515 0.519 0.564 0.573 0.568 0.577 0.505 0.506 CLUS CLUS_ASSIIDELFQDR 67 0.518 0.539 0.591 0.560 0.534 0.546 0.628 0.592 CLUS CLUS_LFDSDPITVTVPVEVSR 68 0.504 0.504 0.589 0.526 0.521 0.511 0.610 0.543 CO5 CO5_TLLPVSKPEIR 70 0.576 0.583 0.522 0.525 0.577 0.589 0.548 0.525 CO5 CO5_VFQFLEK 71 0.583 0.570 0.538 0.519 0.577 0.575 0.540 0.511 CO6 CO6_ALNHLPLEYNSALYSR 72 0.517 0.514 0.536 0.569 0.554 0.566 0.549 0.560 CO8A CO8A_SLLQPNK 74 0.599 0.600 0.579 0.557 0.574 0.557 0.563 0.553 CO8B CO8B_QALEEFQK 76 0.602 0.610 0.580 0.567 0.578 0.567 0.565 0.549 CRIS3 CRIS3_AVSPPAR 78 0.531 0.586 0.576 0.598 0.525 0.571 0.582 0.608 CRIS3 CRIS3_YEDLYSNCK 79 0.541 0.601 0.580 0.603 0.539 0.580 0.596 0.620 CSH CSH_AHQLAIDTYQEFEETYIPK 80 0.523 0.533 0.550 0.513 0.526 0.509 0.535 0.513 CSH CSH_ISLLLIESWLEPVR 81 0.531 0.546 0.548 0.511 0.515 0.505 0.531 0.511 ENPP2 ENPP2_TEFLSNYLTNVDDITLVPGTLGR 82 0.592 0.605 0.593 0.545 0.574 0.571 0.517 0.558 ENPP2 ENPP2_TYLHTYESEI 83 0.595 0.594 0.610 0.550 0.576 0.559 0.500 0.545 F13B F13B_GDTYPAELYITGSILR 84 0.512 0.514 0.607 0.617 0.529 0.528 0.584 0.590 FBLN1 FBLN1_TGYYFDGISR 86 0.506 0.572 0.572 0.581 0.537 0.521 0.542 0.550 FBLN3 FBLN3_IPSNPSHR 87 0.515 0.524 0.571 0.622 0.523 0.506 0.545 0.559 FETUA FETUA_FSVVYAK 88 0.562 0.558 0.532 0.508 0.552 0.534 0.530 0.517 FETUA FETUA_HTLNQIDEVK 89 0.551 0.541 0.511 0.511 0.544 0.529 0.524 0.531 HABP2 HABP2_FLNWIK 92 0.556 0.546 0.539 0.562 0.595 0.592 0.591 0.544 HEMO HEMO_NFPSPVDAAFR 93 0.588 0.552 0.526 0.528 0.567 0.536 0.501 0.538 HLACI HLACI_WAAVVVPSGEEQR 95 0.522 0.564 0.518 0.513 0.527 0.543 0.502 0.508 IBP1 IBP1_VVESLAK 97 0.518 0.510 0.613 0.602 0.537 0.510 0.597 0.563 IBP2 IBP2_LIQGAPTIR 98 0.509 0.521 0.569 0.590 0.522 0.507 0.554 0.552 IBP3 IBP3_FLNVLSPR 99 0.545 0.568 0.525 0.541 0.532 0.566 0.507 0.514 IBP3 IBP3_YGQPLPGYTTK 100 0.573 0.608 0.529 0.501 0.547 0.581 0.552 0.540 IBP4 IBP4_QCHPALDGQR 2 0.674 0.694 0.571 0.570 0.608 0.606 0.539 0.530 IBP6 IBP6_GAQTLYVPNCDHR 101 0.549 0.502 0.541 0.529 0.522 0.533 0.526 0.505 IBP6 IBP6_HLDSVLQQLQTEVYR 102 0.540 0.501 0.515 0.524 0.520 0.521 0.511 0.506 IGF2 IGF2_GIVEECCFR 103 0.593 0.618 0.528 0.513 0.569 0.592 0.578 0.579 INHBC INHBC_LDFHFSSDR 107 0.622 0.652 0.582 0.573 0.608 0.612 0.545 0.517 ITIH3 ITIH3_ALDLSLK 111 0.575 0.567 0.507 0.505 0.557 0.557 0.513 0.519 ITIH4 ITIH4_ILDDLSPR 112 0.542 0.524 0.518 0.559 0.531 0.537 0.501 0.508 ITIH4 ITIH4_NPLVWVHASPEHVVVTR 113 0.551 0.526 0.617 0.683 0.534 0.528 0.559 0.597 ITIH4 ITIH4_QLGLPGPPDVPDHAAYHPF 114 0.511 0.516 0.535 0.645 0.512 0.505 0.520 0.582 KNG1 KNG1_DIPTNSPELEETLTHTITK 116 0.575 0.535 0.508 0.552 0.558 0.535 0.523 0.525 KNG1 KNG1_QVVAGLNFR 117 0.596 0.582 0.596 0.559 0.562 0.554 0.602 0.602 LBP LBP_ITGFLKPGK 118 0.595 0.582 0.504 0.590 0.587 0.559 0.505 0.565 LBP LBP_ITLPDFTGDLR 119 0.619 0.613 0.526 0.543 0.609 0.588 0.524 0.521 LYAM1 LYAM1_SYYWIGIR 120 0.557 0.603 0.678 0.708 0.552 0.596 0.651 0.696 NCAM1 NCAM1_GLGEISAASEFK 121 0.505 0.512 0.541 0.535 0.536 0.531 0.501 0.557 PAPP1 PAPP1_DIPHWLNPTR 122 0.516 0.542 0.530 0.640 0.540 0.519 0.525 0.594 PEDF PEDF_LQSLFDSPDFSK 124 0.568 0.565 0.570 0.600 0.577 0.571 0.545 0.565 PEDF PEDF_TVQAVLTVPK 125 0.566 0.552 0.574 0.592 0.577 0.570 0.577 0.598 PGRP2 PGRP2_AGLLRPDYALLGHR 126 0.549 0.578 0.645 0.717 0.560 0.578 0.576 0.627 PRDX2 PRDX2_GLFIIDGK 128 0.561 0.562 0.619 0.595 0.525 0.530 0.547 0.536 PRG2 PRG2_WNFAYWAAHQPWSR 129 0.564 0.504 0.522 0.569 0.565 0.501 0.520 0.529 PSG11 PSG11_LFIPQITPK 132 0.527 0.507 0.522 0.529 0.511 0.516 0.500 0.501 PSG1 PSG1_FQLPGQK 131 0.519 0.544 0.555 0.516 0.524 0.509 0.508 0.535 PSG2 PSG2_IHPSYTNYR 133 0.528 0.550 0.558 0.624 0.522 0.563 0.597 0.660 PSG3 PSG3_VSAPSGTGHLPGLNPL 134 0.546 0.558 0.550 0.508 0.581 0.563 0.557 0.506 PSG9 PSG9_DVLLLVHNLPQNLPGYFWYK 135 0.516 0.553 0.529 0.505 0.546 0.567 0.547 0.500 PSG9 PSG9_LFIPQITR 136 0.502 0.528 0.542 0.552 0.528 0.541 0.571 0.554 PTGDS PTGDS_GPGEDFR 137 0.568 0.602 0.568 0.592 0.536 0.532 0.537 0.545 SHBG SHBG_IALGGLLFPASNLR 18 0.588 0.585 0.686 0.728 0.585 0.576 0.611 0.613 SOM2.CSH SOM2.CSH_NYGLLYCFR 138 0.560 0.588 0.511 0.546 0.501 0.527 0.513 0.520 SOM2.CSH SOM2.CSH_SVEGSCGF 139 0.509 0.532 0.549 0.573 0.525 0.539 0.542 0.565 SPRL1 SPRL1_VLTHSELAPLR 140 0.512 0.533 0.619 0.582 0.502 0.543 0.578 0.555 TENX TENX_LNWEAPPGAFDSFLLR 141 0.576 0.578 0.558 0.519 0.576 0.573 0.550 0.519 TENX TENX_LSQLSVTDVTTSSLR 142 0.564 0.554 0.504 0.599 0.550 0.542 0.508 0.588 THBG THBG_AVLHIGEK 143 0.557 0.547 0.527 0.529 0.518 0.507 0.520 0.500 TIE1 TIE1_VSWSLPLVPGPLVGDGFLLR 144 0.512 0.506 0.542 0.528 0.513 0.531 0.536 0.502 VTDB VTDB_ELPEHTVK 147 0.542 0.524 0.551 0.597 0.506 0.502 0.528 0.533 VTNC VTNC_GQYCYELDEK 149 0.603 0.618 0.573 0.581 0.623 0.635 0.598 0.617 VTNC VTNC_VDTVDPPYPR 150 0.629 0.626 0.583 0.552 0.625 0.629 0.574 0.553
(445) TABLE-US-00026 TABLE26 Up-anddown-regulatedproteins/transitionsusedforreversals SEQ ID Protein Transition NO: Reg AFAM AFAM_DADPDTFFAK 37 up AFAM AFAM_HFQNLGK 38 up ANGT ANGT_DPTFIPAPIQAK 42 up APOC3 APOC3_GWVTDGFSSLK 47 up APOH APOH_ATVVYQGER 48 up CD14 CD14_LTVGAAQVPAQLLVGALR 61 up CD14 CD14_SWLAELQQWLKPGLK 62 up CLUS CLUS_ASSIIDELFQDR 67 up CLUS CLUS_LFDSDPITVTVPVEVSR 68 up CO8A CO8A_SLLQPNK 74 up CO8B CO8B_QALEEFQK 76 up F13B F13B_GDTYPAELYITGSILR 84 up IBP4 IBP4_QCHPALDGQR 2 up PEDF PEDF_LQSLFDSPDFSK 124 up PEDF PEDF_TVQAVLTVPK 125 up PRDX2 PRDX2_GLFIIDGK 128 up PSG2 PSG2_IHPSYTNYR 133 up PTGDS PTGDS_GPGEDFR 137 up VTNC VTNC_GQYCYELDEK 149 up VTNC VTNC_VDTVDPPYPR 150 up B2MG B2MG_VNHVTLSQPK 51 up BGH3 BGH3_LTLLAPLNSVFK 52 up CBPN CBPN_NNANGVDLNR 60 up CO5 CO5_TLLPVSKPEIR 70 up CO5 CO5_VFQFLEK 71 up IBP6 IBP6_HLDSVLQQLQTEVYR 102 up INHBC INHBC_LDFHFSSDR 107 up KNG1 KNG1_DIPTNSPELEETLTHTITK 116 up KNG1 KNG1_QVVAGLNFR 117 up THBG THBG_AVLHIGEK 143 up CATD CATD_VGFAEAAR 57 up CO6 CO6_ALNHLPLEYNSALYSR 72 up ITIH4 ITIH4_NPLVWVHASPEHVVVTR 113 up A2GL A2GL_DLLLPQPDLR 34 up CAH1 CAH1_GGPFSDSYR 56 up CATD CATD_VSTLPAITLK 58 up CBPN CBPN_EALIQFLEQVHQGIK 59 up HABP2 HABP2_FLNWIK 92 up CFAB CFAB_YGLVTYATYPK 64 up HEMO HEMO_NFPSPVDAAFR 93 up LBP LBP_ITGFLKPGK 118 up LBP LBP_ITLPDFTGDLR 119 up PAPP1 PAPP1_DIPHWLNPTR 122 up FETUA FETUA_FSVVYAK 88 up FETUA FETUA_HTLNQIDEVK 89 up IBP6 IBP6_GAQTLYVPNCDHR 101 up ITIH3 ITIH3_ALDLSLK 111 up B2MG B2MG_VEHSDLSFSK 50 up ENPP2 ENPP2_TYLHTYESEI 83 up HLACI HLACI_WAAVVVPSGEEQR 95 up ITIH4 ITIH4_QLGLPGPPDVPDHAAYHPF 114 up C1QB C1QB_VPGLYYFTYHASSR 55 up ENPP2 ENPP2_TEFLSNYLTNVDDITLVPGTLGR 82 up FBLN3 FBLN3_IPSNPSHR 87 up PSG11 PSG11_LFIPQITPK 132 up ITIH4 ITIH4_ILDDLSPR 112 down PSG1 PSG1_FQLPGQK 131 down CHL1 CHL1_VIAVNEVGR 66 down CSH CSH_ISLLLIESWLEPVR 81 down NCAM1 NCAM1_GLGEISAASEFK 121 down PRG2 PRG2_WNFAYWAAHQPWSR 129 down SOM2.CSH SOM2.CSH_NYGLLYCFR 138 down ALS ALS_IRPHTFTGLSGLR 40 down FBLN1 FBLN1_TGYYFDGISR 86 down PSG9 PSG9_LFIPQITR 136 down CSH CSH_AHQLAIDTYQEFEETYIPK 80 down VTDB VTDB_ELPEHTVK 147 down IBP3 IBP3_FLNVLSPR 99 down IBP3 IBP3_YGQPLPGYTTK 100 down PSG9 PSG9_DVLLLVHNLPQNLPGYFWYK 135 down TENX TENX_LSQLSVTDVTTSSLR 142 down IBP1 IBP1_VVESLAK 97 down IBP2 IBP2_LIQGAPTIR 98 down SOM2.CSH SOM2.CSH_SVEGSCGF 139 down SPRL1 SPRL1_VLTHSELAPLR 140 down TENX TENX_LNWEAPPGAFDSFLLR 141 down TIE1 TIE1_VSWSLPLVPGPLVGDGFLLR 144 down C163A C163A_INPASLDK 54 down IGF2 IGF2_GIVEECCFR 103 down PSG3 PSG3_VSAPSGTGHLPGLNPL 134 down CRIS3 CRIS3_AVSPPAR 78 down CRIS3 CRIS3_YEDLYSNCK 79 down LYAM1 LYAM1_SYYWIGIR 120 down PGRP2 PGRP2_AGLLRPDYALLGHR 126 down SHBG SHBG_IALGGLLFPASNLR 18 down
(446) TABLE-US-00027 TABLE27 ReversalClassificationPerformance,weeks17and18. ReversalAUROCforgestationalweeks17and18using acasevscontrolcut-offof<370/7vs>=370/7 weeks,withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_CHL1_VIAVNEVGR 34&66 0.027 0.633 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.036 0.626 AFAM_DADPDTFFAK_vs_CHL1_VIAVNEVGR 37&66 0.005 0.669 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.001 0.699 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.020 0.640 AFAM_DADPDTFFAK_vs_VTDB_ELPEHTVK 37&147 0.043 0.622 AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR 38&66 0.003 0.679 AFAM_HFQNLGK_vs_NCAM1_GLGEISAASEFK 38&121 0.036 0.626 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.004 0.676 AFAM_HFQNLGK_vs_VTDB_ELPEHTVK 38&147 0.037 0.625 ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR 42&66 0.008 0.659 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.006 0.665 ANGT_DPTFIPAPIQAK_vs_CSH_ISLLLIESWLEPVR 42&81 0.023 0.637 ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR 42&86 0.025 0.635 ANGT_DPTFIPAPIQAK_vs_NCAM1_GLGEISAASEFK 42&121 0.040 0.624 ANGT_DPTFIPAPIQAK_vs_PSG1_FQLPGQK 42&131 0.036 0.626 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.004 0.675 ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 42&135 0.042 0.623 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_NYGLLYCFR 42&138 0.012 0.651 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.032 0.631 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.047 0.619 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.021 0.639 APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR 48&66 0.008 0.660 APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK 48&80 0.039 0.624 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.024 0.636 B2MG_VEHSDLSFSK_vs_CHL1_VIAVNEVGR 50&66 0.042 0.622 B2MG_VNHVTLSQPK_vs_CHL1_VIAVNEVGR 51&66 0.023 0.637 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL 51&134 0.046 0.620 BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR 52&66 0.006 0.666 BGH3_LTLLAPLNSVFK_vs_CSH_AHQLAIDTYQEFEETYIPK 52&80 0.014 0.648 BGH3_LTLLAPLNSVFK_vs_CSH_ISLLLIESWLEPVR 52&81 0.050 0.618 BGH3_LTLLAPLNSVFK_vs_FBLN1_TGYYFDGISR 52&86 0.020 0.640 BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL 52&134 0.024 0.636 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR 52&18 0.029 0.632 BGH3_LTLLAPLNSVFK_vs_SOM2.CSH_NYGLLYCFR 52&138 0.043 0.622 C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR 55&66 0.018 0.643 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.010 0.655 C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR 55&81 0.016 0.645 C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR 55&86 0.046 0.620 C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR 55&98 0.017 0.644 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.032 0.629 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.028 0.632 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.036 0.627 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&138 0.011 0.653 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF 55&139 0.048 0.621 CBPN_EALIQFLEQVHQGIK_vs_PSG3_VSAPSGTGHLPGLNPL 59&134 0.038 0.625 CBPN_EALIQFLEQVHQGIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 59&135 0.037 0.626 CBPN_NNANGVDLNR_vs_CHL1_VIAVNEVGR 60&66 0.044 0.621 CBPN_NNANGVDLNR_vs_PSG3_VSAPSGTGHLPGLNPL 60&134 0.044 0.622 CD14_LTVGAAQVPAQLLVGALR_vs_CHL1_VIAVNEVGR 61&66 0.011 0.652 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.046 0.620 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.032 0.629 CD14_SWLAELQQWLKPGLK_vs_CHL1_VIAVNEVGR 62&66 0.005 0.667 CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK 62&80 0.024 0.636 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.015 0.646 CFAB_YGLVTYATYPK_vs_C163A_INPASLDK 64&54 0.045 0.621 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.001 0.703 CFAB_YGLVTYATYPK_vs_CSH_AHQLAIDTYQEFEETYIPK 64&80 0.011 0.654 CFAB_YGLVTYATYPK_vs_CSH_ISLLLIESWLEPVR 64&81 0.024 0.636 CFAB_YGLVTYATYPK_vs_FBLN1_TGYYFDGISR 64&86 0.023 0.637 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.034 0.628 CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK 64&121 0.005 0.671 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.012 0.651 CFAB_YGLVTYATYPK_vs_PSG1_FQLPGQK 64&131 0.032 0.629 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.000 0.722 CFAB_YGLVTYATYPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 64&135 0.031 0.630 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.015 0.646 CFAB_YGLVTYATYPK_vs_SOM2.CSH_NYGLLYCFR 64&138 0.020 0.640 CFAB_YGLVTYATYPK_vs_SOM2.CSH_SVEGSCGF 64&139 0.027 0.635 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.031 0.630 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.012 0.652 CFAB_YGLVTYATYPK_vs_VTDB_ELPEHTVK 64&147 0.006 0.664 CLUS_ASSIIDELFQDR_vs_CHL1_VIAVNEVGR 67&66 0.002 0.682 CLUS_ASSIIDELFQDR_vs_CSH_AHQLAIDTYQEFEETYIPK 67&80 0.027 0.633 CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR 67&86 0.028 0.633 CLUS_ASSIIDELFQDR_vs_NCAM1_GLGEISAASEFK 67&121 0.042 0.622 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.007 0.664 CLUS_ASSIIDELFQDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 67&135 0.035 0.627 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.032 0.629 CLUS_LFDSDPITVTVPVEVSR_vs_CHL1_VIAVNEVGR 68&66 0.003 0.679 CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK 68&80 0.047 0.620 CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYFDGISR 68&86 0.028 0.633 CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL 68&134 0.014 0.648 CLUS_LFDSDPITVTVPVEVSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 68&135 0.034 0.628 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.038 0.625 CO5_TLLPVSKPEIR_vs_CHL1_VIAVNEVGR 70&66 0.002 0.683 CO5_TLLPVSKPEIR_vs_CSH_AHQLAIDTYQEFEETYIPK 70&80 0.021 0.640 CO5_TLLPVSKPEIR_vs_FBLN1_TGYYFDGISR 70&86 0.033 0.628 CO5_TLLPVSKPEIR_vs_NCAM1_GLGEISAASEFK 70&121 0.033 0.628 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.043 0.622 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.002 0.688 CO5_TLLPVSKPEIR_vs_SOM2.CSH_NYGLLYCFR 70&138 0.038 0.625 CO5_VFQFLEK_vs_CHL1_VIAVNEVGR 71&66 0.002 0.686 CO5_VFQFLEK_vs_CSH_AHQLAIDTYQEFEETYIPK 71&80 0.020 0.640 CO5_VFQFLEK_vs_FBLN1_TGYYFDGISR 71&86 0.033 0.628 CO5_VFQFLEK_vs_NCAM1_GLGEISAASEFK 71&121 0.034 0.628 CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR 71&126 0.046 0.620 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.002 0.685 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.043 0.622 CO5_VFQFLEK_vs_SOM2.CSH_NYGLLYCFR 71&138 0.038 0.625 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.047 0.619 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.000 0.723 CO6_ALNHLPLEYNSALYSR_vs_CSH_AHQLAIDTYQEFEETYIPK 72&80 0.010 0.655 CO6_ALNHLPLEYNSALYSR_vs_CSH_ISLLLIESWLEPVR 72&81 0.035 0.627 CO6_ALNHLPLEYNSALYSR_vs_FBLN1_TGYYFDGISR 72&86 0.013 0.649 CO6_ALNHLPLEYNSALYSR_vs_NCAM1_GLGEISAASEFK 72&121 0.010 0.656 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.049 0.619 CO6_ALNHLPLEYNSALYSR_vs_PSG1_FQLPGQK 72&131 0.043 0.622 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.001 0.699 CO6_ALNHLPLEYNSALYSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 72&135 0.041 0.623 CO6_ALNHLPLEYNSALYSR_vs_SOM2.CSH_NYGLLYCFR 72&138 0.019 0.641 CO6_ALNHLPLEYNSALYSR_vs_SOM2.CSH_SVEGSCGF 72&139 0.028 0.634 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.036 0.626 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.019 0.641 CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK 72&147 0.009 0.657 CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR 74&66 0.007 0.661 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.005 0.671 CO8B_QALEEFQK_vs_CHL1_VIAVNEVGR 76&66 0.019 0.642 CO8B_QALEEFQK_vs_CSH_AHQLAIDTYQEFEETYIPK 76&80 0.046 0.620 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.013 0.649 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3VSAPSGTGHLPGLNPL 82&134 0.033 0.629 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL 83&134 0.032 0.629 F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR 84&66 0.003 0.680 F13B_GDTYPAELYITGSILR_vs_CSH_AHQLAIDTYQEFEETYIPK 84&80 0.035 0.627 F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDGISR 84&86 0.035 0.627 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.007 0.663 FBLN3_IPSNPSHR_vs_CHL1_VIAVNEVGR 87&66 0.049 0.619 FETUA_FSVVYAK_vs_CHL1_VIAVNEVGR 88&66 0.009 0.658 FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGHR 88&126 0.042 0.623 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.009 0.658 FETUA_HTLNQIDEVK_vs_CHL1_VIAVNEVGR 89&66 0.009 0.657 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.017 0.643 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.000 0.739 HABP2_FLNWIK_vs_CSH_AHQLAIDTYQEFEETYIPK 92&80 0.002 0.687 HABP2_FLNWIK_vs_CSH_ISLLLIESWLEPVR 92&81 0.005 0.667 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.003 0.679 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.038 0.625 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.029 0.631 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.008 0.659 HABP2_FLNWIK_vs_ITIH4_ILDDLSPR 92&112 0.003 0.680 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.018 0.643 HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK 92&121 0.002 0.683 HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR 92&126 0.004 0.672 HABP2_FLNWIK_vs_PRG2_WNFAYWAAHQPWSR 92&129 0.027 0.633 HABP2_FLNWIK_vs_PSG1_FQLPGQK 92&131 0.014 0.649 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.000 0.750 HABP2_FLNWIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 92&135 0.015 0.646 HABP2_FLNWIK_vs_PSG9_LFIPQITR 92&136 0.043 0.622 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.010 0.655 HABP2_FLNWIK_vs_SOM2.CSH_NYGLLYCFR 92&138 0.004 0.674 HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF 92&139 0.005 0.673 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.016 0.645 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.004 0.673 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.000 0.711 HEMO_NFPSPVDAAFR_vs_CHL1_VIAVNEVGR 93&66 0.004 0.673 HEMO_NFPSPVDAAFR_vs_CSH_AHQLAIDTYQEFEETYIPK 93&80 0.047 0.619 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.016 0.645 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.023 0.637 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.021 0.640 IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL 102&134 0.032 0.629 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.010 0.655 INHBC_LDFHFSSDR_vs_CSH_AHQLAIDTYQEFEETYIPK 107&80 0.050 0.618 INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQPWSR 107&129 0.048 0.619 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.007 0.663 INHBC_LDFHFSSDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 107&135 0.049 0.619 ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL 111&134 0.041 0.623 KNG1_DIPTNSPELEETLTHTITK_vs_CHL1_VIAVNEVGR 116&66 0.013 0.650 KNG1_DIPTNSPELEETLTHTITK_vs_CSH_AHQLAIDTYQEFEETYIPK 116&80 0.032 0.629 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.007 0.661 KNG1_DIPTNSPELEETLTHTITK_vs_SOM2.CSHNYGLLYCFR 116&138 0.049 0.619 KNG1_QVVAGLNFR_vs_CHL1_VIAVNEVGR 117&66 0.023 0.637 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.041 0.623 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.024 0.636 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.011 0.654 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.008 0.661 LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 119&80 0.041 0.623 LBP_ITLPDFTGDLR_vs_FBLN1_TGYYFDGISR 119&86 0.049 0.619 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.046 0.620 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119&121 0.042 0.623 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.006 0.665 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.047 0.619 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.049 0.620 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.019 0.641 PEDF_LQSLFDSPDFSK_vs_CHL1_VIAVNEVGR 124&66 0.003 0.681 PEDF_LQSLFDSPDFSK_vs_CSH_AHQLAIDTYQEFEETYIPK 124&80 0.020 0.640 PEDF_LQSLFDSPDFSK_vs_CSH_ISLLLIESWLEPVR 124&81 0.044 0.621 PEDF_LQSLFDSPDFSK_vs_FBLN1_TGYYFDGISR 124&86 0.026 0.634 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.050 0.618 PEDF_LQSLFDSPDFSK_vs_PSG1_FQLPGQK 124&131 0.025 0.635 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.006 0.666 PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 124&135 0.036 0.627 PEDF_LQSLFDSPDFSK_vs_SOM2.CSH_NYGLLYCFR 124&138 0.027 0.633 PEDF_LQSLFDSPDFSK_vs_SOM2.CSH_SVEGSCGF 124&139 0.049 0.620 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.043 0.622 PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK 124&147 0.025 0.635 PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR 125&66 0.004 0.675 PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK 125&80 0.015 0.646 PEDF_TVQAVLTVPK_vs_CSH_ISLLLIESWLEPVR 125&81 0.039 0.624 PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR 125&86 0.018 0.642 PEDF_TVQAVLTVPK_vs_NCAM1_GLGEISAASEFK 125&121 0.033 0.628 PEDF_TVQAVLTVPK_vs_PSG1_FQLPGQK 125&131 0.032 0.629 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.004 0.673 PEDF_TVQAVLTVPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 125&135 0.050 0.618 PEDF_TVQAVLTVPK_vs_SOM2.CSH_NYGLLYCFR 125&138 0.040 0.624 PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK 125&147 0.023 0.637 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.000 0.719 VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK 149&80 0.006 0.665 VTNC_GQYCYELDEK_vs_CSH_ISLLLIESWLEPVR 149&81 0.013 0.650 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.008 0.659 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.046 0.620 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.040 0.624 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.020 0.640 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.008 0.659 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.005 0.670 VTNC_GQYCYELDEK_vs_PSG1_FQLPGQK 149&131 0.021 0.639 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.000 0.743 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.029 0.631 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.014 0.648 VTNC_GQYCYELDEK_vs_SOM2.CSH_NYGLLYCFR 149&138 0.010 0.655 VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF 149&139 0.009 0.660 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.023 0.637 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.006 0.665 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.001 0.694 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.000 0.712 VTNC_VDTVDPPYPR_vs_CSH_AHQLAIDTYQEFEETYIPK 150&80 0.010 0.654 VTNC_VDTVDPPYPR_vs_CSH_ISLLLIESWLEPVR 150&81 0.029 0.631 VTNC_VDTVDPPYPR_vs_FBLN1_TGYYFDGISR 150&86 0.034 0.628 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.034 0.628 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.021 0.640 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.039 0.625 VTNC_VDTVDPPYPR_vs_PSG1_FQLPGQK 150&131 0.033 0.628 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.000 0.720 VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 150&135 0.035 0.627 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.043 0.622 VTNC_VDTVDPPYPR_vs_SOM2.CSH_NYGLLYCFR 150&138 0.023 0.637 VTNC_VDTVDPPYPR_vs_SOM2.CSH_SVEGSCGF 150&139 0.023 0.639 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.043 0.622 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.003 0.677
(447) TABLE-US-00028 TABLE28 ReversalClassificationPerformance,weeks17and18. ReversalAUROCforgestationalweeks17and18using acasevscontrolcut-offof<370/7vs>=370/7weeks, withBMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC AFAM_DADPDTFFAK_vs_CHL1_VIAVNEVGR 37&66 0.040 0.647 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.030 0.656 AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR 38&66 0.022 0.664 ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR 42&66 0.017 0.671 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.037 0.650 ANGT_DPTFIPAPIQAK_vs_NCAM1_GLGEISAASEFK 42&121 0.043 0.645 ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 42&144 0.033 0.653 APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR 48&66 0.031 0.655 BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR 52&66 0.016 0.672 C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR 55&66 0.019 0.669 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.038 0.648 C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR 55&81 0.046 0.643 C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR 55&86 0.037 0.650 C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR 55&98 0.042 0.646 C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR 55&120 0.043 0.645 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.030 0.656 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.037 0.650 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&138 0.029 0.657 C1QB_VPGLYYFTYHASSR_vs_SPRL1_VLTHSELAPLR 55&140 0.034 0.652 CBPN_EALIQFLEQVHQGIK_vs_CHL1_VIAVNEVGR 59&66 0.047 0.642 CD14_SWLAELQQWLKPGLK_vs_CHL1_VIAVNEVGR 62&66 0.031 0.655 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.006 0.697 CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK 64&121 0.017 0.671 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.021 0.666 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.038 0.648 CLUS_ASSIIDELFQDR_vs_CHL1_VIAVNEVGR 67&66 0.014 0.675 CLUS_LFDSDPITVTVPVEVSR_vs_CHL1_VIAVNEVGR 68&66 0.022 0.664 CO5_TLLPVSKPEIR_vs_CHL1_VIAVNEVGR 70&66 0.006 0.696 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.044 0.644 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.038 0.648 CO5_VFQFLEK_vs_CHL1_VIAVNEVGR 71&66 0.005 0.701 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.048 0.642 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.038 0.648 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.001 0.741 CO6_ALNHLPLEYNSALYSR_vs_FBLN1_TGYYFDGISR 72&86 0.045 0.643 CO6_ALNHLPLEYNSALYSR_VS_LYAM1_SYYWIGIR 72&120 0.036 0.650 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.028 0.658 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.007 0.693 CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK 72&147 0.041 0.647 F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR 84&66 0.021 0.665 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.001 0.729 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.032 0.654 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.040 0.647 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.018 0.670 HABP2_FLNWIK_vs_ITIH4_ILDDLSPR 92&112 0.030 0.655 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.017 0.671 HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK 92&121 0.014 0.675 HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR 92&126 0.034 0.652 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.005 0.699 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.034 0.652 HABP2_FLNWIK_vs_SPRL1_VLTHSELAPLR 92&140 0.046 0.643 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.003 0.709 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.005 0.700 HEMO_NFPSPVDAAFR_vs_CHL1_VIAVNEVGR 93&66 0.020 0.667 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.034 0.652 KNG1_DIPTNSPELEETLTHTITK_vs_CHL1_VIAVNEVGR 116&66 0.022 0.664 PEDF_LQSLFDSPDFSK_vs_CHL1_VIAVNEVGR 124&66 0.008 0.691 PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR 125&66 0.009 0.688 PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK 125&147 0.049 0.641 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.021 0.665 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.012 0.680 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.025 0.660 PSG2_IHPSYTNYR_VS_NCAM1_GLGEISAASEFK 133&121 0.048 0.642 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.012 0.679 PSG2_IHPSYTNYR_vs_PSG9_LFIPQITR 133&136 0.033 0.653 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133&147 0.043 0.645 VTNC_GQYCYELDEK_vs_C163A_INPASLDK 149&54 0.044 0.644 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.001 0.744 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.038 0.648 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.030 0.655 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.016 0.672 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.020 0.667 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.014 0.677 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.009 0.688 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.045 0.643 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.004 0.704 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.003 0.712 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.002 0.726 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.023 0.663 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.023 0.664 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.028 0.657 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.009 0.688
(448) TABLE-US-00029 TABLE29 ReversalClassificationPerformance,weeks17and18. ReversalAUROCforgestationalweeks17and18usinga casevscontrolcut-offof<350/7vs>=350/7weeks, withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.021 0.744 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.023 0.741 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.017 0.752 CLUS_ASSIIDELFQDR_vs_CHL1_VIAVNEVGR 67&66 0.018 0.749 CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR 67&99 0.043 0.713 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.005 0.795 CLUS_LFDSDPITVTVPVEVSR_vs_CHL1_VIAVNEVGR 68&66 0.046 0.710 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.012 0.765 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.048 0.709 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.018 0.750 CO6_ALNHLPLEYNSALYSR_vs_IBP3_YGQPLPGYTTK 72&100 0.047 0.710 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.007 0.787 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.040 0.717 CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK 72&147 0.034 0.724 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR 82&40 0.012 0.766 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISLLLIESWLEPVR 82&81 0.037 0.721 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1_TGYYFDGISR 82&86 0.026 0.735 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR 82&99 0.025 0.737 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK 82&100 0.029 0.731 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR 82&112 0.010 0.773 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK 82&121 0.007 0.785 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.012 0.767 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG1_FQLPGQK 82&131 0.011 0.769 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.043 0.713 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR 82&136 0.018 0.749 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_VS_SPRL1_VLTHSELAPLR 82&140 0.035 0.722 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR 82&141 0.046 0.710 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR 82&142 0.024 0.739 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 82&144 0.016 0.754 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDBELPEHTVK 82&147 0.008 0.781 ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR 83&40 0.026 0.735 ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR 83&112 0.028 0.732 ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK 83&121 0.021 0.744 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.013 0.762 ENPP2_TYLHTYESEI_vs_PSG1_FQLPGQK 83&131 0.021 0.744 ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.034 0.723 ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR 83&142 0.038 0.719 ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 83&144 0.031 0.728 ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.010 0.770 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.014 0.758 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.040 0.717 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.043 0.714 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.006 0.790 HABP2_FLNWIK_vs_ITIH4_ILDDLSPR 92&112 0.043 0.714 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.028 0.732 HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF 92&139 0.047 0.710 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.020 0.746 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.044 0.712 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.026 0.734 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.025 0.736 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.017 0.751 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.034 0.723 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.018 0.750 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.031 0.728 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.032 0.727 PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR 133&138 0.044 0.712 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.028 0.731 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.032 0.726
(449) TABLE-US-00030 TABLE30 ReversalClassificationPerformance,weeks17and18. ReversalAUROCforgestationalweeks17and18using acasevscontrolcut-offof<350/7vs>=350/7weeks, withBMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.042 0.749 ANGT_DPTFIPAPIQAK_vs_IBP3_FLNVLSPR 42&99 0.033 0.762 ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK 42&100 0.041 0.751 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.017 0.793 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.042 0.749 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.042 0.749 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.020 0.786 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.047 0.744 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.039 0.753 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.026 0.773 CO6_ALNHLPLEYNSALYSR_vs_IBP3_FLNVLSPR 72&99 0.016 0.795 CO6_ALNHLPLEYNSALYSR_vs_IBP3_YGQPLPGYTTK 72&100 0.025 0.775 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.005 0.842 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.025 0.775 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR 82&40 0.041 0.751 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISLLLIESWLEPVR 82&81 0.029 0.767 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR 82&112 0.019 0.788 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK 82&121 0.022 0.782 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.026 0.773 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG1_FQLPGQK 82&131 0.039 0.753 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.044 0.747 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_NYGLLYCFR 82&138 0.049 0.742 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR 82&142 0.029 0.767 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 82&144 0.015 0.799 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_ELPEHTVK 82&147 0.014 0.802 ENPP2_TYLHTYESEI_vs_CSH_ISLLLIESWLEPVR 83&81 0.047 0.744 ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR 83&112 0.038 0.755 ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK 83&121 0.034 0.760 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.033 0.762 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.044 0.747 ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR 83&142 0.033 0.762 ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 83&144 0.021 0.784 ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.011 0.811 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.034 0.760 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.037 0.756 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.016 0.797 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.032 0.764 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.005 0.842 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.028 0.769 HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF 92&139 0.045 0.746 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CRIS3_YEDLYSNCK 114&79 0.046 0.745 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.033 0.762 KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR 117&99 0.018 0.791 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.027 0.771 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.006 0.839 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.030 0.766 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.023 0.778 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.008 0.826 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.010 0.817 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.037 0.756 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.014 0.800 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.015 0.799 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.022 0.780 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.005 0.842 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.008 0.828 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.028 0.769 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.040 0.752 THBG_AVLHIGEK_vs_IGF2_GIVEECCFR 143&103 0.042 0.749 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.042 0.749 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.015 0.799
(450) TABLE-US-00031 TABLE31 ReversalClassificationPerformance,weeks18and19. ReversalAUROCforgestationalweeks18and19usingacasevs controlcut-offof<370/7vs>=370/7weeks,withoutBMI stratification. SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 34&80 0.030 0.603 A2GL_DLLLPQPDLR_vs_FBLN1_TGYYFDGISR 34&86 0.016 0.613 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.003 0.642 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.015 0.615 A2GL_DLLLPQPDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 34&144 0.024 0.607 AFAM_DADPDTFFAK_vs_FBLN1_TGYYFDGISR 37&86 0.034 0.600 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.015 0.615 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.009 0.623 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.025 0.606 AFAM_HFQNLGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 38&144 0.021 0.609 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.014 0.616 ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR 42&86 0.008 0.625 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.005 0.633 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.018 0.612 ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 42&144 0.010 0.621 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.018 0.612 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.002 0.648 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.033 0.601 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.022 0.608 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.014 0.616 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.007 0.627 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.022 0.608 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.012 0.619 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.017 0.613 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.026 0.605 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.016 0.614 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.032 0.601 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.009 0.623 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.028 0.604 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.026 0.605 APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR 47&129 0.024 0.607 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.002 0.644 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.034 0.600 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.018 0.611 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.022 0.608 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.025 0.607 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.018 0.612 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.017 0.612 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.005 0.632 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.025 0.606 APOH_ATVVYQGER_vs_ALS_IRPHTFTGLSGLR 48&40 0.034 0.600 APOH_ATVVYQGER_vs_C163A_INPASLDK 48&54 0.023 0.607 APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK 48&80 0.011 0.620 APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR 48&86 0.002 0.645 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.024 0.607 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.017 0.613 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.025 0.606 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.001 0.664 APOH_ATVVYQGER_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 48&135 0.030 0.603 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.008 0.625 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.016 0.614 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48&142 0.013 0.617 APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 48&144 0.002 0.645 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48&147 0.030 0.602 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL 51&134 0.019 0.611 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.006 0.630 C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR 55&81 0.020 0.610 C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR 55&86 0.006 0.631 C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR 55&120 0.030 0.603 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.024 0.606 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.006 0.630 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.006 0.629 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&138 0.016 0.613 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.028 0.604 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.020 0.610 C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 55&144 0.013 0.618 CBPN_EALIQFLEQVHQGIK_vs_FBLN1_TGYYFDGISR 59&86 0.030 0.603 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.017 0.613 CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR 61&86 0.010 0.622 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.025 0.606 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.003 0.641 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.025 0.606 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.021 0.609 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.019 0.611 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.004 0.637 CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK 62&80 0.024 0.607 CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR 62&86 0.010 0.621 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.006 0.631 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.026 0.605 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.027 0.604 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.025 0.606 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.006 0.631 CFAB_YGLVTYATYPK_vs_C163A_INPASLDK 64&54 0.015 0.615 CFAB_YGLVTYATYPK_vs_CSH_AHQLAIDTYQEFEETYIPK 64&80 0.034 0.600 CFAB_YGLVTYATYPK_vs_FBLN1_TGYYFDGISR 64&86 0.032 0.601 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.006 0.631 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.028 0.604 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.003 0.642 CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR 67&86 0.021 0.609 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.013 0.618 CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYFDGISR 68&86 0.026 0.605 CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL 68&134 0.018 0.611 CO5_TLLPVSKPEIR_vs_FBLN1_TGYYFDGISR 70&86 0.020 0.610 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.011 0.620 CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 70&144 0.012 0.618 CO5_VFQFLEK_vs_FBLN1_TGYYFDGISR 71&86 0.020 0.610 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.024 0.607 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.011 0.620 CO6_ALNHLPLEYNSALYSR_vs_FBLN1_TGYYFDGISR 72&86 0.024 0.607 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.020 0.610 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.006 0.630 COSA_SLLQPNK_vs_CSH_AHQLAIDTYQEFEETYIPK 74&80 0.020 0.610 COSA_SLLQPNK_vs_FBLN1_TGYYFDGISR 74&86 0.021 0.609 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.007 0.627 COSA_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.021 0.609 COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.001 0.652 CO8B_QALEEFQK_vs_CSH_AHQLAIDTYQEFEETYIPK 76&80 0.016 0.614 CO8B_QALEEFQK_vs_FBLN1_TGYYFDGISR 76&86 0.034 0.600 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.007 0.627 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.019 0.611 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.024 0.607 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.001 0.654 F13B_GDTYPAELYITGSILR_VS_FBLN1_TGYYFDGISR 84&86 0.011 0.620 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.005 0.631 F13B_GDTYPAELYITGSILR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 84&144 0.023 0.607 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.031 0.602 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.025 0.606 FETUA_FSVVYAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 88&144 0.033 0.601 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.024 0.607 FETUA_HTLNQIDEVK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 89&144 0.033 0.601 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.013 0.617 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.004 0.635 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.024 0.607 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.029 0.603 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.010 0.622 HEMO_NFPSPVDAAFR_vs_FBLN1_TGYYFDGISR 93&86 0.024 0.607 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.008 0.624 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.030 0.602 HEMO_NFPSPVDAAFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 93&144 0.011 0.620 IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFEETYIPK 2&80 0.025 0.606 IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR 2&86 0.004 0.636 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.033 0.601 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.000 0.668 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.011 0.621 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.028 0.603 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.006 0.629 IBP6_GAQTLYVPNCDHR_vs_FBLN1_TGYYFDGISR 101&86 0.026 0.605 IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL 101&134 0.014 0.617 IBP6_HLDSVLQQLQTEVYR_vs_FBLN1_TGYYFDGISR 102&86 0.023 0.608 IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL 102&134 0.014 0.617 INHBC_LDFHFSSDR_vs_C163A_INPASLDK 107&54 0.013 0.617 INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR 107&86 0.016 0.614 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.005 0.634 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.012 0.618 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.020 0.610 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.011 0.620 ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL 111&134 0.033 0.601 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.024 0.606 ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR 113&86 0.018 0.612 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.015 0.615 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG3_VSAPSGTGHLPGLNPL 114&134 0.029 0.604 KNG1_DIPTNSPELEETLTHTITK_vs_CSH_AHQLAIDTYQEFEETYIPK 116&80 0.023 0.607 KNG1_DIPTNSPELEETLTHTITK_vs_FBLN1_TGYYFDGISR 116&86 0.018 0.612 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.005 0.634 KNG1_DIPTNSPELEETLTHTITK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 116&144 0.010 0.621 KNG1_QVVAGLNFR_Vs_FBLN1_TGYYFDGISR 117&86 0.022 0.608 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.014 0.616 KNG1_QVVAGLNFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 117&144 0.032 0.601 LBP_ITGFLKPGK_vs_C163A_INPASLDK 118&54 0.007 0.627 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.002 0.646 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.019 0.610 LBP_ITGFLKPGK_vs_SOM2.CSH_SVEGSCGF 118&139 0.032 0.602 LBP_ITGFLKPGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 118&144 0.022 0.608 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.004 0.635 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.027 0.605 LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 119&80 0.014 0.616 LBP_ITLPDFTGDLR_vs_FBLN1_TGYYFDGISR 119&86 0.017 0.612 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.031 0.602 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.001 0.652 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.013 0.618 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.018 0.612 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.015 0.615 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.034 0.600 PEDF_LQSLFDSPDFSK_vs_C163A_INPASLDK 124&54 0.033 0.601 PEDF_LQSLFDSPDFSK_vs_FBLN1_TGYYFDGISR 124&86 0.022 0.608 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.005 0.634 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.028 0.604 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.018 0.611 PEDF_LQSLFDSPDFSK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 124&144 0.014 0.616 PEDF_TVQAVLTVPK_vs_C163A_INPASLDK 125&54 0.021 0.609 PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK 125&80 0.027 0.605 PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR 125&86 0.010 0.622 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.003 0.643 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.019 0.611 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.018 0.612 PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 125&144 0.007 0.628 PTGDS_GPGEDFR_vs_FBLN1_TGYYFDGISR 137&86 0.023 0.607 PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL 137&134 0.013 0.618 VTNC_GQYCYELDEK_vs_C163A_INPASLDK 149&54 0.014 0.616 VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK 149&80 0.019 0.611 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.004 0.638 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.007 0.627 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.031 0.602 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.012 0.619 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.001 0.657 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.005 0.632 VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF 149&139 0.034 0.601 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.032 0.601 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.026 0.605 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.001 0.655 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.028 0.604 VTNC_VDTVDPPYPR_vs_FBLN1_TGYYFDGISR 150&86 0.014 0.616 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.012 0.618 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.001 0.650 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.015 0.615 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.004 0.637
(451) TABLE-US-00032 TABLE32 ReversalClassificationPerformance,weeks18and19. ReversalAUROCforgestationalweeks18and19usinga casevscontrolcut-offof<370/7vs>=370/7weeks, withBMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_C163A_INPASLDK 34&54 0.021 0.634 A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR 34&78 0.049 0.614 A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.041 0.619 A2GL_DLLLPQPDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 34&80 0.042 0.618 A2GL_DLLLPQPDLR_vs_FBLN1_TGYYFDGISR 34&86 0.034 0.623 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.011 0.648 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.020 0.636 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.010 0.651 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.018 0.637 A2GL_DLLLPQPDLR_vs_SPRL1_VLTHSELAPLR 34&140 0.019 0.637 A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR 34&141 0.021 0.634 A2GL_DLLLPQPDLR_vs_TENX_LSQLSVTDVTTSSLR 34&142 0.018 0.637 A2GL_DLLLPQPDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 34&144 0.010 0.651 AFAM_DADPDTFFAK_vs_C163A_INPASLDK 37&54 0.048 0.615 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.021 0.634 AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSFLLR 37&141 0.030 0.626 AFAM_DADPDTFFAK_vs_TENX_LSQLSVTDVTTSSLR 37&142 0.033 0.624 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.007 0.656 AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR 38&141 0.034 0.623 AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR 38&142 0.034 0.623 AFAM_HFQNLGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 38&144 0.030 0.626 ANGT_DPTFIPAPIQAK_vs_C163A_INPASLDK 42&54 0.032 0.625 ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR 42&66 0.026 0.629 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.043 0.618 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.038 0.621 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.006 0.658 ANGT_DPTFIPAPIQAK_vs_CSH_ISLLLIESWLEPVR 42&81 0.035 0.622 ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR 42&86 0.011 0.647 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.012 0.645 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.031 0.625 ANGT_DPTFIPAPIQAK_vs_PSG1_FQLPGQK 42&131 0.048 0.615 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.006 0.660 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.012 0.646 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_NYGLLYCFR 42&138 0.046 0.616 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.007 0.660 ANGT_DPTFIPAPIQAK_vs_SPRL1_VLTHSELAPLR 42&140 0.029 0.627 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.012 0.646 ANGT_DPTFIPAPIQAK_vs_TENX_LSQLSVTDVTTSSLR 42&142 0.008 0.654 ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 42&144 0.006 0.660 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.030 0.626 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.001 0.689 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.046 0.616 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.013 0.645 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.009 0.651 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.028 0.628 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.038 0.620 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.020 0.635 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.044 0.617 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.029 0.627 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.011 0.648 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.037 0.621 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47&131 0.034 0.623 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.010 0.651 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.048 0.615 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.043 0.619 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.015 0.641 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.015 0.642 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.012 0.645 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.041 0.619 APOH_ATVVYQGER_vs_C163A_INPASLDK 48&54 0.032 0.625 APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR 48&66 0.049 0.614 APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK 48&80 0.040 0.619 APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR 48&86 0.019 0.636 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.017 0.638 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.031 0.626 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.013 0.644 APOH_ATVVYQGER_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 48&135 0.024 0.631 APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR 48&140 0.039 0.620 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.011 0.648 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48&142 0.008 0.653 APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 48&144 0.015 0.642 C1QB_VPGLYYFTYHASSR_vs_ALS_IRPHTFTGLSGLR 55&40 0.030 0.626 C1QB_VPGLYYFTYHASSR_vs_C163A_INPASLDK 55&54 0.010 0.650 C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR 55&66 0.011 0.647 C1QB_VPGLYYFTYHASSR_vs_CRIS3_AVSPPAR 55&78 0.017 0.638 C1QB_VPGLYYFTYHASSR_vs_CRIS3_YEDLYSNCK 55&79 0.022 0.633 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.004 0.669 C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR 55&81 0.010 0.650 C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR 55&86 0.005 0.665 C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR 55&98 0.036 0.622 C1QB_VPGLYYFTYHASSR_vs_IBP3_FLNVLSPR 55&99 0.022 0.633 C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK 55&100 0.027 0.628 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.011 0.648 C1QB_VPGLYYFTYHASSR_vs_ITIH4_ILDDLSPR 55&112 0.024 0.631 C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR 55&120 0.004 0.668 C1QB_VPGLYYFTYHASSR_vs_NCAM1_GLGEISAASEFK 55&121 0.019 0.636 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.004 0.669 C1QB_VPGLYYFTYHASSR_vs_PSG1_FQLPGQK 55&131 0.020 0.636 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.004 0.665 C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 55&135 0.024 0.632 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.003 0.673 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&138 0.008 0.654 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF 55&139 0.010 0.652 C1QB_VPGLYYFTYHASSR_VS_SPRL1_VLTHSELAPLR 55&140 0.010 0.651 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.004 0.666 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.002 0.681 C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 55&144 0.004 0.666 C1QB_VPGLYYFTYHASSR_vs_VTDB_ELPEHTVK 55&147 0.034 0.623 CAH1_GGPFSDSYR_vs_C163A_INPASLDK 56&54 0.033 0.624 CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK 56&79 0.045 0.617 CAH1_GGPFSDSYR_vs_PSG1_FQLPGQK 56&131 0.046 0.616 CAH1_GGPFSDSYR_vs_PSG3_VSAPSGTGHLPGLNPL 56&134 0.029 0.627 CAH1_GGPFSDSYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 56&135 0.048 0.615 CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR 56&18 0.044 0.617 CAH1_GGPFSDSYR_vs_TENX_LNWEAPPGAFDSFLLR 56&141 0.038 0.621 CAH1_GGPFSDSYR_vs_TENX_LSQLSVTDVTTSSLR 56&142 0.026 0.630 CAH1_GGPFSDSYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 56&144 0.040 0.619 CBPN_EALIQFLEQVHQGIK_vs_FBLN1_TGYYFDGISR 59&86 0.050 0.614 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.030 0.626 CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPGAFDSFLLR 59&141 0.028 0.627 CBPN_EALIQFLEQVHQGIK_vs_TENX_LSQLSVTDVTTSSLR 59&142 0.029 0.627 CBPN_EALIQFLEQVHQGIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 59&144 0.049 0.614 CBPN_NNANGVDLNR_vs_FBLN1_TGYYFDGISR 60&86 0.045 0.617 CBPN_NNANGVDLNR_vs_TENX_LNWEAPPGAFDSFLLR 60&141 0.045 0.617 CD14_LTVGAAQVPAQLLVGALR_vs_C163A_INPASLDK 61&54 0.033 0.624 CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR 61&86 0.036 0.622 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.011 0.648 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.032 0.625 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.024 0.631 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.041 0.619 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.007 0.657 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.004 0.665 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.007 0.657 CD14_SWLAELQQWLKPGLK_vs_C163A_INPASLDK 62&54 0.037 0.621 CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR 62&86 0.034 0.623 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.026 0.630 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.043 0.618 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.010 0.649 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.006 0.661 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.012 0.646 CFAB_YGLVTYATYPK_vs_C163A_INPASLDK 64&54 0.025 0.630 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.040 0.620 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.011 0.648 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.043 0.618 CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR 67&141 0.030 0.626 CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTSSLR 67&142 0.023 0.632 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR 68&141 0.043 0.618 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR 68&142 0.041 0.619 CO5_TLLPVSKPEIR_vs_FBLN1_TGYYFDGISR 70&86 0.045 0.617 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.014 0.643 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.043 0.618 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.019 0.636 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.016 0.640 CO5_TLLPVSKPEIR_vs_TENX_LSQLSVTDVTTSSLR 70&142 0.011 0.647 CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 70&144 0.010 0.650 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.027 0.628 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.016 0.641 CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR 71&142 0.020 0.635 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.016 0.640 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.019 0.637 CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR 72&142 0.016 0.640 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.014 0.642 CO8A_SLLQPNK_vs_C163A_INPASLDK 74&54 0.036 0.622 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.035 0.623 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.030 0.626 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.007 0.656 CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.009 0.651 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.005 0.664 CO8B_QALEEFQK_vs_C163A_INPASLDK 76&54 0.049 0.614 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.037 0.621 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76&140 0.046 0.616 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.005 0.663 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.006 0.659 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.005 0.664 F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR 84&66 0.031 0.625 F13B_GDTYPAELYITGSILR_vs_CSH_AHQLAIDTYQEFEETYIPK 84&80 0.035 0.623 F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDGISR 84&86 0.036 0.622 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.020 0.636 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.022 0.633 F13B_GDTYPAELYITGSILR_vs_TENX_LNWEAPPGAFDSFLLR 84&141 0.011 0.647 F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTDVTTSSLR 84&142 0.006 0.658 F13B_GDTYPAELYITGSILR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 84&144 0.024 0.631 HABP2_FLNWIK_vs_C163A_INPASLDK 92&54 0.027 0.628 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.040 0.620 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.028 0.628 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.022 0.633 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.016 0.640 HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF 92&139 0.048 0.617 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.014 0.642 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.012 0.646 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.008 0.654 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.042 0.618 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.049 0.614 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.017 0.639 HEMO_NFPSPVDAAFR_vs_TENX_LSQLSVTDVTTSSLR 93&142 0.028 0.628 HEMO_NFPSPVDAAFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 93&144 0.041 0.619 IBP4_QCHPALDGQR_vs_C163A_INPASLDK 2&54 0.031 0.625 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.042 0.618 IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFEETYIPK 2&80 0.048 0.615 IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR 2&86 0.030 0.626 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.019 0.636 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.020 0.635 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.008 0.654 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.033 0.624 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.041 0.619 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.013 0.645 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.011 0.648 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.007 0.656 INHBC_LDFHFSSDR_vs_C163A_INPASLDK 107&54 0.011 0.647 INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR 107&86 0.038 0.620 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.047 0.615 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.043 0.618 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.009 0.652 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.026 0.629 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.004 0.666 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.006 0.658 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.016 0.640 ITIH4_NPLVWVHASPEHVVVTR_vs_CHL1_VIAVNEVGR 113&66 0.044 0.617 ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_AVSPPAR 113&78 0.045 0.616 ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_YEDLYSNCK 113&79 0.035 0.622 ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_AHOLAIDTYQEFEETYIPK 113&80 0.042 0.618 ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR 113&86 0.041 0.619 ITIH4_NPLVWVHASPEHVVVTR_vs_LYAM1_SYYWIGIR 113&120 0.017 0.638 ITIH4_NPLVWVHASPEHVVVTR_vs_PGRP2_AGLLRPDYALLGHR 113&126 0.027 0.629 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.042 0.618 ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR 113&18 0.042 0.618 ITIH4_NPLVWVHASPEHVVVTR_vs_SOM2.CSHSVEGSCGF 113&139 0.045 0.618 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR 113&141 0.016 0.641 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR 113&142 0.011 0.647 ITIH4_NPLVWVHASPEHVVVTR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 113&144 0.044 0.617 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.042 0.618 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.049 0.614 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR 116&141 0.038 0.621 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR 116&142 0.024 0.631 KNG1_DIPTNSPELEETLTHTITK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 116&144 0.043 0.618 KNG1_QVVAGLNFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 117&144 0.044 0.617 LBP_ITGFLKPGK_vs_C163A_INPASLDK 118&54 0.037 0.621 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.028 0.628 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.021 0.634 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.045 0.617 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.017 0.639 PEDF_LQSLFDSPDFSK_vs_C163A_INPASLDK 124&54 0.042 0.618 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.034 0.623 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.044 0.617 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.019 0.636 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.009 0.651 PEDF_TVQAVLTVPK_vs_C163A_INPASLDK 125&54 0.009 0.652 PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR 125&66 0.025 0.630 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.049 0.614 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.044 0.617 PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK 125&80 0.039 0.620 PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR 125&86 0.041 0.619 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.012 0.646 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.011 0.647 PEDF_TVQAVLTVPK_vs_SOM2.CSH_SVEGSCGF 125&139 0.040 0.621 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.005 0.663 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.003 0.673 PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 125&144 0.006 0.658 PRDX2_GLFIIDGK_vs_C163A_INPASLDK 128&54 0.013 0.644 PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR 128&78 0.038 0.621 PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK 128&79 0.024 0.632 PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR 128&120 0.035 0.623 PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL 128&134 0.020 0.635 PRDX2_GLFIIDGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 128&135 0.047 0.615 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.029 0.627 PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR 128&141 0.022 0.633 PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR 128&142 0.021 0.634 PRDX2_GLFIIDGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 128&144 0.030 0.626 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.017 0.639 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.037 0.621 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.042 0.618 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.016 0.640 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR 133&141 0.041 0.619 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.026 0.629 PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL 137&134 0.048 0.615 PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR 137&141 0.036 0.622 PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR 137&142 0.043 0.618 PTGDS_GPGEDFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 137&144 0.028 0.628 VTNC_GQYCYELDEK_vs_C163A_INPASLDK 149&54 0.005 0.664 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.019 0.636 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.021 0.634 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.020 0.635 VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK 149&80 0.027 0.629 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.012 0.645 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.002 0.678 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.039 0.620 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.006 0.659 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.004 0.666 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.037 0.621 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.013 0.644 VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF 149&139 0.020 0.637 VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR 149&140 0.023 0.632 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.008 0.653 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.007 0.657 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.001 0.690 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.020 0.636 VTNC_VDTVDPPYPR_vs_C163A_INPASLDK 150&54 0.018 0.638 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.040 0.620 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.038 0.621 VTNC_VDTVDPPYPR_VS_FBLN1_TGYYFDGISR 150&86 0.040 0.619 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.004 0.666 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.027 0.629 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.007 0.658 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.030 0.626 VTNC_VDTVDPPYPR_vs_SOM2.CSH_SVEGSCGF 150&139 0.046 0.617 VTNC_VDTVDPPYPR_vs_SPRL1_VLTHSELAPLR 150&140 0.043 0.618 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.021 0.634 VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR 150&142 0.016 0.640 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.004 0.669 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.032 0.625
(452) TABLE-US-00033 TABLE33 ReversalClassificationPerformance,weeks18and19. ReversalAUROCforgestationalweeks18and19using acasevscontrolcut-offof<350/7vs>=350/7weeks, withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.039 0.650 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.023 0.665 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.018 0.673 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.040 0.650 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.019 0.671 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.042 0.648 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.049 0.644 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.017 0.675 B2MG_VNHVTLSQPK_vs_C163A_INPASLDK 51&54 0.026 0.663 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.019 0.671 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.029 0.659 CBPN_EALIQFLEQVHQGIK_vs_PSG9_LFIPQITR 59&136 0.032 0.656 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.038 0.652 CD14_LTVGAAQVPAQLLVGALR_vs_C163A_INPASLDK 61&54 0.029 0.659 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.039 0.651 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.024 0.664 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.005 0.703 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.032 0.657 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.012 0.684 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.026 0.663 CD14_SWLAELQQWLKPGLK_vs_C163A_INPASLDK 62&54 0.036 0.653 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.047 0.645 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.018 0.672 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.022 0.667 CLUS_ASSIIDELFQDR_vs_C163A_INPASLDK 67&54 0.032 0.656 CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR 67&99 0.038 0.651 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.026 0.662 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.003 0.718 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.004 0.712 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.029 0.659 CLUS_LFDSDPITVTVPVEVSR_vs_C163A_INPASLDK 68&54 0.029 0.660 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.023 0.666 CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK 68&80 0.047 0.645 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR 68&99 0.017 0.674 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK 68&100 0.011 0.686 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.001 0.734 CLUS_LFDSDPITVTVPVEVSR_vs_ITIH4_ILDDLSPR 68&112 0.048 0.644 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.003 0.713 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR 68&141 0.030 0.658 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR 68&142 0.047 0.645 CLUS_LFDSDPITVTVPVEVSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 68&144 0.041 0.649 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.013 0.682 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.021 0.668 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.027 0.661 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.020 0.669 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.009 0.689 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.021 0.669 COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.048 0.644 COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.010 0.687 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.028 0.660 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.043 0.647 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.050 0.643 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR 82&136 0.027 0.662 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.050 0.643 ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.028 0.660 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.045 0.646 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.017 0.674 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.006 0.700 FETUA_FSVVYAK_vs_PSG9_LFIPQITR 88&136 0.030 0.658 FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 89&135 0.037 0.652 FETUA_HTLNQIDEVK_vs_PSG9_LFIPQITR 89&136 0.017 0.673 HABP2_FLNWIK_vs_C163A_INPASLDK 92&54 0.021 0.668 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.030 0.658 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.015 0.677 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.049 0.644 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.021 0.668 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.037 0.652 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.045 0.647 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.035 0.654 IBP4_QCHPALDGQR_vs_C163A_INPASLDK 2&54 0.029 0.660 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.040 0.649 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.020 0.670 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.026 0.662 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.005 0.705 IBP6_GAQTLYVPNCDHR_vs_C163A_INPASLDK 101&54 0.015 0.678 IBP6_GAQTLYVPNCDHR_vs_IGF2_GIVEECCFR 101&103 0.035 0.654 IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR 101&120 0.025 0.664 IBP6_HLDSVLQQLQTEVYR_vs_C163A_INPASLDK 102&54 0.015 0.678 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.032 0.656 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.048 0.644 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.016 0.675 KNG1_QVVAGLNFR_vs_C163A_INPASLDK 117&54 0.049 0.643 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.040 0.650 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.010 0.687 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.007 0.697 KNG1_QVVAGLNFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 117&144 0.043 0.648 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.046 0.646 PEDF_TVQAVLTVPK_VS_LYAM1_SYYWIGIR 125&120 0.021 0.668 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.024 0.665 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.021 0.668 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.013 0.681 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.020 0.670 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.041 0.649 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.010 0.688 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.041 0.649 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.030 0.659 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.007 0.696 PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK 133&121 0.050 0.643 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.024 0.664 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.033 0.655 PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR 133&138 0.037 0.652 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.043 0.648 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR 133&141 0.030 0.658 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.023 0.665 PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 133&144 0.037 0.652 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.045 0.646 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.036 0.653 VTNC_GQYCYELDEK_vs_C163A_INPASLDK 149&54 0.041 0.649 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.032 0.657 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.006 0.700 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.047 0.645 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.015 0.678
(453) TABLE-US-00034 TABLE34 ReversalClassificationPerformance,weeks18and19. ReversalAUROCforgestationalweeks18and19using acasevscontrolcut-offof<350/7vs>=350/7 weeks,withBMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.040 0.686 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.022 0.707 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.045 0.682 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.029 0.699 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.016 0.718 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.033 0.694 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.026 0.702 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.018 0.715 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.028 0.700 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.006 0.748 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.044 0.683 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.041 0.685 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.036 0.691 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.009 0.737 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.010 0.733 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.021 0.710 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.027 0.700 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.017 0.717 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.035 0.691 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.016 0.719 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.014 0.724 COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.024 0.705 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.042 0.684 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR 82&136 0.011 0.731 ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK 83&121 0.047 0.680 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.042 0.684 ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.012 0.727 ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.037 0.689 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.009 0.737 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.006 0.748 FETUA_FSVVYAK_vs_PSG9_LFIPQITR 88&136 0.043 0.684 FETUA_HTLNQIDEVK_vs_PSG9_LFIPQITR 89&136 0.037 0.689 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.045 0.682 IBP4_QCHPALDGQR_vs_C163A_INPASLDK 2&54 0.048 0.679 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.043 0.684 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.010 0.733 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.004 0.759 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.020 0.710 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.010 0.734 KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR 117&99 0.029 0.698 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.034 0.692 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.004 0.760 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.007 0.746 LBP_ITGFLKPGK_vs_PSG9_LFIPQITR 118&136 0.044 0.682 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.046 0.681 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.018 0.714 PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR 133&40 0.038 0.688 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.012 0.728 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.036 0.691 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.008 0.741 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.007 0.743 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.024 0.705 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.044 0.683 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.017 0.716 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.019 0.712 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.025 0.704 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.010 0.733 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133&112 0.026 0.702 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.002 0.777 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.032 0.694 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.010 0.733 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.028 0.699 PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR 133&138 0.036 0.690 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.045 0.682 PSG2_IHPSYTNYR_vs_TENXLNWEAPPGAFDSFLLR 133&141 0.024 0.705 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.018 0.715 PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 133&144 0.046 0.681 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133&147 0.021 0.710 PTGDS_GPGEDFR_vs_C163A_INPASLDK 137&54 0.036 0.690 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137&103 0.043 0.684 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.031 0.696 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.022 0.707 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.006 0.749 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.023 0.705
(454) TABLE-US-00035 TABLE35 ReversalClassificationPerformance,weeks19and20. ReversalAUROCforgestationalweeks19and20using acasevscontrolcut-offof<370/7vs>=370/7 weeks,withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_PRG2_WNFAYWAAHQPWSR 34&129 0.018 0.618 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.013 0.624 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.023 0.613 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.045 0.600 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.021 0.616 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.013 0.624 AFAM_HFQNLGK_vs_PRG2_WNFAYWAAHQPWSR 38&129 0.036 0.605 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.031 0.608 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.007 0.635 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.009 0.631 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.027 0.611 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.007 0.635 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.007 0.635 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.015 0.621 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.027 0.610 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.009 0.631 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.037 0.604 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.001 0.659 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.002 0.651 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.001 0.660 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.007 0.636 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.003 0.648 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.012 0.626 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.011 0.626 APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR 47&129 0.004 0.642 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47&131 0.031 0.608 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.001 0.659 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.044 0.601 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.042 0.602 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.004 0.645 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.028 0.610 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.028 0.610 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.008 0.634 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.005 0.641 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.005 0.640 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.006 0.638 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.005 0.641 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.043 0.601 APOH_ATVVYQGER_vs_IBP3_FLNVLSPR 48&99 0.031 0.608 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.012 0.626 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.004 0.646 APOH_ATVVYQGER_vs_PRG2_WNFAYWAAHQPWSR 48&129 0.033 0.606 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.003 0.650 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.014 0.622 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.025 0.612 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48&142 0.021 0.615 B2MG_VEHSDLSFSK_vs_PSG3_VSAPSGTGHLPGLNPL 50&134 0.036 0.605 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.010 0.628 B2MG_VNHVTLSQPK_vs_PRG2_WNFAYWAAHQPWSR 51&129 0.020 0.617 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL 51&134 0.011 0.626 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.019 0.617 B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR 51&142 0.037 0.604 BGH3_LTLLAPLNSVFK_vs_PRG2_WNFAYWAAHQPWSR 52&129 0.035 0.605 BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL 52&134 0.043 0.601 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.022 0.614 C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR 55&129 0.011 0.627 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.008 0.633 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.012 0.625 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.031 0.608 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.040 0.602 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR 57&129 0.033 0.607 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.011 0.626 CD14_LTVGAAQVPAQLLVGALR_vs_PRG2_WNFAYWAAHQPWSR 61&129 0.028 0.610 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.008 0.633 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.022 0.615 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.027 0.611 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.028 0.610 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.034 0.606 CD14_SWLAELQQWLKPGLK_vs_PRG2_WNFAYWAAHQPWSR 62&129 0.033 0.607 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.014 0.622 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.034 0.606 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.042 0.602 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.030 0.609 CFAB_YGLVTYATYPK_vs_PRG2_WNFAYWAAHQPWSR 64&129 0.037 0.604 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.022 0.615 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.036 0.605 CO5_TLLPVSKPEIR_vs_PRG2_WNFAYWAAHQPWSR 70&129 0.037 0.604 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.017 0.619 CO5_VFQFLEK_vs_PRG2_WNFAYWAAHQPWSR 71&129 0.031 0.608 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.023 0.614 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.035 0.605 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.034 0.606 COSA_SLLQPNK_vs_IBP3_FLNVLSPR 74&99 0.044 0.600 COSA_SLLQPNK_vs_IBP3_YGQPLPGYTTK 74&100 0.026 0.611 COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.004 0.643 CO8A_SLLQPNK_vs_PRG2_WNFAYWAAHQPWSR 74&129 0.021 0.615 COSA_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.009 0.631 COSA_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.019 0.617 COSA_SLLQPNK_vs_SPRL1_VLTHSELAPLR 74&140 0.035 0.605 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.024 0.613 COSA_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.019 0.617 COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.026 0.611 CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK 76&79 0.038 0.604 CO8B_QALEEFQK_vs_IBP3_FLNVLSPR 76&99 0.025 0.612 CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK 76&100 0.019 0.618 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.002 0.654 CO8B_QALEEFQK_vs_PRG2_WNFAYWAAHQPWSR 76&129 0.021 0.616 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.004 0.645 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.020 0.616 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76&140 0.021 0.615 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.015 0.622 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.010 0.628 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.017 0.620 CO8B_QALEEFQK_vs_VTDB_ELPEHTVK 76&147 0.041 0.602 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2WNFAYWAAHQPWSR 82&129 0.033 0.607 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.033 0.606 ENPP2_TYLHTYESEI_vs_PRG2_WNFAYWAAHQPWSR 83&129 0.040 0.603 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL 83&134 0.044 0.601 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.036 0.605 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.038 0.604 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.031 0.608 FETUA_FSVVYAK_vs_PRG2_WNFAYWAAHQPWSR 88&129 0.033 0.606 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&1.34 0.017 0.619 FETUA_HTLNQIDEVK_vs_PRG2_WNFAYWAAHQPWSR 89&129 0.019 0.617 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.010 0.628 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.027 0.610 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.045 0.600 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.031 0.608 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.043 0.601 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.029 0.609 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.028 0.610 IBP4_QCHPALDGQR_vs_ALS_IRPHTFTGLSGLR 2&40 0.024 0.612 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.027 0.610 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.004 0.644 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.003 0.650 IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR 2&86 0.020 0.617 IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR 2&99 0.014 0.622 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.005 0.639 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.000 0.677 IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR 2&112 0.003 0.650 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.005 0.641 IBP4_QCHPALDGQR_vs_NCAM1_GLGEISAASEFK 2&121 0.027 0.610 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.011 0.627 IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQPWSR 2&129 0.002 0.658 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.000 0.710 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.001 0.673 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.004 0.646 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.002 0.655 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.005 0.641 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.004 0.645 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.002 0.658 IBP6_GAQTLYVPNCDHR_vs_PRG2_WNFAYWAAHQPWSR 101&129 0.038 0.604 IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL 101&134 0.024 0.613 IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR 101&18 0.045 0.600 IBP6_HLDSVLQQLQTEVYR_vs_PRG2_WNFAYWAAHQPWSR 102&129 0.032 0.607 IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL 102&134 0.023 0.613 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR 102&18 0.032 0.607 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.043 0.601 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.015 0.621 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.011 0.627 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.002 0.652 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.041 0.602 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.041 0.602 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.040 0.603 INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQPWSR 107&129 0.016 0.620 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.003 0.647 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.008 0.632 INHBC_LDFHFSSDR_VS_SPRL1_VLTHSELAPLR 107&140 0.035 0.605 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.007 0.634 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.009 0.630 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.024 0.612 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.025 0.612 ITIH3_ALDLSLK_vs_PRG2_WNFAYWAAHQPWSR 111&129 0.024 0.613 ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL 111&134 0.042 0.602 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.024 0.612 ITIH4_NPLVWVHASPEHVVVTR_vs_PRG2_WNFAYWAAHQPWSR 113&129 0.020 0.616 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.016 0.620 ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR 113&18 0.034 0.606 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.030 0.609 KNG1_DIPTNSPELEETLTHTITK_vs_PRG2_WNFAYWAAHQPWSR 116&129 0.032 0.607 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.020 0.617 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.041 0.602 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR 116&142 0.043 0.601 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.032 0.607 KNG1_QVVAGLNFR_vs_PRG2_WNFAYWAAHQPWSR 117&129 0.035 0.606 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.014 0.623 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.025 0.612 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.044 0.600 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.043 0.601 LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPWSR 118&129 0.022 0.615 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.006 0.637 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.033 0.606 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.024 0.613 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.018 0.618 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.024 0.613 LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR 119&129 0.011 0.628 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.002 0.652 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.011 0.628 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.015 0.621 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.045 0.600 PEDF_TVQAVLTVPK_vs_PRG2_WNFAYWAAHQPWSR 125&129 0.037 0.604 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.017 0.619 PRDX2_GLFIIDGK_vs_PRG2_WNFAYWAAHQPWSR 128&129 0.018 0.618 PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL 128&134 0.019 0.617 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.026 0.611 PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR 128&141 0.022 0.614 PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR 128&142 0.042 0.602 PTGDS_GPGEDFR_vs_PRG2_WNFAYWAAHQPWSR 137&129 0.026 0.611 PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL 137&134 0.028 0.610 THBG_AVLHIGEK_vs_PRG2_WNFAYWAAHQPWSR 143&129 0.029 0.609 THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL 143&134 0.018 0.618 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.033 0.606 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.030 0.609 VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQPWSR 149&129 0.018 0.618 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.014 0.622 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.009 0.631 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.033 0.607 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.013 0.624 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.033 0.606 VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQPWSR 150&129 0.014 0.623 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.004 0.642 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.004 0.643 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.032 0.607 VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR 150&142 0.043 0.601 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.015 0.621
(455) TABLE-US-00036 TABLE36 ReversalClassificationPerformance,weeks19and20. ReversalAUROCforgestationalweeks19and20using acasevscontrolcut-offof<370/7vs>=370/7weeks, withBMIstratification(>22<=37). SEQID ROC_ Reversal NO: pval AUC A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR 34&78 0.041 0.628 A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.024 0.641 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34& 0.034 0.633 120 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLN 34& 0.011 0.659 PL 134 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.030 0.636 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37& 0.044 0.626 100 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37& 0.036 0.631 103 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGL 37& 0.028 0.637 NPL 134 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.040 0.628 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38& 0.018 0.647 100 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38& 0.018 0.648 103 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38& 0.014 0.654 134 AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR 38& 0.047 0.624 141 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.047 0.624 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPG 42& 0.025 0.640 LNPL 134 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.035 0.632 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.011 0.658 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.009 0.663 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.032 0.634 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47& 0.035 0.632 100 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47& 0.024 0.642 103 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47& 0.046 0.625 112 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47& 0.015 0.652 120 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLP 47& 0.010 0.661 GLNPL 134 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASN 47&18 0.024 0.641 LR APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCG 47& 0.049 0.623 F 139 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47& 0.049 0.623 140 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAF 47& 0.048 0.624 DSFLLR 141 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTS 47& 0.049 0.623 SLR 142 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47& 0.042 0.627 147 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.037 0.631 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48& 0.039 0.629 100 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48& 0.046 0.625 103 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLN 48& 0.013 0.656 PL 134 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.025 0.640 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51& 0.038 0.630 103 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGL 51& 0.028 0.637 NPL 134 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.036 0.631 BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGL 52& 0.031 0.635 NPL 134 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHL 55& 0.019 0.647 PGLNPL 134 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPAS 55&18 0.047 0.624 NLR CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK 56&79 0.036 0.631 CAH1_GGPFSDSYR_vs_PSG3_VSAPSGTGHLPGLNP 56& 0.028 0.637 L 134 CBPN_NNANGVDLNR_vs_PSG3_VSAPSGTGHLPGL 60& 0.023 0.643 NPL 134 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYS 61&79 0.034 0.633 NCK CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPS 61& 0.029 0.637 GTGHLPGLNPL 134 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTG 62& 0.040 0.628 HLPGLNPL 134 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGL 64& 0.020 0.646 NPL 134 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGL 67& 0.027 0.638 NPL 134 CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR 70&78 0.049 0.623 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.039 0.629 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNP 70& 0.010 0.661 L 134 CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK 71&79 0.041 0.628 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71& 0.028 0.637 134 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGH 72& 0.050 0.623 LPGLNPL 134 COSA_SLLQPNK_vs_CRIS3_AVSPPAR 74&78 0.039 0.629 COSA_SLLQPNK_vs_CRIS3_YEDLYSNCK 74&79 0.016 0.651 CO8A_SLLQPNK_vs_IBP3_YGQPLPGYTTK 74& 0.038 0.630 100 COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74& 0.015 0.652 103 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74& 0.004 0.680 134 COSA_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.031 0.635 COSA_SLLQPNK_vs_SPRL1_VLTHSELAPLR 74& 0.018 0.648 140 COSA_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74& 0.022 0.644 141 CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74& 0.017 0.650 142 CO8B_QALEEFQK_vs_ALS_IRPHTFTGLSGLR 76&40 0.035 0.632 CO8B_QALEEFQK_vs_CRIS3_AVSPPAR 76&78 0.017 0.649 CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK 76&79 0.008 0.665 CO8B_QALEEFQK_vs_IBP3_FLNVLSPR 76&99 0.028 0.638 CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK 76& 0.017 0.649 100 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76& 0.005 0.677 103 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76& 0.039 0.629 120 CO8B_QALEEFQK_vs_NCAM1_GLGEISAASEFK 76& 0.035 0.632 121 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76& 0.002 0.698 134 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.027 0.639 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76& 0.008 0.666 140 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSF 76&141 0.008 0.665 LLR CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.005 0.674 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVG 76&144 0.024 0.642 DGFLLR CO8B_QALEEFQK_vs_VTDB_ELPEHTVK 76&147 0.020 0.645 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG 82&18 0.046 0.625 IALGGLLFPASNLR F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNC 84&79 0.040 0.628 K FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLN 88&134 0.038 0.630 PL FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLP 89&134 0.040 0.629 GLNPL IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.002 0.693 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.001 0.704 IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR 2&99 0.034 0.632 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.010 0.660 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.003 0.687 IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR 2&112 0.014 0.654 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.002 0.695 IBP4_QCHPALDGQR_VS_NCAM1_GLGEISAASEF 2&121 0.023 0.642 K IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL 2&126 0.016 0.651 GHR IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPG 2&134 0.000 0.741 LNPL IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNL 2&18 0.002 0.690 R IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.006 0.671 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFD 2&141 0.005 0.674 SFLLR IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSS 2&142 0.009 0.662 LR IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLV 2&144 0.012 0.657 GDGFLLR IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.003 0.686 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.024 0.642 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.029 0.637 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.015 0.652 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.007 0.669 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107& 0.005 0.674 100 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107& 0.002 0.695 103 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107& 0.033 0.633 112 INHBC_LDFHFSSDR_v_LYAM1_SYYWIGIR 107& 0.030 0.636 120 INHBC_LDFHFSSDR_vs_NCAM1_GLGEISAASEF 107& 0.047 0.624 K 121 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLG 107& 0.036 0.631 HR 126 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGL 107& 0.001 0.710 NPL 134 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNL 107&18 0.008 0.666 R INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107& 0.019 0.646 140 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDS 107& 0.002 0.693 FLLR 141 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSS 107& 0.003 0.689 LR 142 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLV 107& 0.029 0.637 GDGFLLR 144 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107& 0.008 0.666 147 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.044 0.626 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YED 116&79 0.040 0.628 LYSNCK KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.049 0.623 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPG 117& 0.033 0.633 LNPL 134 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNP 118& 0.021 0.644 L 134 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.031 0.635 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.021 0.645 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGL 119& 0.008 0.666 NPL 134 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.021 0.644 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLP 124& 0.036 0.631 GLNPL 134 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPG 125& 0.017 0.649 LNPL 134 PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR 128&78 0.019 0.647 PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK 128&79 0.012 0.658 PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR 128& 0.028 0.637 120 PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGH 128& 0.049 0.623 R 126 PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLN 128& 0.005 0.676 PL 134 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.021 0.645 PRDX2_GLFIIDGK_vs_SPRL1_VLTHSELAPLR 128& 0.049 0.623 140 PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFL 128& 0.017 0.650 LR 141 PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR 128& 0.030 0.636 142 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLN 133& 0.044 0.626 PL 134 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.037 0.630 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137& 0.048 0.624 103 PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLN 137& 0.020 0.645 PL 134 THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLN 143& 0.026 0.639 PL 134 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.037 0.630 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPG 149& 0.013 0.655 LNPL 134 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNL 149&18 0.024 0.641 R VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.032 0.634 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.023 0.643 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150& 0.036 0.631 120 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPG 150& 0.005 0.675 LNPL 134 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN 150&18 0.013 0.656 LR
(456) TABLE-US-00037 TABLE37 ReversalClassificationPerformance,weeks19and20. ReversalAUROCforgestationalweeks19and20usinga casevscontrolcut-offof<350/7vs>=350/7weeks, withoutBMIstratification. SEQID ROC_ Reversal NO: pval AUC AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37& 0.047 0.659 120 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.043 0.663 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38& 0.040 0.664 120 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.018 0.690 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.024 0.680 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.008 0.714 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.009 0.710 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEF 47&80 0.018 0.689 EETYIPK APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.025 0.680 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.017 0.691 APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK 47&97 0.022 0.683 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.019 0.688 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47& 0.020 0.686 100 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47& 0.026 0.679 103 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47& 0.016 0.694 112 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47& 0.001 0.756 120 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASE 47& 0.031 0.673 FK 121 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALL 47& 0.009 0.711 GHR 126 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47& 0.027 0.677 131 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLP 47& 0.021 0.684 GLNPL 134 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASN 47&18 0.008 0.713 LR APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYC 47& 0.029 0.675 FR 138 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCG 47& 0.020 0.687 F 139 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47& 0.014 0.697 140 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAF 47& 0.017 0.691 DSFLLR 141 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTS 47& 0.015 0.694 SLR 142 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPL 47& 0.012 0.702 VGDGFLLR 144 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47& 0.010 0.708 147 APOH_ATVVYQGER_vs_ALS_IRPHTFTGLSGLR 48&40 0.039 0.666 APOH_ATVVYQGER_vs_CRIS3_AVSPPAR 48&78 0.018 0.690 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.013 0.698 APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR 48&86 0.029 0.675 APOH_ATVVYQGER_vs_IBP1_VVESLAK 48&97 0.033 0.671 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48& 0.040 0.664 100 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48& 0.045 0.660 103 APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR 48& 0.020 0.686 112 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48& 0.001 0.762 120 APOH_ATVVYQGER_vs_NCAM1_GLGEISAASEFK 48& 0.047 0.659 121 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGH 48& 0.003 0.736 R 126 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLN 48& 0.005 0.725 PL 134 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.005 0.726 APOH_ATVVYQGER_VS_SPRL1_VLTHSELAPLR 48& 0.007 0.718 140 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFL 48& 0.010 0.705 LR 141 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48& 0.012 0.702 142 APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVG 48& 0.041 0.664 DGFLLR 144 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48& 0.002 0.749 147 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50& 0.018 0.690 120 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.047 0.659 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.047 0.659 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51& 0.003 0.735 120 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLG 51& 0.039 0.666 HR 126 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.019 0.688 B2MG_VNHVTLSQPK_vs_SPRL1_VLTHSELAPLR 51& 0.037 0.667 140 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52& 0.025 0.679 120 CAH1_GGPFSDSYR_vs_CRIS3_AVSPPAR 56&78 0.026 0.679 CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK 56&79 0.029 0.675 CAH1_GGPFSDSYR_vs_IBP1_VVESLAK 56&97 0.036 0.668 CAH1_GGPFSDSYR_vs_LYAM1_SYYWIGIR 56& 0.015 0.694 120 CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR 56& 0.032 0.672 126 CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR 56&18 0.017 0.691 CAH1_GGPFSDSYR_vs_TENX_LNWEAPPGAFDSFLL 56& 0.028 0.676 R 141 CAH1_GGPFSDSYR_vs_TENX_LSQLSVTDVTTSSLR 56& 0.039 0.665 142 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.006 0.719 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.012 0.700 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.014 0.696 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIP 57&80 0.011 0.704 K CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.016 0.692 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.012 0.701 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.048 0.659 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57& 0.034 0.670 103 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57& 0.026 0.679 112 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57& 0.001 0.758 120 CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK 57& 0.035 0.669 121 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57& 0.006 0.720 126 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWS 57& 0.048 0.658 R 129 CATD_VGFAEAAR_vs_PSG1_FQLPGQK 57& 0.008 0.713 131 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57& 0.015 0.695 134 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.006 0.719 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57& 0.028 0.676 138 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57& 0.020 0.687 139 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57& 0.007 0.716 140 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLL 57& 0.004 0.730 R 141 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57& 0.004 0.733 142 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDG 57& 0.016 0.693 FLLR 144 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57& 0.019 0.687 147 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.031 0.673 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.026 0.678 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.012 0.702 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.014 0.696 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYI 58&80 0.022 0.683 PK CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.034 0.670 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.011 0.704 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.033 0.671 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58& 0.029 0.675 100 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58& 0.014 0.697 103 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58& 0.030 0.674 112 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58& 0.002 0.749 120 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58& 0.024 0.681 121 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58& 0.005 0.727 126 CATD_VSTLPAITLK_vs_PSG1_FQLPGQK 58& 0.025 0.679 131 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNP 58& 0.009 0.710 L 134 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.005 0.723 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58& 0.039 0.665 138 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58& 0.046 0.660 139 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58& 0.006 0.720 140 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLL 58& 0.003 0.741 R 141 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58& 0.003 0.737 142 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGD 58& 0.026 0.679 GFLLR 144 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58& 0.007 0.717 147 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPA 59&18 0.038 0.667 SNLR CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60& 0.032 0.672 120 CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR 60& 0.018 0.690 140 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPP 61&78 0.042 0.663 AR CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYS 61&79 0.036 0.668 NCK CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAI 61&80 0.043 0.663 DTYQEFEETYIPK CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYF 61&86 0.022 0.684 DGISR CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLA 61&97 0.044 0.661 K CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYW 61& 0.001 0.759 IGIR 120 CD14_LTVGAAQVPAQLLVGALR_vs_NCAM1_GLGE 61& 0.043 0.663 ISAASEFK 121 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLR 61& 0.011 0.704 PDYALLGHR 126 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPS 61& 0.020 0.687 GTGHLPGLNPL 134 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGL 61&18 0.008 0.713 LFPASNLR CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHS 61& 0.015 0.695 ELAPLR 140 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEA 61& 0.026 0.678 PPGAFDSFLLR 141 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSV 61& 0.019 0.688 TDVTTSSLR 142 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLP 61& 0.022 0.683 LVPGPLVGDGFLLR 144 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHT 61& 0.005 0.727 VK 147 CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGI 62&86 0.033 0.671 SR CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGI 62& 0.002 0.743 R 120 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLR 62&126 0.014 0.697 PDYALLGHR CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSG 62&134 0.031 0.673 TGHLPGLNPL CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGL 62&18 0.011 0.703 LFPASNLR CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSE 62&140 0.021 0.685 LAPLR CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEA 62&141 0.042 0.663 PPGAFDSFLLR CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSV 62&142 0.028 0.676 TDVTTSSLR CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPL 62&144 0.026 0.679 VPGPLVGDGFLLR CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHT 62&147 0.007 0.718 VK CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR 67&86 0.048 0.658 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.004 0.728 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALL 67&126 0.036 0.668 GHR CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASN 67&18 0.008 0.713 LR CLUS_ASSIIDELFQDR_vs_SPRL1_VLTHSELAPLR 67&140 0.031 0.673 CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTS 67&142 0.045 0.660 SLR CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.015 0.695 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPA 68&78 0.034 0.670 R CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYS 68&79 0.028 0.676 NCK CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYF 68&86 0.036 0.668 DGISR CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWI 68&120 0.001 0.767 GIR CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLR 68&126 0.013 0.699 PDYALLGHR CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSG 68&134 0.020 0.686 TGHLPGLNPL CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGL 68&18 0.004 0.730 LFPASNLR CLUS_LFDSDPITVTVPVEVSR_vs_SPRL1_VLTHSE 68&140 0.012 0.702 LAPLR CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEA 68&141 0.021 0.684 PPGAFDSFLLR CLUS_LFDSDPITVTVPVEVSR_v_TENX_LSQLSV 68&142 0.013 0.698 TDVTTSSLR CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHT 68&147 0.002 0.753 VK CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.009 0.710 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.027 0.677 CO5_TLLPVSKPEIR_vs_SPRL1_VLTHSELAPLR 70&140 0.028 0.676 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.013 0.699 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.030 0.674 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGI 72&120 0.017 0.692 R CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLF 72&18 0.040 0.665 PASNLR COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.009 0.711 COSA_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.045 0.661 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.033 0.671 COSA_SLLQPNK_vs_SPRL1_VLTHSELAPLR 74&140 0.036 0.668 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGD 74&144 0.040 0.665 GFLLR CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.009 0.711 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGL 76&134 0.035 0.669 NPL CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.036 0.668 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76&140 0.025 0.679 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.043 0.662 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVG 76&144 0.032 0.672 DGFLLR ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.043 0.662 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.024 0.681 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNC 84&79 0.022 0.683 K F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDG 84&86 0.046 0.660 ISR F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGI 84&120 0.001 0.754 R F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPD 84&126 0.037 0.667 YALLGHR F13B_GDTYPAELYITGSILR_VS_SHBG_IALGGLLF 84&18 0.011 0.703 PASNLR F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSEL 84&140 0.016 0.694 APLR F13B_GDTYPAELYITGSILR_vs_TENX_LNWEAPP 84&141 0.046 0.660 GAFDSFLLR F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTD 84&142 0.030 0.673 VTTSSLR F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK 84&147 0.043 0.662 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.017 0.692 HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR 92&126 0.027 0.677 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.020 0.687 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLL 92&141 0.033 0.671 R HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.030 0.673 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.022 0.684 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.020 0.686 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPAS 93&18 0.022 0.684 NLR IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.006 0.720 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.009 0.708 IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR 2&86 0.040 0.664 IBP4_QCHPALDGQR_vs_IBP1_VVESLAK 2&97 0.038 0.666 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.001 0.761 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL 2&126 0.026 0.678 GHR IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLP 2&134 0.013 0.698 GLNPL IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASN 2&18 0.005 0.725 LR IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.007 0.715 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFD 2&141 0.047 0.659 SFLLR IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTS 2&142 0.044 0.661 SLR IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.033 0.671 IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR 101& 0.049 0.657 120 IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFP 101&18 0.033 0.671 ASNLR IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIG 102& 0.026 0.679 IR 120 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLF 102&18 0.033 0.671 PASNLR INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107& 0.038 0.666 120 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALL 107& 0.044 0.661 GHR 126 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNL 107&18 0.043 0.662 R INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDS 107& 0.047 0.659 FLLR 141 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSS 107& 0.047 0.659 LR 142 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYY 116& 0.013 0.700 WIGIR 120 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117& 0.003 0.734 120 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALL 117& 0.048 0.659 GHR 126 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNL 117&18 0.012 0.702 R KNG1_QVVAGLNFR_vs_SPRL1_VLTHSELAPLR 117& 0.020 0.687 140 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.022 0.683 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.026 0.679 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124& 0.005 0.726 120 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPAS 124&18 0.045 0.660 NLR PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.023 0.683 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.024 0.681 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125& 0.003 0.736 120 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPG 125& 0.047 0.659 LNPL 134 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNL 125&18 0.024 0.681 R PEDF_TVQAVLTVPK_vs_SPRL1_VLTHSELAPLR 125& 0.029 0.675 140 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSS 125& 0.038 0.667 LR 142 PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK 125& 0.036 0.668 147 PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR 128&78 0.032 0.672 PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK 128&79 0.029 0.675 PRDX2_GLFIIDGK_vs_IBP1_VVESLAK 128&97 0.033 0.671 PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR 128& 0.013 0.700 120 PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGH 128& 0.028 0.676 R 126 PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLN 128& 0.047 0.659 PL 134 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.012 0.702 PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSF 128& 0.020 0.687 LLR 141 PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR 128& 0.028 0.676 142 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.023 0.682 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133& 0.043 0.662 120 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133& 0.049 0.657 140 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.031 0.673 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.035 0.669 PTGDS_GPGEDFR_vs_FBLN1_TGYYFDGISR 137&86 0.032 0.672 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137& 0.007 0.715 120 PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGH 137& 0.044 0.661 R 126 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.033 0.671 PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF 137& 0.041 0.664 139 PTGDS_GPGEDFR_VS_SPRL1_VLTHSELAPLR 137& 0.016 0.692 140 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143& 0.013 0.698 120 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.041 0.664 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149& 0.015 0.696 120 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASN 149&18 0.031 0.672 LR VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150& 0.008 0.712 120 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALL 150& 0.040 0.664 GHR 126 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN 150&18 0.014 0.696 LR VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150& 0.030 0.673 147
(457) TABLE-US-00038 TABLE38 ReversalClassificationPerformance,weeks19and20. ReversalAUROCforgestationalweeks19and20using acasevscontrolcut-offof<350/7vs >=350/7weeks,withBMIstratification(>22<=37). SEQID ROC_ Reversal NO: pval AUC AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK 37&79 0.048 0.709 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37& 0.027 0.734 120 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLG 37& 0.007 0.788 HR 126 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.010 0.771 AFAM_DADPDTFFAK_vs_VTDB_ELPEHTVK 37& 0.027 0.734 147 AFAM_HFQNLGK_vs_IBP1_VVESLAK 38&97 0.045 0.726 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38& 0.021 0.744 120 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38& 0.012 0.766 126 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.016 0.756 AFAM_HFQNLGK_vs_VTDB_ELPEHTVK 38& 0.036 0.722 147 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNL 42&18 0.025 0.737 R APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47& 0.033 0.726 120 APOH_ATVVYQGER_vs_CRIS3_AVSPPAR 48&78 0.020 0.746 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.013 0.762 APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR 48& 0.043 0.714 112 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48& 0.003 0.816 120 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGH 48& 0.001 0.855 R 126 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.003 0.819 APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR 48& 0.043 0.714 140 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48& 0.001 0.839 147 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51& 0.008 0.782 120 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.022 0.742 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52& 0.028 0.732 120 BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLG 52& 0.034 0.725 HR 126 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNL 52&18 0.027 0.734 R BGH3_LTLLAPLNSVFK_vs_SOM2.CSH_SVEGSCGF 52& 0.040 0.717 139 CAH1_GGPFSDSYR_vs_CRIS3_AVSPPAR 56&78 0.031 0.729 CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK 56&79 0.042 0.715 CAH1_GGPFSDSYR_VS_LYAM1_SYYWIGIR 56& 0.033 0.726 120 CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR 56& 0.045 0.712 126 CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR 56&18 0.020 0.747 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.035 0.723 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.029 0.731 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.038 0.720 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIP 57&80 0.028 0.733 K CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.038 0.720 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57& 0.006 0.789 120 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57& 0.018 0.751 126 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.013 0.762 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57& 0.044 0.713 139 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLL 57& 0.045 0.712 R 141 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.016 0.754 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.014 0.760 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYI 58&80 0.029 0.731 PK CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.041 0.716 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58& 0.024 0.739 112 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58& 0.002 0.822 120 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58& 0.045 0.712 121 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58& 0.004 0.809 126 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.005 0.795 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58& 0.037 0.721 140 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLL 58& 0.014 0.759 R 141 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58& 0.021 0.745 142 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58& 0.013 0.764 147 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNL 60&18 0.040 0.718 R CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPP 61&78 0.041 0.716 AR CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYS 61&79 0.028 0.732 NCK CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYW 61& 0.005 0.799 IGIR 120 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLR 61& 0.012 0.766 PDYALLGHR 126 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGL 61&18 0.011 0.768 LFPASNLR CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHT 61& 0.016 0.756 VK 147 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGI 62& 0.015 0.758 R 120 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPD 62& 0.024 0.739 YALLGHR 126 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFP 62&18 0.017 0.752 ASNLR CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62& 0.034 0.725 147 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.035 0.723 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.040 0.718 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67& 0.018 0.751 120 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLG 67& 0.042 0.715 HR 126 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.013 0.763 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67& 0.040 0.717 147 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.031 0.729 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNC 68&79 0.031 0.728 K CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGI 68& 0.011 0.768 R 120 CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPD 68& 0.031 0.728 YALLGHR 126 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLL 68&18 0.009 0.776 FPASNLR CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHT 68&147 0.035 0.723 VK CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.033 0.726 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.018 0.750 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.031 0.728 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGI 72&120 0.041 0.716 R CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLF 72&18 0.024 0.739 PASNLR COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.029 0.731 CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.044 0.713 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.034 0.725 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.028 0.733 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.041 0.716 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.015 0.757 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNC 84&79 0.016 0.756 K F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGI 84&120 0.003 0.815 R F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPD 84&126 0.015 0.758 YALLGHR F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLF 84&18 0.004 0.801 PASNLR F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK 84&147 0.023 0.740 FBLN3_IPSNPSHR_vs_CHL1_VIAVNEVGR 87&66 0.036 0.722 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPAS 93&18 0.036 0.722 NLR IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.008 0.780 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.012 0.766 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.001 0.861 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL 2&126 0.014 0.761 GHR IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNL 2&18 0.002 0.827 R IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.021 0.745 IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR 101& 0.050 0.708 120 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGI 102& 0.013 0.763 R 120 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLF 102&18 0.026 0.735 PASNLR INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLG 107& 0.043 0.714 HR 126 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117& 0.013 0.762 120 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNL 117&18 0.033 0.726 R PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.048 0.709 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.045 0.712 PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPV 122&81 0.048 0.709 R PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122& 0.021 0.745 120 PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAH 122& 0.033 0.726 QPWSR 129 PAPP1_DIPHWLNPTR_vs_PSG1_FQLPGQK 122& 0.040 0.718 131 PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPAS 122&18 0.035 0.723 NLR PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCG 122& 0.018 0.750 F 139 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124& 0.015 0.758 120 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPAS 124&18 0.024 0.739 NLR PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK 124& 0.048 0.709 147 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.047 0.710 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125& 0.008 0.783 120 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNL 125&18 0.009 0.777 R PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK 125& 0.031 0.729 147 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.019 0.748 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.016 0.756 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.018 0.750 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.030 0.730 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.026 0.736 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133& 0.019 0.749 112 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133& 0.007 0.788 120 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGH 133& 0.022 0.742 R 126 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLN 133& 0.024 0.739 PL 134 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.005 0.794 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133& 0.036 0.722 139 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133& 0.022 0.743 140 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSF 133& 0.028 0.733 LLR 141 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133& 0.029 0.731 142 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133& 0.013 0.764 147 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.020 0.747 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.019 0.749 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137& 0.003 0.814 120 PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGH 137& 0.012 0.766 R 126 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.019 0.748 PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF 137& 0.010 0.774 139 PTGDS_GPGEDFR_vs_VTDB_ELPEHTVK 137& 0.027 0.734 147 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149& 0.024 0.739 120 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNL 149&18 0.030 0.730 R VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150& 0.025 0.738 120 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALL 150& 0.046 0.711 GHR 126 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN 150&18 0.012 0.765 LR 68&18
(458) TABLE-US-00039 TABLE39 ReversalClassificationPerformance,weeks20and21. ReversalAUROCforgestationalweeks20and21using acasevscontrolcut-offof<370/7vs>=370/7 weeks,withoutBMIstratification. SEQID ROC_ Reversal NO: pval AUC A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.028 0.636 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.035 0.631 A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFL 34&141 0.035 0.631 LR AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.011 0.659 AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSF 37&141 0.027 0.638 LLR AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR 38&66 0.036 0.631 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.028 0.636 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.008 0.666 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.001 0.713 AFAM_HFQNLGK_vs_PRG2_WNFAYWAAHQPWS 38&129 0.036 0.631 R AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.035 0.631 AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR 38&141 0.008 0.664 AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR 38&142 0.023 0.641 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDS 42&141 0.020 0.644 FLLR APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.014 0.653 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.045 0.625 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.010 0.660 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.006 0.669 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.006 0.670 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEF 47&80 0.013 0.654 EETYIPK APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.017 0.648 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.012 0.656 APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK 47&97 0.033 0.633 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.021 0.644 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.003 0.685 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.003 0.684 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.001 0.699 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.003 0.682 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.002 0.692 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASE 47&121 0.016 0.650 FK APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALL 47&126 0.001 0.699 GHR APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAH 47&129 0.006 0.670 QPWSR APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLP 47&134 0.010 0.660 GLNPL APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQ 47&135 0.018 0.647 NLPGYFWYK APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.018 0.647 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASN 47&18 0.002 0.688 LR APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYC 47&138 0.028 0.636 FR APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCG 47&139 0.011 0.658 F APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.008 0.665 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAF 47&141 0.002 0.693 DSFLLR APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTS 47&142 0.003 0.682 SLR APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPL 47&144 0.013 0.654 VGDGFLLR APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.003 0.683 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFL 48&141 0.042 0.627 LR B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR 50&103 0.026 0.638 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.037 0.630 B2MG_VEHSDLSFSK_vs_PGRP2_AGLLRPDYALLGH 50&126 0.033 0.633 R B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.021 0.644 B2MG_VEHSDLSFSK_vs_TENX_LNWEAPPGAFDSF 50&141 0.008 0.664 LLR B2MG_VEHSDLSFSK_vs_TENX_LSQLSVTDVTTSSLR 50&142 0.042 0.627 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.046 0.624 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.006 0.672 B2MG_VNHVTLSQPK_vs_ITIH4_ILDDLSPR 51&112 0.038 0.629 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.017 0.648 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLG 51&126 0.012 0.657 HR B2MG_VNHVTLSQPK_vs_PRG2_WNFAYWAAHQP 51&129 0.050 0.622 WSR B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.009 0.662 B2MG_VNHVTLSQPK_vs_TENX_LNWEAPPGAFDS 51&141 0.005 0.675 FLLR B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSL 51&142 0.030 0.635 R BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.023 0.641 BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR 52&103 0.009 0.662 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.048 0.623 BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLG 52&126 0.050 0.622 HR BGH3_LTLLAPLNSVFK_vs_PRG2_WNFAYWAAHQ 52&129 0.043 0.626 PWSR BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNL 52&18 0.045 0.625 R BGH3_LTLLAPLNSVFK_vs_TENXLNWEAPPGAFDS 52&141 0.011 0.658 FLLR BGH3_LTLLAPLNSVFK_vs_TENX_LSQLSVTDVTTSS 52&142 0.039 0.628 LR C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.014 0.652 C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAA 55&129 0.049 0.623 HQPWSR C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPAS 55&18 0.040 0.628 NLR C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGA 55&141 0.009 0.663 FDSFLLR C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTT 55&142 0.038 0.629 SSLR CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.024 0.641 CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR 57&66 0.009 0.662 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.014 0.652 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.008 0.666 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIP 57&80 0.038 0.629 K CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.048 0.623 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.040 0.628 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.049 0.623 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.006 0.671 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.007 0.667 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.001 0.714 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.010 0.661 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.006 0.671 CATD_VGFAEAAR_VS_NCAM1_GLGEISAASEFK 57&121 0.026 0.639 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.003 0.685 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWS 57&129 0.002 0.688 R CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.008 0.666 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.009 0.662 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.039 0.629 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.012 0.656 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLL 57&141 0.000 0.739 R CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.001 0.713 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.008 0.666 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.037 0.630 CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR 58&66 0.009 0.663 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.022 0.643 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.013 0.655 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.049 0.623 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.034 0.632 CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR 58&98 0.037 0.630 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.006 0.671 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.010 0.660 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.001 0.712 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.014 0.653 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.011 0.659 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58&121 0.031 0.634 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.002 0.691 CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPW 58&129 0.005 0.677 SR CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNP 58&134 0.012 0.657 L CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.005 0.677 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.028 0.637 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLL 58&141 0.000 0.731 R CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.001 0.710 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.019 0.646 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPA 59&18 0.037 0.630 SNLR CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPG 59&141 0.027 0.637 AFDSFLLR CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR 60&103 0.030 0.635 CBPN_NNANGVDLNR_vs_PGRP2_AGLLRPDYALLG 60&126 0.041 0.627 HR CBPN_NNANGVDLNR_VS_SHBG_IALGGLLFPASNL 60&18 0.024 0.641 R CBPN_NNANGVDLNR_vs_TENX_LNWEAPPGAFDS 60&141 0.011 0.657 FLLR CBPN_NNANGVDLNR_vs_TENX_LSQLSVTDVTTSSL 60&142 0.031 0.634 R CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEEC 61&103 0.028 0.636 CFR CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGL 61&18 0.033 0.632 LFPASNLR CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEA 61&141 0.014 0.652 PPGAFDSFLLR CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFP 62&18 0.039 0.628 ASNLR CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPP 62&141 0.019 0.646 GAFDSFLLR CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.010 0.660 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLG 64&126 0.044 0.625 HR CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.049 0.623 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSF 64&141 0.015 0.651 LLR CFAB_YGLVTYATYPK_vs_TENX_LSQLSVTDVTTSSL 64&142 0.047 0.623 R CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.047 0.623 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.041 0.627 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLL 70&141 0.021 0.644 R CO5_VFQFLEK_vs_IGF2_GIVEECCFR 71&103 0.041 0.627 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.042 0.627 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.014 0.653 CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR 71&142 0.047 0.623 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGA 72&141 0.043 0.626 FDSFLLR COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.012 0.655 CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.032 0.633 COSA_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.048 0.623 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.009 0.662 COSA_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.021 0.644 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.009 0.663 CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR 76&126 0.040 0.628 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.045 0.625 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLL 76&141 0.006 0.670 R CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.012 0.655 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRP 82&40 0.002 0.695 HTFTGLSGLR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_C163A_I 82&54 0.036 0.631 NPASLDK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CHL1_V 82&66 0.002 0.690 IAVNEVGR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_A 82&78 0.005 0.673 VSPPAR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_Y 82&79 0.004 0.679 EDLYSNCK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_AH 82&80 0.012 0.656 QLAIDTYQEFEETYIPK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISL 82&81 0.014 0.652 LLIESWLEPVR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1 82&86 0.007 0.669 TGYYFDGISR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP1_V 82&97 0.027 0.638 VESLAK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP2_LI 82&98 0.008 0.664 QGAPTIR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FL 82&99 0.001 0.708 NVLSPR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_Y 82&100 0.001 0.708 GQPLPGYTTK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GI 82&103 0.000 0.736 VEECCFR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_IL 82&112 0.001 0.710 DDLSPR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1 82&120 0.001 0.704 SYYWIGIR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1 82&121 0.013 0.655 GLGEISAASEFK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2 82&126 0.001 0.708 AGLLRPDYALLGHR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2 82&129 0.003 0.684 WNFAYWAAHQPWSR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_V 82&134 0.004 0.681 SAPSGTGHLPGLNPL ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_D 82&135 0.016 0.650 VLLLVHNLPQNLPGYFWYK ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_L 82&136 0.027 0.637 FIPQITR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_I 82&18 0.000 0.720 ALGGLLFPASNLR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.C 82&138 0.032 0.633 SH_NYGLLYCFR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.C 82&139 0.020 0.645 SH_SVEGSCGF ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SPRL1 82&140 0.005 0.674 VLTHSELAPLR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_L 82&141 0.001 0.715 NWEAPPGAFDSFLLR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_L 82&142 0.001 0.700 SQLSVTDVTTSSLR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VS 82&144 0.006 0.671 WSLPLVPGPLVGDGFLLR ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_E 82&147 0.001 0.711 LPEHTVK ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR 83&40 0.001 0.707 ENPP2_TYLHTYESEI_vs_C163A_INPASLDK 83&54 0.016 0.650 ENPP2_TYLHTYESEI_vs_CHL1_VIAVNEVGR 83&66 0.002 0.694 ENPP2_TYLHTYESEI_vs_CRIS3_AVSPPAR 83&78 0.004 0.680 ENPP2_TYLHTYESEI_vs_CRIS3_YEDLYSNCK 83&79 0.002 0.689 ENPP2_TYLHTYESEI_vs_CSH_AHQLAIDTYQEFEETY 83&80 0.006 0.670 IPK ENPP2_TYLHTYESEI_vs_CSH_ISLLLIESWLEPVR 83&81 0.008 0.664 ENPP2_TYLHTYESEI_vs_FBLN1_TGYYFDGISR 83&86 0.007 0.669 ENPP2_TYLHTYESEI_vs_IBP1_VVESLAK 83&97 0.028 0.636 ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR 83&98 0.007 0.666 ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR 83&99 0.000 0.719 ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK 83&100 0.001 0.716 ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR 83&103 0.000 0.741 ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR 83&112 0.001 0.716 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.001 0.712 ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEF 83&121 0.010 0.660 K ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLG 83&126 0.001 0.714 HR ENPP2_TYLHTYESEI_vs_PRG2_WNFAYWAAHQ 83&129 0.003 0.686 PWSR ENPP2_TYLHTYESEI_vs_PSG1_FQLPGQK 83&131 0.047 0.623 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPG 83&134 0.004 0.678 LNPL ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQN 83&135 0.018 0.647 LPGYFWYK ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.027 0.637 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNL 83&18 0.000 0.722 R ENPP2_TYLHTYESEI_vs_SOM2.CSH_NYGLLYCFR 83&138 0.019 0.646 ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF 83&139 0.010 0.661 ENPP2_TYLHTYESEI_vs_SPRL1_VLTHSELAPLR 83&140 0.003 0.686 ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDS 83&141 0.000 0.728 FLLR ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSS 83&142 0.001 0.712 LR ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLV 83&144 0.003 0.685 GDGFLLR ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.001 0.713 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.041 0.627 FETUA_FSVVYAK_vs_CHL1_VIAVNEVGR 88&66 0.016 0.650 FETUA_FSVVYAK_vs_CRIS3_AVSPPAR 88&78 0.030 0.635 FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK 88&79 0.017 0.648 FETUA_FSVVYAK_vs_IBP3_FLNVLSPR 88&99 0.018 0.646 FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK 88&100 0.014 0.652 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.001 0.701 FETUA_FSVVYAK_vs_ITIH4_ILDDLSPR 88&112 0.034 0.632 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.023 0.642 FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGH 88&126 0.011 0.659 R FETUA_FSVVYAK_vs_PRG2_WNFAYWAAHQPW 88&129 0.012 0.657 SR FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLN 88&134 0.033 0.633 PL FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.010 0.660 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFL 88&141 0.002 0.694 LR FETUA_FSVVYAK_vs_TENX_LSQLSVTDVTTSSLR 88&142 0.007 0.668 FETUA_FSVVYAK_vs_VTDB_ELPEHTVK 88&147 0.007 0.668 FETUA_HTLNQIDEVK_vs_CHL1_VIAVNEVGR 89&66 0.013 0.654 FETUA_HTLNQIDEVK_vs_CRIS3_AVSPPAR 89&78 0.046 0.624 FETUA_HTLNQIDEVK_vs_CRIS3_YEDLYSNCK 89&79 0.027 0.638 FETUA_HTLNQIDEVK_vs_IBP3_FLNVLSPR 89&99 0.036 0.630 FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK 89&100 0.041 0.627 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.004 0.681 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.041 0.627 FETUA_HTLNQIDEVK_vs_PGRP2_AGLLRPDYALL 89&126 0.024 0.640 GHR FETUA_HTLNQIDEVK_vs_PRG2_WNFAYWAAH 89&129 0.015 0.651 QPWSR FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLP 89&134 0.037 0.630 GLNPL FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASN 89&18 0.009 0.662 LR FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAF 89&141 0.001 0.701 DSFLLR FETUA_HTLNQIDEVK_vs_TENX_LSQLSVTDVTTS 89&142 0.005 0.673 SLR FETUA_HTLNQIDEVK_vs_VTDB_ELPEHTVK 89&147 0.025 0.639 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.039 0.628 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.039 0.629 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.005 0.674 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.046 0.624 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLL 92&141 0.006 0.669 R HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.021 0.644 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.043 0.626 HEMO_NFPSPVDAAFR_vs_PGRP2_AGLLRPDYA 93&126 0.050 0.622 LLGHR HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPAS 93&18 0.017 0.648 NLR HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGA 93&141 0.013 0.654 FDSFLLR IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.023 0.642 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.027 0.638 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.013 0.655 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.005 0.676 IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR 2&112 0.014 0.653 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.013 0.654 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL 2&126 0.005 0.674 GHR IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQ 2&129 0.016 0.649 PWSR IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNL 2&18 0.003 0.685 R IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFD 2&141 0.001 0.702 SFLLR IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSS 2&142 0.016 0.649 LR IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.022 0.643 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.016 0.649 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.044 0.625 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.025 0.639 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.014 0.653 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107& 0.012 0.655 100 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107& 0.001 0.707 103 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107& 0.009 0.662 112 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107& 0.014 0.652 120 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLG 107& 0.006 0.672 HR 126 INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQ 107& 0.031 0.634 PWSR 129 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGL 107& 0.019 0.646 NPL 134 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNL 107&18 0.006 0.672 R INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107& 0.035 0.631 140 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDS 107& 0.003 0.684 FLLR 141 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSS 107& 0.009 0.662 LR 142 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107& 0.008 0.666 147 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.043 0.626 ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR 111& 0.037 0.630 103 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111& 0.034 0.632 120 ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR 111& 0.008 0.665 126 ITIH3_ALDLSLK_vs_PRG2_WNFAYWAAHQPWS 111& 0.035 0.631 R 129 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.010 0.660 ITIH3_ALDLSLK_vs_TENX_LNWEAPPGAFDSFLL 111& 0.016 0.650 R 141 ITIH3_ALDLSLK_vs_TENX_LSQLSVTDVTTSSLR 111& 0.049 0.622 142 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEEC 116& 0.026 0.639 CFR 103 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGG 116&18 0.023 0.642 LLFPASNLR KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWE 116& 0.006 0.671 APPGAFDSFLLR 141 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLS 116& 0.032 0.634 VTDVTTSSLR 142 KNG1_QVVAGLNFR_vs_CHL1_VIAVNEVGR 117&66 0.037 0.630 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.049 0.622 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117& 0.014 0.653 103 KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR 117& 0.026 0.638 112 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117& 0.024 0.641 120 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALL 117& 0.016 0.649 GHR 126 KNG1_QVVAGLNFR_vs_PRG2_WNFAYWAAHQ 117& 0.037 0.630 PWSR 129 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNL 117&18 0.005 0.675 R KNG1_QVVAGLNFR_vs_TENX_LNWEAPPGAFDS 117& 0.003 0.685 FLLR 141 KNG1_QVVAGLNFR_vs_TENX_LSQLSVTDVTTSS 117& 0.032 0.634 LR 142 KNG1_QVVAGLNFR_vs_VTDB_ELPEHTVK 117& 0.030 0.635 147 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.029 0.636 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.009 0.663 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.005 0.674 LBP_ITGFLKPGK_vs_IBP2_LIQGAPTIR 118&98 0.035 0.631 LBP_ITGFLKPGK_vs_IBP3_FLNVLSPR 118&99 0.022 0.642 LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK 118& 0.012 0.657 100 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118& 0.003 0.684 103 LBP_ITGFLKPGK_vs_ITIH4_ILDDLSPR 118& 0.020 0.645 112 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118& 0.008 0.664 120 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118& 0.014 0.653 126 LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPW 118& 0.018 0.646 SR 129 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNP 118& 0.016 0.650 L 134 LBP_ITGFLKPGK_vs_PSG9_DVLLLVHNLPQNLPG 118& 0.045 0.625 YFWYK 135 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.009 0.662 LBP_ITGFLKPGK_vs_SPRL1_VLTHSELAPLR 118& 0.024 0.640 140 LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLL 118& 0.005 0.676 R 141 LBP_ITGFLKPGK_vs_TENX_LSQLSVTDVTTSSLR 118& 0.019 0.646 142 LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK 118& 0.010 0.659 147 LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR 119&40 0.019 0.646 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.009 0.663 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.003 0.686 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.002 0.696 LBP_ITLPDFTGDLR_vs_IBP1_VVESLAK 119&97 0.046 0.624 LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR 119&98 0.012 0.656 LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR 119&99 0.004 0.679 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119& 0.002 0.694 100 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119& 0.001 0.713 103 LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR 119& 0.003 0.688 112 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119& 0.002 0.690 120 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119& 0.040 0.628 121 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLG 119& 0.002 0.692 HR 126 LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQP 119& 0.007 0.667 WSR 129 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGL 119& 0.007 0.667 NPL 134 LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNL 119& 0.025 0.639 PGYFWYK 135 LBP_ITLPDFTGDLR_vs_PSG9_LFIPQITR 119& 0.037 0.630 136 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.002 0.690 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119& 0.032 0.634 139 LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR 119& 0.007 0.668 140 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSF 119& 0.001 0.705 LLR 141 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSL 119& 0.004 0.678 R 142 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVG 119& 0.020 0.645 DGFLLR 144 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119& 0.002 0.695 147 PAPP1_DIPHWLNPTR_vs_C163A_INPASLDK 122&54 0.050 0.622 PAPP1_DIPHWLNPTR_vs_CSH_AHQLAIDTYQEF 122&80 0.035 0.631 EETYIPK PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPV 122&81 0.044 0.625 R PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYC 122& 0.021 0.643 FR 138 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.030 0.635 PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR 124& 0.011 0.658 103 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124& 0.036 0.631 120 PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYAL 124& 0.033 0.632 LGHR 126 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAF 124& 0.008 0.666 DSFLLR 141 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTT 124& 0.035 0.631 SSLR 142 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125& 0.016 0.650 103 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFD 125& 0.016 0.650 SFLLR 141 PSG11_LFIPQITPK_vs_PRG2_WNFAYWAAHQP 132& 0.043 0.626 WSR 129 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.033 0.632 PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSF 137& 0.015 0.651 LLR 141 PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR 137& 0.046 0.624 142 THBG_AVLHIGEK_vs_TENX_LNWEAPPGAFDSFL 143& 0.040 0.628 LR 141 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.038 0.629 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.049 0.623 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.017 0.648 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149& 0.020 0.645 100 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149& 0.002 0.689 103 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149& 0.024 0.641 112 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149& 0.039 0.629 120 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALL 149& 0.028 0.636 GHR 126 VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQ 149& 0.045 0.625 PWSR 129 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPG 149& 0.039 0.629 LNPL 134 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNL 149&18 0.006 0.672 R VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFD 149& 0.003 0.683 SFLLR 141 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSS 149& 0.013 0.654 LR 142 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149& 0.005 0.673 147 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.025 0.640 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.050 0.622 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.040 0.628 VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR 150&99 0.021 0.644 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150& 0.023 0.641 100 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150& 0.003 0.686 103 VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR 150& 0.017 0.648 112 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150& 0.018 0.646 120 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALL 150& 0.020 0.645 GHR 126 VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQ 150& 0.034 0.632 PWSR 129 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN 150&18 0.005 0.675 LR VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFD 150& 0.003 0.687 SFLLR 141 VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTS 150& 0.013 0.654 SLR 142 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150& 0.003 0.686 147
(459) TABLE-US-00040 TABLE40 ReversalClassificationPerformance,weeks20and21. ReversalAUROCforgestationalweeks20and21usingacase vscontrolcut-offof<370/7vs>=370/7weeks,withBMI stratification(>22<=37). Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.022 0.667 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.049 0.644 A2GL_DLLLPQPDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 34&135 0.044 0.647 A2GL_DLLLPQPDLR_vs_PSG9_LFIPQITR 34&136 0.043 0.648 AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR 37&99 0.032 0.656 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37&100 0.005 0.703 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.004 0.710 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.026 0.662 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.038 0.651 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.003 0.718 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.000 0.757 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.000 0.775 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.045 0.646 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.025 0.664 AFAM_HFQNLGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 38&135 0.028 0.660 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.044 0.647 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.031 0.657 ANGT_DPTFIPAPIQAK_vs_IBP3_FLNVLSPR 42&99 0.037 0.653 ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK 42&100 0.011 0.686 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.007 0.697 ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 42&135 0.048 0.645 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.038 0.651 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.024 0.665 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.015 0.678 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.029 0.659 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.019 0.672 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.016 0.675 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.029 0.659 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.021 0.669 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.018 0.673 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.013 0.681 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.017 0.675 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.020 0.670 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.031 0.658 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.050 0.643 B2MG_VEHSDLSFSK_vs_CRIS3_AVSPPAR 50&78 0.049 0.644 B2MG_VEHSDLSFSK_vs_CRIS3_YEDLYSNCK 50&79 0.021 0.668 B2MG_VEHSDLSFSK_vs_IBP3_YGQPLPGYTTK 50&100 0.049 0.644 B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR 50&103 0.017 0.675 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.024 0.665 B2MG_VEHSDLSFSK_vs_PGRP2_AGLLRPDYALLGHR 50&126 0.043 0.648 B2MG_VEHSDLSFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 50&135 0.044 0.647 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.037 0.652 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.047 0.645 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.028 0.661 B2MG_VNHVTLSQPK_vs_IBP3_YGQPLPGYTTK 51&100 0.028 0.661 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.008 0.695 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.016 0.676 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR 51&126 0.020 0.670 B2MG_VNHVTLSQPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 51&135 0.028 0.660 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.019 0.671 BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR 52&78 0.033 0.656 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.006 0.700 BGH3_LTLLAPLNSVFK_vs_IBP3_YGQPLPGYTTK 52&100 0.028 0.660 BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR 52&103 0.010 0.688 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.031 0.657 BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLGHR 52&126 0.036 0.653 BGH3_LTLLAPLNSVFK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 52&135 0.028 0.660 BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR 52&141 0.047 0.645 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.041 0.649 C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 55&135 0.040 0.650 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.022 0.667 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.015 0.678 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.006 0.701 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.003 0.714 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.002 0.726 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.001 0.750 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.019 0.672 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.014 0.679 CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK 57&121 0.030 0.659 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.008 0.693 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR 57&129 0.041 0.649 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.031 0.657 CATD_VGFAEAAR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 57&135 0.011 0.686 CATD_VGFAEAAR_vs_PSG9_LFIPQITR 57&136 0.026 0.662 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.026 0.663 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.027 0.662 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.035 0.654 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.005 0.707 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.020 0.670 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.026 0.662 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.013 0.681 CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR 58&66 0.028 0.660 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.009 0.692 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.004 0.712 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.042 0.648 CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR 58&98 0.038 0.651 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.002 0.730 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.001 0.737 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.000 0.762 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.007 0.695 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.010 0.687 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58&121 0.024 0.665 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.002 0.727 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.038 0.651 CATD_VSTLPAITLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 58&135 0.012 0.684 CATD_VSTLPAITLK_vs_PSG9_LFIPQITR 58&136 0.019 0.672 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.007 0.695 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.027 0.662 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.029 0.659 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.002 0.722 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.007 0.697 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.029 0.659 CBPN_EALIQFLEQVHQGIK_vs_IBP3_YGQPLPGYTTK 59&100 0.037 0.652 CBPN_EALIQFLEQVHQGIK_vs_IGF2_GIVEECCFR 59&103 0.028 0.660 CBPN_NNANGVDLNR_vs_CRIS3_YEDLYSNCK 60&79 0.043 0.648 CBPN_NNANGVDLNR_vs_IBP3_FLNVLSPR 60&99 0.032 0.656 CBPN_NNANGVDLNR_vs_IBP3_YGQPLPGYTTK 60&100 0.013 0.681 CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR 60&103 0.006 0.701 CBPN_NNANGVDLNR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 60&135 0.044 0.647 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR 60&18 0.038 0.651 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.033 0.656 CFAB_YGLVTYATYPK_vs_IBP3_FLNVLSPR 64&99 0.032 0.656 CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK 64&100 0.013 0.681 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.010 0.689 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.035 0.654 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.048 0.645 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.049 0.644 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.027 0.662 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.030 0.659 CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK 76&100 0.039 0.651 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.017 0.675 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR 82&40 0.001 0.737 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_C163A_INPASLDK 82&54 0.019 0.672 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CHL1_VIAVNEVGR 82&66 0.013 0.681 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_AVSPPAR 82&78 0.006 0.700 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_YEDLYSNCK 82&79 0.003 0.716 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_AHQLAIDTYQEFEETYIPK 82&80 0.011 0.686 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISLLLIESWLEPVR 82&81 0.012 0.684 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1_TGYYFDGISR 82&86 0.037 0.653 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP2_LIQGAPTIR 82&98 0.008 0.692 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR 82&99 0.001 0.744 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK 82&100 0.000 0.758 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR 82&103 0.000 0.767 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR 82&112 0.001 0.748 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR 82&120 0.001 0.748 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK 82&121 0.010 0.687 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.001 0.742 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2_WNFAYWAAHQPWSR 82&129 0.033 0.656 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_VSAPSGTGHLPGLNPL 82&134 0.015 0.677 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.002 0.726 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR 82&136 0.005 0.703 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.001 0.747 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_NYGLLYCFR 82&138 0.030 0.659 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_SVEGSCGF 82&139 0.005 0.707 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SPRL1_VLTHSELAPLR 82&140 0.007 0.698 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR 82&141 0.005 0.706 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR 82&142 0.013 0.681 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 82&144 0.009 0.691 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_ELPEHTVK 82&147 0.002 0.722 ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR 83&40 0.001 0.733 ENPP2_TYLHTYESEI_vs_C163A_INPASLDK 83&54 0.015 0.678 ENPP2_TYLHTYESEI_vs_CHL1_VIAVNEVGR 83&66 0.018 0.673 ENPP2_TYLHTYESEI_vs_CRIS3_AVSPPAR 83&78 0.009 0.692 ENPP2_TYLHTYESEI_vs_CRIS3_YEDLYSNCK 83&79 0.003 0.716 ENPP2_TYLHTYESEI_vs_CSH_AHQLAIDTYQEFEETYIPK 83&80 0.007 0.695 ENPP2_TYLHTYESEI_vs_CSH_ISLLLIESWLEPVR 83&81 0.010 0.689 ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR 83&98 0.010 0.689 ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR 83&99 0.002 0.728 ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK 83&100 0.000 0.755 ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR 83&103 0.001 0.749 ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR 83&112 0.002 0.727 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.001 0.733 ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK 83&121 0.020 0.670 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.002 0.725 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL 83&134 0.025 0.664 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.004 0.712 ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.008 0.693 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.001 0.747 ENPP2_TYLHTYESEI_vs_SOM2.CSH_NYGLLYCFR 83&138 0.028 0.661 ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF 83&139 0.003 0.716 ENPP2_TYLHTYESEI_vs_SPRL1_VLTHSELAPLR 83&140 0.009 0.691 ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDSFLLR 83&141 0.006 0.702 ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR 83&142 0.013 0.682 ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 83&144 0.011 0.686 ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.005 0.705 FETUA_FSVVYAK_vs_CRIS3_AVSPPAR 88&78 0.025 0.664 FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK 88&79 0.009 0.692 FETUA_FSVVYAK_vs_IBP3_FLNVLSPR 88&99 0.016 0.676 FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK 88&100 0.006 0.700 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.003 0.718 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.024 0.665 FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGHR 88&126 0.047 0.645 FETUA_FSVVYAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 88&135 0.026 0.663 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.040 0.650 FETUA_FSVVYAK_vs_VTDB_ELPEHTVK 88&147 0.049 0.644 FETUA_HTLNQIDEVK_vs_CRIS3_AVSPPAR 89&78 0.037 0.653 FETUA_HTLNQIDEVK_vs_CRIS3_YEDLYSNCK 89&79 0.015 0.678 FETUA_HTLNQIDEVK_vs_IBP3_FLNVLSPR 89&99 0.017 0.675 FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK 89&100 0.007 0.696 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.003 0.715 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.041 0.649 FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 89&135 0.029 0.659 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.029 0.659 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.044 0.647 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.024 0.664 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.018 0.673 HEMO_NFPSPVDAAFR_vs_CRIS3_AVSPPAR 93&78 0.047 0.645 HEMO_NFPSPVDAAFR_vs_CRIS3_YEDLYSNCK 93&79 0.025 0.664 HEMO_NFPSPVDAAFR_vs_IBP3_FLNVLSPR 93&99 0.045 0.646 HEMO_NFPSPVDAAFR_vs_IBP3_YGQPLPGYTTK 93&100 0.030 0.659 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.014 0.679 HEMO_NFPSPVDAAFR_vs_ITIH4_ILDDLSPR 93&112 0.017 0.674 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.048 0.645 HEMO_NFPSPVDAAFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 93&135 0.031 0.658 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.021 0.669 HLACI_WAAVVVPSGEEQR_vs_CRIS3_YEDLYSNCK 95&79 0.047 0.645 HLACI_WAAVVVPSGEEQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 95&135 0.007 0.695 HLACI_WAAVVVPSGEEQR_vs_PSG9_LFIPQITR 95&136 0.011 0.685 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.010 0.689 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.002 0.722 IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR 2&99 0.028 0.661 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.011 0.685 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.004 0.711 IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR 2&112 0.012 0.684 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.005 0.705 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.007 0.697 IBP4_QCHPALDGQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 2&135 0.019 0.672 IBP4_QCHPALDGQR_vs_PSG9_LFIPQITR 2&136 0.036 0.653 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.007 0.696 IBP4_QCHPALDGQR_vs_SOM2.CSH_SVEGSCGF 2&139 0.018 0.673 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.025 0.664 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.038 0.651 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.028 0.660 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.026 0.663 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.012 0.684 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.011 0.685 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.006 0.703 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.001 0.735 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.016 0.675 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.016 0.675 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.016 0.675 INHBC_LDFHFSSDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 107&135 0.019 0.671 INHBC_LDFHFSSDR_vs_PSG9_LFIPQITR 107&136 0.033 0.656 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.013 0.681 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.036 0.653 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.023 0.666 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.025 0.664 ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR 111&78 0.040 0.650 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.032 0.656 ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR 111&103 0.044 0.647 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.036 0.653 ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR 111&126 0.022 0.667 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.017 0.675 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK 116&79 0.023 0.666 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.019 0.672 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.049 0.644 KNG1_DIPTNSPELEETLTHTITK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 116&135 0.033 0.656 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.044 0.647 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.021 0.669 KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR 117&99 0.028 0.661 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.014 0.680 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.007 0.697 KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR 117&112 0.039 0.651 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.017 0.674 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.034 0.655 KNG1_QVVAGLNFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 117&135 0.028 0.660 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.031 0.657 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.018 0.673 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.006 0.700 LBP_ITGFLKPGK_vs_IBP3_FLNVLSPR 118&99 0.039 0.651 LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK 118&100 0.017 0.674 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.006 0.700 LBP_ITGFLKPGK_vs_ITIH4_ILDDLSPR 118&112 0.037 0.652 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.016 0.676 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118&126 0.023 0.666 LBP_ITGFLKPGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 118&135 0.013 0.682 LBP_ITGFLKPGK_vs_PSG9_LFIPQITR 118&136 0.020 0.670 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.014 0.680 LBP_ITGFLKPGK_vs_SOM2.CSH_SVEGSCGF 118&139 0.024 0.664 LBP_ITGFLKPGK_vs_SPRL1_VLTHSELAPLR 118&140 0.044 0.647 LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK 118&147 0.031 0.658 LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR 119&40 0.031 0.657 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.004 0.710 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.002 0.727 LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR 119&98 0.031 0.658 LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR 119&99 0.007 0.698 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.003 0.717 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.001 0.733 LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR 119&112 0.004 0.710 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.003 0.716 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119&121 0.045 0.646 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.002 0.722 LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 119&135 0.005 0.703 LBP_ITLPDFTGDLR_vs_PSG9_LFIPQITR 119&136 0.010 0.689 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.003 0.716 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.011 0.686 LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR 119&140 0.013 0.681 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.014 0.680 LBPITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.044 0.647 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.039 0.651 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.006 0.701 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.022 0.667 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.009 0.690 PEDF_LQSLFDSPDFSK_vs_IBP3_YGQPLPGYTTK 124&100 0.045 0.646 PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR 124&103 0.011 0.686 PEDF_LQSLFDSPDFSK_vs_ITIH4_ILDDLSPR 124&112 0.049 0.644 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.024 0.665 PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR 124&126 0.035 0.654 PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 124&135 0.037 0.653 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.037 0.652 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.041 0.649 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137&103 0.024 0.665 THBG_AVLHIGEK_vs_CRIS3_YEDLYSNCK 143&79 0.050 0.643 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.047 0.645 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.024 0.665 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.011 0.686 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.003 0.718 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.003 0.719 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.017 0.675 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.026 0.663 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.042 0.648 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.028 0.660 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.013 0.681 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.037 0.653 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.037 0.652 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.022 0.667 VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR 150&99 0.015 0.677 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.006 0.699 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.004 0.710 VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR 150&112 0.037 0.653 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.018 0.673 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.044 0.647 VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 150&135 0.021 0.668 VTNC_VDTVDPPYPR_vs_PSG9_LFIPQITR 150&136 0.041 0.649 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.012 0.684 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.028 0.660 83&126
(460) TABLE-US-00041 TABLE41 ReversalClassificationPerformance,weeks20and21. ReversalAUROCforgestationalweeks20and21usingacasevs controlcut-offsof<350/7vs>=350/7weeks,withoutBMI stratification. Reversal SEQIDNO: pval ROC_AUC AFAM_DADPDTFFAK_vs_IBP2_LIQGAPTIR 37&98 0.042 0.703 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.045 0.701 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.036 0.709 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.020 0.732 AFAM_HFQNLGK_vs_IBP2_LIQGAPTIR 38&98 0.024 0.726 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.048 0.698 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.048 0.698 AFAM_HFQNLGK_vs_ITIH4_ILDDLSPR 38&112 0.033 0.714 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.031 0.715 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.017 0.738 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.029 0.719 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.017 0.738 AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF 38&139 0.048 0.698 AFAM_HFQNLGK_vs_SPRL1_VLTHSELAPLR 38&140 0.018 0.737 AFAM_HFQNLGK_vs_VTDB_ELPEHTVK 38&147 0.014 0.746 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.019 0.735 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.045 0.701 B2MG_VEHSDLSFSK_vs_IBP2_LIQGAPTIR 50&98 0.049 0.697 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.029 0.718 B2MG_VNHVTLSQPK_vs_IBP2_LIQGAPTIR 51&98 0.049 0.697 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.031 0.716 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR 51&126 0.035 0.711 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.028 0.720 B2MG_VNHVTLSQPK_vs_SOM2.CSH_SVEGSCGF 51&139 0.049 0.697 B2MG_VNHVTLSQPK_vs_SPRL1_VLTHSELAPLR 51&140 0.046 0.700 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.001 0.828 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.001 0.832 CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR 57&66 0.023 0.728 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.017 0.738 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.018 0.737 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.001 0.824 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.001 0.819 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.001 0.832 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.004 0.791 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.003 0.793 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.012 0.751 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.007 0.768 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.006 0.776 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.003 0.797 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.001 0.832 CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK 57&121 0.010 0.756 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.000 0.859 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR 57&129 0.001 0.822 CATD_VGFAEAAR_vs_PSG1_FQLPGQK 57&131 0.009 0.760 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.001 0.821 CATD_VGFAEAAR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 57&135 0.006 0.777 CATD_VGFAEAAR_vs_PSG9_LFIPQITR 57&136 0.014 0.747 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.003 0.802 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.001 0.823 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.001 0.831 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.000 0.864 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.001 0.819 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.006 0.776 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.005 0.779 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.000 0.855 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.001 0.826 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.012 0.752 CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR 58&66 0.023 0.727 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.029 0.718 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.028 0.720 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.003 0.798 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.003 0.800 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.001 0.838 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.004 0.791 CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR 58&98 0.003 0.797 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.006 0.774 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.006 0.774 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.005 0.779 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.008 0.767 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.002 0.805 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58&121 0.012 0.750 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.001 0.844 CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR 58&129 0.004 0.785 CATD_VSTLPAITLK_vs_PSG1_FQLPGQK 58&131 0.016 0.740 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.001 0.831 CATD_VSTLPAITLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 58&135 0.018 0.736 CATD_VSTLPAITLK_vs_PSG9_LFIPQITR 58&136 0.033 0.714 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.002 0.803 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.003 0.796 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.003 0.796 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.001 0.830 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.001 0.820 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.008 0.767 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.009 0.760 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.001 0.819 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR 59&18 0.008 0.764 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR 60&18 0.016 0.740 CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR 60&140 0.037 0.709 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.034 0.712 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.027 0.721 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.038 0.708 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.029 0.718 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.026 0.722 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.021 0.731 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.045 0.701 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.045 0.701 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.032 0.715 ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR 83&40 0.031 0.715 ENPP2_TYLHTYESEI_vs_IBP1_VVESLAK 83&97 0.047 0.699 ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR 83&98 0.038 0.708 ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR 83&112 0.047 0.699 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.026 0.722 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.020 0.732 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.049 0.697 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.017 0.739 ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF 83&139 0.036 0.710 ENPP2_TYLHTYESEI_vs_SPRL1_VLTHSELAPLR 83&140 0.028 0.720 ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.025 0.725 F13B_GDTYPAELYITGSILR_vs_IBP2_LIQGAPTIR 84&98 0.031 0.715 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.042 0.703 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.040 0.706 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.021 0.731 F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR 84&140 0.042 0.703 FETUA_FSVVYAK_vs_IBP2_LIQGAPTIR 88&98 0.026 0.722 FETUA_FSVVYAK_vs_ITIH4_ILDDLSPR 88&112 0.024 0.726 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.010 0.756 FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGHR 88&126 0.031 0.715 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.043 0.703 FETUA_FSVVYAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 88&135 0.045 0.701 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.021 0.731 FETUA_FSVVYAK_vs_SOM2.CSH_SVEGSCGF 88&139 0.031 0.716 FETUA_FSVVYAK_vs_SPRL1_VLTHSELAPLR 88&140 0.016 0.741 FETUA_FSVVYAK_vs_VTDB_ELPEHTVK 88&147 0.001 0.818 FETUA_HTLNQIDEVK_vs_ALS_IRPHTFTGLSGLR 89&40 0.033 0.713 FETUA_HTLNQIDEVK_vs_IBP2_LIQGAPTIR 89&98 0.018 0.737 FETUA_HTLNQIDEVK_vs_ITIH4_ILDDLSPR 89&112 0.022 0.729 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.012 0.751 FETUA_HTLNQIDEVK_vs_PGRP2_AGLLRPDYALLGHR 89&126 0.028 0.720 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.024 0.726 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.007 0.768 FETUA_HTLNQIDEVK_vs_SPRL1_VLTHSELAPLR 89&140 0.008 0.764 FETUA_HTLNQIDEVK_vs_VTDB_ELPEHTVK 89&147 0.003 0.792 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.038 0.708 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.036 0.709 IBP6_GAQTLYVPNCDHR_vs_TENX_LSQLSVTDVTTSSLR 101&142 0.044 0.702 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.021 0.732 ITIH4_NPLVWVHASPEHVVVTR_vs_ITIH4_ILDDLSPR 113&112 0.022 0.729 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.040 0.706 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.025 0.725 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.006 0.773 KNG1_QVVAGLNFR_vs_VTDB_ELPEHTVK 117&147 0.049 0.697 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.033 0.713 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.035 0.711 PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK 124&147 0.034 0.712 PRDX2_GLFIIDGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 128&135 0.049 0.697 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.035 0.711 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.041 0.704 THBG_AVLHIGEK_vs_VTDB_ELPEHTVK 143&147 0.023 0.728 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.026 0.723 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.032 0.715 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.033 0.714
(461) TABLE-US-00042 TABLE42 ReversalClassificationPerformance,weeks20and21. ReversalAUROCforgestationalweeks20and21usingacasevs controlcut-offof<350/7vs>=350/7weeks,withBMI stratification(>22<=37). Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK 34&97 0.042 0.734 A2GL_DLLLPQPDLR_vs_IBP2_LIQGAPTIR 34&98 0.043 0.732 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.033 0.745 A2GL_DLLLPQPDLR_vs_SOM2.CSH_SVEGSCGF 34&139 0.048 0.727 AFAM_DADPDTFFAK_vs_IBP2_LIQGAPTIR 37&98 0.034 0.743 AFAM_DADPDTFFAK_vs_ITIH4_ILDDLSPR 37&112 0.032 0.747 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.023 0.761 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.032 0.747 AFAM_DADPDTFFAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 37&135 0.043 0.732 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.015 0.779 AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF 37&139 0.039 0.738 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.019 0.769 AFAM_HFQNLGK_vs_IBP1_VVESLAK 38&97 0.042 0.734 AFAM_HFQNLGK_vs_IBP2_LIQGAPTIR 38&98 0.014 0.781 AFAM_HFQNLGK_vs_ITIH4_ILDDLSPR 38&112 0.008 0.807 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.006 0.817 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.010 0.797 AFAM_HFQNLGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 38&135 0.033 0.745 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.006 0.816 AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF 38&139 0.014 0.783 AFAM_HFQNLGK_vs_SPRL1_VLTHSELAPLR 38&140 0.020 0.767 AFAM_HFQNLGK_vs_VTDB_ELPEHTVK 38&147 0.010 0.797 ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 42&135 0.047 0.729 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.012 0.788 APOH_ATVVYQGER_vs_IBP1_VVESLAK 48&97 0.036 0.741 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.033 0.745 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.020 0.767 B2MG_VEHSDLSFSK_vs_IBP2_LIQGAPTIR 50&98 0.042 0.734 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.026 0.756 B2MG_VEHSDLSFSK_vs_SOM2.CSH_SVEGSCGF 50&139 0.040 0.736 B2MG_VEHSDLSFSK_vs_TENX_LSQLSVTDVTTSSLR 50&142 0.030 0.749 B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK 51&97 0.045 0.731 B2MG_VNHVTLSQPK_vs_IBP2_LIQGAPTIR 51&98 0.032 0.747 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.042 0.734 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.019 0.769 B2MG_VNHVTLSQPK_vs_SOM2.CSH_SVEGSCGF 51&139 0.039 0.738 B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR 51&142 0.019 0.769 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.007 0.812 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.001 0.886 CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR 57&66 0.032 0.747 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.019 0.769 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.020 0.767 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.001 0.866 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.001 0.868 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.010 0.796 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.001 0.870 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.001 0.868 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.029 0.750 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.016 0.776 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.030 0.749 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.003 0.837 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.001 0.866 CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK 57&121 0.008 0.807 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.001 0.892 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR 57&129 0.008 0.805 CATD_VGFAEAAR_vs_PSG1_FQLPGQK 57&131 0.013 0.785 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.016 0.778 CATD_VGFAEAAR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 57&135 0.003 0.846 CATD_VGFAEAAR_vs_PSG9_LFIPQITR 57&136 0.009 0.801 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.003 0.841 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.001 0.868 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.001 0.875 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.002 0.848 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.017 0.774 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.014 0.783 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.002 0.848 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.001 0.866 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.003 0.846 CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR 58&66 0.010 0.796 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.013 0.787 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.011 0.794 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.001 0.886 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.001 0.895 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.003 0.843 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.000 0.906 CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR 58&98 0.001 0.882 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.009 0.799 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.010 0.797 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.016 0.778 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.001 0.870 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.001 0.888 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58&121 0.004 0.826 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.000 0.926 CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR 58&129 0.016 0.776 CATD_VSTLPAITLK_vs_PSG1_FQLPGQK 58&131 0.013 0.787 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.006 0.814 CATD_VSTLPAITLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 58&135 0.004 0.830 CATD_VSTLPAITLK_vs_PSG9_LFIPQITR 58&136 0.010 0.797 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.001 0.875 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.001 0.875 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.001 0.886 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.001 0.868 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.005 0.821 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.028 0.752 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.006 0.816 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.002 0.863 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR 59&18 0.014 0.783 CBPN_EALIQFLEQVHQGIK_vs_TENX_LSQLSVTDVTTSSLR 59&142 0.043 0.732 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR 60&18 0.011 0.794 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.048 0.727 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.017 0.774 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.037 0.740 CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK 62&97 0.047 0.729 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.024 0.759 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.036 0.741 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.042 0.734 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.037 0.740 CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTSSLR 67&142 0.018 0.772 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR 68&142 0.008 0.803 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.045 0.731 CO5_TLLPVSKPEIR_vs_TENX_LSQLSVTDVTTSSLR 70&142 0.012 0.790 CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR 71&142 0.026 0.756 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.029 0.750 CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR 72&142 0.007 0.810 CO8B_QALEEFQK_vs_IBP1_VVESLAK 76&97 0.043 0.732 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.033 0.745 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP1_VVESLAK 82&97 0.048 0.727 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP2_LIQGAPTIR 82&98 0.040 0.736 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.043 0.732 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.033 0.745 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.032 0.747 ENPP2_TYLHTYESEI_vs_IBP1_VVESLAK 83&97 0.045 0.731 ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR 83&98 0.039 0.738 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.043 0.732 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.037 0.740 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.020 0.767 ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF 83&139 0.042 0.734 F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK 84&97 0.048 0.727 F13B_GDTYPAELYITGSILR_vs_IBP2_LIQGAPTIR 84&98 0.020 0.767 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.036 0.741 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.047 0.729 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.011 0.794 F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTDVTTSSLR 84&142 0.040 0.736 FBLN3_IPSNPSHR_vs_TENX_LSQLSVTDVTTSSLR 87&142 0.016 0.778 FETUA_FSVVYAK_vs_IBP1_VVESLAK 88&97 0.034 0.743 FETUA_FSVVYAK_vs_IBP2_LIQGAPTIR 88&98 0.017 0.774 FETUA_FSVVYAK_vs_ITIH4_ILDDLSPR 88&112 0.012 0.790 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.007 0.808 FETUA_FSVVYAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 88&135 0.021 0.765 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.013 0.787 FETUA_FSVVYAK_vs_SOM2.CSH_SVEGSCGF 88&139 0.023 0.761 FETUA_FSVVYAK_vs_VTDB_ELPEHTVK 88&147 0.010 0.797 FETUA_HTLNQIDEVK_vs_IBP1_VVESLAK 89&97 0.036 0.741 FETUA_HTLNQIDEVK_vs_IBP2_LIQGAPTIR 89&98 0.009 0.801 FETUA_HTLNQIDEVK_vs_ITIH4_ILDDLSPR 89&112 0.003 0.837 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.005 0.823 FETUA_HTLNQIDEVK_vs_PGRP2_AGLLRPDYALLGHR 89&126 0.016 0.778 FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 89&135 0.026 0.756 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.003 0.844 FETUA_HTLNQIDEVK_vs_SOM2.CSH_SVEGSCGF 89&139 0.021 0.765 FETUA_HTLNQIDEVK_vs_SPRL1_VLTHSELAPLR 89&140 0.019 0.769 FETUA_HTLNQIDEVK_vs_VTDB_ELPEHTVK 89&147 0.004 0.830 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.021 0.765 HEMO_NFPSPVDAAFR_vs_TENX_LSQLSVTDVTTSSLR 93&142 0.023 0.761 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.023 0.761 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.018 0.772 IBP6_GAQTLYVPNCDHR_vs_TENX_LSQLSVTDVTTSSLR 101&142 0.008 0.805 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR 102&18 0.042 0.734 IBP6_HLDSVLQQLQTEVYR_vs_TENX_LSQLSVTDVTTSSLR 102&142 0.006 0.816 ITIH3_ALDLSLK_vs_IBP1_VVESLAK 111&97 0.032 0.747 ITIH3_ALDLSLK_vs_IBP2_LIQGAPTIR 111&98 0.019 0.770 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.006 0.816 ITIH4_NPLVWVHASPEHVVVTR_vs_ALS_IRPHTFTGLSGLR 113&40 0.028 0.753 ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_AHQLAIDTYQEFEETYIPK 113&80 0.043 0.733 ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR 113&86 0.019 0.769 ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_FLNVLSPR 113&99 0.009 0.799 ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_YGQPLPGYTTK 113&100 0.023 0.762 ITIH4_NPLVWVHASPEHVVVTR_vs_IGF2_GIVEECCFR 113&103 0.010 0.795 ITIH4_NPLVWVHASPEHVVVTR_vs_ITIH4_ILDDLSPR 113&112 0.048 0.727 ITIH4_NPLVWVHASPEHVVVTR_vs_NCAM1_GLGEISAASEFK 113&121 0.033 0.745 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.010 0.797 ITIH4_NPLVWVHASPEHVVVTR_vs_SOM2.CSH_NYGLLYCFR 113&138 0.036 0.742 ITIH4_NPLVWVHASPEHVVVTR_vs_SPRL1_VLTHSELAPLR 113&140 0.038 0.738 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR 113&141 0.021 0.766 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR 113&142 0.003 0.842 ITIH4_NPLVWVHASPEHVVVTR_vs_VTDB_ELPEHTVK 113&147 0.021 0.766 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TENX_LSQLSVTDVTTSSLR 114&142 0.037 0.740 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR 116&142 0.020 0.767 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.028 0.752 KNG1_QVVAGLNFR_vs_TENX_LSQLSVTDVTTSSLR 117&142 0.021 0.765 LBP_ITGFLKPGK_vs_TENX_LSQLSVTDVTTSSLR 118&142 0.018 0.772 PAPP1_DIPHWLNPTR_vs_IBP1_VVESLAK 122&97 0.037 0.740 PAPP1_DIPHWLNPTR_vs_IBP2_LIQGAPTIR 122&98 0.023 0.761 PAPP1_DIPHWLNPTR_vs_PGRP2_AGLLRPDYALLGHR 122&126 0.037 0.740 PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR 122&18 0.033 0.745 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF 122&139 0.010 0.797 PEDF_LQSLFDSPDFSK_vs_IBP1_VVESLAK 124&97 0.036 0.741 PEDF_LQSLFDSPDFSK_vs_IBP2_LIQGAPTIR 124&98 0.040 0.736 PEDF_LQSLFDSPDFSK_vs_ITIH4_ILDDLSPR 124&112 0.025 0.758 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.028 0.752 PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR 124&126 0.048 0.727 PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 124&135 0.045 0.731 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.011 0.794 PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK 124&147 0.030 0.749 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR 125&18 0.024 0.759 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.020 0.767 PSG11_LFIPQITPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 132&135 0.026 0.756 PSG11_LFIPQITPK_vs_SOM2.CSH_SVEGSCGF 132&139 0.028 0.752 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.030 0.749 PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF 137&139 0.042 0.734 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.040 0.736 THBG_AVLHIGEK_vs_TENX_LSQLSVTDVTTSSLR 143&142 0.025 0.758 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.026 0.756 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.029 0.750 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.010 0.797 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.018 0.772
(462) TABLE-US-00043 TABLE43 ReversalClassificationPerformance,weeks17through21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevs controlcut-offof<370/7vs>=370/7weeks,without BMIstratification. Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.002 0.609 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.002 0.610 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.001 0.614 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.003 0.605 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.001 0.620 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.003 0.608 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.001 0.622 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.001 0.623 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.001 0.618 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.001 0.618 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.001 0.623 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.001 0.624 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.002 0.610 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.001 0.618 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.004 0.602 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.000 0.633 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.000 0.632 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.000 0.640 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.001 0.623 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.000 0.633 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.001 0.618 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.000 0.630 APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR 47&129 0.001 0.622 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47&131 0.004 0.603 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.000 0.644 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.003 0.607 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.004 0.601 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.000 0.630 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.003 0.605 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.001 0.616 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.002 0.609 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.000 0.631 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.001 0.624 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.000 0.628 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.000 0.627 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.002 0.613 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.002 0.612 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.003 0.606 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.003 0.607 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL 51&134 0.004 0.603 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.002 0.609 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.002 0.613 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.005 0.601 C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR 55&129 0.005 0.601 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.003 0.605 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.001 0.616 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.003 0.605 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.002 0.612 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.005 0.600 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.003 0.606 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.003 0.606 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.005 0.600 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.005 0.601 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.004 0.604 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.003 0.605 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.003 0.605 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.004 0.602 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.004 0.604 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.002 0.609 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.004 0.602 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.002 0.608 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.001 0.623 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.004 0.603 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.003 0.608 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.000 0.632 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.001 0.621 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.002 0.611 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.001 0.613 CFAB_YGLVTYATYPK_vs_VTDB_ELPEHTVK 64&147 0.004 0.601 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.004 0.603 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.001 0.618 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.002 0.610 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.004 0.602 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.001 0.614 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.002 0.612 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.004 0.602 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.004 0.603 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.001 0.617 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.002 0.613 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.002 0.608 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.002 0.612 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.001 0.620 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.001 0.619 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.003 0.606 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.001 0.616 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.003 0.606 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_VSAPSGTGHLPGLNPL 82&134 0.003 0.604 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.001 0.617 ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR 83&103 0.004 0.602 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.004 0.602 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL 83&134 0.004 0.602 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.002 0.611 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.003 0.605 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.000 0.629 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.001 0.617 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.004 0.604 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR 88&141 0.003 0.607 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.002 0.610 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.002 0.612 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.004 0.603 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.002 0.612 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.003 0.607 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.000 0.628 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.001 0.623 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.003 0.607 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.001 0.617 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.004 0.601 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.005 0.600 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.001 0.614 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.004 0.601 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.002 0.610 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.004 0.601 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.000 0.626 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.003 0.606 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.000 0.625 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.000 0.644 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.000 0.635 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.001 0.619 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.002 0.613 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.001 0.614 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.001 0.617 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.000 0.637 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.005 0.600 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.004 0.601 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.001 0.621 INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQPWSR 107&129 0.003 0.605 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.000 0.636 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.001 0.617 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.000 0.627 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.002 0.610 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.003 0.606 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.001 0.613 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.000 0.625 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.002 0.609 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.004 0.601 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.005 0.601 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.004 0.602 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.003 0.606 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.002 0.612 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.003 0.607 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118&126 0.003 0.605 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.000 0.638 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.001 0.621 LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR 118&141 0.005 0.600 LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK 118&147 0.004 0.601 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.002 0.608 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.001 0.619 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.001 0.615 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.001 0.620 LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 119&80 0.004 0.603 LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR 119&99 0.003 0.604 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.002 0.610 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.000 0.629 LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR 119&112 0.002 0.608 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.000 0.625 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119&121 0.003 0.606 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.001 0.622 LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR 119&129 0.002 0.611 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.000 0.651 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.000 0.636 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.003 0.608 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.001 0.619 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.003 0.606 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.002 0.610 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.000 0.626 PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR 124&103 0.004 0.602 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.005 0.601 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.001 0.617 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.004 0.603 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.001 0.614 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.004 0.602 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.003 0.608 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.002 0.613 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.002 0.610 VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR 149&40 0.005 0.600 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.002 0.613 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.002 0.609 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.001 0.618 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.000 0.636 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.004 0.603 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.001 0.617 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.001 0.621 VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQPWSR 149&129 0.003 0.608 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.000 0.646 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.000 0.640 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.001 0.619 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.004 0.604 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.002 0.609 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.000 0.630 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.001 0.615 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.003 0.606 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.000 0.631 VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR 150&112 0.004 0.604 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.001 0.622 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.005 0.601 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.001 0.617 VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQPWSR 150&129 0.004 0.603 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.000 0.642 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.000 0.632 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.001 0.616 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.000 0.642
(463) TABLE-US-00044 TABLE44 ReversalClassificationPerformance,weeks17through21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevs controlcut-offof<370/7vs>=370/7weeks,with BMIstratification(>22<=37). Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR 34&78 0.016 0.604 A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.008 0.613 A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.006 0.617 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.003 0.629 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.011 0.609 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.009 0.612 AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR 37&99 0.014 0.605 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37&100 0.004 0.623 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.002 0.636 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.020 0.600 AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR 38&66 0.018 0.602 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.005 0.619 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.002 0.635 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.001 0.637 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.011 0.609 ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR 42&66 0.015 0.605 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.007 0.615 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.006 0.618 ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK 42&100 0.019 0.601 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.008 0.614 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.009 0.612 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.016 0.604 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.012 0.608 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.003 0.626 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.013 0.607 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.012 0.607 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.010 0.610 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.003 0.628 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.003 0.627 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.002 0.632 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.004 0.625 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.005 0.621 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.003 0.628 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.016 0.603 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.002 0.630 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.006 0.617 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.005 0.621 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.008 0.613 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.019 0.601 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.008 0.613 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.016 0.604 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.009 0.613 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.009 0.611 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.011 0.609 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.009 0.613 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.008 0.613 B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR 50&103 0.016 0.603 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.008 0.614 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.016 0.603 BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR 52&66 0.017 0.602 BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR 52&78 0.017 0.603 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.007 0.616 BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR 52&103 0.013 0.607 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.008 0.614 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR 52&18 0.019 0.601 BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR 52&141 0.013 0.606 C1QB_VPGLYYFTYHASSR_vs_CRIS3_YEDLYSNCK 55&79 0.018 0.602 C1QB_VPGLYYFTYHASSR_vs_IBP3_FLNVLSPR 55&99 0.012 0.608 C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK 55&100 0.010 0.610 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.002 0.630 C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR 55&120 0.010 0.611 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.006 0.618 C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 55&135 0.015 0.605 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.006 0.617 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.013 0.607 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.018 0.601 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.007 0.615 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR 59&18 0.013 0.606 CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR 60&103 0.015 0.604 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.014 0.606 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.017 0.603 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.012 0.607 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.015 0.605 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.013 0.606 CFAB_YGLVTYATYPK_vs_CRIS3_AVSPPAR 64&78 0.018 0.601 CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK 64&79 0.010 0.611 CFAB_YGLVTYATYPK_vs_IBP3_FLNVLSPR 64&99 0.016 0.603 CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK 64&100 0.010 0.610 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.003 0.628 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.004 0.623 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.012 0.608 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.006 0.619 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.009 0.613 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.019 0.600 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.005 0.620 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.019 0.601 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.014 0.605 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.016 0.603 CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR 70&78 0.015 0.604 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.009 0.612 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.008 0.614 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.004 0.625 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.009 0.611 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.007 0.616 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.008 0.613 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.019 0.601 CO5_VFQFLEK_vs_CRIS3_AVSPPAR 71&78 0.019 0.601 CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK 71&79 0.013 0.607 CO5_VFQFLEK_vs_IGF2_GIVEECCFR 71&103 0.014 0.606 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.005 0.619 CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR 71&126 0.013 0.607 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.016 0.604 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.010 0.610 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.019 0.601 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.017 0.602 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.009 0.612 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.011 0.609 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.017 0.602 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.008 0.613 COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.018 0.602 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.016 0.603 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.006 0.617 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.010 0.610 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR 82&103 0.018 0.601 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR 82&120 0.005 0.620 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.005 0.622 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.013 0.607 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.015 0.605 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.009 0.613 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.004 0.624 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.012 0.608 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.014 0.605 HABP2_FLNWIK_vs_IBP3_FLNVLSPR 92&99 0.010 0.610 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.006 0.618 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.001 0.636 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.012 0.608 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.018 0.602 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.012 0.608 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.013 0.607 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.005 0.621 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.002 0.635 IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR 2&99 0.009 0.611 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.003 0.626 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.001 0.646 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.001 0.640 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.001 0.637 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.005 0.622 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.002 0.634 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.008 0.614 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.007 0.615 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.017 0.603 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.008 0.614 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.007 0.616 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.015 0.604 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.008 0.614 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.002 0.634 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.001 0.639 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.001 0.649 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.016 0.603 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.008 0.613 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.005 0.620 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.002 0.635 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.006 0.619 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.006 0.617 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.001 0.637 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.008 0.614 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.010 0.610 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.003 0.627 ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR 111&78 0.013 0.607 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.009 0.611 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.008 0.615 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.004 0.623 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.013 0.606 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.014 0.605 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.013 0.607 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.019 0.600 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.012 0.608 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.011 0.609 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.019 0.600 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.015 0.604 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.011 0.609 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.004 0.624 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.002 0.630 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.013 0.606 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.005 0.621 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.002 0.635 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.004 0.622 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.006 0.617 LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 119&135 0.017 0.603 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.004 0.624 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.015 0.605 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.017 0.603 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.012 0.608 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.007 0.616 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.004 0.623 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.005 0.621 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.011 0.610 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.010 0.610 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.018 0.602 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.009 0.612 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.016 0.603 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.018 0.602 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.015 0.604 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.014 0.605 VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR 149&40 0.013 0.607 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.005 0.621 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.005 0.621 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.003 0.627 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.002 0.630 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.001 0.647 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.000 0.653 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.011 0.609 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.000 0.650 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.015 0.604 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.002 0.635 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.001 0.640 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.011 0.609 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.001 0.640 VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF 149&139 0.020 0.600 VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR 149&140 0.013 0.607 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.005 0.620 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.004 0.624 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.001 0.646 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.007 0.616 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.004 0.624 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.003 0.629 VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR 150&99 0.006 0.618 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.002 0.630 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.001 0.641 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.000 0.653 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.013 0.607 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.004 0.624 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.002 0.630 VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 150&135 0.012 0.608 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.002 0.633 VTNC_VDTVDPPYPR_vs_SPRL1_VLTHSELAPLR 150&140 0.018 0.601 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.009 0.612 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.012 0.608 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.001 0.648
(464) TABLE-US-00045 TABLE45 ReversalClassificationPerformance,weeks17through21. ReversalAUROCforgestationalweeks170/7through216/7 usingacasevscontrolcut-offof<350/7vs>=350/7 weeks,withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK 34&97 0.046 0.615 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.023 0.631 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.013 0.642 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.012 0.644 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.041 0.618 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.050 0.613 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.035 0.621 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.036 0.621 AFAM_HFQNLGK_vs_IBP1_VVESLAK 38&97 0.044 0.618 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.048 0.614 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.013 0.642 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.005 0.661 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.010 0.648 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.041 0.617 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.010 0.648 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.027 0.627 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.042 0.617 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.015 0.639 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.027 0.627 APOH_ATVVYQGER_vs_IBP1_VVESLAK 48&97 0.046 0.615 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.011 0.647 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.045 0.615 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.009 0.651 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.040 0.618 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.024 0.630 B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK 51&97 0.047 0.614 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.040 0.618 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.002 0.676 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.032 0.624 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.022 0.632 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.001 0.697 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.013 0.643 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.008 0.653 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.005 0.661 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.009 0.651 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.018 0.636 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.010 0.648 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.050 0.613 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.026 0.628 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.019 0.635 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.003 0.669 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.020 0.634 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.001 0.688 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.009 0.650 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.008 0.652 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.012 0.644 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.010 0.649 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.007 0.655 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.009 0.650 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.004 0.666 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.013 0.643 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.014 0.642 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.023 0.631 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.020 0.634 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.004 0.664 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.012 0.645 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.006 0.657 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.013 0.644 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.023 0.631 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.017 0.638 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.012 0.645 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.017 0.637 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.013 0.643 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.003 0.670 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.045 0.615 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.001 0.684 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.010 0.649 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.006 0.658 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.012 0.644 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.023 0.631 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.020 0.634 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.015 0.640 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.004 0.666 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.015 0.640 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.026 0.628 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.037 0.620 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.020 0.634 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.007 0.656 CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR 60&140 0.026 0.628 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.028 0.627 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.044 0.616 CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK 61&97 0.019 0.635 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.015 0.640 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.002 0.681 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.009 0.650 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.045 0.615 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.011 0.647 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.033 0.623 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.034 0.622 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.020 0.633 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.011 0.647 CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK 62&79 0.033 0.623 CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK 62&97 0.021 0.633 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.025 0.629 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.003 0.669 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.015 0.640 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.017 0.638 CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF 62&139 0.041 0.618 CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR 62&140 0.049 0.613 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.024 0.630 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.014 0.641 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.044 0.616 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.028 0.627 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.016 0.638 CLUS_ASSIIDELFQDR_vs_IBP1_VVESLAK 67&97 0.039 0.619 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.047 0.614 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.011 0.645 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.001 0.683 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.026 0.628 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.037 0.620 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.017 0.638 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.013 0.643 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.028 0.627 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.014 0.642 CLUS_LFDSDPITVTVPVEVSR_vs_IBP1_VVESLAK 68&97 0.039 0.619 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK 68&100 0.046 0.615 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.015 0.640 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.004 0.668 CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR 68&126 0.049 0.613 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR 68&18 0.023 0.631 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.014 0.642 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.036 0.620 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.005 0.663 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.043 0.616 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.015 0.641 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.006 0.657 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.039 0.619 CO8A_SLLQPNK_vs_IBP1_VVESLAK 74&97 0.046 0.615 COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.047 0.614 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.007 0.654 CO8B_QALEEFQK_vs_IBP1_VVESLAK 76&97 0.036 0.621 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.046 0.615 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.018 0.636 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.046 0.615 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.021 0.633 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.013 0.643 F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK 84&97 0.033 0.623 F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK 84&100 0.039 0.619 F13B_GDTYPAELYITGSILR_VS_IGF2_GIVEECCFR 84&103 0.011 0.646 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.001 0.695 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.031 0.624 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.020 0.634 F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR 84&140 0.031 0.624 FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK 88&79 0.045 0.615 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.007 0.654 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.016 0.638 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.033 0.623 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.019 0.635 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.021 0.632 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.011 0.647 IBP4_QCHPALDGQR_vs_IBP1_VVESLAK 2&97 0.042 0.617 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.047 0.614 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.003 0.669 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.033 0.623 IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK 102&79 0.044 0.616 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.022 0.631 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.039 0.619 KNG1_DIPTNSPELEETLTHTITK_vs_IBP1_VVESLAK 116&97 0.048 0.614 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.012 0.645 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.041 0.618 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.020 0.634 KNG1_QVVAGLNFR_vs_IBP1_VVESLAK 117&97 0.024 0.630 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.020 0.634 KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR 117&112 0.038 0.619 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.002 0.682 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.027 0.627 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.016 0.639 KNG1_QVVAGLNFR_vs_VTDB_ELPEHTVK 117&147 0.041 0.618 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.031 0.624 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.034 0.622 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.026 0.628 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.004 0.664 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.027 0.627 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.017 0.638 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.029 0.626 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.002 0.677 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.015 0.640 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.011 0.646 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.020 0.634 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.027 0.627 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.028 0.626 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.042 0.617 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.006 0.658 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.025 0.629 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.014 0.642 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.036 0.621 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.036 0.621 PTGDS_GPGEDFR_vs_IBP1_VVESLAK 137&97 0.050 0.613 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.018 0.636 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.015 0.640 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.033 0.622 VTNC_GQYCYELDEK_vs_IBP1_VVESLAK 149&97 0.048 0.614 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.029 0.625 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.002 0.675 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.044 0.616 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.032 0.623 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.030 0.625 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.040 0.618 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.049 0.613 VTNC_VDTVDPPYPR_VS_LYAM1_SYYWIGIR 150&120 0.004 0.665 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.038 0.619
(465) TABLE-US-00046 TABLE46 ReversalClassificationPerformance,weeks17through21. ReversalAUROCforgestationalweeks170/7through216/7 usingacasevscontrolcut-offof<350/7vs>=350/7weeks, withBMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.047 0.637 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.006 0.689 AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK 37&79 0.027 0.652 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.018 0.663 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.007 0.687 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.016 0.666 AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF 37&139 0.049 0.636 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.035 0.645 AFAM_HFQNLGK_vs_CRIS3_AVSPPAR 38&78 0.043 0.640 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.020 0.660 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.039 0.642 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.031 0.648 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.009 0.680 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.005 0.693 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.013 0.672 AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF 38&139 0.026 0.653 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.035 0.645 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.031 0.648 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.004 0.697 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.029 0.650 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.028 0.651 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.049 0.636 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.029 0.650 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.016 0.667 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.016 0.665 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.015 0.668 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.044 0.639 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.031 0.649 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.002 0.709 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.031 0.649 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.001 0.722 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.018 0.664 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.010 0.677 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.008 0.682 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.011 0.676 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.027 0.652 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.036 0.644 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.009 0.679 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.034 0.646 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.001 0.720 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.009 0.680 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.029 0.651 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.016 0.666 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.011 0.675 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.045 0.638 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.028 0.652 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.017 0.664 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.004 0.698 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.009 0.681 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.004 0.698 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.011 0.676 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.020 0.661 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.039 0.642 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.012 0.673 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.019 0.661 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.005 0.693 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.033 0.647 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.001 0.727 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.004 0.700 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.030 0.649 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.019 0.662 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.025 0.654 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.018 0.663 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.014 0.669 CBPN_EALIQFLEQVHQGIK_VS_LYAM1_SYYWIGIR 59&120 0.019 0.662 CBPN_NNANGVDLNR_vs_CRIS3_YEDLYSNCK 60&79 0.047 0.637 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.006 0.689 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR 61&78 0.046 0.637 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.030 0.650 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.003 0.708 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.009 0.679 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.033 0.647 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.044 0.639 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.009 0.679 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.022 0.657 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.038 0.643 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.029 0.651 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.018 0.663 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.003 0.703 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.035 0.645 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.027 0.652 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.021 0.659 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.047 0.637 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.006 0.688 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.024 0.655 CO6_ALNHLPLEYNSALYSR_VS_LYAM1_SYYWIGIR 72&120 0.006 0.689 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.026 0.653 COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.012 0.674 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.036 0.644 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.016 0.665 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.012 0.672 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.035 0.646 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.001 0.729 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.015 0.668 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.031 0.649 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.013 0.671 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.011 0.674 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.026 0.653 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.035 0.645 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.017 0.664 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.003 0.706 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.046 0.638 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.017 0.664 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.028 0.652 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.049 0.636 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.011 0.675 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.034 0.646 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.020 0.661 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.035 0.645 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.002 0.714 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.025 0.654 PAPP1_DIPHWLNPTR_vs_C163A_INPASLDK 122&54 0.050 0.635 PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.014 0.669 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.011 0.675 PAPP1_DIPHWLNPTR_vs_CSH_AHQLAIDTYQEFEETYIPK 122&80 0.044 0.639 PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPVR 122&81 0.040 0.642 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.006 0.689 PAPP1_DIPHWLNPTR_vs_PGRP2_AGLLRPDYALLGHR 122&126 0.039 0.642 PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR 122&129 0.008 0.681 PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR 122&18 0.039 0.643 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYCFR 122&138 0.039 0.642 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF 122&139 0.005 0.693 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.047 0.637 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.005 0.693 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.042 0.640 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.027 0.653 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.003 0.705 PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR 125&126 0.030 0.649 PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR 133&40 0.030 0.649 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.004 0.700 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.004 0.700 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.032 0.648 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.047 0.637 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.040 0.641 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.040 0.641 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.009 0.681 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.028 0.652 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.029 0.650 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.017 0.664 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133&112 0.016 0.666 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.001 0.729 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.007 0.686 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.014 0.669 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.004 0.700 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.013 0.671 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.028 0.652 PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 133&144 0.049 0.635 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133&147 0.021 0.659 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.042 0.640 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.030 0.650 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.011 0.676 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.024 0.655 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.041 0.641 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.023 0.657 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.001 0.719 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.021 0.659 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.047 0.637 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.047 0.637 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.007 0.685
(466) TABLE-US-00047 TABLE47 ReversalClassificationPerformance,weeks17,18and19. ReversalAUROCforgestationalweeks170/7through196/7 usingacasevscontrolcut-offof<370/7vs>=370/7weeks, withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.003 0.628 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.021 0.600 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.007 0.617 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.016 0.606 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.012 0.609 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.017 0.605 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.011 0.610 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.017 0.605 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.006 0.621 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.009 0.614 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.013 0.608 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.017 0.604 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.013 0.608 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.015 0.606 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.020 0.602 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.002 0.633 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.022 0.600 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.009 0.614 APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR 48&66 0.021 0.600 APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK 48&80 0.009 0.614 APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR 48&86 0.011 0.610 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.014 0.607 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.008 0.616 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.000 0.654 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.010 0.612 APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 48&144 0.010 0.613 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48&147 0.021 0.601 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL 51&134 0.010 0.613 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.009 0.613 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.010 0.613 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.013 0.608 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&138 0.021 0.600 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.021 0.600 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.004 0.624 CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK 62&80 0.020 0.601 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.004 0.625 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.020 0.602 CFAB_YGLVTYATYPK_vs_C163A_INPASLDK 64&54 0.007 0.617 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.011 0.611 CFAB_YGLVTYATYPK_vs_CSH_AHQLAIDTYQEFEETYIPK 64&80 0.010 0.612 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.014 0.607 CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK 64&121 0.009 0.614 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.001 0.645 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.008 0.615 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.001 0.639 CFAB_YGLVTYATYPK_vs_VTDB_ELPEHTVK 64&147 0.016 0.605 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.006 0.619 CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL 68&134 0.013 0.608 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.001 0.641 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.020 0.602 CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 70&144 0.011 0.610 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.003 0.629 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.018 0.604 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.009 0.614 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.020 0.601 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.014 0.607 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.002 0.634 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.004 0.626 COSA_SLLQPNK_vs_CSH_AHQLAIDTYQEFEETYIPK 74&80 0.017 0.605 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.002 0.632 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.004 0.625 CO8B_QALEEFQK_vs_CSH_AHQLAIDTYQEFEETYIPK 76&80 0.012 0.609 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.003 0.631 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.003 0.628 F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR 84&66 0.020 0.601 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.004 0.625 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.010 0.612 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.016 0.605 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.019 0.602 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.021 0.601 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.012 0.609 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.001 0.640 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.017 0.604 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.005 0.622 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.021 0.601 IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFE 2&80 0.017 0.604 IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR 2&86 0.017 0.604 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.014 0.607 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.000 0.660 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.011 0.612 IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL 101&134 0.008 0.616 IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL 102&134 0.006 0.621 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.015 0.606 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.003 0.631 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.019 0.602 ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL 111&134 0.018 0.603 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.020 0.602 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.004 0.627 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.017 0.604 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.003 0.631 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.012 0.609 LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 119&80 0.019 0.602 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.001 0.640 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.013 0.608 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.021 0.602 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.002 0.633 PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK 125&80 0.020 0.601 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.002 0.636 PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 125&144 0.018 0.603 PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL 137&134 0.012 0.609 THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL 143&134 0.021 0.601 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.013 0.608 VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK 149&80 0.012 0.609 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.010 0.612 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.016 0.605 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.011 0.611 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.009 0.613 VTNC_GQYCYELDEK_VS_NCAM1_GLGEISAASEFK 149&121 0.010 0.612 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.008 0.616 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.000 0.658 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.004 0.625 VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF 149&139 0.019 0.603 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.002 0.633 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.012 0.610 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.018 0.603 VTNC_VDTVDPPYPR_vs_CSH_AHQLAIDTYQEFEETYIPK 150&80 0.015 0.606 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.018 0.604 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.010 0.613 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.011 0.610 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.021 0.601 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.000 0.656 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.010 0.612 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.007 0.618 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.007 0.617
(467) TABLE-US-00048 TABLE48 ReversalClassificationPerformance,weeks17,18and19. ReversalAUROCforgestationalweeks170/7through196/7 usingacasevscontrolcut-offof<370/7vs>=370/7weeks, withBMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.030 0.616 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.046 0.607 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.030 0.616 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.020 0.624 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.024 0.621 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.022 0.622 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.040 0.610 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.016 0.630 ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 42&144 0.034 0.613 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.007 0.643 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.044 0.607 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.039 0.610 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.045 0.607 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.047 0.606 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.023 0.621 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.050 0.605 APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR 48&66 0.047 0.606 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.043 0.608 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.026 0.619 C1QB_VPGLYYFTYHASSR_vs_C163A_INPASLDK 55&54 0.048 0.605 C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR 55&66 0.033 0.614 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.026 0.619 C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK 55&100 0.049 0.605 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.021 0.623 C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR 55&120 0.024 0.621 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.020 0.624 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.022 0.622 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.017 0.627 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&138 0.040 0.610 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF 55&139 0.040 0.611 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.046 0.606 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.038 0.611 C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 55&144 0.033 0.614 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.044 0.607 CFAB_YGLVTYATYPK_vs_C163A_INPASLDK 64&54 0.008 0.642 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.030 0.616 CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK 64&121 0.022 0.622 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.014 0.631 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.007 0.643 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.048 0.605 CO5_TLLPVSKPEIR_vs_CHL1_VIAVNEVGR 70&66 0.019 0.625 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.014 0.632 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.039 0.610 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.006 0.647 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.037 0.611 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.040 0.609 CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 70&144 0.012 0.635 CO5_TLLPVSKPEIR_vs_VTDB_ELPEHTVK 70&147 0.047 0.606 CO5_VFQFLEK_vs_CHL1_VIAVNEVGR 71&66 0.036 0.612 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.021 0.623 CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR 71&126 0.035 0.612 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.016 0.628 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.034 0.613 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.036 0.612 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.012 0.634 CO6_ALNHLPLEYNSALYSR_vs_C163A_INPASLDK 72&54 0.043 0.608 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.014 0.631 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.043 0.608 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.026 0.619 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.012 0.634 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.022 0.622 CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR 72&142 0.036 0.612 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.004 0.654 CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR 74&66 0.049 0.605 COSA_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.025 0.619 COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.011 0.635 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.032 0.614 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.041 0.609 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.012 0.634 F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR 84&66 0.021 0.623 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.042 0.609 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.040 0.609 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.027 0.618 HABP2_FLNWIK_vs_C163A_INPASLDK 92&54 0.028 0.617 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.017 0.628 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.023 0.622 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.033 0.614 HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK 92&121 0.036 0.612 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.008 0.642 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.044 0.608 HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF 92&139 0.034 0.615 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.009 0.639 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.021 0.623 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.038 0.611 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.039 0.610 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.012 0.633 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.044 0.607 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.037 0.611 INHBC_LDFHFSSDR_vs_C163A_INPASLDK 107&54 0.025 0.620 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.016 0.629 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.030 0.616 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.049 0.605 PEDF_LQSLFDSPDFSK_vs_C163A_INPASLDK 124&54 0.047 0.606 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.037 0.611 PEDF_TVQAVLTVPK_vs_C163A_INPASLDK 125&54 0.021 0.623 PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR 125&66 0.026 0.619 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.038 0.611 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.018 0.627 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.041 0.609 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.042 0.608 PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 125&144 0.028 0.617 PRDX2_GLFIIDGK_vs_C163A_INPASLDK 128&54 0.039 0.610 PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL 128&134 0.047 0.606 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.034 0.613 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.048 0.606 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.045 0.607 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.049 0.605 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.031 0.615 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.024 0.620 PSG2_IHPSYTNYR_vs_PSG1_FQLPGQK 133&131 0.047 0.606 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.028 0.617 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.026 0.619 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.043 0.609 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.037 0.611 VTNC_GQYCYELDEK_vs_C163A_INPASLDK 149&54 0.007 0.643 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.011 0.635 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.035 0.612 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.042 0.609 VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK 149&80 0.040 0.609 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.046 0.606 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.039 0.610 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.035 0.612 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.009 0.640 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.039 0.610 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.017 0.627 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.004 0.652 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.021 0.623 VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF 149&139 0.028 0.618 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.042 0.609 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.003 0.658 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.013 0.632 VTNC_VDTVDPPYPR_vs_C163A_INPASLDK 150&54 0.019 0.625 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.022 0.622 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.047 0.606 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.008 0.640 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.037 0.611 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.044 0.607 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.005 0.648 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.036 0.612 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.010 0.637 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.013 0.633
(468) TABLE-US-00049 TABLE49 ReversalClassificationPerformance,weeks17,18and19. ReversalAUROCforgestationalweeks170/7through196/7 usingacasevscontrolcut-offof<350/7vs>=350/7weeks, withoutBMIstratification. SEQID Reversal NO: pval ROC_AUC AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.036 0.648 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.046 0.641 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.025 0.658 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.038 0.646 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.049 0.639 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.043 0.643 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.039 0.646 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.034 0.650 BGH3_LTLLAPLNSVFK_vs_PSG9_LFIPQITR 52&136 0.049 0.639 CBPN_EALIQFLEQVHQGIK_vs_PSG9_LFIPQITR 59&136 0.047 0.640 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.039 0.646 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.015 0.672 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.014 0.674 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.021 0.663 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.031 0.653 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.038 0.647 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.036 0.648 CLUS_ASSIIDELFQDR_vs_ALS_IRPHTFTGLSGLR 67&40 0.043 0.643 CLUS_ASSIIDELFQDR_vs_C163A_INPASLDK 67&54 0.041 0.644 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.034 0.650 CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR 67&99 0.014 0.674 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.010 0.681 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.001 0.732 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.004 0.702 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.034 0.650 CLUS_LFDSDPITVTVPVEVSR_vs_ALS_IRPHTFTGLSGLR 68&40 0.039 0.645 CLUS_LFDSDPITVTVPVEVSR_vs_C163A_INPASLDK 68&54 0.037 0.647 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.027 0.656 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.012 0.678 CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK 68&80 0.050 0.638 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR 68&99 0.005 0.700 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK 68&100 0.003 0.707 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.000 0.749 CLUS_LFDSDPITVTVPVEVSR_vs_ITIH4_ILDDLSPR 68&112 0.030 0.653 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.004 0.705 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR 68&141 0.028 0.655 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR 68&142 0.045 0.641 CLUS_LFDSDPITVTVPVEVSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 68&144 0.035 0.648 CLUS_LFDSDPITVTVPVEVSR_VS_VTDB_ELPEHTVK 68&147 0.015 0.672 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.047 0.640 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.036 0.648 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.021 0.663 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.039 0.645 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.012 0.677 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.007 0.690 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.038 0.647 CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 72&144 0.017 0.669 COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.036 0.648 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.021 0.663 COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.046 0.641 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.027 0.656 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR 82&136 0.016 0.670 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.034 0.650 ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.023 0.661 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.032 0.651 F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK 84&100 0.049 0.639 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.008 0.686 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.009 0.686 FETUA_FSVVYAK_vs_PSG9_LFIPQITR 88&136 0.034 0.650 FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 89&135 0.037 0.647 FETUA_HTLNQIDEVK_vs_PSG9_LFIPQITR 89&136 0.024 0.659 HABP2_FLNWIK_vs_C163A_INPASLDK 92&54 0.032 0.651 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.014 0.674 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.020 0.664 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.021 0.663 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.029 0.654 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.034 0.649 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.017 0.668 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.015 0.672 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.012 0.676 IBP6_GAQTLYVPNCDHR_vs_C163A_INPASLDK 101&54 0.031 0.652 IBP6_GAQTLYVPNCDHR_vs_CRIS3_YEDLYSNCK 101&79 0.045 0.642 IBP6_GAQTLYVPNCDHR_vs_IGF2_GIVEECCFR 101&103 0.020 0.664 IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR 101&120 0.041 0.644 IBP6_HLDSVLQQLQTEVYR_vs_C163A_INPASLDK 102&54 0.027 0.656 IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK 102&79 0.036 0.648 IBP6_HLDSVLQQLQTEVYR_vs_IGF2_GIVEECCFR 102&103 0.026 0.658 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.045 0.641 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.037 0.647 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.036 0.648 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.031 0.653 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.030 0.653 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.006 0.695 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.013 0.676 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.047 0.640 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.037 0.647 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.042 0.643 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.019 0.665 PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR 133&40 0.029 0.654 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.016 0.670 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.049 0.639 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.008 0.687 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.005 0.697 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.011 0.680 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.026 0.658 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.007 0.689 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.027 0.656 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.031 0.652 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.021 0.663 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.016 0.669 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.010 0.681 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133&112 0.027 0.656 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.004 0.702 PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK 133&121 0.021 0.663 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.013 0.676 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.025 0.658 PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR 133&138 0.019 0.665 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.034 0.650 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.024 0.660 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR 133&141 0.017 0.668 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.014 0.674 PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 133&144 0.019 0.666 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133&147 0.036 0.648 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.043 0.643 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137&103 0.046 0.641 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.025 0.658 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.014 0.674 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.043 0.643 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.020 0.664
(469) TABLE-US-00050 TABLE50 ReversalClassificationPerformance,weeks17,18and19. ReversalAUROCforgestationalweeks170/7through196/7usinga casevscontrolcut-offof<350/7vs>=350/7weeks,with BMIstratification(>22<=37). Reversal SEQIDNO: pval ROC_AUC AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.012 0.718 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.023 0.696 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.019 0.702 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.035 0.682 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.040 0.678 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.033 0.684 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.037 0.680 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.048 0.671 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.020 0.702 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.020 0.702 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.038 0.679 CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR 67&99 0.034 0.684 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.004 0.751 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.010 0.722 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.031 0.687 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR 68&99 0.033 0.685 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.008 0.731 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.028 0.690 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.029 0.689 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.015 0.710 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.045 0.673 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.008 0.731 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.011 0.720 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.049 0.671 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR 82&40 0.033 0.684 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1_TGYYFDGISR 82&86 0.020 0.701 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR 82&112 0.036 0.681 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK 82&121 0.026 0.693 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2_WNFAYWAAHQPWSR 82&129 0.042 0.676 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.019 0.702 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR 82&136 0.006 0.739 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_ELPEHTVK 82&147 0.016 0.709 ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR 83&40 0.042 0.676 ENPP2_TYLHTYESEI_vs_FBLN1_TGYYFDGISR 83&86 0.025 0.693 ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR 83&112 0.043 0.675 ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK 83&121 0.030 0.688 ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 83&135 0.027 0.692 ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR 83&136 0.009 0.727 ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK 83&147 0.015 0.712 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.043 0.675 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.030 0.688 F13B_GDTYPAELYITGSILR_vs_IBP3_FLNVLSPR 84&99 0.040 0.678 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.004 0.750 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.012 0.718 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.045 0.673 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.035 0.682 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.006 0.737 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.013 0.715 IBP6_HLDSVLQQLQTEVYR_vs_IGF2_GIVEECCFR 102&103 0.049 0.670 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.019 0.704 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.030 0.688 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.037 0.681 KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR 117&99 0.019 0.703 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.024 0.696 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.002 0.763 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.014 0.713 PAPP1_DIPHWLNPTR_vs_C163A_INPASLDK 122&54 0.049 0.670 PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.034 0.683 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.025 0.693 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.036 0.681 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.031 0.687 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.022 0.699 PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR 133&40 0.018 0.705 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.010 0.723 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.042 0.676 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.003 0.758 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.003 0.759 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.014 0.713 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.029 0.690 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.014 0.712 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.038 0.679 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.007 0.732 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.010 0.722 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.003 0.754 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133&112 0.015 0.710 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.002 0.773 PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK 133&121 0.035 0.683 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.021 0.700 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.007 0.733 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.028 0.691 PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR 133&138 0.021 0.699 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.023 0.697 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.042 0.676 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR 133&141 0.016 0.708 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.011 0.720 PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 133&144 0.031 0.687 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133&147 0.017 0.707 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.042 0.676 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137&103 0.021 0.700 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.018 0.704 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.017 0.707 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.048 0.671 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.040 0.677
(470) TABLE-US-00051 TABLE51 ReversalClassificationPerformance,weeks18,19and20. ReversalAUROCforgestationalweeks180/7through206/7using acasevscontrolcut-offof<370/7vs>=370/7weeks, withoutBMIstratification. Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.001 0.633 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.008 0.608 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.001 0.630 AFAM_HFQNLGK_vs_PRG2_WNFAYWAAHQPWSR 38&129 0.010 0.605 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.001 0.636 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.013 0.602 AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR 38&141 0.007 0.610 ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR 42&86 0.008 0.608 ANGT_DPTFIPAPIQAK_vs_PRG2_WNFAYWAAHQPWSR 42&129 0.010 0.605 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.001 0.635 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.005 0.614 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.004 0.618 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.001 0.638 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.003 0.620 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.001 0.631 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.001 0.635 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.002 0.627 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.006 0.613 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.001 0.634 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.011 0.603 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.001 0.630 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.002 0.623 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.001 0.633 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.003 0.623 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.001 0.637 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.004 0.617 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.003 0.620 APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR 47&129 0.001 0.637 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47&131 0.009 0.606 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.000 0.662 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.005 0.615 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.006 0.612 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.001 0.632 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.006 0.611 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.008 0.609 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.004 0.618 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.001 0.634 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.001 0.630 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.001 0.638 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.001 0.630 APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR 48&86 0.005 0.614 APOH_ATVVYQGER_vs_PRG2_WNFAYWAAHQPWSR 48&129 0.013 0.601 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.000 0.649 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.006 0.613 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.008 0.607 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48&142 0.013 0.602 B2MG_VEHSDLSFSK_vs_PSG3_VSAPSGTGHLPGLNPL 50&134 0.011 0.604 B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL 51&134 0.002 0.623 BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL 52&134 0.007 0.610 C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR 55&66 0.005 0.613 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.005 0.614 C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR 55&86 0.001 0.630 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.010 0.605 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.010 0.605 C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR 55&129 0.001 0.632 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.000 0.649 C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 55&135 0.013 0.602 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.001 0.641 C1QB_VPGLYYFTYHASSR_vs_SPRL1_VLTHSELAPLR 55&140 0.011 0.603 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.002 0.624 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.003 0.619 C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 55&144 0.007 0.610 CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR 61&86 0.011 0.604 CD14_LTVGAAQVPAQLLVGALR_vs_PRG2_WNFAYWAAHQPWSR 61&129 0.013 0.602 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.000 0.646 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.006 0.611 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.004 0.616 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.007 0.609 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.011 0.604 CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR 62&86 0.013 0.602 CD14_SWLAELQQWLKPGLK_vs_PRG2_WNFAYWAAHQPWSR 62&129 0.013 0.602 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.001 0.637 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.007 0.610 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.006 0.611 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.012 0.603 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.014 0.601 CFAB_YGLVTYATYPK_vs_PRG2_WNFAYWAAHQPWSR 64&129 0.013 0.601 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.000 0.646 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.008 0.607 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.010 0.605 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.004 0.618 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.002 0.628 CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR 67&141 0.014 0.600 CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL 68&134 0.004 0.617 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.001 0.631 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.014 0.600 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.014 0.600 CO5_VFQFLEK_vs_FBLN1_TGYYFDGISR 71&86 0.012 0.603 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.002 0.629 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.009 0.606 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.011 0.604 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.002 0.624 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.013 0.602 CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR 74&66 0.011 0.604 CO8A_SLLQPNK_vs_FBLN1_TGYYFDGISR 74&86 0.013 0.601 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.000 0.643 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.006 0.612 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.002 0.624 CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.007 0.610 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.003 0.622 CO8B_QALEEFQK_vs_FBLN1_TGYYFDGISR 76&86 0.014 0.600 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.000 0.645 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.006 0.612 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.002 0.628 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.004 0.619 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.002 0.627 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_VSAPSGTGHLPGLNPL 82&134 0.012 0.602 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL 83&134 0.013 0.601 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.005 0.615 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.007 0.611 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.001 0.633 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR 88&141 0.013 0.601 FETUA_HTLNQIDEVK_vs_PRG2_WNFAYWAAHQPWSR 89&129 0.010 0.604 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.001 0.640 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.013 0.601 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.005 0.614 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.006 0.613 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.005 0.615 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.005 0.613 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.014 0.601 HABP2_FLNWIK_vs_PRG2_WNFAYWAAHQPWSR 92&129 0.005 0.615 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.000 0.658 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.004 0.618 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.001 0.631 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.003 0.621 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.005 0.613 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.008 0.609 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.002 0.625 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.007 0.610 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.006 0.612 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.003 0.619 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.009 0.607 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.004 0.618 IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR 2&86 0.002 0.629 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.012 0.602 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.008 0.608 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.009 0.606 IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQPWSR 2&129 0.004 0.619 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.000 0.688 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.001 0.639 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.010 0.605 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.001 0.634 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.006 0.612 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.003 0.619 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.007 0.610 IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL 101&134 0.008 0.608 IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL 102&134 0.006 0.612 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.005 0.614 INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR 107&86 0.004 0.616 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.003 0.622 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.008 0.609 INHBC_LDFHFSSDR_v_PRG2_WNFAYWAAHQPWSR 107&129 0.002 0.624 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.000 0.659 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.003 0.620 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.008 0.608 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.001 0.637 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.002 0.624 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.003 0.620 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.008 0.608 ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL 111&134 0.006 0.612 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.006 0.612 ITIH4_NPLVWVHASPEHVVVTR_vs_PRG2_WNFAYWAAHQPWSR 113&129 0.007 0.611 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.003 0.623 ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR 113&18 0.014 0.601 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR 113&141 0.014 0.601 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG3_VSAPSGTGHLPGLNPL 114&134 0.014 0.601 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.000 0.643 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.008 0.608 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR 116&141 0.010 0.606 KNG1_QVVAGLNFR_vs_FBLN1_TGYYFDGISR 117&86 0.013 0.601 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.001 0.636 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.008 0.608 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.009 0.607 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.011 0.603 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.006 0.612 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.011 0.604 LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPWSR 118&129 0.007 0.611 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.000 0.659 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.004 0.617 LBP_ITGFLKPGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 118&144 0.013 0.601 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.006 0.611 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.003 0.621 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.004 0.619 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.002 0.624 LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 119&80 0.013 0.601 LBP_ITLPDFTGDLR_vs_FBLN1_TGYYFDGISR 119&86 0.007 0.610 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.004 0.618 LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR 119&129 0.003 0.623 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.000 0.670 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.001 0.633 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.007 0.610 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.009 0.607 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.006 0.613 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.004 0.618 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.012 0.602 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.008 0.608 PEDF_LQSLFDSPDFSK_vs_FBLN1_TGYYFDGISR 124&86 0.013 0.601 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.000 0.646 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.012 0.602 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.004 0.619 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.004 0.616 PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR 125&66 0.014 0.600 PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR 125&86 0.008 0.608 PEDF_TVQAVLTVPK_vs_PRG2_WNFAYWAAHQPWSR 125&129 0.010 0.605 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.000 0.649 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR 125&18 0.014 0.600 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.004 0.618 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.007 0.609 PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL 137&134 0.005 0.614 THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL 143&134 0.008 0.609 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.008 0.609 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.003 0.620 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.010 0.605 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.005 0.614 VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQPWSR 149&129 0.003 0.623 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.000 0.669 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.000 0.642 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.004 0.618 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.006 0.612 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.002 0.624 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.003 0.623 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.010 0.605 VTNC_VDTVDPPYPR_vs_FBLN1_TGYYFDGISR 150&86 0.007 0.610 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.004 0.618 VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQPWSR 150&129 0.005 0.615 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.000 0.669 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.001 0.634 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.005 0.614 VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR 150&142 0.010 0.605 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.004 0.617 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.001 0.635
(471) TABLE-US-00052 TABLE52 ReversalClassificationPerformance,weeks18,19and20. ReversalAUROCforgestationalweeks180/7through206/7using acasevscontrolcut-offof<370/7vs>=370/7weeks,with BMIstratification(>22<=37). SEQ Reversal IDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR 34&78 0.015 0.621 A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.009 0.631 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.006 0.638 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.032 0.608 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.003 0.648 A2GL_DLLLPQPDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 34&135 0.014 0.623 A2GL_DLLLPQPDLR_vs_PSG9_LFIPQITR 34&136 0.034 0.606 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.010 0.628 A2GL_DLLLPQPDLR_vs_SPRL1_VLTHSELAPLR 34&140 0.017 0.620 A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR 34&141 0.031 0.608 A2GL_DLLLPQPDLR_vs_TENX_LSQLSVTDVTTSSLR 34&142 0.042 0.602 A2GL_DLLLPQPDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 34&144 0.020 0.616 AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK 37&79 0.018 0.619 AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR 37&99 0.041 0.602 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37&100 0.036 0.605 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.013 0.624 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.029 0.609 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.003 0.650 AFAM_DADPDTFFAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 37&135 0.019 0.618 AFAM_DADPDTFFAK_vs_PSG9_LFIPQITR 37&136 0.042 0.602 AFAM_DADPDTFFAK_vs_SPRL1_VLTHSELAPLR 37&140 0.042 0.602 AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSFLLR 37&141 0.011 0.627 AFAM_DADPDTFFAK_vs_TENX_LSQLSVTDVTTSSLR 37&142 0.022 0.614 AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 37&144 0.018 0.619 AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR 38&66 0.018 0.618 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.021 0.615 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.033 0.607 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.026 0.611 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.024 0.613 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.023 0.614 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.003 0.648 AFAM_HFQNLGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 38&135 0.012 0.626 AFAM_HFQNLGK_vs_PSG9_LFIPQITR 38&136 0.029 0.610 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.046 0.600 AFAM_HFQNLGK_vs_SPRL1_VLTHSELAPLR 38&140 0.017 0.619 AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR 38&141 0.009 0.632 AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR 38&142 0.015 0.622 AFAM_HFQNLGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 38&144 0.029 0.610 AFAM_HFQNLGK_vs_VTDB_ELPEHTVK 38&147 0.037 0.605 ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR 42&66 0.010 0.630 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.010 0.628 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.006 0.637 ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK 42&80 0.042 0.602 ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR 42&86 0.036 0.605 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.011 0.627 ANGT_DPTFIPAPIQAK_vs_NCAM1_GLGEISAASEFK 42&121 0.025 0.613 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.028 0.610 ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL 42&134 0.001 0.669 ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 42&135 0.013 0.625 ANGT_DPTFIPAPIQAK_vs_PSG9_LFIPQITR 42&136 0.031 0.608 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.002 0.655 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.019 0.619 ANGT_DPTFIPAPIQAK_vs_SPRL1_VLTHSELAPLR 42&140 0.019 0.618 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.010 0.628 ANGT_DPTFIPAPIQAK_vs_TENX_LSQLSVTDVTTSSLR 42&142 0.011 0.627 ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 42&144 0.019 0.617 ANGT_DPTFIPAPIQAK_vs_VTDB_ELPEHTVK 42&147 0.032 0.607 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.013 0.624 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.001 0.662 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.013 0.624 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.001 0.663 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.001 0.669 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.016 0.621 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.024 0.613 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.015 0.622 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.035 0.606 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.004 0.643 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.008 0.633 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.005 0.641 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.016 0.620 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.001 0.660 APOC3_GWVTDGFSSLK_VS_NCAM1_GLGEISAASEFK 47&121 0.014 0.623 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.008 0.633 APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR 47&129 0.041 0.603 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47&131 0.022 0.615 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.001 0.664 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.005 0.642 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.007 0.636 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.008 0.633 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.035 0.606 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.015 0.624 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.010 0.629 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.005 0.641 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.007 0.636 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.004 0.644 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.007 0.634 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.025 0.612 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.031 0.608 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.013 0.625 APOH_ATVVYQGER_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 48&135 0.008 0.633 APOH_ATVVYQGER_vs_PSG9_LFIPQITR 48&136 0.020 0.617 APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR 48&140 0.036 0.605 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.028 0.610 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48&142 0.027 0.611 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.030 0.609 B2MG_VNHVTLSQPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 51&135 0.024 0.613 BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR 52&66 0.036 0.605 BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR 52&78 0.039 0.604 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.022 0.615 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.027 0.611 BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL 52&134 0.028 0.610 BGH3_LTLLAPLNSVFK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 52&135 0.030 0.609 BGH3_LTLLAPLNSVFK_vs_PSG9_LFIPQITR 52&136 0.046 0.600 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR 52&18 0.043 0.602 BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR 52&141 0.024 0.613 C1QB_VPGLYYFTYHASSR_vs_ALS_IRPHTFTGLSGLR 55&40 0.033 0.607 C1QB_VPGLYYFTYHASSR_vs_C163A_INPASLDK 55&54 0.014 0.623 C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR 55&66 0.005 0.641 C1QB_VPGLYYFTYHASSR_vs_CRIS3_AVSPPAR 55&78 0.004 0.644 C1QB_VPGLYYFTYHASSR_vs_CRIS3_YEDLYSNCK 55&79 0.004 0.646 C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK 55&80 0.007 0.636 C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR 55&81 0.012 0.627 C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR 55&86 0.008 0.634 C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR 55&98 0.031 0.608 C1QB_VPGLYYFTYHASSR_vs_IBP3_FLNVLSPR 55&99 0.010 0.629 C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK 55&100 0.012 0.626 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.004 0.645 C1QB_VPGLYYFTYHASSR_vs_ITIH4_ILDDLSPR 55&112 0.013 0.625 C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR 55&120 0.003 0.651 C1QB_VPGLYYFTYHASSR_vs_NCAM1_GLGEISAASEFK 55&121 0.008 0.633 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.002 0.652 C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR 55&129 0.020 0.617 C1QB_VPGLYYFTYHASSR_vs_PSG1_FQLPGQK 55&131 0.024 0.613 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.001 0.671 C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 55&135 0.002 0.658 C1QB_VPGLYYFTYHASSR_vs_PSG9_LFIPQITR 55&136 0.004 0.643 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.001 0.668 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR 55&18 0.014 0.624 C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF 55&139 0.009 0.631 C1QB_VPGLYYFTYHASSR_vs_SPRL1_VLTHSELAPLR 55&140 0.003 0.648 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.002 0.654 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.002 0.657 C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 55&144 0.006 0.638 C1QB_VPGLYYFTYHASSR_vs_VTDB_ELPEHTVK 55&147 0.013 0.625 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.025 0.613 CBPN_EALIQFLEQVHQGIK_vs_PSG3_VSAPSGTGHLPGLNPL 59&134 0.038 0.604 CBPN_EALIQFLEQVHQGIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 59&135 0.025 0.612 CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPGAFDSFLLR 59&141 0.037 0.605 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.039 0.603 CBPN_NNANGVDLNR_vs_PSG3_VSAPSGTGHLPGLNPL 60&134 0.026 0.611 CBPN_NNANGVDLNR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 60&135 0.025 0.613 CBPN_NNANGVDLNR_vs_TENX_LNWEAPPGAFDSFLLR 60&141 0.043 0.601 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR 61&78 0.043 0.601 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.020 0.617 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.012 0.627 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.008 0.632 CD14_LTVGAAQVPAQLLVGALR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 61&135 0.025 0.612 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.028 0.610 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.008 0.634 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.009 0.632 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.024 0.613 CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK 62&79 0.041 0.603 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.022 0.614 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.015 0.622 CD14_SWLAELQQWLKPGLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 62&135 0.027 0.611 CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR 62&140 0.038 0.604 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.013 0.625 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.016 0.621 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.033 0.607 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.033 0.607 CFAB_YGLVTYATYPK_vs_CRIS3_AVSPPAR 64&78 0.039 0.603 CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK 64&79 0.023 0.614 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.031 0.608 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.003 0.648 CFAB_YGLVTYATYPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 64&135 0.020 0.616 CFAB_YGLVTYATYPK_vs_PSG9_LFIPQITR 64&136 0.039 0.603 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.045 0.601 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.019 0.617 CFAB_YGLVTYATYPK_vs_TENX_LSQLSVTDVTTSSLR 64&142 0.036 0.605 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.008 0.632 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.026 0.612 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.028 0.610 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.023 0.614 CLUS_ASSIIDELFQDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 67&135 0.012 0.626 CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR 67&141 0.028 0.610 CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTSSLR 67&142 0.036 0.605 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.035 0.606 CLUS_LFDSDPITVTVPVEVSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 68&135 0.019 0.617 CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR 70&78 0.023 0.614 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.015 0.622 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.014 0.623 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.003 0.650 CO5_TLLPVSKPEIR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 70&135 0.022 0.615 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.025 0.613 CO5_TLLPVSKPEIR_vs_SPRL1_VLTHSELAPLR 70&140 0.041 0.602 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.014 0.623 CO5_TLLPVSKPEIR_vs_TENX_LSQLSVTDVTTSSLR 70&142 0.020 0.617 CO5_VFQFLEK_vs_CRIS3_AVSPPAR 71&78 0.029 0.610 CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK 71&79 0.019 0.618 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.017 0.620 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.009 0.630 CO5_VFQFLEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 71&135 0.021 0.615 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.030 0.609 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.013 0.624 CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR 71&142 0.028 0.610 CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 71&144 0.035 0.606 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.045 0.601 CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL 72&134 0.026 0.611 CO6_ALNHLPLEYNSALYSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 72&135 0.028 0.611 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.024 0.613 CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR 72&142 0.034 0.606 CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR 74&66 0.016 0.621 CO8A_SLLQPNK_vs_CRIS3_AVSPPAR 74&78 0.035 0.606 CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK 74&79 0.014 0.623 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.019 0.618 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.003 0.649 CO8A_SLLQPNK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 74&135 0.017 0.620 CO8A_SLLQPNK_vs_PSG9_LFIPQITR 74&136 0.038 0.604 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.032 0.607 CO8A_SLLQPNK_vs_SPRL1_VLTHSELAPLR 74&140 0.013 0.624 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.004 0.646 CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.007 0.635 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.012 0.626 CO8B_QALEEFQK_vs_CHL1_VIAVNEVGR 76&66 0.016 0.621 CO8B_QALEEFQK_vs_CRIS3_AVSPPAR 76&78 0.040 0.603 CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK 76&79 0.015 0.622 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.034 0.606 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.035 0.606 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.003 0.648 CO8B_QALEEFQK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 76&135 0.016 0.620 CO8B_QALEEFQK_vs_PSG9_LFIPQITR 76&136 0.032 0.607 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.030 0.609 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76&140 0.009 0.631 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.002 0.659 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.003 0.651 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.006 0.639 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_VS_LYAM1_SYYWIGIR 82&120 0.041 0.602 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.038 0.604 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.021 0.615 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.019 0.617 F13B_GDTYPAELYITGSILR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 84&135 0.037 0.604 F13B_GDTYPAELYITGSILR_vs_TENX_LNWEAPPGAFDSFLLR 84&141 0.041 0.602 F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTDVTTSSLR 84&142 0.039 0.603 FBLN3_IPSNPSHR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 87&135 0.022 0.615 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.038 0.604 FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL 88&134 0.029 0.609 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.023 0.614 FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 89&135 0.038 0.604 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.024 0.613 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.015 0.622 HABP2_FLNWIK_vs_CRIS3_AVSPPAR 92&78 0.028 0.610 HABP2_FLNWIK_vs_CRIS3_YEDLYSNCK 92&79 0.019 0.618 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.014 0.623 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.010 0.629 HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK 92&121 0.026 0.612 HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR 92&126 0.044 0.601 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.003 0.648 HABP2_FLNWIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 92&135 0.015 0.622 HABP2_FLNWIK_vs_PSG9_LFIPQITR 92&136 0.033 0.607 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.022 0.615 HABP2_FLNWIK_vs_SPRL1_VLTHSELAPLR 92&140 0.015 0.622 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.007 0.636 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.008 0.632 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.016 0.620 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.019 0.618 HEMO_NFPSPVDAAFR_vs_CRIS3_YEDLYSNCK 93&79 0.036 0.605 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.041 0.603 HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL 93&134 0.036 0.605 HEMO_NFPSPVDAAFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 93&135 0.030 0.609 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.013 0.624 HEMO_NFPSPVDAAFR_vs_TENX_LSQLSVTDVTTSSLR 93&142 0.037 0.604 HLACI_WAAVVVPSGEEQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 95&135 0.043 0.602 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.014 0.624 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.006 0.639 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.002 0.652 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.018 0.619 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.003 0.648 IBP4_QCHPALDGQR_vs_NCAM1_GLGEISAASEFK 2&121 0.041 0.602 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.010 0.630 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.000 0.675 IBP4_QCHPALDGQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 2&135 0.010 0.630 IBP4_QCHPALDGQR_vs_PSG9_LFIPQITR 2&136 0.023 0.614 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.004 0.643 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.007 0.635 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.003 0.648 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.008 0.633 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.006 0.638 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.026 0.611 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.023 0.614 INHBC_LDFHFSSDR_vs_C163A_INPASLDK 107&54 0.030 0.609 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.008 0.633 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.019 0.618 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.010 0.629 INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR 107&86 0.029 0.610 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.007 0.636 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.007 0.635 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.003 0.648 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.024 0.613 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.016 0.621 INHBC_LDFHFSSDR_vs_NCAM1_GLGEISAASEFK 107&121 0.018 0.618 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.011 0.628 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.000 0.681 INHBC_LDFHFSSDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 107&135 0.012 0.626 INHBC_LDFHFSSDR_vs_PSG9_LFIPQITR 107&136 0.015 0.622 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.007 0.634 INHBC_LDFHFSSDR_VS_SPRL1_VLTHSELAPLR 107&140 0.003 0.647 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.000 0.675 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.001 0.664 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.006 0.639 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.005 0.639 ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR 111&78 0.040 0.603 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.023 0.614 ITIH3_ALDLSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 111&135 0.037 0.605 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.036 0.605 ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_AVSPPAR 113&78 0.016 0.621 ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_YEDLYSNCK 113&79 0.011 0.628 ITIH4_NPLVWVHASPEHVVVTR_vs_LYAM1_SYYWIGIR 113&120 0.009 0.631 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.020 0.617 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 113&135 0.010 0.630 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG9_LFIPQITR 113&136 0.031 0.608 ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR 113&18 0.033 0.607 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR 113&141 0.018 0.619 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR 113&142 0.021 0.615 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CRIS3_YEDLYSNCK 114&79 0.042 0.602 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG3_VSAPSGTGHLPGLNPL 114&134 0.035 0.606 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 114&135 0.035 0.606 KNG1_DIPTNSPELEETLTHTITK_vs_CHL1_VIAVNEVGR 116&66 0.045 0.601 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_AVSPPAR 116&78 0.036 0.605 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK 116&79 0.019 0.617 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.014 0.623 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.012 0.626 KNG1_DIPTNSPELEETLTHTITK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 116&135 0.035 0.606 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR 116&141 0.028 0.610 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR 116&142 0.034 0.606 KNG1_QVVAGLNFR_vs_CHL1_VIAVNEVGR 117&66 0.040 0.603 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.027 0.611 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.015 0.622 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.016 0.621 KNG1_QVVAGLNFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 117&135 0.028 0.610 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.046 0.600 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.025 0.613 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.013 0.624 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.019 0.618 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.004 0.646 LBP_ITGFLKPGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 118&135 0.033 0.607 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.029 0.610 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.021 0.616 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.014 0.623 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.006 0.638 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.004 0.644 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.005 0.642 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119&121 0.025 0.613 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.028 0.610 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.001 0.665 LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 119&135 0.012 0.626 LBP_ITLPDFTGDLR_vs_PSG9_LFIPQITR 119&136 0.033 0.607 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.007 0.636 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.022 0.616 LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR 119&140 0.034 0.606 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.027 0.611 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.024 0.613 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.027 0.611 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.023 0.614 PEDF_LQSLFDSPDFSK_vs_CHL1_VIAVNEVGR 124&66 0.038 0.604 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.012 0.626 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.008 0.633 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.015 0.622 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.006 0.637 PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 124&135 0.024 0.613 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.043 0.601 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.009 0.631 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.010 0.630 PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR 125&66 0.018 0.619 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.017 0.619 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.011 0.628 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.010 0.629 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.002 0.654 PEDF_TVQAVLTVPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 125&135 0.021 0.616 PEDF_TVQAVLTVPK_vs_PSG9_LFIPQITR 125&136 0.040 0.603 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR 125&18 0.043 0.602 PEDF_TVQAVLTVPK_vs_SPRL1_VLTHSELAPLR 125&140 0.031 0.608 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.006 0.637 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.009 0.632 PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 125&144 0.038 0.604 PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR 128&78 0.029 0.609 PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK 128&79 0.016 0.621 PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL 128&134 0.014 0.623 PRDX2_GLFIIDGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 128&135 0.029 0.609 PRDX2_GLFIIDGK_vs_PSG9_LFIPQITR 128&136 0.041 0.602 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.044 0.601 PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR 128&141 0.044 0.601 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.037 0.605 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.028 0.610 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.021 0.616 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.024 0.613 PSG2_IHPSYTNYR_VS_LYAM1_SYYWIGIR 133&120 0.026 0.612 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.011 0.628 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.003 0.647 PSG2_IHPSYTNYR_vs_PSG9_LFIPQITR 133&136 0.012 0.626 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.044 0.601 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR 133&141 0.028 0.610 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.020 0.617 PTGDS_GPGEDFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 137&135 0.026 0.611 PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR 137&141 0.034 0.607 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.034 0.606 THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL 143&134 0.045 0.601 THBG_AVLHIGEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 143&135 0.020 0.617 VTNC_GQYCYELDEK_vs_C163A_INPASLDK 149&54 0.024 0.613 VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR 149&66 0.007 0.635 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.006 0.638 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.004 0.645 VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR 149&86 0.040 0.603 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.032 0.608 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.013 0.624 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.011 0.627 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.034 0.606 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.001 0.664 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.014 0.623 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.007 0.635 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.000 0.681 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.005 0.639 VTNC_GQYCYELDEK_vs_PSG9_LFIPQITR 149&136 0.016 0.621 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.002 0.654 VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR 149&140 0.006 0.637 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.004 0.644 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.005 0.639 VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 149&144 0.003 0.650 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.003 0.647 VTNC_VDTVDPPYPR_vs_C163A_INPASLDK 150&54 0.037 0.604 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.013 0.625 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.006 0.637 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.004 0.645 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.032 0.608 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.001 0.663 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.015 0.622 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.018 0.619 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.000 0.676 VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 150&135 0.006 0.637 VTNC_VDTVDPPYPR_vs_PSG9_LFIPQITR 150&136 0.020 0.617 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.004 0.643 VTNC_VDTVDPPYPR_vs_SPRL1_VLTHSELAPLR 150&140 0.009 0.630 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.009 0.631 VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR 150&142 0.010 0.629 VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 150&144 0.008 0.634 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.002 0.652
(472) TABLE-US-00053 TABLE53 ReversalClassificationPerformance,weeks18,19and20. ReversalAUROCforgestationalweeks180/7through206/7using acasevscontrolcut-offof<350/7vs>=350/7weeks,without BMIstratification. SEQ Reversal IDNO: pval ROC_AUC AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.037 0.636 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.021 0.651 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.034 0.639 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.026 0.645 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.018 0.654 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.030 0.642 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.016 0.658 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.013 0.662 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.010 0.669 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.020 0.652 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.037 0.636 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.034 0.639 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.023 0.649 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.024 0.648 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.025 0.646 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.037 0.636 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.003 0.692 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.034 0.639 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.042 0.633 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.025 0.647 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.034 0.638 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.025 0.647 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.033 0.640 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.043 0.632 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.038 0.636 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.023 0.648 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.024 0.648 APOH_ATVVYQGER_vs_CRIS3_AVSPPAR 48&78 0.025 0.646 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.014 0.660 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.040 0.634 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.003 0.691 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.030 0.642 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.045 0.631 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48&147 0.011 0.666 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.025 0.646 B2MG_VNHVTLSQPK_vs_C163A_INPASLDK 51&54 0.033 0.639 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.039 0.635 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.024 0.647 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.003 0.692 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.018 0.655 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.008 0.674 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.046 0.631 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.030 0.642 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.042 0.633 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.009 0.670 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.047 0.630 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.028 0.643 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.046 0.630 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.035 0.638 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.047 0.630 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.032 0.640 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.013 0.663 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.046 0.630 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.035 0.638 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.047 0.630 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.013 0.662 CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR 60&140 0.043 0.632 CD14_LTVGAAQVPAQLLVGALR_vs_C163A_INPASLDK 61&54 0.041 0.633 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR 61&78 0.044 0.632 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.021 0.651 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.013 0.662 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_ISLLLIESWLEPVR 61&81 0.038 0.636 CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR 61&86 0.024 0.647 CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK 61&97 0.043 0.633 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.022 0.650 CD14_LTVGAAQVPAQLLVGALR_vs_ITIH4_ILDDLSPR 61&112 0.037 0.637 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.001 0.717 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.017 0.655 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.008 0.673 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.015 0.659 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.020 0.652 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.026 0.646 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.024 0.647 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.020 0.652 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.008 0.673 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.002 0.700 CD14_SWLAELQQWLKPGLK_vs_C163A_INPASLDK 62&54 0.041 0.634 CD14_SWLAELQQWLKPGLK_vs_CRIS3_AVSPPAR 62&78 0.047 0.630 CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK 62&79 0.028 0.643 CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK 62&80 0.027 0.645 CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR 62&86 0.035 0.638 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.039 0.635 CD14_SWLAELQQWLKPGLK_vs_ITIH4_ILDDLSPR 62&112 0.036 0.637 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.002 0.701 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.027 0.644 CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL 62&134 0.014 0.660 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.021 0.650 CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF 62&139 0.024 0.647 CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR 62&140 0.036 0.637 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.041 0.634 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.033 0.639 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.013 0.662 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.004 0.686 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.049 0.629 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.026 0.646 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.018 0.654 CLUS_ASSIIDELFQDR_vs_CSH_AHQLAIDTYQEFEETYIPK 67&80 0.042 0.633 CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR 67&86 0.029 0.643 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.013 0.663 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.001 0.712 CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL 67&134 0.015 0.660 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.022 0.650 CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR 67&141 0.048 0.629 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.005 0.682 CLUS_LFDSDPITVTVPVEVSR_vs_C163A_INPASLDK 68&54 0.046 0.631 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.013 0.662 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.008 0.674 CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK 68&80 0.029 0.643 CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYFDGISR 68&86 0.041 0.634 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR 68&99 0.043 0.632 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK 68&100 0.028 0.644 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.007 0.675 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.001 0.717 CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL 68&134 0.019 0.653 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR 68&18 0.015 0.658 CLUS_LFDSDPITVTVPVEVSR_vs_SPRL1_VLTHSELAPLR 68&140 0.048 0.629 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR 68&141 0.026 0.646 CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR 68&142 0.044 0.632 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.002 0.705 CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR 70&78 0.038 0.635 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.027 0.644 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.005 0.683 CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK 71&79 0.047 0.630 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.008 0.674 CO6_ALNHLPLEYNSALYSR_vs_CRIS3_YEDLYSNCK 72&79 0.042 0.633 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.005 0.684 CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR 72&141 0.048 0.629 CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK 72&147 0.042 0.633 CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK 74&79 0.032 0.640 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.046 0.630 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.003 0.693 CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.019 0.653 CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 74&144 0.028 0.644 CO8A_SLLQPNK_vs_VTDB_ELPEHTVK 74&147 0.047 0.630 CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK 76&79 0.031 0.641 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.044 0.631 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.012 0.664 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.023 0.649 CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 76&144 0.033 0.640 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.022 0.649 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.014 0.661 F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDGISR 84&86 0.048 0.629 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.040 0.634 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.001 0.711 F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL 84&134 0.034 0.638 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.045 0.631 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.041 0.633 HABP2_FLNWIK_vs_C163A_INPASLDK 92&54 0.025 0.647 HABP2_FLNWIK_vs_CRIS3_AVSPPAR 92&78 0.036 0.637 HABP2_FLNWIK_vs_CRIS3_YEDLYSNCK 92&79 0.023 0.649 HABP2_FLNWIK_vs_CSH_AHQLAIDTYQEFEETYIPK 92&80 0.033 0.639 HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR 92&86 0.021 0.651 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.018 0.655 HABP2_FLNWIK_vs_ITIH4_ILDDLSPR 92&112 0.028 0.644 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.002 0.699 HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR 92&126 0.023 0.649 HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL 92&134 0.009 0.670 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.015 0.659 HABP2_FLNWIK_vs_SOM2.CSH_NYGLLYCFR 92&138 0.037 0.637 HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF 92&139 0.025 0.647 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.017 0.656 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.021 0.651 HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 92&144 0.011 0.665 HABP2_FLNWIK_vs_VTDB_ELPEHTVK 92&147 0.002 0.704 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.019 0.653 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.012 0.665 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.008 0.674 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.002 0.705 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.020 0.652 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.039 0.635 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.048 0.629 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.031 0.641 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK 116&79 0.042 0.633 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.007 0.678 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.040 0.634 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.020 0.652 KNG1_QVVAGLNFR_vs_CSH_AHQLAIDTYQEFEETYIPK 117&80 0.025 0.647 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.040 0.634 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.002 0.703 KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL 117&134 0.039 0.635 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.029 0.642 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.050 0.628 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.048 0.629 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.031 0.641 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.024 0.647 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.007 0.677 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.023 0.648 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.017 0.656 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.003 0.692 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.015 0.659 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.011 0.666 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.036 0.637 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.006 0.680 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.050 0.628 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.047 0.630 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.008 0.674 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.011 0.665 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.021 0.651 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.037 0.637 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.039 0.635 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.029 0.642 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.013 0.662 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.011 0.665 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.039 0.635 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.003 0.697 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.021 0.651 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.047 0.630 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.045 0.631 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.042 0.633 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.035 0.638 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.004 0.687 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.036 0.637
(473) TABLE-US-00054 TABLE54 ReversalClassificationPerformance,weeks18,19and20. ReversalAUROCforgestationalweeks180/7through206/7using acasevscontrolcut-offof<350/7vs>350/7weeks,with BMIstratification(>22<=37). SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.017 0.699 AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK 37&79 0.031 0.679 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.036 0.674 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.012 0.708 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.039 0.672 AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF 37&139 0.044 0.668 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.018 0.697 AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF 38&139 0.046 0.666 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.044 0.667 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.007 0.722 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.044 0.667 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.043 0.668 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.019 0.694 APOH_ATVVYQGER_vs_CRIS3_AVSPPAR 48&78 0.022 0.690 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.013 0.706 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.005 0.735 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.014 0.704 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48&147 0.011 0.712 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.040 0.671 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.035 0.675 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.027 0.684 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.004 0.741 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.033 0.677 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.020 0.693 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.015 0.701 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.039 0.672 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.048 0.664 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.030 0.681 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.011 0.711 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.017 0.698 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR 61&78 0.028 0.683 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.016 0.699 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.001 0.777 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.013 0.707 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.043 0.668 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.019 0.695 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.009 0.718 CD14_SWLAELQQWLKPGLK_vs_CRIS3_AVSPPAR 62&78 0.049 0.663 CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK 62&79 0.041 0.669 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.005 0.732 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.027 0.683 CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF 62&139 0.040 0.671 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.040 0.671 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.024 0.688 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.020 0.693 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.004 0.736 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.026 0.684 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.019 0.694 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.010 0.714 CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR 70&78 0.048 0.664 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.039 0.671 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.008 0.720 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.015 0.701 CO6_ALNHLPLEYNSALYSR_vs_CRIS3_YEDLYSNCK 72&79 0.043 0.668 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.005 0.731 CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK 74&79 0.033 0.677 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.005 0.735 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.025 0.686 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.014 0.705 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.010 0.713 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.001 0.768 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.012 0.710 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.027 0.683 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.015 0.702 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.011 0.710 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.001 0.774 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.045 0.666 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.017 0.698 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_AVSPPAR 116&78 0.047 0.665 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK 116&79 0.045 0.667 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.005 0.735 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.026 0.685 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.018 0.696 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.048 0.665 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.002 0.761 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.031 0.679 PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR 122&129 0.033 0.677 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.010 0.714 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.033 0.677 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.029 0.681 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.004 0.739 PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR 133&40 0.016 0.700 PSG2_IHPSYTNYR_vs_C163A_INPASLDK 133&54 0.020 0.693 PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR 133&66 0.014 0.704 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.001 0.764 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.002 0.759 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.008 0.721 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.015 0.703 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.007 0.725 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.013 0.705 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.013 0.707 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.017 0.699 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.010 0.713 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133&112 0.008 0.719 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.000 0.790 PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK 133&121 0.043 0.668 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.011 0.712 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.002 0.753 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.003 0.743 PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR 133&138 0.013 0.706 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.007 0.726 PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR 133&140 0.018 0.697 PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR 133&141 0.022 0.690 PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR 133&142 0.019 0.694 PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 133&144 0.026 0.685 PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK 133&147 0.005 0.732 PTGDS_GPGEDFR_vs_C163A_INPASLDK 137&54 0.035 0.675 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.027 0.683 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.022 0.691 PTGDS_GPGEDFR_VS_LYAM1_SYYWIGIR 137&120 0.006 0.729 PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF 137&139 0.034 0.677 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.019 0.695 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.031 0.679 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.027 0.684 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.002 0.760 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.049 0.663 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.041 0.669 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.034 0.676 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.006 0.728
(474) TABLE-US-00055 TABLE55 ReversalClassificationPerformance,weeks19,20and21 ReversalAUROCforgestationalweeks190/7through216/7usinga casevscontrolcut-offof<370/7vs>=370/7weeks,without BMIstratification. SEQID Reversal NO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_IBP3_FLNVLSPR 34&99 0.021 0.602 A2GL_DLLLPQPDLR_vs_IBP3_YGQPLPGYTTK 34&100 0.013 0.610 A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.002 0.639 A2GL_DLLLPQPDLR_vs_PRG2_WNFAYWAAHQPWSR 34&129 0.019 0.604 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.022 0.602 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.003 0.630 A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR 34&141 0.011 0.612 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37&100 0.022 0.602 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.009 0.616 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.018 0.605 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.003 0.631 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.001 0.642 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.001 0.648 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.002 0.634 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.009 0.617 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.003 0.631 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.002 0.635 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.003 0.634 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.005 0.624 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.003 0.631 APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK 47&97 0.023 0.601 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.012 0.611 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.000 0.666 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.000 0.662 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.000 0.675 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.001 0.646 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.000 0.658 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.003 0.630 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.001 0.652 APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR 47&129 0.003 0.632 APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK 47&131 0.016 0.607 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.001 0.646 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.016 0.607 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.020 0.603 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.001 0.652 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR 47&138 0.009 0.617 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.003 0.631 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.002 0.637 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.001 0.653 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.001 0.651 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.001 0.642 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.001 0.646 APOH_ATVVYQGER_vs_IBP3_FLNVLSPR 48&99 0.010 0.614 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.003 0.631 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.000 0.657 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.019 0.604 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.018 0.605 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.024 0.600 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.007 0.620 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.004 0.627 APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR 48&142 0.006 0.623 B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR 50&103 0.003 0.630 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.012 0.611 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.008 0.617 B2MG_VEHSDLSFSK_vs_TENX_LNWEAPPGAFDSFLLR 50&141 0.013 0.610 B2MG_VEHSDLSFSK_vs_TENX_LSQLSVTDVTTSSLR 50&142 0.014 0.609 B2MG_VNHVTLSQPK_vs_IBP3_FLNVLSPR 51&99 0.013 0.610 B2MG_VNHVTLSQPK_vs_IBP3_YGQPLPGYTTK 51&100 0.010 0.614 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.000 0.658 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.006 0.622 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR 51&126 0.009 0.615 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.003 0.634 B2MG_VNHVTLSQPK_vs_TENX_LNWEAPPGAFDSFLLR 51&141 0.006 0.621 B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR 51&142 0.008 0.618 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.004 0.627 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.011 0.613 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.012 0.612 C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR 55&142 0.020 0.603 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.018 0.605 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.011 0.613 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.012 0.611 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.001 0.645 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.011 0.613 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.011 0.613 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR 57&129 0.007 0.619 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.010 0.614 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.006 0.621 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.002 0.636 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.003 0.631 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.014 0.609 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.015 0.608 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.002 0.640 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.016 0.607 CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR 58&129 0.023 0.601 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.022 0.602 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.008 0.618 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.004 0.628 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.007 0.620 CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_FLNVLSPR 61&99 0.009 0.615 CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_YGQPLPGYTTK 61&100 0.011 0.612 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.001 0.649 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.015 0.608 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.024 0.600 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.007 0.619 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.005 0.623 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR 61&142 0.012 0.611 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.003 0.630 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.022 0.602 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.011 0.613 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.009 0.615 CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR 62&142 0.024 0.600 CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK 64&100 0.017 0.606 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.003 0.634 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.015 0.608 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.006 0.622 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.016 0.607 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.016 0.607 CO5_VFQFLEK_vs_IGF2_GIVEECCFR 71&103 0.010 0.614 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.017 0.606 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.015 0.608 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.020 0.603 CO8A_SLLQPNK_vs_ALS_IRPHTFTGLSGLR 74&40 0.023 0.601 CO8A_SLLQPNK_vs_IBP3_FLNVLSPR 74&99 0.012 0.611 CO8A_SLLQPNK_vs_IBP3_YGQPLPGYTTK 74&100 0.006 0.623 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.000 0.656 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.021 0.602 CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.018 0.605 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.010 0.615 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.005 0.624 CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.005 0.624 CO8B_QALEEFQK_vs_ALS_IRPHTFTGLSGLR 76&40 0.012 0.612 CO8B_QALEEFQK_vs_IBP3_FLNVLSPR 76&99 0.009 0.617 CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK 76&100 0.005 0.624 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.000 0.663 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.015 0.608 CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR 76&126 0.019 0.604 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.020 0.603 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.011 0.613 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.003 0.632 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.002 0.637 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR 82&99 0.016 0.607 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK 82&100 0.013 0.610 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR 82&103 0.004 0.629 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_VS_LYAM1_SYYWIGIR 82&120 0.011 0.613 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.017 0.606 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2_WNFAYWAAHQPWSR 82&129 0.024 0.600 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.003 0.633 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR 82&141 0.014 0.609 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR 82&142 0.019 0.604 ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR 83&99 0.012 0.611 ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK 83&100 0.012 0.611 ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR 83&103 0.003 0.631 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.008 0.618 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.013 0.610 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.004 0.627 ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDSFLLR 83&141 0.008 0.617 ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR 83&142 0.014 0.610 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.022 0.602 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.017 0.606 FETUA_FSVVYAK_vs_IBP3_FLNVLSPR 88&99 0.012 0.611 FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK 88&100 0.006 0.622 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.001 0.654 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.011 0.613 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR 88&141 0.007 0.620 FETUA_FSVVYAK_vs_TENX_LSQLSVTDVTTSSLR 88&142 0.013 0.610 FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK 89&100 0.017 0.606 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.002 0.636 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.007 0.619 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.005 0.625 FETUA_HTLNQIDEVK_vs_TENX_LSQLSVTDVTTSSLR 89&142 0.010 0.615 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.010 0.614 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.022 0.602 HEMO_NFPSPVDAAFR_vs_IBP3_YGQPLPGYTTK 93&100 0.018 0.605 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.003 0.632 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.005 0.625 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.012 0.611 IBP4_QCHPALDGQR_vs_ALS_IRPHTFTGLSGLR 2&40 0.007 0.619 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.023 0.601 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.004 0.628 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.002 0.637 IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR 2&99 0.002 0.635 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.001 0.648 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.000 0.684 IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR 2&112 0.001 0.641 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.001 0.650 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.000 0.655 IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQPWSR 2&129 0.006 0.622 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.001 0.651 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.000 0.670 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.006 0.622 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.000 0.661 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.001 0.642 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.003 0.634 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.003 0.632 IBP6_GAQTLYVPNCDHR_vs_IGF2_GIVEECCFR 101&103 0.008 0.617 IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR 101&18 0.020 0.604 IBP6_HLDSVLQQLQTEVYR_vs_IGF2_GIVEECCFR 102&103 0.010 0.615 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR 102&18 0.013 0.610 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.015 0.608 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.023 0.601 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.003 0.631 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.002 0.638 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.000 0.664 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.013 0.610 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.007 0.620 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.004 0.628 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.007 0.619 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.002 0.635 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.019 0.604 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.001 0.643 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.002 0.636 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.013 0.611 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.010 0.614 ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR 111&103 0.015 0.608 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.022 0.602 ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR 111&126 0.012 0.611 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.002 0.636 ITIH3_ALDLSLK_vs_TENX_LNWEAPPGAFDSFLLR 111&141 0.014 0.609 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.002 0.637 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.010 0.615 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.015 0.608 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR 116&141 0.007 0.619 KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR 116&142 0.013 0.611 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.020 0.603 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.003 0.630 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.010 0.615 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.020 0.603 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.007 0.619 KNG1_QVVAGLNFR_vs_TENX_LNWEAPPGAFDSFLLR 117&141 0.012 0.612 KNG1_QVVAGLNFR_vs_TENX_LSQLSVTDVTTSSLR 117&142 0.023 0.601 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.016 0.606 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.010 0.615 LBP_ITGFLKPGK_vs_IBP3_FLNVLSPR 118&99 0.015 0.608 LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK 118&100 0.010 0.614 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.002 0.638 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.012 0.612 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118&126 0.012 0.611 LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPWSR 118&129 0.022 0.601 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.004 0.627 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.004 0.628 LBP_ITGFLKPGK_vs_SPRL1_VLTHSELAPLR 118&140 0.024 0.600 LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR 118&141 0.010 0.614 LBP_ITGFLKPGK_vs_TENX_LSQLSVTDVTTSSLR 118&142 0.018 0.605 LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR 119&40 0.013 0.611 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.017 0.606 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.024 0.600 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.005 0.624 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.003 0.633 LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR 119&98 0.024 0.600 LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR 119&99 0.003 0.630 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.002 0.638 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.000 0.655 LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR 119&112 0.006 0.621 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.003 0.632 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.003 0.630 LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR 119&129 0.009 0.615 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.002 0.640 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.001 0.645 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.023 0.601 LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR 119&140 0.009 0.616 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.002 0.634 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.005 0.625 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.011 0.613 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.007 0.621 PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR 124&103 0.008 0.617 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.012 0.612 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.013 0.610 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.003 0.630 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.014 0.609 PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR 125&142 0.018 0.604 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137&103 0.008 0.618 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.016 0.607 PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR 137&141 0.013 0.610 PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR 137&142 0.016 0.607 THBG_AVLHIGEK_vs_IGF2_GIVEECCFR 143&103 0.011 0.612 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.013 0.610 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.016 0.607 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.006 0.621 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.001 0.641 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.015 0.608 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.002 0.639 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.012 0.612 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.018 0.605 VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR 150&99 0.007 0.619 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.004 0.628 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.001 0.649 VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR 150&112 0.016 0.606 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.005 0.625 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.009 0.616 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.021 0.602 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.001 0.644 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.005 0.624 VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR 150&142 0.009 0.615 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.008 0.618
(475) TABLE-US-00056 TABLE56 ReversalClassificationPerformance,weeks19,20and21 ReversalAUROCforgestationalweeks190/7through216/7 usingacasevscontrolcut-offof<370/7vs >=370/7weeks,withBMIstratification(>22<=37). Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR 34&78 0.023 0.622 A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.011 0.636 A2GL_DLLLPQPDLR_vs_IBP3_FLNVLSPR 34&99 0.023 0.622 A2GL_DLLLPQPDLR_vs_IBP3_YGQPLPGYTTK 34&100 0.015 0.631 A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.003 0.660 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.003 0.658 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.021 0.624 A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL 34&134 0.044 0.608 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.012 0.636 A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR 34&141 0.024 0.622 AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR 37&99 0.033 0.614 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37&100 0.004 0.653 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.004 0.656 AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSFLLR 37&141 0.046 0.607 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.035 0.614 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.035 0.613 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.004 0.653 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.001 0.683 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.001 0.685 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.034 0.614 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.036 0.613 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.045 0.608 AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR 38&141 0.028 0.618 AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR 38&142 0.043 0.609 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.026 0.620 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.017 0.629 ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK 42&100 0.040 0.611 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.017 0.628 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.022 0.623 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.037 0.612 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.026 0.620 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.018 0.627 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.009 0.641 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.006 0.649 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.010 0.639 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.009 0.641 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.005 0.653 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.020 0.625 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.006 0.649 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.045 0.608 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.011 0.637 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.020 0.625 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.027 0.619 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.011 0.636 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.018 0.627 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.035 0.613 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.016 0.630 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.030 0.617 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.030 0.616 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.026 0.619 APOH_ATVVYQGER_vs_CRIS3_AVSPPAR 48&78 0.031 0.616 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.015 0.631 APOH_ATVVYQGER_vs_IBP3_FLNVLSPR 48&99 0.035 0.613 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.007 0.645 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.005 0.652 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.022 0.623 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.030 0.616 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.033 0.615 APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR 48&141 0.033 0.615 B2MG_VEHSDLSFSK_vs_CRIS3_AVSPPAR 50&78 0.036 0.613 B2MG_VEHSDLSFSK_vs_CRIS3_YEDLYSNCK 50&79 0.015 0.631 B2MG_VEHSDLSFSK_vs_IBP3_YGQPLPGYTTK 50&100 0.022 0.623 B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR 50&103 0.007 0.644 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.007 0.645 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.036 0.613 B2MG_VEHSDLSFSK_vs_TENX_LNWEAPPGAFDSFLLR 50&141 0.035 0.613 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.019 0.627 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.009 0.641 B2MG_VNHVTLSQPK_vs_IBP3_FLNVLSPR 51&99 0.019 0.626 B2MG_VNHVTLSQPK_vs_IBP3_YGQPLPGYTTK 51&100 0.011 0.637 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.002 0.669 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.005 0.651 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR 51&126 0.015 0.630 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.013 0.634 B2MG_VNHVTLSQPK_vs_TENX_LNWEAPPGAFDSFLLR 51&141 0.031 0.616 B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR 51&142 0.042 0.609 BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR 52&78 0.038 0.611 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.012 0.635 BGH3_LTLLAPLNSVFK_vs_IBP3_YGQPLPGYTTK 52&100 0.042 0.609 BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR 52&103 0.025 0.620 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.023 0.622 BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR 52&141 0.030 0.617 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.017 0.628 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.049 0.606 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.024 0.622 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.013 0.634 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.032 0.616 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.022 0.623 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.010 0.639 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.022 0.623 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.042 0.609 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.041 0.610 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.011 0.637 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.022 0.623 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.020 0.625 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.009 0.639 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.015 0.631 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.010 0.638 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.005 0.652 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.026 0.620 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.021 0.624 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.023 0.622 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.007 0.646 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.017 0.628 CBPN_EALIQFLEQVHQGIK_vs_CRIS3_YEDLYSNCK 59&79 0.035 0.614 CBPN_EALIQFLEQVHQGIK_vs_IBP3_YGQPLPGYTTK 59&100 0.035 0.613 CBPN_EALIQFLEQVHQGIK_vs_IGF2_GIVEECCFR 59&103 0.029 0.617 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.021 0.624 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR 59&18 0.032 0.615 CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPGAFDSFLLR 59&141 0.049 0.606 CBPN_NNANGVDLNR_vs_CRIS3_YEDLYSNCK 60&79 0.027 0.619 CBPN_NNANGVDLNR_vs_IBP3_YGQPLPGYTTK 60&100 0.021 0.624 CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR 60&103 0.008 0.642 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.019 0.626 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR 60&18 0.033 0.615 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.028 0.618 CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_FLNVLSPR 61&99 0.037 0.612 CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_YGQPLPGYTTK 61&100 0.028 0.618 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.007 0.644 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.018 0.627 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.050 0.606 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.047 0.607 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.032 0.615 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.027 0.619 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.030 0.617 CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK 64&79 0.033 0.615 CFAB_YGLVTYATYPK_vs_IBP3_FLNVLSPR 64&99 0.043 0.609 CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK 64&100 0.013 0.633 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.005 0.650 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.020 0.625 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.041 0.610 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.030 0.617 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.039 0.611 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.017 0.629 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.044 0.608 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.046 0.607 CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR 70&78 0.047 0.607 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.023 0.622 CO5_TLLPVSKPEIR_vs_IBP3_YGQPLPGYTTK 70&100 0.043 0.609 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.014 0.632 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.019 0.626 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.042 0.609 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.032 0.615 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.046 0.607 CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK 71&79 0.036 0.613 CO5_VFQFLEK_vs_IGF2_GIVEECCFR 71&103 0.030 0.617 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.022 0.623 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.047 0.607 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.037 0.612 CO8A_SLLQPNK_vs_ALS_IRPHTFTGLSGLR 74&40 0.043 0.609 CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK 74&79 0.015 0.631 CO8A_SLLQPNK_vs_IBP3_FLNVLSPR 74&99 0.024 0.622 CO8A_SLLQPNK_vs_IBP3_YGQPLPGYTTK 74&100 0.009 0.640 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.002 0.663 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.021 0.624 CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.036 0.613 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.028 0.618 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.015 0.630 CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR 74&142 0.020 0.625 CO8B_QALEEFQK_vs_ALS_IRPHTFTGLSGLR 76&40 0.014 0.633 CO8B_QALEEFQK_vs_CRIS3_AVSPPAR 76&78 0.028 0.618 CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK 76&79 0.013 0.634 CO8B_QALEEFQK_vs_IBP3_FLNVLSPR 76&99 0.012 0.635 CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK 76&100 0.007 0.645 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.001 0.676 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.012 0.635 CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR 76&126 0.025 0.620 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.027 0.619 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.027 0.619 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76&140 0.041 0.610 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.008 0.643 CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR 76&142 0.007 0.645 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR 82&40 0.037 0.612 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_C163A_INPASLDK 82&54 0.043 0.609 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_AVSPPAR 82&78 0.031 0.616 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_YEDLYSNCK 82&79 0.021 0.624 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR 82&99 0.021 0.624 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK 82&100 0.013 0.634 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR 82&103 0.007 0.644 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR 82&112 0.028 0.618 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR 82&120 0.006 0.648 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.017 0.628 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 82&135 0.030 0.617 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.005 0.652 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_SVEGSCGF 82&139 0.029 0.617 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR 82&141 0.030 0.617 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR 82&142 0.048 0.606 ENPP2_TYLHTYESEI_vs_C163A_INPASLDK 83&54 0.047 0.607 ENPP2_TYLHTYESEI_vs_CRIS3_AVSPPAR 83&78 0.050 0.606 ENPP2_TYLHTYESEI_vs_CRIS3_YEDLYSNCK 83&79 0.029 0.618 ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR 83&99 0.032 0.615 ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK 83&100 0.022 0.623 ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR 83&103 0.014 0.632 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.011 0.637 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.036 0.613 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.010 0.638 ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF 83&139 0.042 0.610 ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDSFLLR 83&141 0.038 0.612 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.029 0.617 F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK 84&100 0.040 0.610 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.018 0.628 FETUA_FSVVYAK_vs_CRIS3_AVSPPAR 88&78 0.039 0.611 FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK 88&79 0.015 0.631 FETUA_FSVVYAK_vs_IBP3_FLNVLSPR 88&99 0.033 0.615 FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK 88&100 0.013 0.633 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.002 0.664 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.038 0.612 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR 88&141 0.049 0.606 FETUA_HTLNQIDEVK_vs_CRIS3_YEDLYSNCK 89&79 0.027 0.619 FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK 89&100 0.024 0.621 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.005 0.652 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.048 0.606 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.042 0.610 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.035 0.613 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.041 0.610 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.022 0.623 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.046 0.607 HEMO_NFPSPVDAAFR_vs_CRIS3_AVSPPAR 93&78 0.044 0.608 HEMO_NFPSPVDAAFR_vs_CRIS3_YEDLYSNCK 93&79 0.024 0.621 HEMO_NFPSPVDAAFR_vs_IBP3_YGQPLPGYTTK 93&100 0.041 0.610 HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR 93&103 0.013 0.633 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.032 0.615 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.028 0.618 HLACI_WAAVVVPSGEEQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 95&135 0.037 0.612 IBP4_QCHPALDGQR_vs_ALS_IRPHTFTGLSGLR 2&40 0.009 0.641 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.001 0.682 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.000 0.695 IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFEETYIPK 2&80 0.031 0.616 IBP4_QCHPALDGQR_vs_IBP2_LIQGAPTIR 2&98 0.046 0.607 IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR 2&99 0.002 0.663 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.001 0.684 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.000 0.708 IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR 2&112 0.004 0.657 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.000 0.707 IBP4_QCHPALDGQR_vs_NCAM1_GLGEISAASEFK 2&121 0.025 0.620 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.001 0.687 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.002 0.663 IBP4_QCHPALDGQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 2&135 0.040 0.610 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.001 0.680 IBP4_QCHPALDGQR_vs_SOM2.CSH_SVEGSCGF 2&139 0.014 0.632 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.007 0.644 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.001 0.675 IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR 2&142 0.009 0.641 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.002 0.663 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.003 0.660 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.004 0.654 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.012 0.635 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.006 0.649 INHBC_LDFHFSSDR_vs_CSH_AHQLAIDTYQEFEETYIPK 107&80 0.048 0.606 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.001 0.673 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.001 0.685 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.000 0.704 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.014 0.633 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.005 0.649 INHBC_LDFHFSSDR_vs_NCAM1_GLGEISAASEFK 107&121 0.033 0.614 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.005 0.650 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.005 0.651 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.003 0.657 INHBC_LDFHFSSDR_vs_SOM2.CSH_SVEGSCGF 107&139 0.020 0.625 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.013 0.633 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.001 0.681 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.002 0.665 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.018 0.627 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.004 0.653 ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR 111&78 0.019 0.626 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.012 0.634 ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR 111&103 0.041 0.610 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.013 0.633 ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR 111&126 0.027 0.619 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.015 0.631 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_AVSPPAR 116&78 0.043 0.609 KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK 116&79 0.017 0.628 KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR 116&103 0.013 0.634 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.015 0.631 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.032 0.615 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.016 0.630 KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK 117&100 0.019 0.626 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.007 0.645 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.008 0.642 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.045 0.608 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.022 0.623 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.011 0.637 LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK 118&100 0.032 0.615 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.010 0.639 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.016 0.630 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118&126 0.025 0.620 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.036 0.613 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.012 0.635 LBP_ITGFLKPGK_vs_SOM2.CSH_SVEGSCGF 118&139 0.026 0.619 LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR 118&141 0.047 0.607 LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR 119&40 0.047 0.607 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.031 0.616 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.006 0.648 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.003 0.660 LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR 119&98 0.048 0.606 LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR 119&99 0.018 0.628 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.007 0.645 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.003 0.658 LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR 119&112 0.022 0.623 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.003 0.657 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119&121 0.049 0.606 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.005 0.651 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.015 0.631 LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 119&135 0.039 0.611 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.004 0.654 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.010 0.639 LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR 119&140 0.030 0.617 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.011 0.637 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.021 0.624 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.049 0.606 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.022 0.623 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.037 0.612 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.019 0.626 PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR 124&103 0.037 0.612 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.025 0.620 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.033 0.615 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.048 0.606 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.021 0.624 PEDF_TVQAVLTVPK_vs_IBP3_YGQPLPGYTTK 125&100 0.049 0.606 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.025 0.620 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.038 0.611 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.049 0.606 PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK 128&79 0.049 0.606 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.015 0.631 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.007 0.646 PTGDS_GPGEDFR_vs_IBP3_FLNVLSPR 137&99 0.042 0.609 PTGDS_GPGEDFR_vs_IBP3_YGQPLPGYTTK 137&100 0.015 0.631 PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR 137&103 0.004 0.655 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.019 0.626 PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGHR 137&126 0.033 0.615 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.021 0.624 PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR 137&141 0.012 0.636 PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR 137&142 0.021 0.624 THBG_AVLHIGEK_vs_CRIS3_YEDLYSNCK 143&79 0.028 0.618 THBG_AVLHIGEK_vs_IGF2_GIVEECCFR 143&103 0.026 0.620 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.025 0.620 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.047 0.607 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.032 0.616 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.016 0.630 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.032 0.616 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.006 0.647 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.004 0.656 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.030 0.616 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.008 0.643 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.033 0.614 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.036 0.613 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.007 0.645 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.032 0.615 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.043 0.609 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.015 0.630 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.009 0.640 VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR 150&99 0.019 0.626 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.005 0.652 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.004 0.655 VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR 150&112 0.037 0.612 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.005 0.651 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.022 0.623 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.039 0.611 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.005 0.650 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.026 0.620 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.030 0.616
(476) TABLE-US-00057 TABLE57 ReversalClassificationPerformance,weeks19,20and21 ReversalAUROCforgestationalweeks190/7through216/7usingacasevs controlcut-offof<350/7vs>=350/7weeks,withoutBMIstratification. Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.043 0.639 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.021 0.659 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.018 0.662 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.018 0.663 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.018 0.663 AFAM_HFQNLGK_vs_IBP1_VVESLAK 38&97 0.036 0.648 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.010 0.677 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.017 0.664 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.014 0.670 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.030 0.649 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.013 0.671 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.040 0.641 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.038 0.643 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.038 0.643 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.040 0.641 APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK 47&97 0.023 0.656 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.037 0.644 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.048 0.636 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.032 0.647 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.005 0.693 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.011 0.675 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.011 0.674 APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF 47&139 0.038 0.643 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.027 0.653 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.027 0.652 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.026 0.653 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.035 0.645 APOH_ATVVYQGER_vs_IBP1_VVESLAK 48&97 0.021 0.659 APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR 48&112 0.025 0.655 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.002 0.712 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.002 0.717 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.020 0.661 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.003 0.704 APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR 48&140 0.011 0.674 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48&147 0.007 0.684 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.007 0.687 B2MG_VEHSDLSFSK_vs_PGRP2_AGLLRPDYALLGHR 50&126 0.044 0.639 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.012 0.673 B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK 51&97 0.046 0.638 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.002 0.717 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR 51&126 0.009 0.681 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.005 0.692 B2MG_VNHVTLSQPK_vs_SPRL1_VLTHSELAPLR 51&140 0.023 0.656 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.039 0.642 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR 52&18 0.049 0.635 CAH1_GGPFSDSYR_vs_IBP1_VVESLAK 56&97 0.033 0.647 CAH1_GGPFSDSYR_vs_LYAM1_SYYWIGIR 56&120 0.015 0.668 CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR 56&126 0.020 0.661 CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR 56&18 0.008 0.682 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.001 0.720 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.000 0.772 CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR 57&66 0.045 0.638 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.004 0.700 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.004 0.700 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.001 0.739 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.001 0.733 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.001 0.728 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.003 0.702 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.010 0.678 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.005 0.694 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.002 0.708 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.001 0.721 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.001 0.739 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.000 0.778 CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK 57&121 0.004 0.701 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.000 0.773 CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR 57&129 0.010 0.677 CATD_VGFAEAAR_vs_PSG1_FQLPGQK 57&131 0.001 0.719 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.001 0.729 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.000 0.749 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.001 0.723 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.001 0.722 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.000 0.762 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.000 0.757 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.000 0.744 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.000 0.743 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.001 0.739 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.001 0.728 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.001 0.725 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.004 0.698 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.004 0.700 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.001 0.724 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.002 0.716 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.001 0.728 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.004 0.700 CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR 58&98 0.009 0.680 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.003 0.707 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.001 0.719 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.001 0.732 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.001 0.724 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.000 0.771 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58&121 0.003 0.704 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.000 0.775 CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR 58&129 0.028 0.652 CATD_VSTLPAITLK_vs_PSG1_FQLPGQK 58&131 0.005 0.693 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.001 0.737 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.000 0.755 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.003 0.707 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.004 0.696 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.000 0.753 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.000 0.765 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.000 0.742 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.001 0.729 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.000 0.745 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.042 0.640 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR 59&18 0.011 0.674 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.020 0.660 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR 60&18 0.019 0.661 CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR 60&140 0.016 0.665 CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK 61&97 0.028 0.651 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.002 0.717 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.004 0.699 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.003 0.703 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.049 0.635 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.020 0.660 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.031 0.648 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.009 0.680 CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK 62&97 0.029 0.650 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.002 0.709 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.005 0.692 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.005 0.695 CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR 62&140 0.025 0.654 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.028 0.652 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.007 0.684 CLUS_ASSIIDELFQDR_vs_IBP1_VVESLAK 67&97 0.048 0.636 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.007 0.686 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.016 0.665 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.006 0.691 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.036 0.644 CLUS_LFDSDPITVTVPVEVSR_vs_IBP1_VVESLAK 68&97 0.047 0.637 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.006 0.688 CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR 68&126 0.023 0.656 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR 68&18 0.007 0.687 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.020 0.660 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.012 0.674 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.043 0.639 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.016 0.666 CO5_TLLPVSKPEIR_vs_SPRL1_VLTHSELAPLR 70&140 0.042 0.640 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.025 0.654 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.023 0.656 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.043 0.639 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.027 0.653 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.013 0.670 CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.026 0.653 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.022 0.658 CO8B_QALEEFQK_vs_IBP1_VVESLAK 76&97 0.044 0.639 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.012 0.673 CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR 76&126 0.030 0.649 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.024 0.655 CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR 76&140 0.040 0.641 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR 82&120 0.036 0.644 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR 82&126 0.037 0.643 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.029 0.650 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.021 0.659 ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR 83&126 0.025 0.655 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.026 0.653 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.044 0.639 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.039 0.643 F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK 84&97 0.033 0.647 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.001 0.732 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.005 0.694 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.003 0.708 F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR 84&140 0.007 0.685 F13B_GDTYPAELYITGSILR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 84&144 0.046 0.638 F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK 84&147 0.037 0.644 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.012 0.674 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.017 0.664 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.023 0.657 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.019 0.662 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.014 0.668 HEMO_NFPSPVDAAFR_vs_PGRP2_AGLLRPDYALLGHR 93&126 0.046 0.637 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.008 0.683 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.024 0.655 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.024 0.656 IBP4_QCHPALDGQR_vs_IBP1_VVESLAK 2&97 0.026 0.653 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.002 0.713 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.008 0.683 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.002 0.709 IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR 2&140 0.015 0.667 IBP6_GAQTLYVPNCDHR_vs_PGRP2_AGLLRPDYALLGHR 101&126 0.030 0.650 IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR 101&18 0.013 0.671 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.020 0.660 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR 102&18 0.010 0.677 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.046 0.637 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.028 0.652 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.033 0.647 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.026 0.653 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.017 0.665 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.027 0.653 KNG1_QVVAGLNFR_vs_IBP1_VVESLAK 117&97 0.032 0.648 KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR 117&112 0.028 0.651 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.002 0.711 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.010 0.677 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.003 0.703 KNG1_QVVAGLNFR_vs_SPRL1_VLTHSELAPLR 117&140 0.019 0.662 PEDF_LQSLFDSPDFSK_vs_IBP1_VVESLAK 124&97 0.044 0.639 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.004 0.697 PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR 124&126 0.043 0.640 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.017 0.665 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.003 0.702 PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR 125&126 0.025 0.654 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR 125&18 0.012 0.673 PEDF_TVQAVLTVPK_vs_SPRL1_VLTHSELAPLR 125&140 0.036 0.645 PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR 128&78 0.028 0.651 PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK 128&79 0.026 0.653 PRDX2_GLFIIDGK_vs_IBP1_VVESLAK 128&97 0.024 0.655 PRDX2_GLFIIDGK_vs_IBP2_LIQGAPTIR 128&98 0.040 0.641 PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR 128&120 0.009 0.681 PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGHR 128&126 0.009 0.679 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.004 0.697 PRDX2_GLFIIDGK_vs_SPRL1_VLTHSELAPLR 128&140 0.042 0.640 PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR 128&141 0.038 0.643 PRDX2_GLFIIDGK_vs_VTDB_ELPEHTVK 128&147 0.041 0.641 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.049 0.635 PTGDS_GPGEDFR_vs_IBP1_VVESLAK 137&97 0.039 0.642 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.009 0.681 PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGHR 137&126 0.017 0.665 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.010 0.677 PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF 137&139 0.048 0.636 PTGDS_GPGEDFR_vs_SPRL1_VLTHSELAPLR 137&140 0.035 0.645 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.018 0.663 THBG_AVLHIGEK_vs_PGRP2_AGLLRPDYALLGHR 143&126 0.025 0.655 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.023 0.657 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.008 0.684 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.020 0.660 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.012 0.674 VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR 149&140 0.047 0.637 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.008 0.684 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.019 0.661 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.007 0.686 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.030 0.649
(477) TABLE-US-00058 TABLE58 ReversalClassificationPerformance,weeks19,20and21 ReversalAUROCforgestationalweeks190/7through216/7using acasevscontrolcut-offof<350/7vs>=350/7weeks,with BMIstratification(>22<=37). Reversal SEQIDNO: pval ROC_AUC A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.025 0.688 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.029 0.683 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.026 0.687 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.011 0.714 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.002 0.755 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.006 0.730 AFAM_DADPDTFFAK_vs_VTDB_ELPEHTVK 37&147 0.024 0.689 AFAM_HFQNLGK_vs_IBP1_VVESLAK 38&97 0.034 0.684 AFAM_HFQNLGK_vs_ITIH4_ILDDLSPR 38&112 0.025 0.688 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.004 0.744 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.001 0.770 AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR 38&18 0.004 0.738 AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF 38&139 0.023 0.690 AFAM_HFQNLGK_vs_VTDB_ELPEHTVK 38&147 0.009 0.719 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.023 0.690 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.037 0.675 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.006 0.730 APOH_ATVVYQGER_vs_IBP1_VVESLAK 48&97 0.049 0.665 APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR 48&112 0.049 0.665 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.006 0.729 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.001 0.788 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.003 0.750 APOH_ATVVYQGER_vs_VTDB_ELPEHTVK 48&147 0.012 0.711 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.027 0.686 B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR 50&18 0.027 0.685 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.004 0.740 B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR 51&126 0.009 0.718 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.006 0.731 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.043 0.670 BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLGHR 52&126 0.027 0.685 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR 52&18 0.027 0.685 CAH1_GGPFSDSYR_vs_LYAM1_SYYWIGIR 56&120 0.041 0.671 CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR 56&126 0.041 0.671 CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR 56&18 0.013 0.708 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.008 0.723 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.000 0.791 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.010 0.716 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.009 0.717 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.001 0.773 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.001 0.771 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.034 0.677 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.012 0.711 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.016 0.701 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.018 0.698 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.014 0.705 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.012 0.711 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.002 0.765 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.000 0.807 CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK 57&121 0.014 0.706 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.000 0.811 CATD_VGFAEAAR_vs_PSG1_FQLPGQK 57&131 0.008 0.723 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.014 0.706 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.001 0.787 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.003 0.751 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.002 0.753 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.003 0.746 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.003 0.745 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.013 0.708 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.005 0.735 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.004 0.743 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.002 0.761 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.002 0.758 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.006 0.731 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.004 0.741 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.001 0.775 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.001 0.769 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.022 0.692 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.006 0.730 CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR 58&98 0.011 0.714 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.005 0.733 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.006 0.729 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.004 0.744 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.001 0.784 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.000 0.825 CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK 58&121 0.006 0.728 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.000 0.841 CATD_VSTLPAITLK_vs_PSG1_FQLPGQK 58&131 0.016 0.701 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.005 0.734 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.000 0.810 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.003 0.745 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.004 0.741 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.002 0.759 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.001 0.780 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.005 0.736 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.002 0.753 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.001 0.778 CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR 59&18 0.023 0.690 CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR 60&120 0.038 0.674 CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR 60&18 0.016 0.702 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.008 0.721 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.005 0.735 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.006 0.731 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.041 0.671 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.015 0.704 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.011 0.712 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.010 0.716 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.020 0.695 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.014 0.705 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.011 0.712 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.044 0.668 CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR 68&126 0.045 0.668 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR 68&18 0.020 0.694 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.039 0.672 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.018 0.698 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.039 0.672 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.022 0.692 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.044 0.669 CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR 74&126 0.032 0.679 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.032 0.679 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.041 0.671 CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR 76&126 0.037 0.674 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.039 0.672 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.050 0.664 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.002 0.765 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.002 0.755 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.002 0.764 F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK 84&147 0.041 0.671 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.039 0.673 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.019 0.697 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.034 0.678 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.018 0.699 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.042 0.670 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.015 0.704 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.048 0.666 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.002 0.756 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.004 0.741 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.002 0.760 IBP6_GAQTLYVPNCDHR_vs_PGRP2_AGLLRPDYALLGHR 101&126 0.019 0.697 IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR 101&18 0.024 0.689 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.014 0.706 IBP6_HLDSVLQQLQTEVYR_vs_PGRP2_AGLLRPDYALLGHR 102&126 0.027 0.686 IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR 102&18 0.009 0.720 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.037 0.675 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.021 0.693 ITIH4_NPLVWVHASPEHVVVTR_vs_ALS_IRPHTFTGLSGLR 113&40 0.034 0.678 ITIH4_NPLVWVHASPEHVVVTR_vs_CHL1_VIAVNEVGR 113&66 0.045 0.667 ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_AHQLAIDTYQEFEETYIPK 113&80 0.044 0.668 ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR 113&86 0.016 0.701 ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_FLNVLSPR 113&99 0.025 0.688 ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_YGQPLPGYTTK 113&100 0.030 0.682 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL 113&134 0.033 0.678 ITIH4_NPLVWVHASPEHVVVTR_vs_SOM2.CSH_NYGLLYCFR 113&138 0.021 0.693 ITIH4_NPLVWVHASPEHVVVTR_vs_SPRL1_VLTHSELAPLR 113&140 0.042 0.670 ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR 113&142 0.028 0.684 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TENX_LSQLSVTDVTTSSLR 114&142 0.029 0.683 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.040 0.672 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.009 0.717 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.020 0.695 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.012 0.711 PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.039 0.672 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.035 0.676 PAPP1_DIPHWLNPTR_vs_CSH_AHQLAIDTYQEFEETYIPK 122&80 0.029 0.683 PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPVR 122&81 0.019 0.696 PAPP1_DIPHWLNPTR_vs_IBP1_VVESLAK 122&97 0.047 0.666 PAPP1_DIPHWLNPTR_vs_IBP2_LIQGAPTIR 122&98 0.027 0.686 PAPP1_DIPHWLNPTR_vs_ITIH4_ILDDLSPR 122&112 0.046 0.667 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.007 0.726 PAPP1_DIPHWLNPTR_vs_PGRP2_AGLLRPDYALLGHR 122&126 0.007 0.725 PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR 122&129 0.021 0.693 PAPP1_DIPHWLNPTR_vs_PSG1_FQLPGQK 122&131 0.043 0.670 PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR 122&18 0.005 0.734 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYCFR 122&138 0.028 0.684 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF 122&139 0.004 0.743 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.008 0.722 PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR 124&126 0.024 0.689 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.008 0.720 PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK 124&147 0.023 0.690 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.008 0.722 PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR 125&126 0.019 0.697 PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR 125&18 0.007 0.726 PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR 128&120 0.034 0.677 PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGHR 128&126 0.026 0.687 PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR 128&18 0.011 0.713 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.038 0.674 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.023 0.690 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.031 0.680 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.009 0.717 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.006 0.728 PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGHR 137&126 0.006 0.731 PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR 137&18 0.009 0.719 PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF 137&139 0.027 0.685 THBG_AVLHIGEK_vs_PGRP2_AGLLRPDYALLGHR 143&126 0.047 0.666 THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR 143&18 0.039 0.673 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.009 0.717 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.012 0.711 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.011 0.714 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.023 0.690 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.024 0.688 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.008 0.722
(478) TABLE-US-00059 TABLE59 AdditionalReversals Reversal SEQIDNO: AFAM_DADPDTFFAK_vs_ALS_IRPHTFTGLSGLR 37&40 AFAM_DADPDTFFAK_vs_CRIS3_AVSPPAR 37&78 AFAM_DADPDTFFAK_vs_CSH_AHQLAIDTYQEFEETYIPK 37&80 AFAM_DADPDTFFAK_vs_CSH_ISLLLIESWLEPVR 37&81 AFAM_DADPDTFFAK_vs_IBP1_VVESLAK 37&97 AFAM_HFQNLGK_vs_C163A_INPASLDK 38&54 AFAM_HFQNLGK_vs_CSH_AHQLAIDTYQEFEETYIPK 38&80 AFAM_HFQNLGK_vs_CSH_ISLLLIESWLEPVR 38&81 AFAM_HFQNLGK_vs_FBLN1_TGYYFDGISR 38&86 ANGT_DPTFIPAPIQAK_vs_ALS_IRPHTFTGLSGLR 42&40 ANGT_DPTFIPAPIQAK_vs_IBP1_VVESLAK 42&97 ANGT_DPTFIPAPIQAK_vs_ITIH4_ILDDLSPR 42&112 APOH_ATVVYQGER_vs_CSH_ISLLLIESWLEPVR 48&81 APOH_ATVVYQGER_vs_IBP2_LIQGAPTIR 48&98 APOH_ATVVYQGER_vs_SOM2.CSH_SVEGSCGF 48&139 B2MG_VEHSDLSFSK_vs_C163A_INPASLDK 50&54 B2MG_VEHSDLSFSK_vs_IBP1_VVESLAK 50&97 B2MG_VEHSDLSFSK_vs_PSG9_LFIPQITR 50&136 B2MG_VEHSDLSFSK_vs_SPRL1_VLTHSELAPLR 50&140 B2MG_VNHVTLSQPK_vs_CSH_AHQLAIDTYQEFEETYIPK 51&80 B2MG_VNHVTLSQPK_vs_FBLN1_TGYYFDGISR 51&86 B2MG_VNHVTLSQPK_vs_PSG9_LFIPQITR 51&136 B2MG_VNHVTLSQPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 51&144 B2MG_VNHVTLSQPK_vs_VTDB_ELPEHTVK 51&147 BGH3_LTLLAPLNSVFK_vs_C163A_INPASLDK 52&54 BGH3_LTLLAPLNSVFK_vs_IBP1_VVESLAK 52&97 BGH3_LTLLAPLNSVFK_vs_SPRL1_VLTHSELAPLR 52&140 BGH3_LTLLAPLNSVFK_vs_VTDB_ELPEHTVK 52&147 CAH1_GGPFSDSYR_vs_ALS_IRPHTFTGLSGLR 56&40 CAH1_GGPFSDSYR_vs_CSH_AHQLAIDTYQEFEETYIPK 56&80 CAH1_GGPFSDSYR_vs_CSH_ISLLLIESWLEPVR 56&81 CAH1_GGPFSDSYR_vs_FBLN1_TGYYFDGISR 56&86 CAH1_GGPFSDSYR_vs_IBP2_LIQGAPTIR 56&98 CAH1_GGPFSDSYR_vs_IBP3_YGQPLPGYTTK 56&100 CAH1_GGPFSDSYR_vs_IGF2_GIVEECCFR 56&103 CAH1_GGPFSDSYR_vs_ITIH4_ILDDLSPR 56&112 CAH1_GGPFSDSYR_vs_PRG2_WNFAYWAAHQPWSR 56&129 CAH1_GGPFSDSYR_vs_SOM2.CSH_SVEGSCGF 56&139 CAH1_GGPFSDSYR_vs_SPRL1_VLTHSELAPLR 56&140 CAH1_GGPFSDSYR_vs_VTDB_ELPEHTVK 56&147 CBPN_EALIQFLEQVHQGIK_vs_CRIS3_AVSPPAR 59&78 CBPN_EALIQFLEQVHQGIK_vs_IBP1_VVESLAK 59&97 CBPN_EALIQFLEQVHQGIK_vs_PGRP2_AGLLRPDYALLGHR 59&126 CBPN_EALIQFLEQVHQGIK_vs_SPRL1_VLTHSELAPLR 59&140 CBPN_NNANGVDLNR_vs_CRIS3_AVSPPAR 60&78 CBPN_NNANGVDLNR_vs_IBP1_VVESLAK 60&97 CBPN_NNANGVDLNR_vs_PSG9_LFIPQITR 60&136 CD14_LTVGAAQVPAQLLVGALR_vs_ALS_IRPHTFTGLSGLR 61&40 CD14_LTVGAAQVPAQLLVGALR_vs_IBP2_LIQGAPTIR 61&98 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_NYGLLYCFR 61&138 CD14_SWLAELQQWLKPGLK_vs_ALS_IRPHTFTGLSGLR 62&40 CD14_SWLAELQQWLKPGLK_vs_CSH_ISLLLIESWLEPVR 62&81 CD14_SWLAELQQWLKPGLK_vs_IBP3_FLNVLSPR 62&99 CD14_SWLAELQQWLKPGLK_vs_IBP3_YGQPLPGYTTK 62&100 CD14_SWLAELQQWLKPGLK_vs_NCAM1_GLGEISAASEFK 62&121 CD14_SWLAELQQWLKPGLK_vs_PSG9_LFIPQITR 62&136 CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_NYGLLYCFR 62&138 CFAB_YGLVTYATYPK_vs_IBP1_VVESLAK 64&97 CLUS_ASSIIDELFQDR_vs_CSH_ISLLLIESWLEPVR 67&81 CLUS_ASSIIDELFQDR_vs_ITIH4_ILDDLSPR 67&112 CLUS_ASSIIDELFQDR_vs_PRG2_WNFAYWAAHQPWSR 67&129 CLUS_ASSIIDELFQDR_vs_PSG9_LFIPQITR 67&136 CLUS_ASSIIDELFQDR_vs_SOM2.CSH_SVEGSCGF 67&139 CLUS_ASSIIDELFQDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 67&144 CLUS_LFDSDPITVTVPVEVSR_vs_CSH_ISLLLIESWLEPVR 68&81 CLUS_LFDSDPITVTVPVEVSR_vs_NCAM1_GLGEISAASEFK 68&121 CLUS_LFDSDPITVTVPVEVSR_vs_PSG9_LFIPQITR 68&136 CLUS_LFDSDPITVTVPVEVSR_vs_SOM2.CSH_NYGLLYCFR 68&138 CLUS_LFDSDPITVTVPVEVSR_vs_SOM2.CSH_SVEGSCGF 68&139 CO5_TLLPVSKPEIR_vs_C163A_INPASLDK 70&54 CO5_TLLPVSKPEIR_vs_IBP1_VVESLAK 70&97 CO5_TLLPVSKPEIR_vs_IBP3_FLNVLSPR 70&99 CO5_TLLPVSKPEIR_vs_PSG9_LFIPQITR 70&136 CO5_VFQFLEK_vs_IBP1_VVESLAK 71&97 CO5_VFQFLEK_vs_PSG9_LFIPQITR 71&136 CO5_VFQFLEK_vs_SPRL1_VLTHSELAPLR 71&140 CO6_ALNHLPLEYNSALYSR_vs_CRIS3_AVSPPAR 72&78 CO6_ALNHLPLEYNSALYSR_vs_IBP1_VVESLAK 72&97 CO6_ALNHLPLEYNSALYSR_vs_PSG9_LFIPQITR 72&136 CO6_ALNHLPLEYNSALYSR_vs_SPRL1_VLTHSELAPLR 72&140 CO8A_SLLQPNK_vs_CSH_ISLLLIESWLEPVR 74&81 CO8A_SLLQPNK_vs_ITIH4_ILDDLSPR 74&112 CO8A_SLLQPNK_vs_SOM2.CSH_NYGLLYCFR 74&138 CO8A_SLLQPNK_vs_SOM2.CSH_SVEGSCGF 74&139 CO8B_QALEEFQK_vs_CSH_ISLLLIESWLEPVR 76&81 CO8B_QALEEFQK_vs_ITIH4_ILDDLSPR 76&112 F13B_GDTYPAELYITGSILR_vs_ALS_IRPHTFTGLSGLR 84&40 F13B_GDTYPAELYITGSILR_vs_C163A_INPASLDK 84&54 F13B_GDTYPAELYITGSILR_vs_CSH_ISLLLIESWLEPVR 84&81 F13B_GDTYPAELYITGSILR_vs_ITIH4_ILDDLSPR 84&112 F13B_GDTYPAELYITGSILR_vs_NCAM1_GLGEISAASEFK 84&121 F13B_GDTYPAELYITGSILR_vs_PSG9_LFIPQITR 84&136 F13B_GDTYPAELYITGSILR_vs_SOM2.CSH_NYGLLYCFR 84&138 F13B_GDTYPAELYITGSILR_vs_SOM2.CSH_SVEGSCGF 84&139 FBLN3_IPSNPSHR_vs_ALS_IRPHTFTGLSGLR 87&40 FBLN3_IPSNPSHR_vs_FBLN1_TGYYFDGISR 87&86 FBLN3_IPSNPSHR_vs_IBP3_FLNVLSPR 87&99 FBLN3_IPSNPSHR_vs_ITIH4_ILDDLSPR 87&112 FBLN3_IPSNPSHR_vs_NCAM1_GLGEISAASEFK 87&121 FBLN3_IPSNPSHR_vs_PSG3_VSAPSGTGHLPGLNPL 87&134 FBLN3_IPSNPSHR_vs_PSG9_LFIPQITR 87&136 FBLN3_IPSNPSHR_vs_VTDB_ELPEHTVK 87&147 FETUA_FSVVYAK_vs_NCAM1_GLGEISAASEFK 88&121 FETUA_HTLNQIDEVK_vs_NCAM1_GLGEISAASEFK 89&121 HABP2_FLNWIK_vs_ALS_IRPHTFTGLSGLR 92&40 HABP2_FLNWIK_vs_IBP1_VVESLAK 92&97 HEMO_NFPSPVDAAFR_vs_IBP1_VVESLAK 93&97 HEMO_NFPSPVDAAFR_vs_PSG9_LFIPQITR 93&136 HEMO_NFPSPVDAAFR_vs_SPRL1_VLTHSELAPLR 93&140 HLACI_WAAVVVPSGEEQR_vs_IBP1_VVESLAK 95&97 HLACI_WAAVVVPSGEEQR_vs_LYAM1_SYYWIGIR 95&120 IBP6_GAQTLYVPNCDHR_vs_ALS_IRPHTFTGLSGLR 101&40 IBP6_GAQTLYVPNCDHR_vs_CRIS3_AVSPPAR 101&78 IBP6_GAQTLYVPNCDHR_vs_IBP1_VVESLAK 101&97 IBP6_GAQTLYVPNCDHR_vs_IBP2_LIQGAPTIR 101&98 IBP6_GAQTLYVPNCDHR_vs_IBP3_FLNVLSPR 101&99 IBP6_GAQTLYVPNCDHR_vs_IBP3_YGQPLPGYTTK 101&100 IBP6_GAQTLYVPNCDHR_vs_SPRL1_VLTHSELAPLR 101&140 IBP6_GAQTLYVPNCDHR_vs_TENX_LNWEAPPGAFDSFLLR 101&141 IBP6_GAQTLYVPNCDHR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 101&144 IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_AVSPPAR 102&78 IBP6_HLDSVLQQLQTEVYR_vs_IBP1_VVESLAK 102&97 IBP6_HLDSVLQQLQTEVYR_vs_IBP2_LIQGAPTIR 102&98 IBP6_HLDSVLQQLQTEVYR_vs_IBP3_FLNVLSPR 102&99 IBP6_HLDSVLQQLQTEVYR_vs_IBP3_YGQPLPGYTTK 102&100 IBP6_HLDSVLQQLQTEVYR_vs_PSG9_LFIPQITR 102&136 IBP6_HLDSVLQQLQTEVYR_vs_SOM2.CSH_SVEGSCGF 102&139 IBP6_HLDSVLQQLQTEVYR_vs_SPRL1_VLTHSELAPLR 102&140 IBP6_HLDSVLQQLQTEVYR_vs_TENX_LNWEAPPGAFDSFLLR 102&141 IBP6_HLDSVLQQLQTEVYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 102&144 INHBC_LDFHFSSDR_vs_IBP1_VVESLAK 107&97 ITIH3_ALDLSLK_vs_PSG9_LFIPQITR 111&136 ITIH4_NPLVWVHASPEHVVVTR_vs_C163A_INPASLDK 113&54 ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_ISLLLIESWLEPVR 113&81 ITIH4_NPLVWVHASPEHVVVTR_vs_PSG1_FQLPGQK 113&131 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_ALS_IRPHTFTGLSGLR 114&40 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_C163A_INPASLDK 114&54 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CHL1_VIAVNEVGR 114&66 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CSH_AHQLAIDTYQEFEETYIPK 114&80 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_FBLN1_TGYYFDGISR 114&86 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_IBP3_FLNVLSPR 114&99 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_IBP3_YGQPLPGYTTK 114&100 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_IGF2_GIVEECCFR 114&103 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_ITIH4_ILDDLSPR 114&112 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_NCAM1_GLGEISAASEFK 114&121 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PRG2_WNFAYWAAHQPWSR 114&129 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG1_FQLPGQK 114&131 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_SOM2.CSH_NYGLLYCFR 114&138 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_SPRL1_VLTHSELAPLR 114&140 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TENX_LNWEAPPGAFDSFLLR 114&141 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 114&144 ITIH4_QLGLPGPPDVPDHAAYHPF_vs_VTDB_ELPEHTVK 114&147 KNG1_DIPTNSPELEETLTHTITK_vs_C163A_INPASLDK 116&54 KNG1_DIPTNSPELEETLTHTITK_vs_IBP3_FLNVLSPR 116&99 KNG1_DIPTNSPELEETLTHTITK_vs_IBP3_YGQPLPGYTTK 116&100 KNG1_DIPTNSPELEETLTHTITK_vs_PGRP2_AGLLRPDYALLGHR 116&126 KNG1_DIPTNSPELEETLTHTITK_vs_PSG9_LFIPQITR 116&136 KNG1_DIPTNSPELEETLTHTITK_vs_SOM2.CSH_SVEGSCGF 116&139 KNG1_DIPTNSPELEETLTHTITK_vs_VTDB_ELPEHTVK 116&147 KNG1_QVVAGLNFR_vs_ALS_IRPHTFTGLSGLR 117&40 KNG1_QVVAGLNFR_vs_CSH_ISLLLIESWLEPVR 117&81 KNG1_QVVAGLNFR_vs_PSG9_LFIPQITR 117&136 KNG1_QVVAGLNFR_vs_SOM2.CSH_NYGLLYCFR 117&138 KNG1_QVVAGLNFR_vs_SOM2.CSH_SVEGSCGF 117&139 LBP_ITGFLKPGK_vs_FBLN1_TGYYFDGISR 118&86 LBP_ITGFLKPGK_vs_NCAM1_GLGEISAASEFK 118&121 PAPP1_DIPHWLNPTR_vs_ALS_IRPHTFTGLSGLR 122&40 PAPP1_DIPHWLNPTR_vs_CHL1_VIAVNEVGR 122&66 PAPP1_DIPHWLNPTR_vs_FBLN1_TGYYFDGISR 122&86 PAPP1_DIPHWLNPTR_vs_IBP3_FLNVLSPR 122&99 PAPP1_DIPHWLNPTR_vs_IBP3_YGQPLPGYTTK 122&100 PAPP1_DIPHWLNPTR_vs_IGF2_GIVEECCFR 122&103 PAPP1_DIPHWLNPTR_vs_NCAM1_GLGEISAASEFK 122&121 PAPP1_DIPHWLNPTR_vs_PSG3_VSAPSGTGHLPGLNPL 122&134 PAPP1_DIPHWLNPTR_vs_SPRL1_VLTHSELAPLR 122&140 PAPP1_DIPHWLNPTR_vs_TENX_LNWEAPPGAFDSFLLR 122&141 PAPP1_DIPHWLNPTR_vs_TENX_LSQLSVTDVTTSSLR 122&142 PAPP1_DIPHWLNPTR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 122&144 PAPP1_DIPHWLNPTR_vs_VTDB_ELPEHTVK 122&147 PEDF_LQSLFDSPDFSK_vs_PSG9_LFIPQITR 124&136 PEDF_LQSLFDSPDFSK_vs_SPRL1_VLTHSELAPLR 124&140 PEDF_TVQAVLTVPK_vs_IBP1_VVESLAK 125&97 PEDF_TVQAVLTVPK_vs_IBP2_LIQGAPTIR 125&98 PEDF_TVQAVLTVPK_vs_IBP3_FLNVLSPR 125&99 PEDF_TVQAVLTVPK_vs_ITIH4_ILDDLSPR 125&112 PRDX2_GLFIIDGK_vs_ALS_IRPHTFTGLSGLR 128&40 PRDX2_GLFIIDGK_vs_CSH_AHQLAIDTYQEFEETYIPK 128&80 PRDX2_GLFIIDGK_vs_CSH_ISLLLIESWLEPVR 128&81 PRDX2_GLFIIDGK_vs_FBLN1_TGYYFDGISR 128&86 PRDX2_GLFIIDGK_vs_IBP3_FLNVLSPR 128&99 PRDX2_GLFIIDGK_vs_IBP3_YGQPLPGYTTK 128&100 PRDX2_GLFIIDGK_vs_IGF2_GIVEECCFR 128&103 PRDX2_GLFIIDGK_vs_ITIH4_ILDDLSPR 128&112 PRDX2_GLFIIDGK_vs_NCAM1_GLGEISAASEFK 128&121 PRDX2_GLFIIDGK_vs_PSG1_FQLPGQK 128&131 PRDX2_GLFIIDGK_vs_SOM2.CSH_NYGLLYCFR 128&138 PRDX2_GLFIIDGK_vs_SOM2.CSH_SVEGSCGF 128&139 PSG11_LFIPQITPK_vs_LYAM1_SYYWIGIR 132&120 PSG11_LFIPQITPK_vs_SHBG_IALGGLLFPASNLR 132&18 PSG2_IHPSYTNYR_vs_PRG2_WNFAYWAAHQPWSR 133&129 PTGDS_GPGEDFR_vs_CSH_AHQLAIDTYQEFEETYIPK 137&80 PTGDS_GPGEDFR_vs_CSH_ISLLLIESWLEPVR 137&81 PTGDS_GPGEDFR_vs_IBP2_LIQGAPTIR 137&98 PTGDS_GPGEDFR_vs_PSG9_LFIPQITR 137&136 THBG_AVLHIGEK_vs_CRIS3_AVSPPAR 143&78 THBG_AVLHIGEK_vs_IBP1_VVESLAK 143&97 THBG_AVLHIGEK_vs_IBP3_FLNVLSPR 143&99 THBG_AVLHIGEK_vs_PSG9_LFIPQITR 143&136 THBG_AVLHIGEK_vs_SPRL1_VLTHSELAPLR 143&140 VTNC_VDTVDPPYPR_vs_IBP1_VVESLAK 150&97
(479) TABLE-US-00060 TABLE60 ClockProteins ShortName ProteinName Analyte SEQIDNO: ADA12 Adam12 FGFGGSTDSGPIR 151 ADA12 Adam12 LIEIANHVDK 152 ANGT Angiotensinogen DPTFIPAPIQAK 42 CSH Chorionicsomatomammotropinhormone AHQLAIDTYQEFEETYIPK 80 1&2 CSH Chorionicsomatomammotropinhormone ISLLLIESWLEPVR 81 1&2 FBLN1 Fibulin-1 TGYYFDGISR 86 PAI2 Plasminogenactivatorinhibitor2 LNIGYIEDLK 153 PAPP1 Pappalysin-1 DIPHWLNPTR 122 PSG11 Pregnancy-specificbeta-1-glycoprotein11 DLYHYITSYVVDGEIIIYGPAYSGR 130 PSG1 Pregnancy-specificbeta-1-glycoprotein1 FQLPGQK 131 PSG2 Pregnancy-specificbeta-1-glycoprotein2 IHPSYTNYR 133 PSG6 Pregnancy-specificbeta-1-glycoprotein6 SNPVTLNVLYGPDLPR 154 PSG9 Pregnancy-specificbeta-1-glycoprotein9 DVLLLVHNLPQNLPGYFWYK 135 PSG9 Pregnancy-specificbeta-1-glycoprotein9 LFIPQITR 136 SOM2.CSH Placenta-specificgrowthhormone& NYGLLYCFR 138 Chorionicsomatomammotropinhormone 1&2 SOM2.CSH Placenta-specificgrowthhormone& SVEGSCGF 139 Chorionicsomatomammotropinhormone 1&2 TENX Tenascin-X LSQLSVTDVTTSSLR 142 TIE1 Tyrosine-proteinkinasereceptor VSWSLPLVPGPLVGDGFLLR 144 VGFR3 Vascularendothelialgrowthfactorreceptor SGVDLADSNQK 155 3 VGFR3 Vascularendothelialgrowthfactorreceptor HATLSLSIPR 156 3
(480) TABLE-US-00061 TABLE61 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through21 6/7usingacasevscontrolcut-offof<370/7vs>=37 0/7weeks,withoutBMIstratification,separatelyfor PPROMandPTL. 119_ 119_ 119_ 119_ 153_ 153_ 153_ 153_ aBMI_37 aBMI_37 aBMI_37 aBMI_37 SEQID PTL PTL PPROM PPROM Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.56 0.18 0.66 0.001 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.58 0.0951 0.65 0.0019 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.56 0.2369 0.66 0.0012 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.57 0.1185 0.67 5.00E-04 APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR 47&40 0.58 0.0739 0.66 8.00E-04 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.58 0.0834 0.67 7.00E-04 APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR 47&66 0.58 0.0919 0.66 0.0011 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.56 0.1948 0.68 2.00E-04 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.57 0.1492 0.68 2.00E-04 APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK 47&80 0.59 0.0705 0.66 7.00E-04 APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR 47&81 0.58 0.1112 0.65 0.0026 APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR 47&86 0.56 0.1845 0.68 3.00E-04 APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR 47&98 0.54 0.3592 0.66 8.00E-04 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.6 0.0431 0.67 3.00E-04 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.59 0.0487 0.67 4.00E-04 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.6 0.0289 0.68 2.00E-04 APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR 47&112 0.59 0.0664 0.66 8.00E-04 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.57 0.1171 0.69 1.00E-04 APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK 47&121 0.58 0.081 0.65 0.0014 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.58 0.0931 0.68 2.00E-04 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.63 0.0045 0.65 0.0014 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.56 0.2234 0.66 0.001 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.55 0.2511 0.65 0.0018 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.59 0.0618 0.67 4.00E-04 APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR 47&140 0.56 0.2251 0.66 7.00E-04 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.58 0.0834 0.68 2.00E-04 APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR 47&142 0.58 0.0829 0.67 5.00E-04 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.59 0.0703 0.67 4.00E-04 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.59 0.0703 0.67 4.00E-04 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.66 0.001 0.57 0.1723 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.55 0.2492 0.67 6.00E-04 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.55 0.2632 0.65 0.0018 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.57 0.1178 0.66 9.00E-04 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.55 0.3208 0.67 6.00E-04 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.55 0.3012 0.66 7.00E-04 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.54 0.403 0.67 5.00E-04 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.55 0.2536 0.67 6.00E-04 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.54 0.3953 0.67 6.00E-04 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.57 0.1412 0.65 0.0023 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.67 3.00E-04 0.59 0.0542 CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR 64&18 0.6 0.0426 0.65 0.0024 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.66 0.001 0.58 0.1098 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.57 0.1453 0.65 0.0016 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.55 0.2704 0.65 0.0015 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.65 0.0013 0.57 0.129 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.57 0.1316 0.66 0.0013 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.56 0.2455 0.65 0.0018 COSA_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL 74&134 0.65 0.002 0.58 0.1094 CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR 74&18 0.57 0.1375 0.65 0.0024 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.58 0.1016 0.65 0.0021 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.65 0.002 0.59 0.0605 CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR 76&18 0.56 0.181 0.65 0.0017 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.58 0.1026 0.66 0.0012 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.57 0.1566 0.67 5.00E-04 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.55 0.3336 0.66 8.00E-04 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.55 0.2717 0.67 3.00E-04 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.59 0.0659 0.67 4.00E-04 FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR 88&18 0.54 0.4516 0.67 3.00E-04 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR 88&141 0.54 0.3979 0.68 2.00E-04 FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR 89&18 0.54 0.3878 0.67 5.00E-04 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.55 0.3019 0.68 2.00E-04 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.56 0.2049 0.66 0.0013 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.61 0.0245 0.65 0.0019 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.55 0.26 0.66 8.00E-04 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.56 0.2393 0.68 2.00E-04 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.54 0.3466 0.66 9.00E-04 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.56 0.2286 0.67 3.00E-04 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.54 0.4212 0.67 5.00E-04 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.55 0.2684 0.65 0.0016 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.55 0.2523 0.66 9.00E-04 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.57 0.1643 0.69 1.00E-04 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.67 3.00E-04 0.61 0.0185 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.6 0.0371 0.67 3.00E-04 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.57 0.1255 0.67 6.00E-04 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.56 0.188 0.67 6.00E-04 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.56 0.243 0.68 3.00E-04 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.56 0.188 0.67 3.00E-04 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.59 0.0635 0.69 1.00E-04 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.54 0.3936 0.66 7.00E-04 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.53 0.549 0.68 2.00E-04 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.54 0.3911 0.71 0 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.6 0.0281 0.67 4.00E-04 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.56 0.1922 0.68 3.00E-04 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.56 0.2054 0.7 0 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.55 0.2724 0.67 4.00E-04 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.55 0.29 0.66 7.00E-04 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.55 0.3313 0.68 1.00E-04 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.56 0.1969 0.69 1.00E-04 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.55 0.3283 0.66 0.001 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.53 0.4899 0.67 3.00E-04 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.56 0.2357 0.65 0.0019 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.54 0.3459 0.67 4.00E-04 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.58 0.1007 0.65 0.0024 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.53 0.487 0.68 1.00E-04 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118&126 0.53 0.4842 0.68 2.00E-04 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.63 0.0062 0.65 0.0024 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.56 0.2049 0.69 1.00E-04 LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR 118&141 0.54 0.382 0.66 8.00E-04 LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK 118&147 0.54 0.3672 0.66 8.00E-04 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.54 0.3746 0.68 3.00E-04 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.57 0.1308 0.67 5.00E-04 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.55 0.3298 0.69 1.00E-04 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.56 0.2228 0.69 1.00E-04 LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK 119&80 0.56 0.1911 0.65 0.0025 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.6 0.0373 0.66 9.00E-04 LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR 119&112 0.54 0.3482 0.67 3.00E-04 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.55 0.3048 0.71 0 LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK 119&121 0.57 0.1553 0.65 0.0025 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.55 0.3105 0.7 0 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.64 0.0028 0.66 9.00E-04 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.57 0.115 0.7 0 LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF 119&139 0.57 0.1245 0.65 0.0027 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.56 0.2387 0.68 1.00E-04 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.55 0.2921 0.67 6.00E-04 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.56 0.1974 0.66 8.00E-04 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.56 0.1703 0.69 1.00E-04 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.53 0.5622 0.68 2.00E-04 PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR 124&18 0.55 0.2724 0.66 0.0012 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.55 0.2473 0.68 3.00E-04 PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR 124&142 0.56 0.2393 0.65 0.0019 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.56 0.2022 0.66 0.0012 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.54 0.403 0.68 1.00E-04 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.57 0.1428 0.67 5.00E-04 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.57 0.1518 0.68 3.00E-04 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.68 2.00E-04 0.61 0.0197 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.6 0.0293 0.68 2.00E-04 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.57 0.1513 0.67 3.00E-04 VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR 149&142 0.56 0.1901 0.65 0.0023 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.6 0.029 0.66 0.0011 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.59 0.0722 0.65 0.0025 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.62 0.0142 0.65 0.0023 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.57 0.1416 0.68 2.00E-04 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.55 0.2479 0.68 2.00E-04 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.67 5.00E-04 0.62 0.0164 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.59 0.0644 0.68 2.00E-04 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.56 0.1805 0.67 4.00E-04 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.61 0.0248 0.68 2.00E-04
(481) TABLE-US-00062 TABLE62 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7using acasevscontrolcut-offof<370/7vs>=370/7weeks,with BMIstratification(>22<=37),separatelyforPPROMandPTL. 119_ 119_ 119_ 119_ 153_ 153_ 153_ 153_ rBMI_37 rBMI_37 rBMI_37 rBMI_37 SEQID PTL PTL PPROM PPROM Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.65 0.0065 0.58 0.195 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.61 0.0376 0.65 0.015 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.57 0.1794 0.65 0.0119 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.58 0.153 0.65 0.0106 AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR 37&99 0.57 0.2071 0.65 0.0131 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.61 0.0383 0.66 0.0068 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.56 0.2409 0.69 0.0019 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.61 0.0525 0.67 0.0047 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.61 0.0559 0.68 0.0034 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.57 0.1892 0.67 0.0053 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.58 0.1223 0.66 0.0082 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.54 0.4394 0.7 0.0011 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.53 0.6034 0.7 0.0011 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.55 0.371 0.72 3.00E-04 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.55 0.4081 0.68 0.0023 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.59 0.1051 0.68 0.0034 APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR 47&78 0.6 0.0815 0.67 0.006 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.61 0.0525 0.66 0.0066 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.61 0.0538 0.65 0.0142 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.6 0.082 0.67 0.004 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.58 0.1338 0.66 0.0079 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.57 0.223 0.67 0.0046 APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR 47&136 0.55 0.3213 0.66 0.0088 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.59 0.1185 0.65 0.0145 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.65 0.0057 0.57 0.2705 BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR 52&120 0.57 0.1883 0.67 0.0059 BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR 52&18 0.54 0.4803 0.68 0.0032 BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR 52&141 0.56 0.2834 0.66 0.0062 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.58 0.1331 0.66 0.0068 C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 55&135 0.54 0.4346 0.68 0.0027 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.59 0.1159 0.65 0.0102 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.65 0.0075 0.56 0.3512 CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK 64&100 0.66 0.0032 0.55 0.4332 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.67 0.0019 0.57 0.2156 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.65 0.008 0.6 0.1111 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.7 3.00E-04 0.52 0.7399 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.67 0.0026 0.56 0.2866 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.66 0.0034 0.56 0.345 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.69 4.00E-04 0.52 0.7583 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.59 0.1116 0.65 0.0156 CO5_VFQFLEK_vs_IGF2_GIVEECCFR 71&103 0.67 0.0024 0.53 0.6116 CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL 71&134 0.69 6.00E-04 0.5 0.994 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.65 0.0073 0.57 0.2475 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.55 0.3239 0.66 0.0075 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.67 0.0017 0.54 0.5019 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.66 0.0044 0.57 0.2487 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR 82&120 0.58 0.1424 0.67 0.0051 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.58 0.1601 0.68 0.0033 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.57 0.2271 0.66 0.0091 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.55 0.3581 0.67 0.0044 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.65 0.0059 0.62 0.0489 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.56 0.3019 0.67 0.0045 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.56 0.2726 0.67 0.0059 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.59 0.1197 0.66 0.0063 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.61 0.0378 0.66 0.0073 IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK 2&100 0.66 0.0034 0.58 0.1711 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.67 0.0015 0.61 0.0651 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.61 0.0451 0.68 0.0032 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.58 0.1417 0.71 6.00E-04 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.68 0.0014 0.56 0.3528 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.6 0.0834 0.68 0.0024 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.56 0.2846 0.68 0.0026 INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR 107&66 0.58 0.1366 0.66 0.0088 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.55 0.3173 0.67 0.006 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.57 0.2179 0.67 0.0043 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.59 0.1086 0.69 0.0015 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.61 0.0439 0.67 0.004 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.63 0.0188 0.67 0.0039 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.54 0.441 0.68 0.0031 INHBC_LDFHFSSDR_VS_LYAM1_SYYWIGIR 107&120 0.55 0.3239 0.69 0.0021 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.56 0.3109 0.7 9.00E-04 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.57 0.2071 0.68 0.0029 INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR 107&140 0.57 0.21 0.68 0.0034 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.59 0.1074 0.7 0.001 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.58 0.1633 0.66 0.0078 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.56 0.2388 0.67 0.0056 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.56 0.2531 0.71 6.00E-04 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.58 0.1338 0.67 0.0042 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.56 0.3147 0.67 0.005 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.56 0.2882 0.67 0.0055 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.56 0.2822 0.65 0.012 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.57 0.1725 0.65 0.0135 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.56 0.307 0.67 0.004 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.54 0.4442 0.68 0.0027 LBP_ITLPDFTGDLR_vs_C163A_INPASLDK 119&54 0.54 0.4604 0.69 0.0013 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.58 0.1395 0.68 0.0035 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.59 0.0853 0.67 0.0039 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.58 0.1601 0.71 6.00E-04 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.56 0.2519 0.69 0.0012 LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 119&135 0.54 0.4236 0.67 0.0037 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.56 0.2553 0.7 9.00E-04 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.56 0.3057 0.67 0.0044 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.58 0.1461 0.66 0.0074 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.6 0.082 0.66 0.0088 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.57 0.1856 0.68 0.0027 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.57 0.2324 0.66 0.0065 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.57 0.2139 0.66 0.0075 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.55 0.393 0.69 0.0014 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.55 0.3856 0.67 0.0045 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.56 0.2919 0.66 0.0065 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.66 0.0043 0.6 0.1065 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.69 4.00E-04 0.59 0.1378 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.69 4.00E-04 0.6 0.0916 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.65 0.0078 0.65 0.01 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.61 0.0463 0.67 0.0057 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.7 2.00E-04 0.56 0.3077 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.57 0.1975 0.66 0.0093 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.62 0.0297 0.67 0.0059 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.66 0.0031 0.63 0.0374 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.67 0.0021 0.58 0.1711 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.68 0.0011 0.6 0.1139 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.64 0.0101 0.67 0.0056 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.59 0.0914 0.66 0.0072 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.69 4.00E-04 0.55 0.3901 VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 150&135 0.57 0.2139 0.66 0.0089 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.6 0.0628 0.67 0.0047 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.65 0.0051 0.64 0.0187
(482) TABLE-US-00063 TABLE63 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7using acasevscontrolcut-offof<350/7vs>=350/7weeks,without BMIstratification,separatelyforPPROMandPTL. 119_ 119_ 119_ 119_ 153_ 153_ 153_ 153_ aBMI_35 aBMI_35 aBMI_35 SEQID aBMI_35 PTL PPROM PPROM Reversal NO: PTLAUC P-value AUC P-value A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK 34&97 0.52 0.8126 0.67 0.0107 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.52 0.8436 0.68 0.0079 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.59 0.3629 0.67 0.0124 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.56 0.5765 0.68 0.0077 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.54 0.7315 0.66 0.018 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.54 0.6701 0.66 0.0228 AFAM_HFQNLGK_vs_IBP1_VVESLAK 38&97 0.53 0.7973 0.65 0.0251 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.51 0.959 0.67 0.0126 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.53 0.8024 0.7 0.0037 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.54 0.6798 0.72 0.0014 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.52 0.8411 0.7 0.0029 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.54 0.7117 0.65 0.025 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.52 0.8101 0.72 0.001 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.53 0.787 0.67 0.0122 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.5 0.9669 0.68 0.0083 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.51 0.9537 0.71 0.0018 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.58 0.4588 0.65 0.0262 APOH_ATVVYQGER_vs_IBP1_VVESLAK 48&97 0.5 1 0.66 0.0156 APOH_ATVVYQGER_VS_LYAM1_SYYWIGIR 48&120 0.57 0.4771 0.68 0.0079 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.58 0.4409 0.75 2.00E-04 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.53 0.7692 0.68 0.0068 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.5 0.9802 0.69 0.0059 B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK 51&97 0.55 0.6485 0.68 0.0074 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.51 0.9379 0.68 0.0076 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.53 0.7516 0.77 1.00E-04 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.51 0.888 0.68 0.01 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.51 0.9537 0.69 0.0048 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.51 0.9379 0.77 1.00E-04 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.52 0.8281 0.71 0.0016 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.51 0.93 0.72 0.0014 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.57 0.5063 0.7 0.0029 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.57 0.5063 0.69 0.0064 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.54 0.6774 0.71 0.0017 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.53 0.8024 0.72 0.0012 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.56 0.5342 0.69 0.0057 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.5 0.9907 0.69 0.0062 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.5 0.9749 0.69 0.0042 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.54 0.6847 0.73 8.00E-04 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.57 0.5063 0.72 0.0012 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.52 0.8644 0.78 1.00E-04 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.51 0.9274 0.71 0.0019 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.55 0.597 0.75 2.00E-04 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.5 1 0.71 0.0024 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.57 0.4895 0.68 0.0074 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.61 0.2945 0.68 0.0101 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.51 0.9247 0.72 0.0013 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.52 0.8462 0.73 7.00E-04 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.53 0.7566 0.72 0.001 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.53 0.7845 0.72 0.0014 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.58 0.4311 0.72 0.0011 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.52 0.8853 0.69 0.006 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.5 0.9775 0.73 7.00E-04 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.5 0.9749 0.71 0.002 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.53 0.7491 0.71 0.0017 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.57 0.4916 0.68 0.0091 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.56 0.5563 0.66 0.0177 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.55 0.639 0.72 0.0013 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.52 0.8333 0.72 0.0015 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.52 0.8436 0.69 0.0049 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.53 0.7794 0.7 0.0041 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.57 0.5277 0.72 0.0012 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.55 0.6438 0.69 0.0063 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.5 0.9907 0.76 1.00E-04 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.52 0.8359 0.7 0.0027 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.53 0.7415 0.75 3.00E-04 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.51 0.8932 0.7 0.003 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.56 0.5342 0.66 0.0194 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.6 0.3182 0.65 0.0282 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.51 0.9116 0.7 0.0038 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.55 0.6605 0.72 0.001 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.51 0.9511 0.71 0.0021 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.53 0.7415 0.7 0.0031 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.55 0.5993 0.7 0.0038 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.57 0.5299 0.66 0.0166 CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR 157&120 0.59 0.4063 0.68 0.0067 CBPN_NGVDLNR_vs_SPRL1_VLTHSELAPLR 157&140 0.56 0.5787 0.65 0.0235 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.59 0.3989 0.65 0.0332 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.66 0.1165 0.6 0.1512 CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK 61&97 0.52 0.8411 0.68 0.0075 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.62 0.2535 0.66 0.0218 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.6 0.3208 0.71 0.0016 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.61 0.2972 0.67 0.0121 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.63 0.2169 0.66 0.0202 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.68 0.084 0.6 0.1355 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.56 0.5585 0.65 0.0309 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.6 0.3508 0.65 0.0271 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.59 0.3734 0.67 0.0112 CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK 62&79 0.56 0.5563 0.65 0.0272 CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK 62&97 0.51 0.959 0.69 0.0064 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.57 0.4936 0.66 0.0192 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.56 0.5765 0.72 0.0013 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.57 0.4916 0.67 0.0113 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.61 0.3049 0.66 0.0204 CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF 62&139 0.65 0.1421 0.61 0.1227 CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR 62&140 0.53 0.7819 0.65 0.0299 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.56 0.5652 0.66 0.0169 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.52 0.8749 0.7 0.0042 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.56 0.5787 0.65 0.0294 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.6 0.3128 0.65 0.0257 CLUS_ASSIIDELFQDR_vs_IBP1_VVESLAK 67&97 0.52 0.8671 0.66 0.0187 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.64 0.1768 0.65 0.0256 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.63 0.1944 0.7 0.0028 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.62 0.236 0.65 0.0322 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.65 0.1389 0.64 0.0437 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.57 0.4709 0.65 0.0308 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.6 0.3208 0.66 0.0213 CLUS_LFDSDPITVTVPVEVSR_vs_IBP1_VVESLAK 68&97 0.52 0.8775 0.66 0.0188 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.65 0.147 0.64 0.0395 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.62 0.2386 0.69 0.0064 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.63 0.2145 0.65 0.0299 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.57 0.5234 0.65 0.0313 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.6 0.3473 0.7 0.0041 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.59 0.3989 0.67 0.0137 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.57 0.4853 0.69 0.0042 CO8A_SLLQPNK_vs_IBP1_VVESLAK 74&97 0.5 0.9987 0.66 0.0164 COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.6 0.3525 0.68 0.0076 CO8B_QALEEFQK_vs_IBP1_VVESLAK 76&97 0.5 0.9987 0.67 0.012 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.57 0.5105 0.67 0.0131 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.55 0.6179 0.66 0.0157 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.58 0.4488 0.67 0.0134 F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK 84&97 0.51 0.9379 0.67 0.0123 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.6 0.3273 0.67 0.0146 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.58 0.437 0.74 4.00E-04 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.58 0.4429 0.66 0.0197 F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR 84&140 0.54 0.6677 0.65 0.0254 FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK 88&79 0.55 0.6629 0.69 0.0056 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.6 0.3456 0.76 1.00E-04 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.57 0.5212 0.73 7.00E-04 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.6 0.3372 0.72 0.0012 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.5 0.996 0.7 0.0041 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.53 0.7769 0.71 0.0025 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.52 0.8566 0.71 0.0022 IBP4_QCHPALDGQR_vs_IBP1_VVESLAK 2&97 0.54 0.6798 0.69 0.0062 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.56 0.5924 0.65 0.0254 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.51 0.9142 0.75 2.00E-04 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.53 0.787 0.67 0.0125 IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK 102&79 0.54 0.6994 0.69 0.0063 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.57 0.5277 0.72 0.0016 KNG1_DIPTNSPELEETLTHTITK_vs_IBP1_VVESLAK 116&97 0.53 0.7769 0.67 0.0108 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.52 0.8644 0.7 0.003 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.6 0.3144 0.65 0.0294 KNG1_QVVAGLNFR_vs_IBP1_VVESLAK 117&97 0.51 0.9168 0.68 0.0087 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.65 0.1517 0.63 0.0487 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.61 0.2896 0.71 0.0017 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.6 0.3128 0.66 0.0214 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.55 0.6319 0.71 0.0026 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.5 0.9775 0.68 0.0093 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.52 0.8359 0.68 0.01 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.53 0.787 0.73 9.00E-04 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.5 0.9749 0.68 0.0084 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.54 0.729 0.68 0.0071 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.54 0.7216 0.67 0.013 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.53 0.7491 0.74 4.00E-04 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.61 0.2762 0.65 0.0254 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.63 0.2244 0.66 0.0228 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.58 0.4429 0.65 0.0299 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.63 0.1978 0.67 0.0132 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.65 0.1498 0.62 0.0668 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.63 0.2194 0.65 0.0315 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.57 0.5105 0.65 0.0303 PTGDS_GPGEDFR_vs_IBP1_VVESLAK 137&97 0.51 0.9037 0.67 0.0143 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.52 0.8152 0.68 0.0071 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.56 0.5742 0.68 0.01 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.56 0.5697 0.66 0.0213 VTNC_GQYCYELDEK_vs_IBP1_VVESLAK 149&97 0.51 0.9168 0.67 0.0124 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.59 0.3664 0.65 0.0232 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.57 0.5212 0.73 8.00E-04 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.57 0.5256 0.67 0.0152 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.58 0.4508 0.66 0.0227 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.52 0.8307 0.67 0.0145 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.52 0.8307 0.67 0.0143 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.5 0.9669 0.74 4.00E-04 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.53 0.7642 0.66 0.0159
(483) TABLE-US-00064 TABLE64 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7 usingacasevscontrolcut-offof<350/7vs>=350/7weeks, withBMIstratification(>22<=37),separatelyforPPROMandPTL. 119_ 119_ 119_ 119_ 153_ 153_ 153_ 153_ rBMI_35 rBMI_35 rBMI_35 rBMI_35 SEQID PTL PTL PPROM PPROM Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.59 0.4023 0.67 0.0438 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.56 0.6023 0.77 0.0014 AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK 37&79 0.63 0.2599 0.67 0.0425 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.64 0.2206 0.69 0.0268 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.59 0.4116 0.75 0.0043 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.6 0.3694 0.71 0.0154 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.56 0.6023 0.7 0.0193 AFAM_HFQNLGK_vs_CRIS3_AVSPPAR 38&78 0.56 0.5612 0.69 0.0271 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.6 0.3665 0.7 0.0184 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.52 0.8893 0.73 0.008 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.53 0.7955 0.73 0.0071 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.58 0.4597 0.75 0.0037 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.56 0.5686 0.77 0.0014 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.56 0.5797 0.74 0.0051 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.52 0.8807 0.73 0.0077 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.53 0.7913 0.72 0.0088 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.53 0.7704 0.8 5.00E-04 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.54 0.7455 0.72 0.0091 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.58 0.4664 0.7 0.02 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.61 0.3141 0.71 0.0166 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.61 0.3115 0.7 0.0216 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.53 0.8124 0.79 8.00E-04 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.53 0.7787 0.71 0.0151 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.56 0.5723 0.71 0.0151 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.52 0.8336 0.82 2.00E-04 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.57 0.5466 0.69 0.024 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.53 0.8039 0.83 1.00E-04 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.54 0.6924 0.74 0.0061 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.58 0.4697 0.74 0.0055 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.65 0.1786 0.7 0.0191 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.65 0.17 0.69 0.0306 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.58 0.5004 0.7 0.0188 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.56 0.5835 0.7 0.0209 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.61 0.3115 0.72 0.0095 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.52 0.8336 0.74 0.005 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.55 0.6684 0.82 2.00E-04 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.57 0.5215 0.74 0.0047 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.56 0.6138 0.7 0.0174 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.64 0.2085 0.68 0.0387 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.56 0.6176 0.69 0.0286 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.53 0.7913 0.73 0.0084 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.59 0.4178 0.71 0.0154 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.52 0.855 0.8 4.00E-04 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.56 0.5835 0.75 0.0032 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.61 0.3355 0.76 0.0028 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.65 0.1858 0.7 0.0229 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.64 0.2105 0.67 0.0443 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.52 0.8507 0.74 0.0056 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.6 0.3932 0.73 0.0085 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.59 0.4023 0.71 0.0152 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.64 0.2186 0.73 0.0065 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.5 0.9848 0.73 0.0071 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.56 0.5872 0.83 1.00E-04 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.58 0.463 0.77 0.0017 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.5 0.9674 0.75 0.0042 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.57 0.5393 0.72 0.0103 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.55 0.6487 0.75 0.0043 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.56 0.6099 0.73 0.007 CBPN_NGVDLNR_vs_CRIS3_YEDLYSNCK 157&79 0.59 0.4147 0.67 0.0466 CBPN_NGVDLNR_VS_LYAM1_SYYWIGIR 157&120 0.59 0.4305 0.75 0.0032 CD14_LTVGAAQVPAQLLVGALR_VS_LYAM1_SYYWIGIR 61&120 0.65 0.1858 0.75 0.0038 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.63 0.2289 0.71 0.0156 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.73 0.0354 0.59 0.315 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.6 0.3812 0.73 0.0071 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.6 0.3782 0.7 0.0226 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.67 0.1206 0.73 0.0083 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.64 0.2085 0.67 0.0429 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.65 0.1751 0.72 0.0096 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.64 0.2186 0.68 0.0403 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.63 0.2247 0.73 0.0078 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.64 0.2227 0.67 0.0466 COSA_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.64 0.2027 0.7 0.0204 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.61 0.341 0.68 0.0412 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.62 0.2716 0.69 0.0248 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.64 0.2027 0.69 0.024 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.62 0.2692 0.79 6.00E-04 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.6 0.3812 0.71 0.0166 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.61 0.3194 0.67 0.0456 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.58 0.4935 0.82 2.00E-04 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.54 0.7127 0.81 3.00E-04 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.53 0.8209 0.73 0.0064 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.53 0.7871 0.72 0.0093 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.57 0.5074 0.73 0.007 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.54 0.7372 0.82 2.00E-04 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.58 0.4901 0.68 0.0326 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.53 0.7787 0.78 0.001 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.61 0.3328 0.69 0.0302 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.57 0.525 0.74 0.0045 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.65 0.17 0.75 0.003 PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.62 0.2861 0.7 0.0224 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.65 0.1913 0.69 0.0234 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.61 0.3274 0.74 0.006 PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR 122&129 0.77 0.0162 0.63 0.1266 PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR 122&18 0.59 0.4369 0.67 0.0434 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYCFR 122&138 0.73 0.0405 0.58 0.3298 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF 122&139 0.77 0.0155 0.65 0.0869 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.59 0.4336 0.67 0.0466 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.6 0.3522 0.76 0.0029 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.57 0.5109 0.68 0.0319 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.6 0.3636 0.69 0.0265 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.6 0.3551 0.77 0.0016 PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR 125&126 0.58 0.4498 0.69 0.0302 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.67 0.1232 0.72 0.0099 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.68 0.1011 0.72 0.012 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.59 0.4241 0.67 0.0416 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.67 0.1232 0.69 0.0268 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.66 0.1429 0.67 0.0429 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.68 0.0966 0.76 0.0024 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.66 0.1414 0.7 0.0204 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.68 0.1081 0.67 0.0456 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.68 0.1057 0.71 0.0134 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.74 0.0336 0.64 0.1069 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.6 0.3812 0.72 0.0088 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.61 0.341 0.69 0.0265 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.6 0.3871 0.68 0.0383 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.62 0.2886 0.69 0.0245 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.62 0.2788 0.79 8.00E-04 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.62 0.2986 0.7 0.0209 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.61 0.3355 0.67 0.0476 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.57 0.5144 0.69 0.0286 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.55 0.6253 0.78 0.0012
(484) TABLE-US-00065 TABLE65 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevs controlcut-offof<370/7vs>=370/7weeks,withoutBMIstratification, separatelyforprimigravidaandmultigravida. 119_153_ 119_153_ 119_153_ 119_153_ aBMI_37 aBMI_37 aBMI_37 aBMI_37 SEQID multi multi primi primi Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.59 0.0399 0.67 0.0102 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.65 4.00E?04 0.53 0.6818 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.65 5.00E?04 0.56 0.3992 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.65 3.00E?04 0.62 0.0687 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.63 0.0017 0.65 0.0238 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.62 0.0049 0.67 0.0104 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.65 4.00E?04 0.65 0.0277 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.62 0.0049 0.66 0.0148 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.62 0.0036 0.65 0.0218 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.59 0.0394 0.65 0.0255 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.57 0.0849 0.7 0.0029 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.57 0.1204 0.68 0.0058 C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL 55&134 0.58 0.0476 0.66 0.0171 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.58 0.0754 0.71 0.0017 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.58 0.0678 0.68 0.0077 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.57 0.0986 0.68 0.0055 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.58 0.0743 0.69 0.0038 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.57 0.1127 0.69 0.0049 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.57 0.1066 0.69 0.0035 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.58 0.0737 0.68 0.0068 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.58 0.0622 0.66 0.0135 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.59 0.0371 0.66 0.0148 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.59 0.0404 0.65 0.023 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.66 2.00E?04 0.55 0.493 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.6 0.0247 0.65 0.0255 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.65 6.00E?04 0.61 0.1087 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.58 0.066 0.69 0.0049 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.58 0.0557 0.67 0.0119 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.59 0.0314 0.66 0.013 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.58 0.0515 0.65 0.0234 COSA_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.66 2.00E?04 0.52 0.8158 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.66 2.00E?04 0.53 0.6297 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.61 0.0121 0.66 0.0171 ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL 83&134 0.59 0.0287 0.65 0.023 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.59 0.0253 0.66 0.0135 FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR 87&18 0.55 0.2452 0.73 4.00E?04 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.68 0 0.51 0.862 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.66 2.00E?04 0.51 0.9138 HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR 92&18 0.59 0.0407 0.66 0.0162 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.59 0.0277 0.67 0.0108 HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR 93&18 0.59 0.0432 0.67 0.0088 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.58 0.0642 0.66 0.0128 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.57 0.0774 0.73 5.00E?04 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.63 0.0017 0.67 0.0095 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.6 0.0241 0.72 7.00E?04 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.59 0.0444 0.69 0.0048 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.65 6.00E?04 0.54 0.5224 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.67 1.00E?04 0.55 0.4254 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.61 0.009 0.65 0.0242 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.66 2.00E?04 0.59 0.1755 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.61 0.0073 0.65 0.0207 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.59 0.0285 0.66 0.0138 KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR 116&18 0.56 0.1468 0.69 0.0045 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.56 0.1453 0.68 0.0062 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.65 3.00E?04 0.61 0.0989 LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR 118&18 0.61 0.0097 0.65 0.0277 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.65 5.00E?04 0.55 0.4254 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.65 3.00E?04 0.57 0.3108 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.65 4.00E?04 0.57 0.3015 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.61 0.0103 0.67 0.0116 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.66 1.00E?04 0.64 0.0397 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.62 0.0039 0.66 0.0128 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.61 0.0132 0.65 0.0218 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.59 0.0331 0.65 0.0222 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.66 1.00E?04 0.57 0.2689 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.59 0.0262 0.68 0.0069 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.65 6.00E?04 0.65 0.0218 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.62 0.0039 0.68 0.0058 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.6 0.0134 0.65 0.0204 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.62 0.0036 0.65 0.0255 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.66 1.00E?04 0.56 0.3883 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.59 0.0402 0.68 0.0078 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.64 7.00E?04 0.65 0.0215 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.61 0.0068 0.67 0.0114 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.65 4.00E?04 0.63 0.0558
(485) TABLE-US-00066 TABLE66 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevscontrolcut-offof <370/7vs>=370/7weeks,withBMIstratification(>22<=37), separatelyforprimigravidaandmultigravida. 119_153_ 119_153_ 119_153_ 119_153_ rBMI_37 rBMI_37 rBMI_37 rBMI_37 SEQID multi multi primi primi Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR 34&78 0.65 0.0038 0.52 0.8315 A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.65 0.0037 0.52 0.8126 A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.65 0.0026 0.51 0.9467 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.62 0.0209 0.65 0.071 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.57 0.1962 0.72 0.0073 A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR 34&18 0.59 0.0826 0.69 0.0219 AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR 37&99 0.67 9.00E?04 0.57 0.4118 AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK 37&100 0.68 3.00E?04 0.55 0.5885 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.71 0 0.57 0.4118 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.67 9.00E?04 0.51 0.8792 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.68 4.00E?04 0.5 0.9854 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.7 1.00E?04 0.53 0.7565 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.66 0.001 0.54 0.6484 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.66 0.0016 0.5 1 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.65 0.003 0.51 0.8696 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.6 0.0486 0.69 0.0212 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.57 0.1908 0.71 0.0121 APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK 47&54 0.6 0.0479 0.68 0.0291 APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK 47&79 0.63 0.0104 0.65 0.0673 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.61 0.0229 0.65 0.0789 APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK 47&100 0.61 0.036 0.65 0.0789 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.6 0.0418 0.71 0.0129 APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR 47&126 0.57 0.1362 0.72 0.0088 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.6 0.0572 0.69 0.0257 APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR 47&18 0.58 0.1164 0.7 0.0186 APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR 47&141 0.58 0.1194 0.7 0.0163 APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 47&144 0.58 0.0932 0.67 0.0393 APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK 47&147 0.58 0.1312 0.69 0.0249 APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK 48&100 0.65 0.0021 0.51 0.908 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.67 5.00E?04 0.58 0.3523 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.65 0.0034 0.5 1 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.57 0.1547 0.68 0.0339 BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR 52&78 0.65 0.0022 0.52 0.841 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.66 0.0015 0.5 0.9854 BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR 52&103 0.66 0.0014 0.56 0.4998 BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR 52&141 0.58 0.112 0.66 0.0496 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.57 0.1483 0.71 0.0109 C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR 55&18 0.57 0.1962 0.72 0.0073 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.55 0.3241 0.72 0.0082 CBPN_NGVDLNR_vs_IGF2_GIVEECCFR 157&103 0.66 0.0017 0.55 0.5392 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.65 0.0038 0.51 0.8696 CFAB_YGLVTYATYPK_vs_CRIS3_AVSPPAR 64&78 0.65 0.0037 0.53 0.6838 CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK 64&79 0.65 0.0033 0.5 0.9951 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.67 8.00E?04 0.51 0.9273 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.57 0.1865 0.7 0.0175 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.55 0.3241 0.7 0.018 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.65 0.0021 0.54 0.6311 CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR 70&103 0.65 0.0028 0.51 0.9177 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.6 0.0461 0.68 0.0291 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.55 0.2997 0.74 0.0035 CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL 70&134 0.59 0.0814 0.68 0.0309 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.57 0.1519 0.73 0.0066 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.54 0.4195 0.75 0.0032 CO5_VFQFLEK_vs_CRIS3_AVSPPAR 71&78 0.65 0.0033 0.55 0.5801 CO5_VFQFLEK_vs_IGF2_GIVEECCFR 71&103 0.65 0.0035 0.54 0.6397 CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR 71&126 0.55 0.2779 0.73 0.0068 CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR 71&18 0.58 0.1217 0.69 0.0199 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.55 0.3581 0.72 0.0076 CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR 72&103 0.66 0.0016 0.54 0.6311 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.56 0.2613 0.7 0.0148 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.66 0.0015 0.52 0.7751 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.55 0.2952 0.72 0.0094 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.66 0.0018 0.51 0.9273 CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR 76&141 0.55 0.2894 0.72 0.0076 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR 82&18 0.6 0.058 0.69 0.0206 ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR 83&120 0.57 0.1612 0.67 0.0429 ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR 83&18 0.56 0.1973 0.7 0.0175 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.65 0.0029 0.52 0.8315 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.69 1.00E?04 0.57 0.4188 FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR 89&103 0.68 4.00E?04 0.57 0.3847 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.65 0.0025 0.58 0.3158 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.54 0.4049 0.74 0.0033 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.65 0.0034 0.54 0.6224 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.65 0.0022 0.57 0.3847 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.68 3.00E?04 0.54 0.6139 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.62 0.022 0.7 0.0163 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.58 0.1353 0.77 0.0013 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.59 0.0656 0.69 0.0199 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.59 0.0724 0.75 0.0027 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.54 0.3716 0.75 0.0025 IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 2&144 0.59 0.0826 0.67 0.0455 IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK 2&147 0.57 0.17 0.7 0.0158 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.65 0.0036 0.53 0.7658 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.65 0.0033 0.52 0.8601 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.66 0.0011 0.52 0.8505 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.67 9.00E?04 0.53 0.7381 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.69 2.00E?04 0.51 0.8984 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.59 0.0661 0.67 0.036 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.6 0.0414 0.65 0.0655 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.6 0.0447 0.73 0.0068 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.59 0.075 0.68 0.0319 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.62 0.0177 0.65 0.081 ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR 111&78 0.66 0.002 0.54 0.6572 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.65 0.0031 0.51 0.937 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.61 0.031 0.65 0.0673 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.57 0.1519 0.67 0.0417 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.57 0.1632 0.68 0.0349 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.66 0.0016 0.53 0.7381 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.66 0.002 0.57 0.4188 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.66 0.0018 0.5 0.9854 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.59 0.0661 0.69 0.0219 LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR 119&18 0.61 0.0352 0.66 0.0525 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.56 0.2302 0.68 0.0291 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.67 6.00E?04 0.54 0.6749 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.67 0.001 0.5 0.9661 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.56 0.2086 0.71 0.0109 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.66 0.0019 0.55 0.5312 PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR 125&141 0.54 0.3854 0.73 0.0055 PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 133&135 0.67 5.00E?04 0.58 0.3399 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.66 0.0014 0.51 0.9177 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.66 0.0018 0.55 0.5718 VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR 149&99 0.66 0.002 0.56 0.4845 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.68 4.00E?04 0.56 0.4921 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.7 1.00E?04 0.51 0.9273 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.64 0.0058 0.67 0.0442 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.59 0.061 0.72 0.0076 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.62 0.0184 0.68 0.0273 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.62 0.0198 0.71 0.0125 VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR 149&141 0.58 0.1345 0.72 0.0085 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.63 0.0085 0.68 0.0291 VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR 150&78 0.66 0.0014 0.5 0.9661 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.66 0.0018 0.54 0.6484 VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK 150&100 0.66 0.002 0.56 0.4998 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.68 3.00E?04 0.5 0.9854 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.64 0.0066 0.69 0.0249 VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR 150&126 0.58 0.1345 0.72 0.0079 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.6 0.0516 0.72 0.0098 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.6 0.0375 0.7 0.0175 VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR 150&141 0.57 0.1962 0.71 0.0101 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.64 0.0066 0.68 0.0339
(486) TABLE-US-00067 TABLE67 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevs controlcut-offof<350/7vs>=350/7weeks,withoutBMIstratification, separatelyforprimigravidaandmultigravida. 119_153_ 119_153_ 119_153_ 119_153_ aBMI_35 aBMI_35 aBMI_35 aBMI_35 SEQID multi multi primi primi Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK 34&97 0.65 0.0463 0.58 0.4028 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.68 0.0136 0.61 0.2481 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.7 0.0065 0.56 0.5483 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.55 0.5449 0.73 0.0121 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.54 0.6027 0.71 0.0204 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.69 0.0121 0.5 1 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.69 0.0122 0.54 0.6691 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.69 0.0097 0.51 0.9348 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.74 0.0012 0.52 0.8343 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.73 0.0021 0.55 0.5667 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.55 0.5034 0.73 0.0137 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.72 0.0028 0.59 0.335 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.58 0.2847 0.71 0.0219 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.61 0.1507 0.75 0.0069 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.71 0.0043 0.53 0.778 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.66 0.0299 0.68 0.0561 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.56 0.4083 0.71 0.0241 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.7 0.0068 0.61 0.2128 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.74 0.001 0.51 0.8771 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.75 7.00E?04 0.51 0.942 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.74 0.0014 0.54 0.6624 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.72 0.0034 0.66 0.0808 B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR 51&18 0.57 0.3602 0.71 0.0241 CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR 57&40 0.68 0.015 0.56 0.5423 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.69 0.0114 0.74 0.0103 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.72 0.0038 0.57 0.4449 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.73 0.0021 0.57 0.4183 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.67 0.0256 0.69 0.0425 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.65 0.0392 0.68 0.0505 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.65 0.0378 0.65 0.1035 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.65 0.0428 0.65 0.096 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.57 0.3353 0.7 0.0318 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.71 0.0057 0.53 0.778 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.71 0.0044 0.54 0.7025 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.75 9.00E?04 0.57 0.4669 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.67 0.0239 0.58 0.3777 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.71 0.0054 0.71 0.0247 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.62 0.0991 0.72 0.0148 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.66 0.0353 0.65 0.1035 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.59 0.2231 0.74 0.0098 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.66 0.0372 0.67 0.0689 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.64 0.0634 0.7 0.0293 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.66 0.0292 0.68 0.0454 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.66 0.0356 0.71 0.0204 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.65 0.0437 0.67 0.0689 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.68 0.0163 0.62 0.1965 CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR 58&40 0.68 0.018 0.57 0.4669 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.66 0.034 0.69 0.039 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.73 0.0024 0.55 0.5667 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.73 0.0016 0.56 0.4894 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.66 0.0353 0.65 0.1115 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.66 0.0292 0.63 0.1431 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.65 0.0463 0.65 0.0925 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.71 0.0049 0.55 0.6233 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.72 0.0032 0.55 0.6105 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.74 0.0012 0.58 0.3876 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.7 0.0071 0.7 0.0277 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.61 0.1448 0.74 0.0093 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.66 0.0295 0.68 0.055 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.59 0.2532 0.75 0.0073 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.65 0.0447 0.62 0.2095 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.64 0.0557 0.68 0.0484 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.65 0.0444 0.73 0.0115 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.66 0.0308 0.62 0.1997 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.71 0.0055 0.56 0.5244 CBPN_NGVDLNR_VS_LYAM1_SYYWIGIR 157&120 0.72 0.0034 0.6 0.2791 CBPN_NGVDLNR_vs_SPRL1_VLTHSELAPLR 157&140 0.68 0.0137 0.55 0.5544 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.75 9.00E?04 0.52 0.8485 CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK 61&80 0.68 0.0131 0.54 0.6957 CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK 61&97 0.66 0.0301 0.61 0.2371 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.81 0 0.58 0.3876 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.76 4.00E?04 0.62 0.1934 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.66 0.0364 0.68 0.0484 CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL 61&134 0.67 0.0237 0.56 0.5483 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.62 0.1048 0.69 0.0349 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.67 0.0206 0.57 0.4491 CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR 61&140 0.72 0.0038 0.55 0.5544 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.76 6.00E?04 0.52 0.8272 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.73 0.0023 0.52 0.8272 CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK 62&79 0.74 0.0012 0.51 0.9059 CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK 62&97 0.66 0.0301 0.6 0.2791 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.79 1.00E?04 0.57 0.4235 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.75 8.00E?04 0.62 0.2029 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.61 0.1334 0.68 0.0484 CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF 62&139 0.66 0.0297 0.57 0.4714 CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR 62&140 0.7 0.0069 0.55 0.5979 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.74 0.0013 0.51 0.942 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.71 0.0047 0.54 0.6691 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.67 0.0215 0.58 0.3826 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.71 0.0041 0.53 0.771 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.73 0.0024 0.53 0.716 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.72 0.0026 0.54 0.6757 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.74 0.0012 0.52 0.87 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.71 0.0056 0.68 0.0484 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.56 0.4152 0.74 0.0098 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.57 0.3539 0.73 0.0115 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR 68&78 0.7 0.0059 0.53 0.7296 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.72 0.0035 0.55 0.5544 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK 68&100 0.72 0.0036 0.53 0.7572 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.73 0.0021 0.52 0.806 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.67 0.0199 0.68 0.0444 CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR 68&126 0.55 0.5309 0.73 0.0137 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR 68&18 0.55 0.4899 0.73 0.0106 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.73 0.0023 0.5 1 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.69 0.0089 0.68 0.0538 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.54 0.5469 0.72 0.0164 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.69 0.0108 0.62 0.1873 CO6_ALNHLPLEYNSALYSR_VS_LYAM1_SYYWIGIR 72&120 0.7 0.0069 0.65 0.1074 CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR 72&18 0.55 0.5053 0.72 0.0176 CO8A_SLLQPNK_vs_IGF2_GIVEECCFR 74&103 0.73 0.002 0.55 0.6233 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.71 0.0049 0.62 0.1842 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.72 0.0037 0.52 0.792 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.67 0.0194 0.62 0.1965 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.73 0.0018 0.5 0.9927 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.74 0.0012 0.52 0.792 F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK 84&100 0.74 0.0015 0.56 0.4952 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.75 7.00E?04 0.51 0.8771 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.72 0.0026 0.68 0.0538 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.59 0.2445 0.69 0.0407 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.57 0.3445 0.7 0.0265 F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR 84&140 0.65 0.0392 0.61 0.2335 FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK 88&79 0.7 0.0069 0.53 0.7572 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.67 0.0258 0.67 0.0689 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.67 0.022 0.61 0.2128 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.66 0.0271 0.64 0.1335 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.75 8.00E?04 0.51 0.9348 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.76 4.00E?04 0.51 0.8987 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.71 0.0039 0.52 0.806 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.7 0.0078 0.67 0.0649 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.56 0.4544 0.71 0.023 IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK 102&79 0.75 6.00E?04 0.57 0.4235 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.7 0.0067 0.54 0.6559 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.7 0.008 0.65 0.1135 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.72 0.0035 0.51 0.8987 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.73 0.0023 0.54 0.6691 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.76 4.00E?04 0.53 0.7572 KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR 117&112 0.69 0.0121 0.54 0.6559 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.73 0.0021 0.65 0.0925 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.61 0.1533 0.7 0.0333 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.59 0.2433 0.7 0.0259 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.71 0.0055 0.55 0.5728 PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR 124&78 0.74 0.0011 0.52 0.799 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.75 8.00E?04 0.52 0.8557 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.7 0.0062 0.63 0.156 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.75 9.00E?04 0.52 0.8343 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.76 6.00E?04 0.5 0.9927 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.77 3.00E?04 0.58 0.3876 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.72 0.0033 0.64 0.1156 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.72 0.0036 0.54 0.6757 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.72 0.0033 0.55 0.5728 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.67 0.0189 0.59 0.3215 PSG2_IHPSYTNYR_vs_IBP1_VVESLAK 133&97 0.66 0.0372 0.58 0.3583 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.69 0.0123 0.52 0.8414 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.7 0.008 0.62 0.1965 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.73 0.0023 0.52 0.8343 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.67 0.0224 0.61 0.2299 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.69 0.0106 0.59 0.3215 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.7 0.0066 0.54 0.6298 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.7 0.0064 0.54 0.6823 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.68 0.0136 0.7 0.0297 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.54 0.6305 0.75 0.0065 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.59 0.2185 0.7 0.0311 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.55 0.4842 0.73 0.0137 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.69 0.0095 0.55 0.6169 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.68 0.0139 0.53 0.7434 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.66 0.0361 0.72 0.0168 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.54 0.5818 0.73 0.0121
(487) TABLE-US-00068 TABLE68 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevs controlcut-offof<350/7vs>=350/7weeks,withBMIstratification(>22<=37), separatelyforprimigravidaandmultigravida. 119_153_ 119_153_ 119_153_ 119_153_ rBMI_35 rBMI_35 rBMI_35 rBMI_35 SEQID multi multi primi primi Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.79 0.0013 0.51 0.9432 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.73 0.0091 0.68 0.1013 AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK 37&79 0.74 0.0073 0.56 0.5959 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.79 0.0015 0.51 0.9432 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.69 0.0371 0.71 0.0525 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.68 0.0404 0.72 0.0388 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.63 0.1361 0.72 0.047 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.75 0.0048 0.54 0.7456 AFAM_HFQNLGK_vs_CRIS3_AVSPPAR 38&78 0.72 0.015 0.56 0.585 AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK 38&79 0.75 0.0062 0.57 0.5215 AFAM_HFQNLGK_vs_IBP3_FLNVLSPR 38&99 0.75 0.0057 0.51 0.9558 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.78 0.0022 0.54 0.7099 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.81 7.00E?04 0.5 0.9811 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.64 0.115 0.72 0.0436 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.79 0.0012 0.51 0.9684 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.8 9.00E?04 0.52 0.893 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.76 0.0037 0.67 0.1152 ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF 42&139 0.7 0.0293 0.57 0.5528 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.73 0.0107 0.59 0.4241 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.65 0.0888 0.73 0.032 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.6 0.283 0.77 0.0116 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.76 0.0038 0.54 0.7099 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.77 0.0028 0.56 0.585 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.71 0.0201 0.75 0.0213 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.69 0.0387 0.8 0.0057 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.7 0.0256 0.66 0.1431 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.72 0.0126 0.66 0.152 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.7 0.0292 0.7 0.0629 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.68 0.0409 0.7 0.0629 CATD_VGFAEAAR_vs_IBP3_FLNVLSPR 57&99 0.69 0.0346 0.63 0.2259 CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK 57&100 0.68 0.0404 0.62 0.2782 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.74 0.0077 0.62 0.2853 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.69 0.0341 0.82 0.0037 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.61 0.2372 0.83 0.0027 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.58 0.3917 0.78 0.0092 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.68 0.0409 0.66 0.1388 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.62 0.167 0.73 0.0374 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.62 0.1968 0.73 0.0307 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.66 0.0685 0.76 0.0165 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.73 0.01 0.66 0.1475 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.75 0.0057 0.67 0.1189 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.7 0.0275 0.67 0.1152 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.68 0.0426 0.67 0.1266 CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR 58&99 0.71 0.0217 0.68 0.0949 CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK 58&100 0.7 0.0287 0.65 0.1565 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.73 0.0098 0.66 0.1306 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.69 0.0304 0.83 0.0026 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.61 0.226 0.85 0.0012 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.64 0.1317 0.72 0.0404 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.58 0.3639 0.81 0.0043 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.69 0.0327 0.62 0.2853 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.63 0.1584 0.77 0.0121 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.71 0.0186 0.63 0.2199 CBPN_NGVDLNR_vs_CRIS3_YEDLYSNCK 157&79 0.77 0.0023 0.52 0.8805 CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR 157&120 0.73 0.0094 0.68 0.1047 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR 61&78 0.77 0.0029 0.52 0.893 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.78 0.0022 0.52 0.8308 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.76 0.0043 0.71 0.0585 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.68 0.0444 0.72 0.0452 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.75 0.0057 0.51 0.9055 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.74 0.0082 0.67 0.1116 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.68 0.0463 0.64 0.2026 CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR 67&78 0.75 0.0051 0.54 0.6865 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.76 0.0035 0.57 0.5528 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.7 0.0292 0.74 0.0295 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.59 0.3461 0.74 0.0295 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.74 0.0088 0.57 0.5215 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.62 0.1871 0.73 0.0374 CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK 70&79 0.76 0.0042 0.52 0.8805 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.7 0.0252 0.74 0.0283 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.71 0.0207 0.73 0.0307 CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR 72&126 0.61 0.226 0.76 0.0172 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.71 0.0173 0.67 0.1116 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.78 0.0021 0.54 0.6981 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.79 0.0015 0.56 0.5741 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.78 0.0017 0.55 0.6405 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.74 0.0081 0.74 0.0295 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.63 0.1346 0.72 0.0404 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.65 0.0989 0.74 0.0283 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.66 0.0703 0.72 0.0436 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.62 0.1705 0.74 0.0241 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.74 0.0075 0.57 0.5011 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.77 0.0027 0.59 0.4241 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.7 0.0283 0.78 0.0111 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.56 0.5187 0.73 0.036 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.73 0.0098 0.6 0.3711 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.76 0.0045 0.56 0.585 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.68 0.0475 0.58 0.4911 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.67 0.0557 0.74 0.0251 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.73 0.011 0.59 0.4241 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.74 0.0079 0.61 0.3148 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.78 0.0016 0.52 0.8431 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.71 0.022 0.76 0.0158 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.6 0.2655 0.75 0.0204 PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.72 0.0148 0.58 0.4812 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.72 0.0134 0.59 0.3883 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF 122&139 0.68 0.043 0.68 0.1047 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.78 0.0021 0.51 0.9684 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.75 0.0062 0.66 0.152 PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR 125&78 0.78 0.0022 0.5 0.9811 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.79 0.0015 0.52 0.8555 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.75 0.0065 0.68 0.0949 PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR 133&40 0.68 0.0482 0.62 0.2853 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.78 0.0022 0.6 0.3463 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.78 0.0022 0.61 0.2998 PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK 133&80 0.69 0.0393 0.6 0.3382 PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR 133&81 0.68 0.0438 0.58 0.4714 PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR 133&99 0.7 0.023 0.58 0.4426 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.7 0.0237 0.58 0.4812 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.73 0.0105 0.57 0.5422 PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR 133&112 0.69 0.0361 0.64 0.197 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.75 0.0054 0.72 0.0452 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.69 0.0356 0.69 0.0776 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.69 0.0361 0.72 0.0452 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.71 0.0202 0.62 0.2853 PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR 137&78 0.75 0.0057 0.53 0.8062 PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK 137&79 0.76 0.0038 0.55 0.6519 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.68 0.0409 0.7 0.0724 VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR 149&78 0.72 0.0157 0.59 0.3971 VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK 149&79 0.74 0.0078 0.6 0.3544 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.7 0.0292 0.8 0.0052 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.56 0.486 0.79 0.0066 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.56 0.4824 0.74 0.0272 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.7 0.0241 0.61 0.3225 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.63 0.1518 0.82 0.0032
(488) TABLE-US-00069 TABLE69 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevs controlcut-offof<370/7vs>=370/7weeks, withoutBMIstratification,separatelybyfetalgender. 119_153_ 119_153_ 119_153_ 119_153_ aBMI_37 aBMI_37 aBMI_37 aBMI_37 SEQID Female Female Male Male Reversal NO: ROC_AUC P-value ROC_AUC P-value AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.56 0.2281 0.66 0.001 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.58 0.1136 0.65 0.0019 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.54 0.5033 0.67 3.00E?04 APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR 47&99 0.61 0.0344 0.65 0.0024 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.61 0.0397 0.66 9.00E?04 APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL 47&134 0.62 0.0235 0.66 7.00E?04 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.57 0.1935 0.65 0.0025 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.54 0.4302 0.67 4.00E?04 APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL 48&134 0.53 0.6338 0.69 1.00E?04 APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR 48&18 0.53 0.5575 0.67 5.00E?04 C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR 55&141 0.66 0.003 0.56 0.1846 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.56 0.2984 0.66 0.0012 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.54 0.4632 0.65 0.0022 CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR 61&141 0.66 0.0035 0.56 0.199 CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR 62&141 0.66 0.0025 0.56 0.2459 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.65 0.0043 0.57 0.1591 CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL 64&134 0.61 0.0329 0.66 9.00E?04 CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR 64&141 0.67 0.0015 0.57 0.1549 CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR 70&141 0.67 0.0016 0.55 0.334 CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR 71&141 0.66 0.0037 0.55 0.2611 CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR 74&141 0.66 0.0025 0.58 0.0994 CO8B_QALEEFQK_vs_IGF2_GIVEECCFR 76&103 0.57 0.1956 0.66 8.00E?04 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.59 0.0972 0.65 0.002 FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR 88&141 0.67 0.0019 0.56 0.1782 FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL 89&134 0.57 0.1999 0.65 0.0014 FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR 89&141 0.65 0.0044 0.58 0.096 HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR 92&141 0.67 0.0016 0.58 0.1096 HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR 92&142 0.66 0.0033 0.55 0.254 HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR 93&141 0.66 0.0034 0.56 0.2346 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.59 0.0866 0.65 0.0018 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.58 0.1291 0.7 0 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.58 0.1611 0.68 1.00E?04 IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR 2&141 0.65 0.0064 0.59 0.049 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.55 0.307 0.67 4.00E?04 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.57 0.2257 0.67 5.00E?04 INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR 107&103 0.57 0.1988 0.7 0 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.53 0.5951 0.66 9.00E?04 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.56 0.2695 0.7 0 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.54 0.4196 0.68 2.00E?04 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.56 0.2577 0.65 0.0018 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.54 0.4632 0.68 2.00E?04 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.59 0.0821 0.65 0.0017 KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL 116&134 0.56 0.2885 0.66 0.001 LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR 118&66 0.65 0.0056 0.56 0.1773 LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR 118&103 0.66 0.0037 0.58 0.0905 LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR 118&126 0.65 0.004 0.56 0.2517 LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL 118&134 0.65 0.0046 0.63 0.0063 LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR 118&141 0.66 0.0032 0.55 0.2563 LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR 119&66 0.67 0.0019 0.58 0.0905 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.65 0.0049 0.6 0.0403 LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR 119&99 0.66 0.0037 0.57 0.1693 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.67 0.0017 0.57 0.1667 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.68 0.0011 0.59 0.0503 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.66 0.0024 0.6 0.0414 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.68 6.00E?04 0.57 0.1746 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.66 0.0025 0.65 0.0021 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.68 0.001 0.57 0.1241 LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR 119&142 0.67 0.0013 0.55 0.2757 LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 119&144 0.66 0.0032 0.57 0.1276 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.67 0.0015 0.59 0.0516 PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL 124&134 0.57 0.1704 0.67 3.00E?04 PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR 124&141 0.65 0.0056 0.59 0.058 PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL 125&134 0.57 0.2234 0.66 7.00E?04 VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR 149&40 0.55 0.3415 0.65 0.0022 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.6 0.0581 0.67 5.00E?04 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.59 0.0871 0.69 1.00E?04 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.59 0.0774 0.68 2.00E?04 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.59 0.0805 0.66 0.001 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.59 0.0871 0.66 7.00E?04 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.54 0.4502 0.65 0.0017 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.58 0.137 0.7 0 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.59 0.1055 0.67 3.00E?04 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.6 0.0523 0.68 2.00E?04
(489) TABLE-US-00070 TABLE70 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevscontrol cut-offof<370/7vs>=370/7weeks,withBMIstratification(>22<=37), separatelybyfetalgender. 119_153_ 119_153_ 119_153_ 119_153_ rBMI_37 rBMI_37 rBMI_3 rBMI SEQID Female Female 7Male 37Male Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR 34&103 0.65 0.0229 0.6 0.0902 A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR 34&126 0.66 0.0133 0.56 0.3335 AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR 37&103 0.62 0.069 0.65 0.0081 AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL 37&134 0.52 0.7127 0.66 0.0057 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.66 0.0169 0.63 0.026 AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL 38&134 0.55 0.4359 0.66 0.0069 ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR 42&66 0.67 0.0087 0.55 0.382 ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR 42&78 0.68 0.0059 0.57 0.1945 ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK 42&79 0.68 0.0048 0.58 0.1677 ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR 42&103 0.65 0.0197 0.59 0.1059 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.66 0.0164 0.58 0.1661 ANGT_DPTFIPAPIQAK_VS_PGRP2_AGLLRPDYALLGHR 42&126 0.67 0.0074 0.54 0.5241 ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR 42&141 0.65 0.018 0.57 0.2186 APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR 47&103 0.59 0.1479 0.65 0.0087 APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 47&135 0.57 0.2718 0.65 0.0081 APOH_ATVVYQGER_vs_IGF2_GIVEECCFR 48&103 0.56 0.3934 0.66 0.0056 B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR 50&103 0.65 0.0222 0.57 0.2386 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.66 0.0169 0.58 0.1465 BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR 52&66 0.65 0.0206 0.57 0.2597 BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK 52&79 0.65 0.0262 0.6 0.0892 C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR 55&103 0.65 0.0226 0.62 0.0321 C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR 55&126 0.66 0.0164 0.58 0.1629 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.65 0.0247 0.57 0.2206 CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR 64&66 0.66 0.014 0.57 0.2284 CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK 64&79 0.65 0.0226 0.59 0.1395 CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK 64&100 0.65 0.0236 0.59 0.1381 CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR 64&103 0.65 0.0209 0.62 0.0435 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.65 0.0222 0.61 0.0601 CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR 64&126 0.67 0.0108 0.56 0.3133 CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 64&144 0.66 0.0166 0.6 0.0902 CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR 70&126 0.66 0.0123 0.57 0.2206 CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR 70&18 0.56 0.3419 0.65 0.0106 CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR 71&126 0.66 0.0159 0.56 0.3387 CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR 72&66 0.65 0.0209 0.56 0.2753 ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR 82&103 0.65 0.0216 0.56 0.3083 FETUA_FSVVYAK_vs_IGF2_GIVEECCFR 88&103 0.65 0.0229 0.62 0.0429 HABP2_FLNWIK_vs_CHL1_VIAVNEVGR 92&66 0.65 0.02 0.56 0.3011 HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK 92&100 0.65 0.0229 0.59 0.1104 HABP2_FLNWIK_vs_IGF2_GIVEECCFR 92&103 0.65 0.0254 0.62 0.0321 IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR 2&66 0.66 0.014 0.57 0.2597 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.66 0.0159 0.64 0.018 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.61 0.0895 0.65 0.0073 IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR 2&126 0.66 0.0149 0.6 0.0942 IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL 2&134 0.57 0.2572 0.66 0.0058 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.58 0.2385 0.67 0.0024 INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR 107&40 0.51 0.8798 0.72 2.00E?04 INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR 107&78 0.55 0.4808 0.66 0.0068 INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK 107&79 0.57 0.2644 0.65 0.0082 INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR 107&99 0.56 0.3903 0.7 6.00E?04 INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK 107&100 0.57 0.2718 0.7 5.00E?04 INHBC_LDFHFSSDR_VS_IGF2_GIVEECCFR 107&103 0.57 0.2768 0.71 2.00E?04 INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR 107&112 0.51 0.9204 0.67 0.0028 INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR 107&120 0.54 0.5585 0.67 0.004 INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR 107&126 0.57 0.3082 0.65 0.0073 INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL 107&134 0.53 0.6459 0.72 1.00E?04 INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR 107&18 0.51 0.8439 0.7 6.00E?04 INHBC_LDFHFSSDR_VS_SPRL1_VLTHSELAPLR 107&140 0.56 0.3419 0.66 0.0062 INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR 107&141 0.59 0.1479 0.67 0.0027 INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR 107&142 0.56 0.3477 0.66 0.0061 INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 107&144 0.55 0.4632 0.67 0.004 INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK 107&147 0.52 0.7688 0.71 2.00E?04 ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK 111&79 0.65 0.024 0.59 0.1116 ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR 111&18 0.57 0.3082 0.66 0.0044 LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR 118&78 0.65 0.0209 0.56 0.2708 LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK 118&79 0.67 0.0089 0.57 0.2469 LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR 118&120 0.65 0.0216 0.57 0.1963 LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR 119&78 0.68 0.005 0.58 0.1523 LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK 119&79 0.7 0.0026 0.59 0.1327 LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK 119&100 0.69 0.0044 0.56 0.3387 LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR 119&103 0.7 0.0024 0.57 0.2148 LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR 119&120 0.69 0.0038 0.6 0.0882 LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR 119&126 0.69 0.0029 0.56 0.3133 LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL 119&134 0.65 0.0197 0.6 0.0932 LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR 119&141 0.66 0.0121 0.56 0.2986 LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK 119&147 0.68 0.0059 0.56 0.3059 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.65 0.0229 0.61 0.0497 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.65 0.0229 0.56 0.2708 VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR 149&40 0.55 0.4844 0.67 0.0035 VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK 149&100 0.65 0.0251 0.66 0.0071 VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR 149&103 0.63 0.0519 0.68 0.0023 VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR 149&112 0.55 0.4325 0.65 0.0086 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.63 0.0407 0.66 0.0052 VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK 149&121 0.53 0.6174 0.65 0.0082 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.65 0.0247 0.62 0.0369 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.57 0.2596 0.69 0.0012 VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 149&135 0.55 0.4359 0.66 0.0051 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.58 0.2273 0.69 0.0013 VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK 149&147 0.6 0.1311 0.68 0.0017 VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR 150&66 0.65 0.0226 0.59 0.1211 VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR 150&103 0.62 0.0555 0.66 0.0065 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.63 0.0396 0.66 0.0063 VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK 150&121 0.54 0.5662 0.66 0.0068 VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL 150&134 0.57 0.3028 0.67 0.0027 VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK 150&135 0.54 0.5282 0.67 0.0034 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.58 0.204 0.68 0.0023 VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK 150&147 0.61 0.0832 0.68 0.0015
(490) TABLE-US-00071 TABLE71 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevscontrol cut-offof<350/7vs>=350/7weeks,withoutBMIstratification,separatelyby fetalgender. 119_153_ 119_153_ 119_153_ 119_153_ aBMI_35 aBMI35 aBMI_3 aBMI SEQID Female Female 5Male 35Male Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.57 0.4262 0.67 0.0243 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.51 0.9381 0.73 0.0018 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.51 0.9466 0.69 0.0116 AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR 37&18 0.53 0.7662 0.66 0.0248 AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK 38&100 0.7 0.0336 0.62 0.1104 AFAM_HFQNLGK_vs_IGF2_GIVEECCFR 38&103 0.71 0.0263 0.63 0.0778 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.51 0.921 0.73 0.0018 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.51 0.9594 0.69 0.0098 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.54 0.643 0.71 0.0035 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.55 0.6315 0.67 0.0217 APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR 47&120 0.57 0.4262 0.68 0.0146 APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK 48&79 0.6 0.2924 0.65 0.0451 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.53 0.7377 0.71 0.0037 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.52 0.8198 0.69 0.0097 B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR 50&120 0.6 0.285 0.68 0.0166 B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR 51&103 0.72 0.0217 0.56 0.4027 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.62 0.1848 0.71 0.0044 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.63 0.176 0.73 0.0014 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.57 0.4387 0.68 0.0125 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.59 0.3124 0.68 0.0119 CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK 57&80 0.63 0.183 0.68 0.0138 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.59 0.3443 0.69 0.0095 CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR 57&86 0.57 0.4547 0.68 0.0157 CATD_VGFAEAAR_vs_IBP1_VVESLAK 57&97 0.61 0.2593 0.67 0.02 CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR 57&98 0.52 0.8198 0.67 0.0205 CATD_VGFAEAAR_vs_IGF2_GIVEECCFR 57&103 0.66 0.0821 0.67 0.0224 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.54 0.6623 0.69 0.0111 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.57 0.4324 0.76 4.00E?04 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.53 0.7621 0.72 0.0029 CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL 57&134 0.57 0.4678 0.7 0.0055 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.56 0.5538 0.69 0.0087 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.61 0.2593 0.68 0.0139 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.58 0.381 0.71 0.0051 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.6 0.2826 0.68 0.0125 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.59 0.3202 0.71 0.0051 CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR 57&142 0.59 0.347 0.67 0.0181 CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 57&144 0.59 0.3124 0.67 0.0207 CATD_VGFAEAAR_vs_VTDB_ELPEHTVK 57&147 0.56 0.5395 0.67 0.0187 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.58 0.3987 0.71 0.004 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.56 0.4911 0.7 0.0071 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.59 0.3497 0.7 0.0064 CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK 58&80 0.59 0.3308 0.66 0.0274 CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR 58&81 0.57 0.458 0.66 0.0259 CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR 58&86 0.57 0.4645 0.68 0.0131 CATD_VSTLPAITLK_vs_IBP1_VVESLAK 58&97 0.58 0.3957 0.67 0.0181 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.66 0.0802 0.67 0.0203 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.52 0.8575 0.68 0.0152 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.55 0.6088 0.77 2.00E?04 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.5 0.9679 0.74 0.0013 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.58 0.4138 0.71 0.0043 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.53 0.7296 0.7 0.0052 CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR 58&138 0.58 0.4077 0.66 0.0299 CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF 58&139 0.55 0.5755 0.69 0.0116 CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR 58&140 0.57 0.4645 0.68 0.0136 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.58 0.3927 0.72 0.0032 CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR 58&142 0.57 0.458 0.68 0.0141 CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 58&144 0.56 0.536 0.67 0.0235 CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK 58&147 0.54 0.6976 0.67 0.0187 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.61 0.2395 0.66 0.0302 CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR 157&120 0.63 0.1693 0.68 0.0159 CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR 61&103 0.72 0.0193 0.6 0.1921 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.61 0.2526 0.73 0.0014 CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR 61&126 0.57 0.4711 0.68 0.0139 CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR 61&18 0.58 0.3898 0.68 0.0153 CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 61&144 0.69 0.0425 0.6 0.1631 CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK 61&147 0.64 0.1428 0.67 0.0179 CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR 62&103 0.72 0.0175 0.57 0.3174 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.62 0.1901 0.7 0.0059 CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR 62&126 0.57 0.4387 0.66 0.0306 CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR 62&18 0.58 0.3898 0.65 0.0351 CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR 62&144 0.71 0.029 0.59 0.204 CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK 62&147 0.66 0.0961 0.65 0.0442 CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR 64&120 0.52 0.866 0.67 0.0187 CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK 67&79 0.63 0.176 0.65 0.0465 CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK 67&100 0.71 0.0267 0.56 0.4076 CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR 67&103 0.7 0.031 0.61 0.1288 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.59 0.3334 0.73 0.0014 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.54 0.6937 0.67 0.0189 CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR 67&18 0.58 0.4017 0.67 0.0172 CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK 67&147 0.6 0.2779 0.68 0.0148 CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK 68&79 0.63 0.1627 0.65 0.0446 CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK 68&100 0.7 0.0359 0.56 0.3861 CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR 68&103 0.71 0.0267 0.6 0.1593 CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR 68&120 0.58 0.3898 0.72 0.0027 CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR 68&126 0.53 0.7867 0.66 0.0326 CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR 68&18 0.57 0.4324 0.66 0.0254 CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK 68&147 0.58 0.3839 0.68 0.0146 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.61 0.2593 0.7 0.0056 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.53 0.7498 0.71 0.0043 CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR 72&120 0.58 0.4077 0.71 0.0049 CO8A_SLLQPNK_vs_IBP1_VVESLAK 74&97 0.57 0.4844 0.65 0.0398 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.51 0.9551 0.74 0.001 CO8B_QALEEFQK_vs_IBP1_VVESLAK 76&97 0.55 0.5939 0.67 0.024 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.55 0.5939 0.75 7.00E?04 CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL 76&134 0.51 0.8828 0.68 0.0161 F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK 84&100 0.74 0.0113 0.54 0.5451 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.74 0.011 0.59 0.2071 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.63 0.1812 0.74 0.0011 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.54 0.7016 0.67 0.021 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.59 0.3281 0.66 0.0262 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.56 0.5324 0.71 0.0037 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.51 0.9295 0.72 0.0032 HABP2_FLNWIK_vs_LYAM1_SYYWIGIR 92&120 0.54 0.6858 0.68 0.0161 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.5 1 0.71 0.0037 IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR 2&78 0.58 0.3898 0.66 0.0248 IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK 2&79 0.61 0.229 0.67 0.0219 IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR 2&103 0.68 0.0541 0.57 0.33 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.54 0.6353 0.74 0.0013 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.53 0.7498 0.67 0.0229 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.55 0.5755 0.68 0.0122 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.51 0.9423 0.73 0.002 KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR 117&78 0.57 0.4515 0.65 0.042 KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK 117&79 0.61 0.229 0.65 0.0428 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.58 0.4169 0.75 7.00E?04 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.54 0.6468 0.67 0.0212 KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR 117&18 0.6 0.285 0.66 0.0248 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.6 0.2899 0.71 0.0044 PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR 125&103 0.7 0.0294 0.58 0.2682 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.59 0.3361 0.73 0.0015 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.61 0.2395 0.66 0.0326 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.63 0.1611 0.66 0.0316 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.57 0.4645 0.67 0.0189 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.57 0.4483 0.66 0.0316 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.59 0.3415 0.7 0.0072 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.6 0.3099 0.65 0.0363 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.58 0.3723 0.67 0.0189 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.55 0.6051 0.69 0.0094 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.56 0.5395 0.69 0.0091 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.53 0.7176 0.76 4.00E?04 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.53 0.7826 0.7 0.0069 VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL 149&134 0.53 0.7703 0.68 0.0127 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.53 0.7296 0.68 0.0159 VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK 150&79 0.58 0.3752 0.65 0.0451 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.52 0.8407 0.75 6.00E?04 VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR 150&18 0.52 0.8744 0.68 0.0134
(491) TABLE-US-00072 TABLE72 ReversalClassificationPerformance,weeks17-21. ReversalAUROCforgestationalweeks170/7through216/7usingacasevscontrol cut-offof<350/7vs>=350/7weeks,withBMIstratification(>22<=37), separatelybyfetalgender. 119_153_ 119_153_ 119_153_ 119_153_ rBMI_35 rBMI_35 rBMI_3 rBMI SEQID Female Female 5Male 35Male Reversal NO: ROC_AUC P-value ROC_AUC P-value A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK 34&79 0.76 0.0345 0.59 0.3046 A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR 34&120 0.7 0.0972 0.68 0.0323 AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR 37&120 0.53 0.828 0.76 0.0018 AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR 37&126 0.51 0.962 0.74 0.0044 AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF 37&139 0.55 0.6755 0.67 0.0422 AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR 38&40 0.61 0.3649 0.67 0.0493 AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR 38&120 0.54 0.7626 0.76 0.0019 AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR 38&126 0.5 0.9789 0.74 0.004 AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF 38&139 0.57 0.5494 0.69 0.0278 ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR 42&120 0.59 0.4361 0.75 0.0034 ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR 42&126 0.54 0.7626 0.69 0.0224 ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR 42&18 0.55 0.6755 0.69 0.0257 APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR 48&120 0.54 0.7226 0.73 0.0071 APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR 48&126 0.51 0.9535 0.73 0.0072 B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR 51&78 0.74 0.0446 0.59 0.3046 B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK 51&79 0.78 0.02 0.6 0.251 B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR 51&120 0.71 0.091 0.71 0.0134 CATD_VGFAEAAR_vs_C163A_INPASLDK 57&54 0.68 0.1393 0.73 0.006 CATD_VGFAEAAR_vs_CRIS3_AVSPPAR 57&78 0.64 0.2374 0.67 0.0476 CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK 57&79 0.67 0.1572 0.67 0.0412 CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR 57&81 0.64 0.2416 0.68 0.0294 CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR 57&112 0.55 0.6833 0.68 0.0362 CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR 57&120 0.61 0.3705 0.77 0.0013 CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR 57&126 0.58 0.5353 0.72 0.011 CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR 57&18 0.56 0.6147 0.68 0.0342 CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR 57&138 0.66 0.1835 0.67 0.0493 CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF 57&139 0.67 0.1572 0.68 0.0371 CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR 57&140 0.58 0.4876 0.67 0.0397 CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR 57&141 0.53 0.8363 0.72 0.011 CATD_VSTLPAITLK_vs_C163A_INPASLDK 58&54 0.64 0.2416 0.72 0.0087 CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR 58&78 0.65 0.2092 0.69 0.0233 CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK 58&79 0.69 0.118 0.7 0.0179 CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR 58&103 0.74 0.0469 0.67 0.0484 CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR 58&112 0.53 0.828 0.68 0.0362 CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR 58&120 0.59 0.481 0.79 5.00E?04 CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR 58&126 0.57 0.578 0.74 0.0042 CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL 58&134 0.55 0.7068 0.7 0.0175 CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR 58&18 0.54 0.7226 0.71 0.0149 CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR 58&141 0.52 0.8529 0.74 0.0048 CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR 59&120 0.6 0.4115 0.7 0.0206 CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR 157&120 0.63 0.2821 0.72 0.0087 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR 61&78 0.76 0.0319 0.57 0.3774 CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK 61&79 0.77 0.0237 0.6 0.2605 CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR 61&120 0.71 0.091 0.73 0.0077 CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF 61&139 0.75 0.0393 0.59 0.2954 CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR 62&120 0.69 0.1156 0.68 0.0311 CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR 67&120 0.6 0.4115 0.74 0.0038 CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR 67&126 0.54 0.7305 0.67 0.0435 CLUS_LFDSDPITVTVPVEVSR_VS_YAM1_SYYWIGIR 68&120 0.57 0.5708 0.7 0.0168 CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR 70&120 0.63 0.2681 0.72 0.0101 CO5_VFQFLEK_vs_LYAM1_SYYWIGIR 71&120 0.54 0.7147 0.71 0.0128 CO6_ALNHLPLEYNSALYSR_Vs_LYAM1_SYYWIGIR 72&120 0.68 0.1451 0.7 0.0211 CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR 74&120 0.53 0.8363 0.74 0.0042 CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR 76&120 0.54 0.7385 0.73 0.0068 F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR 84&78 0.75 0.0364 0.63 0.125 F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK 84&79 0.77 0.0264 0.63 0.1307 F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR 84&103 0.77 0.0271 0.59 0.2905 F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR 84&120 0.68 0.1422 0.76 0.0022 F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR 84&126 0.58 0.5146 0.68 0.0305 F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR 84&18 0.6 0.4055 0.67 0.0493 FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR 88&120 0.59 0.4614 0.71 0.0145 FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR 89&120 0.56 0.6448 0.73 0.0077 HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR 93&120 0.51 0.9451 0.72 0.0099 IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR 2&120 0.58 0.5146 0.76 0.0021 IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR 2&18 0.52 0.8612 0.67 0.0443 IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR 102&120 0.61 0.3593 0.7 0.0158 ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR 111&120 0.63 0.2727 0.68 0.0342 KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR 116&120 0.55 0.6678 0.73 0.006 KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR 117&103 0.74 0.0435 0.61 0.2099 KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR 117&120 0.62 0.3375 0.76 0.0023 KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR 117&126 0.54 0.7385 0.69 0.0237 PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR 122&78 0.68 0.1338 0.67 0.0443 PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK 122&79 0.71 0.0795 0.67 0.0467 PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR 122&120 0.64 0.2459 0.72 0.0106 PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR 122&129 0.76 0.0319 0.62 0.1714 PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF 122&139 0.72 0.0708 0.69 0.0268 PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK 124&79 0.74 0.0493 0.61 0.1762 PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR 124&120 0.65 0.217 0.72 0.0079 PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK 125&79 0.75 0.0373 0.62 0.1489 PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR 125&120 0.63 0.2774 0.76 0.0023 PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR 125&126 0.57 0.5494 0.67 0.0451 PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR 133&78 0.76 0.0345 0.68 0.0355 PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK 133&79 0.77 0.0286 0.68 0.0369 PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR 133&86 0.61 0.3649 0.67 0.0476 PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR 133&98 0.69 0.118 0.68 0.039 PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK 133&100 0.74 0.0446 0.62 0.1599 PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR 133&103 0.76 0.0336 0.63 0.1287 PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR 133&120 0.72 0.0759 0.74 0.005 PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR 133&126 0.69 0.1156 0.68 0.03 PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL 133&134 0.67 0.1541 0.68 0.0362 PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR 133&18 0.68 0.1283 0.71 0.0149 PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF 133&139 0.76 0.0345 0.63 0.1122 PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR 137&120 0.59 0.4614 0.72 0.0099 THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR 143&120 0.59 0.4361 0.7 0.0211 VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR 149&120 0.53 0.8363 0.81 3.00E?04 VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR 149&126 0.54 0.7626 0.75 0.0037 VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR 149&18 0.51 0.9282 0.69 0.0219 VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR 150&120 0.51 0.9451 0.76 0.0023
(492) TABLE-US-00073 TABLE 73 SHBG Antibody Pair Screening Pair 1 2 3 4 5 6 7 8 9 10 11 12 Capture MAB MAB MAB 6001- 6001- 6001- 6002- 6002- 6002- 2656 2656 2656 AF2656 AF2656 AF2656 100050 100050 100050 100051 100051 100051 Detection 6001- 6002- MAB 6001- 6002- MAB 6002- MAB 6001- AF2656 100050 100051 2656 100050 100051 2656 AF2656 100051 2656 AF2656 100050 Conc. (pg/mL) Avg. Signal 200,000 196,199 1,482 40 17,248 77 82 87 493 140 15 357 59 50,000 45,345 230 68 6,424 81 72 77 323 134 74 286 62 12,500 10,250 111 62 1,309 69 85 27 205 74 52 253 3 3,125 2,218 5 31 310 45 66 83 240 137 29 194 60 781 586 58 43 135 57 50 80 253 174 74 212 116 195 285 112 69 85 68 58 73 281 156 95 236 32 48.8 192 78 51 79 80 57 35 241 82 51 239 45 0 134 57 36 65 31 81 70 222 145 61 207 50 Sample Dil. Factor Avg. Signal Sera Ser 100 24,276 759,257 95,554 72,420 540,435 33,723 52,016 1,519,054 124,739 257,126 2,651,568 2,483,374 SHBG High Sera Ser 500 11,920 151,855 25,205 53,509 435,835 28,879 39,185 1,310,604 112,980 103,294 1,365,240 1,236,988 SHBG High Sera Ser 100 4,968 466,625 60,954 81,666 488,908 30,966 54,664 1,409,717 113,560 211,022 2,093,523 1,854,111 SHBG Low Sera Ser 500 2,323 77,558 13,979 51,484 341,422 24,496 39,792 1,092,474 98,450 66,981 741,153 635,079 SHBG Low Sera 100 16,046 543,595 67,876 70,299 537,819 32,769 55,762 1,448,544 117,378 211,125 2,290,099 2,161,934 Pregnant Pool Sera 200 8,181 265,320 36,282 62,676 484,876 31,089 45,555 1,387,992 117,090 144,146 1,756,643 1,644,496 Pregnant Pool Sera 400 3,798 126,947 20,332 50,249 430,699 27,311 35,459 1,240,271 110,478 106,820 1,148,673 1,023,157 Pregnant Pool Sera 800 1,854 48,533 8,691 39,042 337,119 14,848 29,455 1,053,286 93,762 61,748 660,872 591,820 Pregnant Pool
(493) TABLE-US-00074 TABLE 74 Top Performing SHBG Antibody Pairs with Additional Calibrators Pair 2 3 10 12 Capture MAB MAB MAB MAB MAB MAB 6001- 6001- 6001- 6001- 6001- 6001- 2656 2656 2656 2656 2656 2656 100051 100051 100051 100051 100051 100051 Detection 6001- 6001- 6001- 6002- 6002- 6002- MAB MAB MAB 6001- 6001- 6001- 10050 10050 10050 100051 100051 100051 2656 2656 2656 10050 10050 10050 Calibrator Conc. R&D Bios R&D Bios R&D Bios R&D Bios (pg/mL) Systems Pacific NIBSC Systems Pacific NIBSC Systems Pacific NIBSC Systems Pacific NIBSC Std-01 200,000 238,290 249,922 412,613 186,867 196,012 426,503 596,225 293,312 554,954 1,898,159 1,779,244 3,175,127 Std-02 50,000 88,340 76,077 107,001 77,374 88,009 134,934 158,181 150,021 237,546 554,319 882,130 1,538,720 Std-03 12,500 22,003 14,194 18,988 20,160 20,899 33,358 35,226 32,464 54,024 129,885 227,721 452,461 Std-04 3,125 5,261 3,137 3,960 5,215 5,151 8,048 8,701 7,791 12,118 32,771 57,949 117,096 Std-05 781 1,650 813 1,126 1,351 1,211 2,121 2,165 1,781 2,842 9,383 14,943 33,614 Std-06 195 534 247 323 474 371 554 751 482 766 2,869 3,630 8,559 Std-07 48.8 193 107 108 173 151 145 260 198 265 832 1,045 2,337 Std-08 0 87 68 42 83 60 58 93 127 100 171 232 210 Hill 0.96 1.09 1.07 0.99 1.04 1.05 1.00 1.13 1.08 0.96 1.04 0.99 Slope LLCD 34 96 65 42 51 36 25 51 29 15 12 2.4 (pg/mL) Sig- Std-02 100% 86% 121% 100% 114% 174% 100% 95% 150% 100% 159% 278% nals Std-03 100% 65% 86% 100% 104% 165% 100% 92% 153% 100% 175% 348% Norm. Std-04 100% 60% 75% 100% 99% 154% 100% 90% 139% 100% 177% 357% to Std-05 100% 49% 68% 100% 90% 157% 100% 82% 131% 100% 159% 358% R&D Average 100% 65% 88% 100% 101% 163% 100% 90% 144% 100% 138% 335% (STD02-05)
(494) TABLE-US-00075 TABLE 75 IGFBP-4 Antibody Screen Pair 1 2 Capture Ansh AI039 Ansh AI042 Detection Ansh AI042 Ansh AI039 Cond. (pg/mL) Avg. Signal Ratio STD01 200,000 425,323 1,804,559 4.2 STD02 50,000 119,806 532,966 4.4 STD03 12,500 24,178 117,219 4.8 STD04 3,125 6,232 37,258 6.0 STD05 781 2,816 17,032 6.0 STD06 195 2,176 13,425 6.2 STD07 48.8 2,019 11,901 5.9 STD08 0 1,710 10,995 6.4 Hill Slope 1.20 1.10 LLOD (pg/mL) 317 129 Sample Dil. Factor Avg. Signal Ratio Sera Serum 5 80,262 923,638 11.5 IGFBP-4 High Sera Serum 5 57,033 671,088 11.8 IGFBP-4 Low Pregnant Pooled 2 177,461 1,608,197 9.1 Serum 1 Pregnant Pooled 4 68,359 771,385 11.3 Serum 2 Pregnant Pooled 8 26,032 335,292 12.9 Serum 3 Pregnant Pooled 16 10,001 143,381 14.3 Serum 4 Pregnant Pooled 32 4,813 60,651 12.6 Serum 5 Pregnant Pooled 64 2,796 21,126 7.6 Serum 6 MSD Serum 1 2 103,259 1,249,741 12.1 MSD Serum 1 4 37,414 571,584 15.3 MSD Serum 1 8 17,946 291,750 16.3 MSD Serum 1 16 7,203 126,275 17.5 MSD Serum 2 2 66,061 767,724 11.6 MSD Serum 2 4 29,099 425,207 14.6 * Pregnant Pooled Serum 6 sample exhibited signals within 2X assay background
(495) TABLE-US-00076 TABLE76 TransitionClassificationPerformance,weeks 19-20.TransitionAUROCforgestationalweeks 191/7through206/7usingacasevscontrol cut-offof<370/7vs>=370/7weeks,without BMIstratification,forPTL. 134_146_aBMI_37 Transition SEQIDNO: PTLROC_AUC PSG3_VSAPSGTGHLPGLNPL 134 0.66 IGF2_GIVEECCFR 103 0.66 IBP4_QCHPALDGQR 2 0.64 IBP3_YGQPLPGYTTK 100 0.64 F13B_GDTYPAELYITGSILR 84 0.61 APOH_ATVVYQGER 48 0.6 IBP3_FLNVLSPR 99 0.6
(496) TABLE-US-00077 TABLE77 TransitionClassificationPerformance,weeks 19-20.TransitionAUROCforgestationalweeks 191/7through206/7usingacasevscontrol cut-offof<370/7vs>=370/7weeks,without BMIstratification,forPPROM. SEQID 134_146_aBMI_ Analytes NO: 37ROC_AUC APOC3_GWVTDGFSSLK 47 0.76 PEDF_TVQAVLTVPK 125 0.76 INHBC_LDFHFSSDR 107 0.76 IBP4_QCHPALDGQR 2 0.73 PEDF_LQSLFDSPDFSK 124 0.73 A1AT_LSITGTYDLK 33 0.73 KNG1_QVVAGLNFR 117 0.72 CD14_LTVGAAQVPAQLLVGALR 61 0.72 VTNC_VDTVDPPYPR 150 0.71 KNG1_DIPTNSPELEETLTHTITK 116 0.71 CD14_SWLAELQQWLKPGLK 62 0.71 CO8A_SLLQPNK 74 0.69 CATD_VGFAEAAR 57 0.69 SHBG_IALGGLLFPASNLR 18 0.69 CO5_VFQFLEK 71 0.69 FETUA_FSVVYAK 88 0.68 HABP2_FLNWIK 92 0.68 VTNC_GQYCYELDEK 149 0.68 B2MG_VNHVTLSQPK 51 0.68 ENPP2_TYLHTYESEI 83 0.67 AFAM_HFQNLGK 38 0.67 APOH_ATVVYQGER 48 0.66 ITIH4_NPLVWVHASPEHVVVTR 113 0.66 CFAB_YGLVTYATYPK 64 0.66 CO8B_QALEEFQK 76 0.65 BGH3_LTLLAPLNSVFK 52 0.65 FETUA_HTLNQIDEVK 89 0.65 CO3_IHWESASLLR 69 0.65 ENPP2_TEFLSNYLTNVDDITLVPGTLGR 82 0.65 HEMO_NFPSPVDAAFR 93 0.65 LBP_ITLPDFTGDLR 119 0.65 CO5_TLLPVSKPEIR 70 0.65 FIBA_ESSSHHPGIAEFPSR 90 0.64 AFAM_DADPDTFFAK 37 0.64 ITIH3_ALDLSLK 111 0.64 LBP_ITGFLKPGK 118 0.64 CATD_VSTLPAITLK 58 0.64 PRDX2_GLFIIDGK 128 0.63 CO6_ALNHLPLEYNSALYSR 72 0.63 ANGT_DPTFIPAPIQAK 42 0.62 PRG2_WNFAYWAAHQPWSR 129 0.62 CBPN_NNANGVDLNR 60 0.62 IBP6_HLDSVLQQLQTEVYR 102 0.62 ITIH4_ILDDLSPR 112 0.62 IBP6_GAQTLYVPNCDHR 101 0.62 F13B_GDTYPAELYITGSILR 84 0.61 CLUS_LFDSDPITVTVPVEVSR 68 0.61 FBLN1_TGYYFDGISR 86 0.61 PAPP1_DIPHWLNPTR 122 0.61 TIE1_VSWSLPLVPGPLVGDGFLLR 144 0.6 CAH1_GGPFSDSYR 56 0.6 A2GL_DLLLPQPDLR 34 0.6 B2MG_VEHSDLSFSK 50 0.6 PSG2_IHPSYTNYR 133 0.6